AUSEA A M EDICAL D ICTIONARY , B IBLIOGRAPHY , AND A NNOTATED R ESEARCH G UIDE TO I NTERNET R E FERENCES
J AMES N. P ARKER , M.D. AND P HILIP M. P ARKER , P H .D., E DITORS
ii
ICON Health Publications ICON Group International, Inc. 4370 La Jolla Village Drive, 4th Floor San Diego, CA 92122 USA Copyright 2004 by ICON Group International, Inc. Copyright 2004 by ICON Group International, Inc. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America. Last digit indicates print number: 10 9 8 7 6 4 5 3 2 1
Publisher, Health Care: Philip Parker, Ph.D. Editor(s): James Parker, M.D., Philip Parker, Ph.D. Publisher's note: The ideas, procedures, and suggestions contained in this book are not intended for the diagnosis or treatment of a health problem. As new medical or scientific information becomes available from academic and clinical research, recommended treatments and drug therapies may undergo changes. The authors, editors, and publisher have attempted to make the information in this book up to date and accurate in accord with accepted standards at the time of publication. The authors, editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of this book. Any practice described in this book should be applied by the reader in accordance with professional standards of care used in regard to the unique circumstances that may apply in each situation. The reader is advised to always check product information (package inserts) for changes and new information regarding dosage and contraindications before prescribing any drug or pharmacological product. Caution is especially urged when using new or infrequently ordered drugs, herbal remedies, vitamins and supplements, alternative therapies, complementary therapies and medicines, and integrative medical treatments. Cataloging-in-Publication Data Parker, James N., 1961Parker, Philip M., 1960Nausea: A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References / James N. Parker and Philip M. Parker, editors p. cm. Includes bibliographical references, glossary, and index. ISBN: 0-597-84525-5 1. Nausea-Popular works. I. Title.
iii
Disclaimer This publication is not intended to be used for the diagnosis or treatment of a health problem. It is sold with the understanding that the publisher, editors, and authors are not engaging in the rendering of medical, psychological, financial, legal, or other professional services. References to any entity, product, service, or source of information that may be contained in this publication should not be considered an endorsement, either direct or implied, by the publisher, editors, or authors. ICON Group International, Inc., the editors, and the authors are not responsible for the content of any Web pages or publications referenced in this publication.
Copyright Notice If a physician wishes to copy limited passages from this book for patient use, this right is automatically granted without written permission from ICON Group International, Inc. (ICON Group). However, all of ICON Group publications have copyrights. With exception to the above, copying our publications in whole or in part, for whatever reason, is a violation of copyright laws and can lead to penalties and fines. Should you want to copy tables, graphs, or other materials, please contact us to request permission (E-mail:
[email protected]). ICON Group often grants permission for very limited reproduction of our publications for internal use, press releases, and academic research. Such reproduction requires confirmed permission from ICON Group International, Inc. The disclaimer above must accompany all reproductions, in whole or in part, of this book.
iv
Acknowledgements The collective knowledge generated from academic and applied research summarized in various references has been critical in the creation of this book which is best viewed as a comprehensive compilation and collection of information prepared by various official agencies which produce publications on nausea. Books in this series draw from various agencies and institutions associated with the United States Department of Health and Human Services, and in particular, the Office of the Secretary of Health and Human Services (OS), the Administration for Children and Families (ACF), the Administration on Aging (AOA), the Agency for Healthcare Research and Quality (AHRQ), the Agency for Toxic Substances and Disease Registry (ATSDR), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Healthcare Financing Administration (HCFA), the Health Resources and Services Administration (HRSA), the Indian Health Service (IHS), the institutions of the National Institutes of Health (NIH), the Program Support Center (PSC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). In addition to these sources, information gathered from the National Library of Medicine, the United States Patent Office, the European Union, and their related organizations has been invaluable in the creation of this book. Some of the work represented was financially supported by the Research and Development Committee at INSEAD. This support is gratefully acknowledged. Finally, special thanks are owed to Tiffany Freeman for her excellent editorial support.
v
About the Editors James N. Parker, M.D. Dr. James N. Parker received his Bachelor of Science degree in Psychobiology from the University of California, Riverside and his M.D. from the University of California, San Diego. In addition to authoring numerous research publications, he has lectured at various academic institutions. Dr. Parker is the medical editor for health books by ICON Health Publications. Philip M. Parker, Ph.D. Philip M. Parker is the Eli Lilly Chair Professor of Innovation, Business and Society at INSEAD (Fontainebleau, France and Singapore). Dr. Parker has also been Professor at the University of California, San Diego and has taught courses at Harvard University, the Hong Kong University of Science and Technology, the Massachusetts Institute of Technology, Stanford University, and UCLA. Dr. Parker is the associate editor for ICON Health Publications.
vi
About ICON Health Publications To discover more about ICON Health Publications, simply check with your preferred online booksellers, including Barnes&Noble.com and Amazon.com which currently carry all of our titles. Or, feel free to contact us directly for bulk purchases or institutional discounts: ICON Group International, Inc. 4370 La Jolla Village Drive, Fourth Floor San Diego, CA 92122 USA Fax: 858-546-4341 Web site: www.icongrouponline.com/health
vii
Table of Contents FORWARD .......................................................................................................................................... 1 CHAPTER 1. STUDIES ON NAUSEA .................................................................................................... 3 Overview........................................................................................................................................ 3 The Combined Health Information Database................................................................................. 3 Federally Funded Research on Nausea........................................................................................... 4 E-Journals: PubMed Central ....................................................................................................... 34 The National Library of Medicine: PubMed ................................................................................ 35 CHAPTER 2. NUTRITION AND NAUSEA .......................................................................................... 59 Overview...................................................................................................................................... 59 Finding Nutrition Studies on Nausea ......................................................................................... 59 Federal Resources on Nutrition ................................................................................................... 61 Additional Web Resources ........................................................................................................... 61 CHAPTER 3. ALTERNATIVE MEDICINE AND NAUSEA .................................................................... 67 Overview...................................................................................................................................... 67 The Combined Health Information Database............................................................................... 67 National Center for Complementary and Alternative Medicine.................................................. 69 Additional Web Resources ........................................................................................................... 79 General References ..................................................................................................................... 103 CHAPTER 4. DISSERTATIONS ON NAUSEA .................................................................................... 105 Overview.................................................................................................................................... 105 Dissertations on Nausea ............................................................................................................ 105 Keeping Current ........................................................................................................................ 106 CHAPTER 5. CLINICAL TRIALS AND NAUSEA ............................................................................... 107 Overview.................................................................................................................................... 107 Recent Trials on Nausea ............................................................................................................ 107 Keeping Current on Clinical Trials ........................................................................................... 110 CHAPTER 6. PATENTS ON NAUSEA ............................................................................................... 113 Overview.................................................................................................................................... 113 Patents on Nausea...................................................................................................................... 113 Patent Applications on Nausea.................................................................................................. 139 Keeping Current ........................................................................................................................ 172 CHAPTER 7. BOOKS ON NAUSEA .................................................................................................. 173 Overview.................................................................................................................................... 173 Book Summaries: Federal Agencies............................................................................................ 173 Book Summaries: Online Booksellers......................................................................................... 182 Chapters on Nausea ................................................................................................................... 183 Directories.................................................................................................................................. 184 CHAPTER 8. MULTIMEDIA ON NAUSEA ........................................................................................ 187 Overview.................................................................................................................................... 187 Video Recordings ....................................................................................................................... 187 CHAPTER 9. PERIODICALS AND NEWS ON NAUSEA ..................................................................... 191 Overview.................................................................................................................................... 191 News Services and Press Releases.............................................................................................. 191 Newsletters on Nausea............................................................................................................... 193 Newsletter Articles .................................................................................................................... 194 Academic Periodicals covering Nausea...................................................................................... 195 CHAPTER 10. RESEARCHING MEDICATIONS................................................................................. 197 Overview.................................................................................................................................... 197 U.S. Pharmacopeia..................................................................................................................... 197 Commercial Databases ............................................................................................................... 208 APPENDIX A. PHYSICIAN RESOURCES .......................................................................................... 213
Contents
viii
Overview.................................................................................................................................... 213 NIH Guidelines.......................................................................................................................... 213 NIH Databases........................................................................................................................... 215 Other Commercial Databases..................................................................................................... 217 The Genome Project and Nausea ............................................................................................... 217 APPENDIX B. PATIENT RESOURCES ............................................................................................... 221 Overview.................................................................................................................................... 221 Patient Guideline Sources.......................................................................................................... 221 Finding Associations.................................................................................................................. 242 APPENDIX C. FINDING MEDICAL LIBRARIES ................................................................................ 245 Overview.................................................................................................................................... 245 Preparation................................................................................................................................. 245 Finding a Local Medical Library................................................................................................ 245 Medical Libraries in the U.S. and Canada ................................................................................. 245 ONLINE GLOSSARIES................................................................................................................ 251 Online Dictionary Directories ................................................................................................... 254 NAUSEA DICTIONARY.............................................................................................................. 255 INDEX .............................................................................................................................................. 349
1
FORWARD In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading."1 Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and printing. Since only the smallest fraction of information dealing with nausea is indexed in search engines, such as www.google.com or others, a nonsystematic approach to Internet research can be not only time consuming, but also incomplete. This book was created for medical professionals, students, and members of the general public who want to know as much as possible about nausea, using the most advanced research tools available and spending the least amount of time doing so. In addition to offering a structured and comprehensive bibliography, the pages that follow will tell you where and how to find reliable information covering virtually all topics related to nausea, from the essentials to the most advanced areas of research. Public, academic, government, and peer-reviewed research studies are emphasized. Various abstracts are reproduced to give you some of the latest official information available to date on nausea. Abundant guidance is given on how to obtain free-of-charge primary research results via the Internet. While this book focuses on the field of medicine, when some sources provide access to non-medical information relating to nausea, these are noted in the text. E-book and electronic versions of this book are fully interactive with each of the Internet sites mentioned (clicking on a hyperlink automatically opens your browser to the site indicated). If you are using the hard copy version of this book, you can access a cited Web site by typing the provided Web address directly into your Internet browser. You may find it useful to refer to synonyms or related terms when accessing these Internet databases. NOTE: At the time of publication, the Web addresses were functional. However, some links may fail due to URL address changes, which is a common occurrence on the Internet. For readers unfamiliar with the Internet, detailed instructions are offered on how to access electronic resources. For readers unfamiliar with medical terminology, a comprehensive glossary is provided. For readers without access to Internet resources, a directory of medical libraries, that have or can locate references cited here, is given. We hope these resources will prove useful to the widest possible audience seeking information on nausea. The Editors
1
From the NIH, National Cancer Institute (NCI): http://www.cancer.gov/cancerinfo/ten-things-to-know.
3
CHAPTER 1. STUDIES ON NAUSEA Overview In this chapter, we will show you how to locate peer-reviewed references and studies on nausea.
The Combined Health Information Database The Combined Health Information Database summarizes studies across numerous federal agencies. To limit your investigation to research studies and nausea, you will need to use the advanced search options. First, go to http://chid.nih.gov/index.html. From there, select the “Detailed Search” option (or go directly to that page with the following hyperlink: http://chid.nih.gov/detail/detail.html). The trick in extracting studies is found in the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer, and the format option “Journal Article.” At the top of the search form, select the number of records you would like to see (we recommend 100) and check the box to display “whole records.” We recommend that you type “nausea” (or synonyms) into the “For these words:” box. Consider using the option “anywhere in record” to make your search as broad as possible. If you want to limit the search to only a particular field, such as the title of the journal, then select this option in the “Search in these fields” drop box. The following is what you can expect from this type of search: •
Nausea, Vomiting and Diarrhea: An Unusual Presentation of Multiple Sclerosis Source: Canadian Journal of Gastroenterology. 11(4): 367-370. May-June 1997. Contact: Available from Pulsus Group, Inc. 2902 South Sheridan Way, Oakville, Ontario, Canada L6J 7L6. Summary: This article presents the case of a young woman who presented with nausea, vomiting, and diarrhea. The etiology turned out to be a first attack of multiple sclerosis (MS). MS is a multifocal demyelinating disorder that usually affects young adults with subacute onset of focal neurological symptoms. The majority (80 percent) of patients present with visual, sensory or gait disturbances; patients older than 40 years more commonly exhibit symptoms of progressive myelopathy. The 33-year-old woman presented to the emergency room with a two-week history of nausea, vomiting and
4
Nausea
intermittent (one to four times per day) loose watery stools without blood. The vomiting and diarrhea were not associated with cramps, fever, or chills. She experienced mild light- headedness, especially on arising, and complained of mild left neck pain. There was no history of alcohol or substance abuse. The patient's mother died of disabling MS and a younger brother was recently diagnosed with MS. Physical examination at admission disclosed a thin woman in no acute distress, with normal vital signs; general and neurological examinations were entirely within normal limits. The gastroenterologic workup was normal. Because symptoms persisted and nausea was a prominent feature, and because of the family history, neurological consultation was obtained and supported the diagnosis of MS. The authors describe her treatment and subsequent improvement. She has been well without gastrointestinal or neurological symptoms for the five years of followup. The authors conclude that cases such as these should alert non-neurology physicians that persistent upper and lower gastrointestinal symptoms may, on occasion, be a consequence of primary central nervous system pathology. 1 figure. 23 references. (AA-M). •
Will the Nausea Ever End? Source: Diabetes Forecast. 50(7): 31-32, 35-36. July 1997. Contact: Available from American Diabetes Association. 1701 North Beauregard Street, Alexandria, VA 22311. (800) 232-3472. Website: www.diabetes.org. Summary: This article, the first in a series on how diabetes affects the gastrointestinal tract, discusses gastroparesis (stomach paralysis). When severe, gastroparesis can be one of the most debilitating of all gastrointestinal complications of diabetes. Typical symptoms of gastroparesis include nausea, vomiting, abdominal bloating, the feeling of filling up too quickly while eating, loss of appetite, and heartburn. The author also describes the problems of matching food absorption to insulin delivery when food remains in the stomach because of gastroparesis. The author discusses diagnostic tests that may be used to confirm gastroparesis, treatment options including diet therapy and drug therapy, and prognosis issues. Drugs discussed include bethanecol, metoclopramide, cisapride, erythromycin, and domperidone. The author encourages readers to continue to search for treatments that work in their own individual cases, and not to be discouraged if it takes some time to get the symptoms under control. The article also presents the experiences of two patients and their struggles with gastroparesis.
Federally Funded Research on Nausea The U.S. Government supports a variety of research studies relating to nausea. These studies are tracked by the Office of Extramural Research at the National Institutes of Health.2 CRISP (Computerized Retrieval of Information on Scientific Projects) is a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other institutions.
2
Healthcare projects are funded by the National Institutes of Health (NIH), Substance Abuse and Mental Health Services (SAMHSA), Health Resources and Services Administration (HRSA), Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDCP), Agency for Healthcare Research and Quality (AHRQ), and Office of Assistant Secretary of Health (OASH).
Studies
5
Search the CRISP Web site at http://crisp.cit.nih.gov/crisp/crisp_query.generate_screen. You will have the option to perform targeted searches by various criteria, including geography, date, and topics related to nausea. For most of the studies, the agencies reporting into CRISP provide summaries or abstracts. As opposed to clinical trial research using patients, many federally funded studies use animals or simulated models to explore nausea. The following is typical of the type of information found when searching the CRISP database for nausea: •
Project Title: 153 SM-EDTMP FOR BONE METASTASES--PHASE I DOSE ESCALATION STUDY Principal Investigator & Institution: Anderson, Peter; Mayo Clinic Rochester 200 1St St Sw Rochester, Mn 55905 Timing: Fiscal Year 2002 Summary: The purpose of this study is to learn the dose of the investigational drug 153Sm-EDTMP that can be given to patients with cancer or those whom have not responded to therapy with surgery and chemotherapy. The study will also evaluate the side effects of this drug. 153Sm-EDTMP was eliminated relatively quickly after each infusion with uptake remaining in metastases or skeleton only by 24 hr. Bladder toxicity has not occurred. We are currently using IV hydration as the only means of cystitis prevention. Total body radiation levels on day 13 have been consistently very low, well below 1 mRem/hr at 1 meter safety limit. All patients have had stem cells infused 14 days after high dose 153Sm-EDTMP. Stem cell infusions have been given as outpatient observation with side effects limited to those usually associated with DMSO cryopreservative (temporary nausea, anorexia for 4-6 hrs). All patients have become temporarily pancytopenic after 153Sm-EDTMP. Once ANC is less than 500, patients have been provided with G-CSF to speed neutrophil recovery. Platelet transfusion requirements have been variable. Most patients have required only 1-3 platelet transfusions for platelet counts <20,000. Some but not all patients have also been transfused with packet red blood cells. Recovery of neutrophil count has generally occurred before day 14. No serious infections have been documented. Only 1 patient out of 8 has had a hospital admission associated with fever and antibiotic administration during neutropenia. The fever was probably catheter related and resolved with catheter removal. Since all patients have recovered from hematopoietic toxicity within 30 days, stem cell support successfully ameliorated hematopoietic toxicity in all patients treated with high dose 153Sm-EDTMP. Furthermore, since no serious non-hematologic toxicities have been seen, stem cell infusion offers promise of a means to escalate doses of 153Sm-EDTMP to even higher levels. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: A GASTROPARESIS
MULTI-CHANNEL
GASTRIC
PACER
FOR
TREATING
Principal Investigator & Institution: Ross, Robert A.; Virginia Technologies, Inc. 2015 Ivy Rd, Ste 423 Charlottesville, Va 22903 Timing: Fiscal Year 2003; Project Start 15-SEP-2000; Project End 31-JUL-2006 Summary: (provided by applicant): In a new therapeutic approach for delayed gastric emptying and gastroparesis, Virginia Technologies, Inc. (VTI) proposes: (1) to develop a 4-channel implantable gastric pacemaker, using pulse train electrical signals and capacitive coupling for patient safety and energy efficiency; (2) to develop a multi-
6
Nausea
channel pacing lead, optimized for gastric applications; (3) to develop a transcutaneous programmer and wand, enabling healthcare providers to customize and optimize pacing parameters to the needs of each patient; and (4) to test this system in animal models, studying safety and efficacy. The long-term goal of this research is to develop an implantable device for the superior treatment of motility disorders associated with gastroparesis in humans. Electrical stimulation of the gastrointestinal organs represents a promising new treatment for gastric motility disorders. These organs have natural pacemakers that generate myoelectrical activity, regulating contractions and motility. Myoelectrical abnormalities can disturb muscular activity, impairing contraction and leading to delay or failure of gastric emptying. In gastroparesis, impaired gastric emptying can lead to nausea, vomiting, premature satiety, abdominal pain, abdominal bloating, weight loss, bacterial overgrowth, and obstruction, as well as difficulties in managing blood glucose levels in diabetics. Traditional therapies for gastroparesis including, prokinetic medications, tube feeding via jejunostomy and total parenteral nutrition (TPN), have various limitations. A number of patients are refractory to the available medications, which also pose the risk of side effects and medicinal interactions. Jejunostomy and TPN offer nutritional support and address the symptoms of gastroparesis, but pose quality-of-life issues and do not correct the underlying disorder. Single-point, low-energy electrical stimulation, such as that provided by Medtronic's Enterra TM Therapy, also generally treats symptoms of nausea and vomiting, rather than the underlying disorder. In a new treatment option for motility disorders, the multi-channel phased gastric pacemaker uses electrical pacing to mimic the natural propagation of gastric slow waves. It generates peristaltic electrical waves that progress from the proximal to the distal stomach, seeking to entrain gastric slow waves, normalize gastric myoelectrical dysrhythmias, and normalize gastric emptying. Recent studies have shown that multi-channel pacing entrains gastric slow waves more effectively than prior single-channel high-energy approaches, and that a multi-channel design requires less energy, making it more appropriate for a long-term humanimplantable therapeutic device. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: ACUPUNCTURE TO PREVENT POSTOPERATIVE PARALYTIC LLEUS Principal Investigator & Institution: Chiang, Joseph S.; Anesthesiology; University of Texas Md Anderson Can Ctr Cancer Center Houston, Tx 77030 Timing: Fiscal Year 2003; Project Start 15-JUN-2003; Project End 28-FEB-2005 Summary: (provided by applicant): The primary aim of this prospective randomized trial is to determine if acupuncture is effective in preventing postoperative paralytic ileus (PPI) among cancer survivors undergoing colostomy/ileostomy closure. Additional objectives are to: 1) compare post-surgical quality of life status between treatment and control groups in terms of pain, use of opioid analgesics, nausea, vomiting, insomnia, abdominal distention/fullness, activity, and sense of well-being; and 2) compare costs due to extended hospital stay and care related to ileus between patients who develop PPI and those who do not. This study will also provide preliminary data for subsequent large scale projects and serve as a basis for future research in an area where existing evidence is sparse, yet potential benefits to patient care are considerable. The treatment group will receive acupuncture with electrical stimulation twice each day for 20 minutes beginning on postoperative day 1 and ending on postoperative day 4 for a total of 8 treatments. With each treatment session, 10 needles will be placed on points LI-4, Sp-6, St-36, St-25, CV-6, and CV-12, and electro-
Studies
7
acupuncture will be applied at points LI-4 and St-36. A bowel motility index including bowel sounds, passage of flatus, bowel movement, and diet tolerance will be recorded for both groups until 72 hours after acupuncture treatments have been stopped or until hospital discharge. Information regarding pain, use of opioid analgesics, nausea, vomiting, insomnia, abdominal distention/fullness, activity, and general sense of wellbeing will be compared between groups. Time (in hours) for each bowel motility indicator (bowel sounds, passage of flatus, and bowel movement) and time to hospital discharge will be compared between groups using standard survival techniques both as Kaplan-Meier analysis and adjusting for the other measured parameters in the study using proportional hazards analyses. Contingency table methods and logistic regression will be used to determine related parameters. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: AGGREGATIVE E COLI Principal Investigator & Institution: Wanke, Christine A.; Associate Professor; New England Medical Center Hospitals 750 Washington St Boston, Ma 021111533 Timing: Fiscal Year 2002 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: BEHAVIORAL AND NEURAL EFFECTS OF STATIC MAGNETIC FIELDS Principal Investigator & Institution: Houpt, Thomas A.; Assistant Professor; Biological Science; Florida State University 97 South Woodward Avenue Tallahassee, Fl 323064166 Timing: Fiscal Year 2002; Project Start 01-MAY-2001; Project End 30-APR-2004 Summary: Advances in magnetic resonance imaging (MRI) are driving the development of MRI machines beyond conventional static magnetic field strengths to fields of 4-9 tesla (T). Little is known about the sensory or physiological effects of high strength static magnetic fields on mammals and humans. We have recently discovered that 30 min exposure to a 9.4 T field has behavioral and neural effects in rats. At the behavioral level, magnetic field exposure induced a conditioned taste aversion (CTA) after pairing with the taste of saccharin. CTA has proven to be a sensitive index of visceral perturbation or malaise induced by a treatment; therefore the magnetic field may be experienced by the rat as an aversive stimulus. At the neural level, the same exposure induced specific and significant c-Fos immunoreactivity in brainstem visceral relays (e.g. the nucleus of the solitary tract and parabrachial nucleus) and in vestibular nucluei (e.g., medial vestibular nucleus). Both the behavioral response and the pattern of c-Fos activation are similar to the effects of vestibular disturbances, such as rotation. We hypothesize that the magnetic field activates the rats' vestibular apparatus, causing vertigo; this would b consistent with reports of vertigo and nausea in humans exposed to 4 T fields. These findings suggest that CTA and c-Fos expression can be used in an animal model of the effects of high-strength, static magnetic fields. We propose to determine the sensitivity of rats using the large-bore, high-strength NMR magnets available at the National High Magnetic Field Laboratory. We will make lesions of sensory sites and nerves to determine the pathways for detection of the magnetic field. We will probe the underlying pharmacology with anti-emetics and other drugs that may attenuate the effects of the field. The acute behavioral effects will be measured by observational scoring; aversive or delayed effects will be measured by CTA expression; and the neural response will be quantified by c-Fos expression throughout the brain. These experiments
8
Nausea
will help predict the effects of future high-strength MRI on humans, and contribute to understanding the neural pathways underlying the effects. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: CEREBROVASCULAR HYPERTENSION
CHANGES
IN
PREGNANCY
AND
Principal Investigator & Institution: Cipolla, Marilyn J.; Neurology; University of Vermont & St Agric College 340 Waterman Building Burlington, Vt 05405 Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2007 Summary: (provided by applicant): Eclampsia is a serious complication of pregnancy that occurs when hypertension develops with neurologic symptoms, including headaches, nausea, visual disturbances and convulsions. While numerous organs are affected by hypertension in pregnancy, cerebrovascular involvement is the direct cause of death in approximately 40 percent of patients. The major cerebrovascular changes that occur have been shown to be similar to hypertensive encephalopathy in which acute elevations in blood pressure (i.e., acute hypertension) overcome the myogenic vasoconstriction of the cerebral arteries and arterioles causing autoregulatory failure, hyperperfusion and edema. Because women who develop eclampsia in general are normotensive prior to pregnancy, there is evidence that pregnancy affects the cerebral circulation in a way that makes the vessels susceptible to autoregulatory failure and hyperperfusion during acute hypertension. The long-term objective of this proposal is to investigate how pregnancy affects the structure and function of the cerebral circulation focusing on diameter regulation in response to changes in pressure (myogenic reactivity) and how those changes affect vascular permeability that promotes edema. Aim 1 will use isolated and pressurized posterior cerebral arteries from pregnant and nonpregnant rats to determine the pressure at which forced dilatation occurs and investigate underlying mechanisms of pregnancy-induced alterations in diameter regulation, including vascular smooth muscle actin and endothelial cell influences (e.g., nitric oxide and prostaglandins). In addition, since hypertension alone has been shown to cause significant remodeling and reactivity changes in the cerebral circulation, Aim 1 will also investigate how elevated mean arterial pressure during pregnancy affects myogenic activity and diameter regulation in a rat model of hypertension in pregnancy (nitric oxide inhibition). Acute hypertension and eclampsia are associated with significant edema formation due to disruption of the normally impermeable cerebral endothelium. Therefore, Aim 2 will investigate pregnancy-induced changes in endothelial cell permeability during acute hypertension, including enhanced fluid phase endocytosis (transcellular flux) and tight junction disruption (paracellular flux). The influence of pregnancy on permeability during forced dilatation will be determined using a combination of techniques, including clearance of fluorescent tracers and transmission electron microscopy. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: COMBINATION THERAPY RITONAVIR (ABT 538), LAMIVUDINE AND ZIDOVUDINE IN HIV Principal Investigator & Institution: Markowitz, Martin H.; Clincal Director; Rockefeller University New York, Ny 100216399 Timing: Fiscal Year 2002 Summary: Our group has recently reported a mean reduction in viral load of 2.1 logs in our series of 20 patients treated with the protease inhibitor ritonavir (ABT-538) in a dose
Studies
9
range of 600 mg to 1200 mg daily. Durability of response appears to be dose related. Data recently presented by others were equally encouraging, with the most durable responses seen in the patients treated with 600 mg BID. Therefore, we have chosen the most active drugs available -- zidovudine (AZT) and lamivudine (3TC) and ritonavir -to treat the acutely infected person, the host with the least genetic diversity, and therefore the one least likely to harbor multiply resistant viruses. We propose that achieving a four-to-five-log reduction in viral load, which would then be followed by the appearance of the immune response, should dramatically alter the natural history of HIV-1 infection. Ritonavir (ABT-538) will be administered at 300 mg orally BID on Day 1, 400 mg orally BID on days 2 and 3, 500 mg orally BID on day 4, and 600 mg orally BID on Day 5 and subsequently, provided the patient can tolerate the dose escalation without severe nausea and/or vomiting. If needed, the dose escalations may be delayed. AZT will be administered at 200 mg orally TID, and 3TC at 150 mg orally BID. Virologic studies will include plasma RNA determinations, quantitative plasma and cell culture for HIV-1, and quantitative DNA PCR on patient PBMC. In addition, frequent monitoring of T-cell subsets will be performed to assess the viral load in the cellular compartment using flow cytometric techniques. Pharmacokinetic studies will also be performed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: COMBINED PHARMACOTHERAPIES FOR ALCOHOLISM Principal Investigator & Institution: Johnson, Bankole A.; Wurzbach Distinguished Professor and Dep; Psychiatry; University of Texas Hlth Sci Ctr San Ant 7703 Floyd Curl Dr San Antonio, Tx 78229 Timing: Fiscal Year 2002; Project Start 10-SEP-2001; Project End 31-JUL-2006 Summary: Recent scientific and clinical interest in combining therapeutic agents for the treatment of alcoholism are based on the fact that derangement of multipleneurotransmitter systems are likely to underlie biological predisposition to the disease. Thus, combining effective medications working at different neurotransmitters should produce a synergistic or at least an added clinical response. In animals, the combination of the 5-HT3 antagonist, ondansetron, and the mu receptor antagonist, naltrexone show synergism of action at reducing ethanol consumption. Alcoholics with an early onset of disease are effectively treated by ondansetron, and those with a family history of alcoholism in first degree relatives may have the best clinical outcome to treatment with naltrexone. Given that family history of alcoholism is associated with an early onset of disease, it reasonable for us to predict that the combination of ondansetron and naltrexone should be more optimal than either alone for the treatment of Early Onset Alcoholics (EOA). Indeed, preliminary clinical data from our group provide strong support that the medication combination is an effective treatment for EOA. We will test this hypothesis by comparing the effectiveness of ondansetron (4 mg/kg) and naltrexone(50 mg/day), both alone and in combination, in treating EOA vs. Late Onset Alcoholics (LOA) (total N of 45 subjects/cell x 8 cells = 360) in a randomized, doubleblind, placebo-controlled, 12-week (1 week of single-blind placebo followed by 11 weeks of the double-blind condition) outpatient clinical trial. All subjects will receive standardized Cognitive Behavioral Therapy, and follow-up at 1, 3, 6, and 9 months posttreatment. Specifically, we predict that: 1) EOA, compared with LOA, will be more responsive to treatment with either ondansetron or naltrexone alone, and 2) that the combination of ondansetron and naltrexone will be superior to either medication alone in the treatment of EOA. We will have the unique opportunity to test with adequate power the secondary hypothesis that the combination of ondansetron and naltrexone
10
Nausea
will be better tolerated than naltrexone alone, thereby improving compliance. This is because nausea is an important side-effect of naltrexone which can limit compliance, and as shown in our preliminary study, ondansetron by having anti-nausea and antiemetic properties counteracts this naltrexone side-effect. We support NIAAA's mission to develop effective pharmacotherapies as adjuncts to psychotherapy for the treatment of alcoholism. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: VOMITING
CORTICOTROPIN-RELEASING
FACTOR
ROLE
IN
CYCLIC
Principal Investigator & Institution: Li, B U.; Children's Memorial Hospital (Chicago) Chicago, Il 606143394 Timing: Fiscal Year 2002; Project Start 15-AUG-2002; Project End 31-JUL-2005 Summary: (provided by applicant): Cyclic vomiting syndrome (CVS) is the most severe recurrent vomiting disorder in humans and is more prevalent than previously appreciated (1 in 50 school-aged children). Although the pathogenesis remains unknown, corticotropin-releasing factor (CRF) is a tenable candidate brain-gut neuroendocrine mediator of vomiting in CVS. CRF has a well-established role in inducing gastric stasis and vomiting in animals and its resulting behavioral, autonomic, endocrine effects resemble those clinical features seen in CVS. The model of CRFinduced emeses may explain the antiemetic utility of dexamethasone during chemotherapy-induced vomiting and migraine headaches. We hypothesize that systemic CRF levels and hypothalamic-pituitary-ad renal (HPA) axis activity are heightened during episodes of CVS and migraine headache especially in those who experience concomitant nausea and vomiting. To provide direct clinical evidence of involvement of CRF pathways in CVS and migraine, we will examine CRF and HPA axis activation (ACTH, cortisol, catecholamines) in subjects with CVS, migraine headaches and controls under three conditions including: 1) when well (i.e. in between episodes), 2) during acute episodes of cyclic vomiting or migraine headaches treated with a saline placebo, and, 3) during acute episodes of cyclic vomiting or migraine headaches in which CRF is treated by dexamethasone. Under each condition, we will establish the diurnal variation of CRF and HPA axis activity and compare them to pediatric controls, both healthy and with non-CVS vomiting (gastroenteritis). In a randomized, double blind, cross-over design, we will examine the effect of dexamethasone on CRF and HPA axis activity, objective signs and subjective GI and migraine headache symptoms. CVS and migraine headaches may ultimately both be disorders involving dysregulation of CRF pathways. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DETERMINING THERAPEUTIC EFFICACY OF AGE IN AD Principal Investigator & Institution: Chauhan, Neelima B.; Assistant Professor; Anesthesiology; University of Illinois at Chicago 1737 West Polk Street Chicago, Il 60612 Timing: Fiscal Year 2004; Project Start 01-FEB-2004; Project End 31-JAN-2006 Summary: (provided by applicant): Based on the fact that genesis of A-beta derived from amyloidogenic processing of APP is a key event in Alzheimer's pathogenesis including inflammation, and that cholesterol homeostasis and cholinergic system regulate APP processing, current Alzheimer's therapy targets cholinergic enhancement [Tacrine, Aricept/Donezepil, Rivastigmine, Galantamine]; and regulation of inflammation by NSAIDs [Aspirin, Ibuprofen, Indomethacin]; COX-2 inhibitors
Studies
11
[Celebrex, Vioxx]. These drugs exert serious side effects including gastrointestinal bleeding, liver and renal toxicity, nausea, and are not effective with patients carrying ApoE gene 1. Current investigational drugs include Xanthine derivativesPropentofylline and cholesterol-lowering agents [HMG-CoA reductase inhibitorsStatins]. Although some statins are shown to be anti-amyloidogenic, few clinical trials with statins are non-conclusive due to their proinflammatory nature/39. In this respect, natural alternative(s) with pleiotropic useful properties and with least adverse effects may provide greater therapeutic benefit over single-ingredient synthetic pharmaceutical drugs having serious side effects. One such alternative is garlic. Aged garlic extract (AGE) contains multipotent phytochemicals. S-Allyl-Cystein (SAC) component of AGE inhibits NFkAPPAB, TNFalpha, IL-1Beta 3, 20, and iNOS/24. Our preliminary data show that AGE reduced TNFalpha and IL-1Beta in Tg2576 in a dose-dependent manner. SAC and Diallyl disulfide (DADS) components of AGE are natural HMG-CoA reductase inhibitors 34/46. Our preliminary data show that AGE reduced cerebral amyloid in AIzheimer's transqenic model (Tg2576). In addition, AGE is known to be free-radical scavenger that enhances anti-oxidant enzymes (SOD, catalase and glutathione reductase) 3, inhibits lipid peroxidation 20, inhibits A-beta-induced apoptosis and improves memory deficits in senescence-accelerated mice. Thus, AGE is a natural "NSAID, Statin, anti-oxidant and anti-apoptotic agent"-a combination of many singleingredient synthetic pharmaceutical drugs currently used for Alzheimer's therapy. However, the validity of AGE as Alzheimer's therapy has not been explored. This project is to determine pleiotropic effects of AGE in Alzheimer's Swedish double mutant (K670M/N671L) model (Tg2576). Hypothesis: Multi-potent natural alternative AGE will prevent or reverse AD-like pathology and ameliorate behavioral deficits in Tg2576. Specific Aims: [1] Determine if dietary AGE will promote non-amyloidogenic processing and reduce pre-existing amyloid burden in Tg2576; [2] Determine if dietary AGE will attenuate A-beta-induced inflammatory cascade in Tg2576; [3] Determine if dietary AGE will inhibit apoptosis in Tg2576; [4] Determine if dietary AGE will improve hippocampal-based Morris Water Maze performance in Tg2576. Significance: Current AD-treatment utilizing cholinergic enhancers and NSAIDs is limited due to their adverse side effects and do not modify the disease process. If successful, this project will validate the use of safe, naturally well-tolerated, cost-effective and alternative herbal pharmacotherapy for treating AD. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DEVELOPMENT OF POLY-L-GLUTAMIC ACID PACLITAXEL CONJUGATE Principal Investigator & Institution: Wallace, Sidney; Fem Cadet 3324 Pittsburgh St Houston, Tx 77005 Timing: Fiscal Year 2002; Project Start 15-APR-1999; Project End 31-MAY-2006 Summary: Chemoradiation improves survival for patients with locally advanced nonsmall cell lung cancer (NSCLC) over radiotherapy (R) alone. Les than 20% of patients have complete pathologic response to combination therapy. Paclitaxel (TXL) is effective as an anti-tumor agent and a radiosensitizer. Peripheral neurotoxicity and granulocytopenia limit its dosage; acute effects from TXL's infusion include nausea, hypotension, and cardiac arrhythmias related to Cremophor and ethanol. Conjugating TXL with poly-L-glutamate (PG-TXL/CT-2103) makes it water-soluble, allowing infusion of twice the amount of free TXL and higher intratumoral drug concentrations, which was confirmed by preclinical testing. Combining PG-TXL with radiation demonstrated synergistic radiation enhancement higher than that seen with other
12
Nausea
taxane or nucleoside analog. A phase I clinical trial of CT-2103 as single agent salvage therapy for patients with advanced solid tumors demonstrated safety and tolerability in dose up to 266 mg equivalent paclitaxel/m2 without significant alopecia. This Phase II STTR proposes a Phase I/II clinical trial of CT-213 given concurrently with chest RT in patients with unresectable Stage III or medically inoperable Stage II NSCLC. This study will determine MTD, DLT, pharmacokinetics, assess toxicity, and document patient costs. We expect this combination RT and CT-2103 to improve patient survival and response to treatment. PROPOSED COMMERCIAL APPLICATIONS: At M.D. Anderson Cancer Center, the combination of Taxol and cisplatin given concurrently with radiation therapy is the treatment of choice for lung cancer patients. In animal studies, CT-2103 is water soluble, infectable intravenously in 10 minutes without premedication, more effective (2-3X) and less toxic than Taxol. CT-2103 could possibly replace Taxol. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: DEVELOPMENT STUDIES OF THE INNER EAR Principal Investigator & Institution: Fekete, Donna M.; Associate Professor; Biological Sciences; Purdue University West Lafayette West Lafayette, in 479072040 Timing: Fiscal Year 2002; Project Start 01-AUG-1995; Project End 31-AUG-2004 Summary: (Adapted from the Investigator's Abstract) The goal of this research is to understand the molecular mechanisms that control patterning and cell fate determination in the developing inner ear. The inner ear, unique to vertebrates, is remarkable for the complex three-dimensional arrangement of its constituent cells, which include neurons, sensory receptors and non-sensory cells organized into tubules, ducts and other specialized tissues. It is likely that the morphogenetic mechanisms required to form such structures will be shared by vertebrates. In humans and animal models, disruption of the precise morphology of the inner ear due to congenital anomalities or disease can result in deafness, and/or difficulties with balance and equilibrium, often accompanied by profound vertigo and nausea. The PI's efforts to understand the fundamental defects that result in inner ear abnormalities are focused on both the normal processes of development and on the cascade of events that can arise as a result of a specific gene defect. The aims are to: (1) undertake a lineage analysis of the progenitor cells in the early chick otocyst to reveal when distinct cell lineages diverge, such as neurogenic vs. non-neurogenic or sensory vs. non-sensory; (2) undertake a lineage analysis of the mouse organ of Corti to determine whether hair cells and supporting cells share a common progenitor; (3) generate a fate map the chick otic cup to understand the relationships between gene expression and morphogenetic movements; and (4) force both focal and global perturbations of gene expression domains to help define the rules governing pattern formation in the eveloping inner ear. The studies will employ focal dye injections as well as infection with pseudotyped replication-defective retroviral vectors to limit gene transfer to a small number of otic cells and their progeny. The fourth aim will use replication-competent viruses to generate widespread misexpression of patterning genes. Together, the proposed studies should provide insight on the divergence of inner ear lineages and what role, if any, morphogenic movements and patterning genes play in the process. Their studies are designed to test a model of inner ear patterning that is based on the establishment of compartments and boundaries. The information provided by these animal studies may aid in understanding the molecular-genetic basis of human birth defects that cause deafness and vestibular dysfunction in humans. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
Studies
•
13
Project Title: DIFFERENCES BETWEEN MEN & WOMEN IN ACUTE PAIN FROM INTRATHECAL NEOSTI Principal Investigator & Institution: Eisenach, James C.; Professor; Wake Forest University 2240 Reynolda Rd Winston-Salem, Nc 27106 Timing: Fiscal Year 2002 Summary: This abstract is not available. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EFFECTS OF ACUPUNCTURE ON PAIN,NAUSEA,QUALITY OF LIFE Principal Investigator & Institution: Rosenthal, David S.; Dana-Farber Cancer Institute 44 Binney St Boston, Ma 02115 Timing: Fiscal Year 2003; Project Start 28-SEP-2001; Project End 29-FEB-2004 Summary: (provided by applicant): Over the past several decades, an increasing number of the US public are using complementary and alternative medicine (CAM) to maintain or improve health and well being. It is estimated that within the US alone, the use of CAM has grown 380 percent since 1990 and that the public is now spending billions of dollars per year for these therapies. A large percentage of the practice and use of these methods is focused on cancer. Whether the CAM use is aimed at reducing one's risk of developing cancer or improving the quality of life of a cancer patient during treatment or at the end of life, the public focus on CAM and cancer has created a driving force for cancer centers to address the efficacy and science of these methods. At the Dana Farber Cancer Institute, CAM clinical services have been established and integrated within the oncology practice. Acupuncture, massage therapy, Reiki, spirituality programs, mind body techniques, herbal consults and a number of other clinical programs are offered through the newly established Zakim Center for Integrated Therapies. The issues of palliative care in the end of life of a cancer patient are extremely important as currently, the majority of cancer patients do not receive adequate palliative care. In this proposal, we are addressing the use of' acupuncture by traditional Chinese clinicians to address the quality of life and symptoms of patients with incurable cancer. Acupuncture has been shown to be effective in the treatment of pain and nausea and has also been shown to improve one's general well being. Acupuncture has some effectiveness in anxiety and depression as well. We seek to determine if studying such an intervention be feasible in ambulatory patients at the end of life? The study population will be women with recurrent metastatic ovarian cancer and similar patients with advanced cancer who are ambulatory and receiving conventional palliative care. These patients will continue to receive high quality conventional clinical interventions, including chemotherapy and pain and symptom reduction programs, but in addition receive acupuncture. Evaluation tools such as Satisfaction with Life Domains Scale for Cancer (SLDS-C), Brief Pain Inventory and Rotterdam Symptom Check List will be piloted to determine appropriate end points of the study as well as the feasibility of end of life patients completing the surveys. The Behavioral Research Center of the American Cancer Society will provide additional in-kind support for data analysis and evidence of effectiveness of Quality of Life measures for end of life evaluation. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: EFFECTS OF ORAL MARINOL ON TIME ESTIMATION AND REGIONAL CEREBRAL BLOOD FLOW Principal Investigator & Institution: Pearlson, Godfrey D.; Professor; Johns Hopkins University 3400 N Charles St Baltimore, Md 21218
14
Nausea
Timing: Fiscal Year 2002; Project Start 01-DEC-2001; Project End 30-NOV-2002 Summary: Very little research has been conducted on marijuana in the past 25 years. The AMA is urging federal funding of research to determine the validity of marijuana as an effective medical treatment and to further evaluate the abuse potential of this drug. Marinol (dronabinol) is a synthetic orally active cannabinoid with few/no mind-altering properties and limited abuse potential, prescribed for clinicaL use in AIDS and chemotherapy patients in order to reduce nausea and/or stimulate appetite. This project is based on the hypothesis that Marinol will provoke similar cerebral blood flow changes, assessed via Oxygen (015) Water PET, to those observed by other researchers after their subjects were administered THC via injection or by smoking marijuana, although Marinol will not cause intoxication ('high'). Subjects are assessed blind to dose, on 2 doses of Marinol and placebo. Data will be analyzed when the subject N is sufficiently large. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EFFICACY OF ACUPUNCTURE WITH PT FOR KNEE OSTEOARTHRITIS Principal Investigator & Institution: Farrar, John T.; Senior Scholar; Biostatistics and Epidemiology; University of Pennsylvania 3451 Walnut Street Philadelphia, Pa 19104 Timing: Fiscal Year 2002; Project Start 15-JUL-2001; Project End 31-MAR-2006 Summary: Acupuncture is an ancient Chinese technique of using a fine needle to stimulate points along theoretical meridians of energy to correct imbalances thought to be responsible for specific disease states. In the United States, acupuncture is often used for the treatment of painful conditions. The 1997 NIH Consensus Conference concluded that there was adequate evidence of efficacy in an acute dental pain model and in nausea. In chronic pain, most studies were too small, poorly designed, poorly executed, or improperly controlled to adequately demonstrate that needle acupuncture worked better than sham acupuncture, placebo, standard medical therapy, or even no treatment. Osteoarthritis (OA) of the knee has been proposed as a good model to test the efficacy of acupuncture in a chronic pain condition because it is an extremely common, well defined, and disabling condition with well established outcome measures for symptoms and functional status. There is clinical trial evidence of efficacy for the standard treatments of acetaminophen and NSAIDs, and exercise physical therapy (EPT), which is usually added when the patient develops functional limitations. One high quality study of acupuncture for knee OA, demonstrated moderate benefit in an unblinded comparison to a usual care control group. As such, a major question remains about whether acupuncture, used in addition to exercise therapy, will provide a clinically meaningful improvement in pain and function. Since pain can be the primary limiting factor in improved exercise capacity, if acupuncture has any efficacy in reducing the pain of knee OA, then the combination with an EPT program should be substantially more effective than EPT alone. Another major concern is that the effect of the acupuncture may be predominantly mediated by non- specific placebo effects rather than the specific effects of the placement of a needle. Another important component of this proposal is our use of a validated blinded placebo needle instead of sham acupuncture points. Therefore, the primary goal of this proposal is to use a properly designed randomized blinded clinical trial, using American College of Rheumatology (ACR) criteria and Food and Drug Administration (FDA) recommended outcome measures, to determine whether the addition of acupuncture to standard EPT provides an overall clinically important benefit to patients with symptomatic knee OA compared to placebo acupuncture. As a secondary goal, we will use the clinical trial data to
Studies
15
develop prognostic and etiologic models for the patients that are most likely to respond to acupuncture. If a clinically important benefit for acupuncture is found, a broader application of this technique would be justified. However, if the results are negative, then the addition of acupuncture to EPT should be generally curtailed. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: EVALUATION OF CHEMOTHERAPY CLAIMS FOR BREAST CANCER Principal Investigator & Institution: Du, Xianglin; Internal Medicine; University of Texas Medical Br Galveston 301 University Blvd Galveston, Tx 77555 Timing: Fiscal Year 2002; Project Start 01-MAR-2001; Project End 28-FEB-2004 Summary: (provided by applicant): Over the past several decades, numerous clinical trials have consistently demonstrated that chemotherapy is efficacious in both premenopausal and postmenopausal women with breast cancer. However, little is known about the use of chemotherapy and its effectiveness in the community because of a lack of large population-based data. While the Surveillance, Epidemiology and End Results (SEER) tumor registries provide data on radiation therapy and surgical treatment for breast cancer, they do not provide information on chemotherapy. They are not required to collect this information, and the medical records in oncologists' offices, where chemotherapy is likely to be administered, may not be routinely reviewed for data on the primary course of cancer-directed therapy. Medicare claims are a potential source of national data on chemotherapy use for breast cancer cases aged 65 and older. However, no study has examined the validity of this information. If Medicare claims provide accurate and complete data on chemotherapy, their utility for breast cancer research would be considerably enhanced, allowing for population-based analyses of the current uses of chemotherapy as well as effectiveness studies in the community. Therefore, we propose to examine the utility of information on chemotherapy from Medicare claims data for women aged 65 and older who have been diagnosed with breast cancer. Our approach is to identify women aged 65 years or older who have been diagnosed with breast cancer in the New Mexico Tumor Registry (a SEER registry), that can be linked with Medicare claims data by unique identifiers. We will contract with the registry to abstract the medical records on chemotherapy administration for eligible patients in all facilities including medical oncologists' offices where patients may have received chemotherapy. We will then compare information on the use of chemotherapy from medical chart review with information obtained from Medicare claims data. Our aims are 1) to determine whether Medicare data can identify women who received chemotherapy for breast cancer; 2) to determine whether Medicare data can differentiate among the specific regimens of chemotherapy; and 3) to determine whether the number of claims can be used to estimate the number of cycles of chemotherapy. Based on this information, we will characterize the nature and extent of error in using Medicare claims for chemotherapy effectiveness research among older women diagnosed with breast cancer. We will then use the Medicare-SEER linked data for all SEER areas to examine patterns and outcomes of chemotherapy among older women with breast cancer. Information generated from the medical chart reviews will also allow us to examine patterns of chemotherapy care independent of the Medicare claims data or independent of those parts of the claims that we find generate invalid estimates. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
16
•
Nausea
Project Title: GINGER CONTROL OF CHEMOTHERAPY INDUCED NAUSEA AND EMESIS Principal Investigator & Institution: Zick, Suzanna M.; Family Medicine; University of Michigan at Ann Arbor 3003 South State, Room 1040 Ann Arbor, Mi 481091274 Timing: Fiscal Year 2003; Project Start 15-MAY-2003; Project End 28-FEB-2005 Summary: (provided by applicant): Chemotherapy induced nausea and vomiting significantly reduces patients' quality of life, increases fatigue, anxiety, and increases costs of health care delivery. Ginger (Zingiber officinalis) is already used in traditional folk medicine to treat nausea and vomiting in various populations. Ginger's ability to block 5-HT3 receptors and its free-radical scavenging in the intestines suggest that it may be beneficial for reducing both the prevalence and severity of chemotherapy induced nausea and vomiting. Despite ginger's possible benefits in reducing the prevalence and severity of chemotherapy induced nausea and vomiting, no dosing and/or safety studies have been performed. Therefore we propose a double-blind, placebo-controlled, five-armed, randomized clinical trial to assess the efficacy and safety of four dose levels (100 mg, 500 mg, 1000 mg, or 1500 mg, orally/day) of Zingiber officinalis extract (standardized for 5% gingerols) in patients undergoing chemotherapy (cisplastin or adriamycin) who have experienced at least one episode of chemotherapy induced nausea and vomiting despite optimal conventional medical therapy. The primary aim of the study is to determine the most efficacious dose of powdered gingerroot for reducing the prevalence and severity of acute nausea and vomiting. Secondary aims of the study include (1) determination of the most efficacious dose of powdered ginger-root for reducing the prevalence and severity of delayed nausea and vomiting; (2) assessment of the safety of different doses of oral powdered ginger root in patients receiving chemotherapy; and (3) determination if study participants can discern if they are receiving placebo or ginger. Participants receiving either adriamycin or cisplatin for cancer related treatment will be randomized to receive one of four doses of powdered ginger or placebo immediately prior to chemotherapy infusion. Participants will be followed for 48 hours after infusion in order to assess frequency and severity of nausea and vomiting. Baseline and 48 hour post chemotherapy labs will be used to assess safety profile of ginger. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: SENSITIVITY
INTERSTITIAL
CELL
OF
CAJAL
IN
VAGAL
AFFERENT
Principal Investigator & Institution: Ward, Sean M.; Associate Professor; Physiology and Cell Biology; University of Nevada Reno 204 Ross Hall Mailstop 325 Reno, Nv 89557 Timing: Fiscal Year 2002; Project Start 01-SEP-2000; Project End 30-JUN-2005 Summary: The smooth muscle layers of the gastric fundus generate tonic contraction or relaxation and are critical in the regulation of gastric volume. Upon food ingestion the proximal stomach relaxes to accommodate the increases in gastric volume without concurrent changes in gastric pressure. This accommodation, known as adaptive relaxation, is under both intrinsic and extrinsic neural control. Vagal afferent stretch sensitive fibers located in the muscle layers are stimulated by gastric distension and trigger vagovagal efferent and local enteric pathways that increase gastric motility and gastric emptying. Millions of patients with functional dyspepsia and gastroparesis, both idiopathic and that associated with diabetes mellitus, have low vagal tone and impaired postprandial gastric meal accommodation which is often accompanied with symptoms of abdominal pain, bloating and nausea. Using a combined morphological and
Studies
17
physiological approach, the broad long term objective of the present study is to determine the changes which occur in vagal and enteric afferent sensitive mechanisms that are associated with dramatic changes in gastric accommodation in animals lacking interstitial cells of Cajal (ICC). To address this main objective, the specific aims of this project will examine the importance of interstitial cells of Cajal (ICC), which are found as intramuscular arrays in the muscle layers of the stomach in: I) The development, guidance and maintenance of vagal afferent fibers in the stomach. ii) Whether ICC possess in-series stretch sensitive channels that could trigger afferent pathways and stomach accommodation. iii) To determine the role of ICC in gastric accommodation and whether loss of ICC affects vagal afferent discharge and gastric accommodation in mutant mice lacking ICC. These studies work will be combined with structural studies to determine the morphological relationships between vagal afferent arrays and intramuscular ICC in adult and developing animals. Experiments outlined in this proposal will provide important novel information on the role of ICC in afferent stretch sensitivity in the stomach. This information could also be extended to other organs of the gastrointestinal tract. In doing so we will aid future studies toward understanding how these cells may be critical in pathophysiological disease states. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MASSAGE FOR HOSPITALIZED PATIENTS WITH METASTATIC CANCER Principal Investigator & Institution: Phillips, Russell S.; Chief, Division of General Medicine And; Beth Israel Deaconess Medical Center St 1005 Boston, Ma 02215 Timing: Fiscal Year 2004; Project Start 01-APR-2004; Project End 31-MAR-2006 Summary: (provided by applicant): Symptoms such as pain and nausea are common among patients with metastatic cancer, and symptom control is often inadequate. Massage therapy has been advocated as adjunctive therapy in the management of cancer related pain, but has received little careful study. We propose to examine the safety, acceptability, and tolerated duration of massage therapy among hospitalized patients with metastatic solid malignancies associated with poor prognoses. We will determine the feasibility of a randomized controlled trial of massage among hospitalized patients with cancer, and gather preliminary data on the efficacy of massage. Hospitalized patients will be screened at the time of admission for enrollment into the proposed study. Patients with a planned length of stay of 3 days or less will be excluded, as will patients who do not report pain related to their cancer. After obtaining informed consent, we will randomize patients to receive either daily massage, to a simple presence non-touch control group, or usual care. To optimize our ability to study safety and tolerated duration of massage, 50 patients will be randomized to massage while 25 patients will be randomized to usual care, and 25 patients will be randomized to a simple presence control group. The massage intervention will be provided daily by therapists using a standard scope of practice. Detailed data will be obtained by chart review and patient, physician, nurse, and caregiver interviews. Primary outcomes evaluated will be the safety and tolerated duration of massage. We will gather preliminary data on massage efficacy by collecting data on pain, anxiety, nausea, depression, shortness of breath, and satisfaction with symptom management during the hospitalization, and gain experience with a novel control group. Following completion of the first phase of data collection, we will provide instruction to caregivers enabling them to provide massage for patients at home, and we will gather data on the use of caregiver massage. We will also explore the potential for the intervention to improve the caregivers' experience caring for a loved one with metastatic cancer. The results of the
18
Nausea
proposed study will provide information on safety and dosage and provide the basis for more extensive study of the effects of massage among patients with cancer. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MATERNAL HYPOTENSION & EPIDURAL ANESTHESIA FOR CSECTION Principal Investigator & Institution: Fiedler, Michael A.; None; University of Tennessee Health Sci Ctr Memphis, Tn 38163 Timing: Fiscal Year 2002; Project Start 01-APR-2002 Summary: Data on central hemodynamics of pregnant women during regional anesthesia is lacking. The purpose of this study is to determine the 1) influence of heart rate (HR), stroke volume (SV), systemic vascular resistance (SVR) and IV fluid administration on maternal hypotension after epidural anesthesia and 2) the pattern of these variables throughout C-section. Despite preventative measures, hypotension during regional anesthesia for cesarean section is common. Maternal hypotension poses a risk to fetal oxygenation, causes maternal nausea and vomiting, and poses maternal danger when extreme. Intravenous fluid is most often used to prevent hypotension, but an optimal volume of fluid has not been found and the incidence of hypotension varies widely. Fluid alone at best reduces the incidence of hypotension at 38%. An underlying practice assumption is that regional anesthesia, which results in a chemical sympathectomy, causes hypotension by reducing venous return and does not significantly reduce widely. Fluid alone at best reduces the incidence of hypotension at 38%. An underlying practice assumption is that regional anesthesia, which results in a chemical sympathectomy, causes hypotension by reducing venous return and does not significantly reduce SVR. This view is based on an average 15% (range up to 40%) reduction in SVR in non-pregnant persons. But there is evidence that SVR is reduced more in pregnant than non-pregnant women during regional anesthesia. If SVR is reduced sufficiently, fluid alone will not increase cardiac output enough to prevent hypotension. In this case, addressing SVR should result in superior prevention of hypotension. Determining which variables have a significant influence on the pattern of hypotension over time is necessary to direct future interventional studies. Elimination of maternal hypotension will reduce the risk of fetal hypoxemia, maternal discomfort, and maternal morbidity while improving maternal enjoyment of the birth experience. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: MECHANISMS OF REGULATION OF CARDIAC AFFERENTS Principal Investigator & Institution: Longhurst, John C.; Professor; Medicine; University of California Irvine Irvine, Ca 926977600 Timing: Fiscal Year 2002; Project Start 01-JUL-2002; Project End 30-JUN-2006 Summary: (provided by the applicant): Reflexes from the heart play an important role in regulation of the cardiovascular system during myocardial ischemia and reperfusion. Responses can include profound alterations in hemodynamic function manifested as either reflex cardiovascular depression during stimulation of vagal afferent endings or excitation with activation of sympathetic (spinal) afferents. Stimulation of sensory nerves in the heart thus can cause hypotension, bradyarrhythmias, nausea and vomiting (vagal afferents) or angina, hypertension and tachyarrhythmias (sympathetic afferents). Limited information is available on mechanisms of activation of sympathetic cardiac afferents that also function as cardiac nociceptors, although our recent data in cats indicate that, in contrast to adenosine, reactive oxygen species (ROS), especially
Studies
19
hydroxyl radicals ('OH), kinins, protons (H+) and prostaglandins are important stimuli. Because inhibition of these stimuli and their receptor interactions does not fully eliminate the response of these sensory afferent endings to ischemia, we suspect that other metabolic or mechanical stimuli play a role in their activation and that interactions between stimuli are present. We propose a series of studies to test the hypotheses that platelets are a source of serotonin (5HT) and histamine. Activated platelets release serotonin and histamine that, through 5HT3 and H1 and possibly H2 receptors, respectively, stimulate cardiac sympathetic afferents during ischemia and reperfusion. Interactions between these two putative and other known chemical mediators will be explored. In addition, the role of diacylglycerol/protein kinase C (PKC) and cyclic adenosine monophosphate (cAMP)/protein kinaseA (PKA) signaling systems in histamine's action on ischemically sensitive cardiac sympathetic afferents will be defined. We will employ liquid chromatography to measure the production of mediators in blood and tissue. Single unit afferent electrical activity will be recorded and selective pharmacological receptor blockade or enzymatic pathway inhibition will be used to evaluate the role of each potential chemical mediator. Chemosensitive, mechanosensitive and bimodal endings of unmyelinated and myelinated fibers will be identified through a series of chemical and mechanical challenges, the latter assessed by hemodynamic measurement and regional myocardial deformation. The proposed studies therefore will define mechanisms by which cardiac sympathetic endings are activated during ischemia and reperfusion. Such information will provide physicians with a better understanding of angina and potentially dangerous sympathoexcitatory cardiac reflexes and may suggest therapeutic approaches designed to limit these events that impact patient morbidity and mortality during myocardial ischemia. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: MITOCHONDRIAL DNA ANALYSIS IN CYCLIC VOMITING SYNDROME Principal Investigator & Institution: Boles, Richard G.; Children's Hospital Los Angeles 4650 Sunset Blvd Los Angeles, Ca 90027 Timing: Fiscal Year 2002; Project Start 01-SEP-2000; Project End 31-AUG-2004 Summary: (from applicants abstract): Cyclic vomiting syndrome (CVS) is a disabling condition characterized by multiple severe and distinct episodes of nausea, vomiting, lethargy and variable other symptoms separated by asymptomatic intervals. Although CVS is generally believed to be a (predominantly) childhood variant of migraine, its etiology and pathogenesis are poorly understood. Several features of CVS, including a maternal bias in inheritance, suggest that mitochondrial DNA (mtDNA) sequence variations/mutations may be involved in its etiology. A significant subset of children with CVS have additional neuromuscular disease manifestations including cognitive dysfunction and epilepsy. Maternal inheritance of migraine and/or various neuromuscular disorders and lactic acidosis are present in ten children with CVS followed by the investigators, strongly suggesting that mtDNA mutations are involved in at least some cases. An inherited complex mtDNA rearrangement was found in one. Preliminary results using temporal temperature gradient gel electrophoresis (TTGE) found heteroplasmic sequence variations in the mtDNA D-loop in 2 additional CVS cases. TTGE is a novel mutation detection assay which was developed for use with mtDNA by the PI and collaborators. TTGE is sensitive and cost effective relative to other methods and for the first time permits the screening of large groups of patients for mutations throughout the entire mtDNA. Since mtDNA sequence variations are postulated to be more likely involved among CVS sufferers with additional
20
Nausea
neuromuscular disease manifestations, in the first sub-study 50 of these individuals will be screened by TTGE for all sequence variations throughout the mtDNA. The incidence of CVS cases caused by mtDNA sequence variations will be determined in a second substudy in which the mtDNA in an unbiased group of 100 CVS sufferers will be screened. All sequence variations found in CVS sufferers will be compared against those found upon an identical screening of 100 control individuals, and any of interest will be sequenced. Pathogenicity of suspected mutations will be determined in rho negative cybrids. An extensive amount of clinical and laboratory data will be collected in all patients, allowing for the comparison of CVS sufferers with and without mtDNA mutations. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NK1 ONDANSETRON
ANTAGONIST
GR205171
&
IN
COMBINATION
W
Principal Investigator & Institution: Koch, Kenneth L.; Pennsylvania State Univ Hershey Med Ctr 500 University Drive Hershey, Pa 170332390 Timing: Fiscal Year 2002 Summary: There is no text on file for this abstract. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NOVEL DYSMOTILITY
EVALUATION
AND
TREATMENT
OF
GASTRIC
Principal Investigator & Institution: Parkman, Henry P.; Associate Professor; Medicine; Temple University 406 Usb, 083-45 Philadelphia, Pa 19122 Timing: Fiscal Year 2002; Project Start 01-MAR-2001; Project End 28-FEB-2006 Summary: Gastric dysmotility may be due to delayed gastric emptying, antral hypomotility, and/or gastric dysrhythmias. Gastric motor dysfunction is an important component of several clinical disorders including gastroparesis, functional dyspepsia, and intestinal pseudoobstruction. Our overall hypothesis is that gastric motility can be measured conveniently with noninvasive tests which can have widespread availability and provide clinically relevant information. The studies described in this research protocol will address our long-term research objectives of evaluating and treating disorders of gastric motility using simpler, less expensive, and less invasive techniques. Each of these patient-oriented research protocols involves the close interaction between the principal investigator and beginning clinical investigators in order to encourage and develop their clinical research potential. The first specific aim is to demonstrate the clinical validity of two novel noninvasive techniques to assess gastric motility. We will develop the 13C-octanoate breath test for gastric emptying into a practical, clinically useful test for the measurement of gastric emptying using an easily prepared standardized meal. We will also assess the clinical utility of a newly modified electrogastrographic instrument that records high frequency gastric myoelectric activity (up to 120 cycles per minute), in addition to the usual 3 cpm activity. The second specific aim is to use these two noninvasive tests (breath testing and electrogastrography) to assess gender-related aspects of gastric motility. We will demonstrate the effects of gender and the menstrual cycle on gastric motility and determine if the changes in gastric motility during the menstrual cycle correlate with estrogen. and progesterone levels. We will determine whether gastric motility is altered during pregnancy, and to investigate if nausea and vomiting that occurs in the first trimester of pregnancy are related to gastric dysmotility and/or alterations of estrogen, progesterone, and/or
Studies
21
chorionic gonadotropin blood levels. The third specific aim is to explore novel treatment strategies for abnormal gastric emptying. We will determine whether accelerating or delaying gastric emptying affects postprandial glucose tolerance in diabetic patients. We will determine whether botulinum toxin injection into the pyloric sphincter improves gastric emptying and symptoms in gastroparesis. The fourth specific aim is to enable the principal investigator to continue and even expand his mentoring activities for beginning clinical investigators in patient- oriented research to include mentoring of specialized motility fellows, gastroenterology fellows, medical residents, medical students, and college students. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: NOVEL INHALATION DEVICE FOR DELIVERING VAPOR-STATE DRUGS Principal Investigator & Institution: Rabinowitz, Joshua D.; Alexza Molecular Delivery Corporation 1001 E Meadow Cir Palo Alto, Ca 94303 Timing: Fiscal Year 2003; Project Start 01-NOV-2001; Project End 31-MAR-2005 Summary: (provided by applicant): Poor appetite is one of the subjective symptoms that cancer patients find most frustrating, and resulting cachexia is a common cause of death from cancer. In addition, nausea is a frequent side effect of cancer treatment. Oral delivery of the cannabinoid agonist dronabinol is approved by the FDA as both an antiemetic agent and an appetite-enhancer. Its clinical utility, however, is limited by extensive first pass metabolism and resulting inconsistent oral bioavailability. In Phase I of this grant application, we have demonstrated the ability to form high purity, small particle size aerosols of dronabinol for reliable systemic delivery through inhalation. These aerosols can be produced by simple, breath-actuated devices. In Phase II of the grant, we now propose to prove the consistency of systemic absorption of these aerosols when inhaled by dogs. In addition, we plan to conduct the animal toxicology experiments and produce the clinical trial materials required to initiate human studies of inhaled dronabinol. Accomplishment of these goals of Phase II will lead directly to human clinical testing of a cost effective, commercially viable dronabinol inhalation delivery system. Beyond providing for improved dronabinol delivery, this drug product addresses a major unmet need in the cancer area: an appetite-enhancing and nauseadecreasing medication that works rapidly and does not require painful injection or for patients with gastrointestinal distress to consume oral medication. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: NOVEL INHALATION SYSTEM FOR DELIVERING VAPOR-STATE DRUGS Principal Investigator & Institution: Mufson, Daniel; Alexza Molecular Delivery Corporation 1001 E Meadow Cir Palo Alto, Ca 94303 Timing: Fiscal Year 2002; Project Start 27-AUG-2002; Project End 31-OCT-2002 Summary: Delta-9-tetrahydrocannibinol (THC) is approved for AIDS-related anorexia, chemotherapy-related nausea and vomiting, and clinical evidence supports efficacy of THC in pain, even suggesting an opioid sparing strategy with equivalent analgesia. Current THC formulations have significant disadvantages, including imprecise dosing, variable absorption, poor bioavailability, slow onset of action, and toxic components and legal issues if smoked. Medical experts agree that a rapid-onset, reliable and safe delivery system for THC represents an unmet patient need. MDC proposes its handheld inhaler to meet this need. The inhaler is the first to deliver vapor-state drug
22
Nausea
without excipients. The inhaled, reproducible dose will be absorbed from the lung rapidly with high bioavailability, providing effective blood levels, and rapid-onset of action. Utilizing an in vitro test apparatus, MDC demonstrate feasibility by generating ultrafine particles of optimal size and distribution, without degradation, for vapor-state inhalation delivery. In Phase I we propose developing a benchtop prototype device and conducting in-vitro verification. Phase I AIMS include: 1) designing, constructing and testing a benchtop prototype producing acceptable, ultrafine particle sizes and PSD, 2) producing doses reproducibly without degradation, and 3) analyzing economical scaledown for hand-help operation. The ultimate goal is clinical evaluation of efficacy and safety leading to an NDA and regulatory approval. PROPOSED COMMERCIAL APPLICATION: The commercial market potential for the MDC Inhalation Delivery of THC alone includes, among others, millions of cancer patients and thousands of AIDS patients who would benefit from improved management of pain, cachexia, nausea, and other symptoms using inhaled analgesia medications (as prescribed by their doctors) in the United States and other countries. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PERIPHERAL TRANSMISSION
CANNABINOID
MODULATION
OF
PAIN
Principal Investigator & Institution: Hohmann, Andrea G.; Assistant Professor; Psychology; University of Georgia 617 Boyd, Gsrc Athens, Ga 306027411 Timing: Fiscal Year 2002; Project Start 30-SEP-2002; Project End 31-AUG-2005 Summary: (provided by applicant): One in three Americans suffer from chronic pain. Available therapeutic interventions show limited efficacy and are plagued by adverse side effects (e g, altered mental status, sedation, nausea) that accompany systemic routes of drug administration Novel pharmacotherapies that specifically target the periphery therefore represent an alternative strategy for managing pain in the absence of unwanted central side-effects. Activation of a cannabinoid system- a nonopioid system that acts through a marijuana-like mechanism- in the periphery attenuates nociceptive responding The proposed research combines correlative behavioral and neurophysiological approaches to examine the functional consequences of peripheral cannabinoid actions on nociceptive transmission in vivo The use of subtype selective competitive antagonists and high affinity agonists provide the pharmacological tools required to study peripheral cannabinoid actions The proposed work uses a rat model of inflammation to test the hypothesis that a peripheral cannabinoid mechanism suppresses responses evoked by natural cutaneous stimulation in physiologically identified neurons of the spinothalamic tract Behavioral correlates for the electrophysiological studies will be established by assessing peripheral cannabinoid modulation of responsiveness to thermal and punctate mechanical stimulation under similar conditions The consequences of peripheral inflammation on axonal transport of cannabinoid receptors to peripheral nerve terminals is evaluated The development of effective pharmacotherapies for pain that are non-toxic, non-addicting and devoid of side-effects is likely to have a profound impact by improving quality of human life and reducing socioeconomic costs associated with inadequate pain management. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PHOTOPHYSICAL PROPERTIES OF TRICYCLIC ANTIEPILEPTIC DRUGS Principal Investigator & Institution: Garcia, Carmelo; University of Puerto Rico at Humacao Box 428, Barrio Tejas Humacao, Pr 00791
Studies
23
Timing: Fiscal Year 2003; Project Start 01-APR-2003; Project End 31-MAR-2007 Summary: The intense research devoted over the last few years to the study of epilepsy and antiepileptic drugs (AEDs) has only dealt with the physiology of the disease. This quality research has been aimed to replace the older AEDs with broad activity profiles and several severe side effects with new AEDs with better defined mechanism of action and fewer side effects. Nevertheless, most of these drugs still produce serious adverse reactions, including among others, dizziness, ataxia, somnolence, headache, blurred vision, nausea, vomiting, skin, allergy and photosensitization. The molecular photochemical mechanisms for the photosensitizing ability of some AEDs has never been studied, even through it was reported over ten years ago. Recent studies on the laser flash phototysis of related neuroleptic drugs (imipramine) showed that the triplet state can be efficiently quenched by the protons in the solution. The effectiveness of the quenching is very sensitive to the structure of the drug and seems to be involve in their phototoxicity. We propose to perfor the same set of experiments on several phototoxic antiepileptics. The goal of this project is to measure the photophysicat properties of a selected group of tricydic antiepileptic drugs and to study their short-lived transients. Special attention will be given to those transients associated with adverse effects in vivo: the cation radical, the first triplet excited state and singlet oxygen, Basic UV-Vis and luminescence techniques will be employed to study their absorption/emission properties. The transients will be characterized using optical absorption measurements with a Nd-YAG laser set-up. For the triplet state of these compounds, the extinction coefficient and the quantum yield will be determined using a comparative method and the triplet-triplet energy transfer principle, respectively. The triplet state will be bleached with a second delayed pulse to elucidate the reaction mechanism of these u'ansients. Combined MM+/PM3/RHF theoretical calculations will be performed with HyperCHEM (TM) 7.0 on the whole set ofphotophysical parameters, The theoretical values will be correlated with the experimental ones. The major goal of this project is to find a molecular/photophysical descriptor for the phototoxic side effect of tricydic antiepileptics. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PREGNANCY ESTROGENS, DIET, AND BREAST CANCER RISK Principal Investigator & Institution: Hilakivi-Clarke, Leena A.; Professor; V T Lombardi Cancer Res Center; Georgetown University Washington, Dc 20057 Timing: Fiscal Year 2002; Project Start 15-AUG-2001; Project End 31-JUL-2006 Summary: Estrogen levels are elevated by 50-100 -fold during pregnancy, and interindividual variability in pregnancy estrogen levels is 4-6 -fold. Women exhibiting highest pregnancy estrogen levels are suggested to be at a significantly increased risk to develop breast cancer, perhaps due to an estrogen-induced promotion of existing transformed cells. Diet, particularly dietary fats, may affect pregnancy estrogen levels and later breast cancer risk. In our animal study, a high fat intake significantly increased pregnancy estrogen levels and increased pregnancy-promoted mammary tumor incidence. Polymorphism in genes that metabolize estrogens and have been linked to increased breast cancer risk, may also affect pregnancy estrogen levels. Our proposed study has two general aims: (1) to study whether dietary fat intake affects pregnancy estrogen levels in women, perhaps by interacting with polymorphism in CYP17 and COMT, and (2) to study whether highest pregnancy estrogen levels might increase breast cancer risk by increasing growth factor levels. These growth factors could originate from mutated or already transformed mammary cells, which during pregnancy are stimulated by high estrogen levels. Growth factor levels will be measured
24
Nausea
in nipple aspirate fluid (NAF) that can be obtained using a breast pump from nonlactating breast. Consequently, the following hypotheses will be tested: Hypothesis-1. We hypothesize that high dietary fat intake and weight gain increase pregnancy estrogen levels. We further hypothesize that polymorphism in CYP17 or COMT influences these interactions. Hypothesis-2. We hypothesize that higher circulating estradiol levels during pregnancy are associated with increased growth factor levels in nipple aspirate fluid, including EGF, TGFalpha and IGF-1/IGF binding protein 3. These aims will be studied in 200 pregnant women attending the Maternity Clinic at Solna in NAF will be obtained 12 months after giving birth. Our results may lead to modifications of pregnancy diet to reduce the risk to develop breast cancer. In particular, women who already are at high risk, for example, due to family history of breast cancer, age at first pregnancy (greater than 30 years), or other reproductive risk factors, may significantly benefit from pregnancy dietary modifications. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PRESURGERY HYPNOSIS--BENEFITS ANALYSIS IN BREAST CANCER Principal Investigator & Institution: Montgomery, Guy; Ruttenberg Cancer Center; Mount Sinai School of Medicine of Nyu of New York University New York, Ny 10029 Timing: Fiscal Year 2002; Project Start 17-AUG-2001; Project End 31-JUL-2004 Summary: Over 90% of the 184,000 women diagnosed with breast cancer in 2000 will undergo surgery as part of their curative treatment. Despite improvements in pharmacological management, surgical procedures under general anesthesia continue to be associated with clinically significant side effects, chief among which are pain and nausea. These clinical problems are particularly severe following surgical treatment for breast cancer and can require additional pharmacologic intervention, prolong recovery room stay, delay discharge, and lead to unanticipated readmission. Clinical research with other surgical populations has indicated that hypnosis can reduce intraoperative complications, reduce postoperative symptoms and enhance recovery (e.g., reduce pain, nausea, hospital stays), however, the treatment efficacy of hypnotic techniques with breast cancer surgical patients has yet to be established. A separate line of previous clinical research with surgery populations has indicated that preoperative psychological factors (emotional distress and cognitive expectations) are predictive of patients' postoperative experiences of side effects, but again research on breast cancer surgical patients is scant. The proposed research will bridge the two previous lines of research by combining a randomized clinical trial, (in which the effects of a preoperative hypnosis intervention to control side effects are compared to attention control), with a prospective quasi-naturalistic study, (in which the relations between preoperative psychological factors and patients' reactions to surgery are examined). In addition to establishing the applicability to breast cancer patients of findings in the general psychological, hypnosis and surgical literatures, the goal of proposed study is to make novel theoretical contribution by examining the potential role of psychological factors as the "active ingredients" in the beneficial effects of hypnosis. The proposed study will also make a novel practical contribution by examining cost-effectiveness of the hypnosis intervention, an approach which may have compelling implications for clinical practice as well as future behavioral research. The Specific Aims of the study are: 1) To investigate the impact of a presurgical hypnosis intervention on women scheduled for surgical treatment for breast cancer; 2) To investigate the contribution of preoperative emotional distress, and cognitive expectations to post- surgery side effects and recovery; 3) To determine whether the beneficial effects of the hypnosis intervention are
Studies
25
accounted for (mediated) by differences in presurgery cognitive expectations and emotional distress; and 4) To investigate the cost-effectiveness of the presurgical hypnosis invention. o achieve these aims, 140 breast cancer patients scheduled for mastectomy will be randomly assigned to a hypnosis intervention group or an attention control group. The impact of the hypnosis intervention on postoperative nausea, pain, recovery from surgery, and cost- effectiveness will be analyzed within an experimental study design. The influence of presurgery distress and expectations of side effects will be analyzed within quasi-naturalistic study designs. The possible mediational role of these factors in hypnosis effects will be examined will classic statistical approaches. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: PSYCHOIMMUNE OUTCOMES: INTERVENTION IN BREAST CANCER Principal Investigator & Institution: Kang, Duck-Hee H.; Associate Professor; None; University of Alabama at Birmingham Uab Station Birmingham, Al 35294 Timing: Fiscal Year 2002; Project Start 01-MAY-2000; Project End 31-JAN-2004 Summary: The specific aims of this study are (1) to examine immunological, psychosocial, and clinical symptom outcomes of an 8-week integrated support program for patients with newly diagnosed breast cancer, and (2) to determine whether the support program has differential effects on patients with persistently low versus high baseline natural killer cell (NK) activity pattern (below versus above median NK activity x 2). The integrated support program includes weekly stress management and social support programs and exercise training activities three times a week. Background and Significance: Cancer diagnosis and treatment are a major source of significant psychological, emotional, and physical distress. Most previous interventions have been limited by a unidimensional approach (psychosocial or physical support, not both), and by the lack of immunological assessments. Given the importance of mind-body interactions in human functioning, an integrated approach of concurrent psychological and physical support will be most beneficial to assist patients in distress. Further, there is indication that breast cancer patients with lower baseline NK activity pattern have a poorer prognosis than those with higher baseline NK activity pattern. A comprehensive examination of an integrated approach will provide insights to improving quality of life for patients with newly diagnosed breast cancer. Design and Method: Using a longitudinal, experimental design with pretest and posttest, 90 patients with stage I-IV newly diagnosed breast cancer will be stratified by disease stage (I-IIB vs. locally advanced) and randomly assigned to the Experimental (intervention) or Control (waitlist) group. NK activity will be examined twice prior to the beginning of intervention to determine the pattern of NK activity. The intervention will begin at the start of chemoor radiotherapy. Post-intervention data will be collected immediately after intervention and at 6 and 12 months from the initiation of intervention, coinciding with patients' routine clinic visits. Dependent Measures and Analysis: The impact of intervention will be measured on immune responses (NK activity and number, lymphokine activated killer cell activity, IL-1alpha, IL-2 and interferon-gamma), psychosocial well-being (distress, mood states, and quality of life), and clinical symptoms (fatigue, nausea, vomiting, and sleep). Longitudinal data analysis methods will be employed to analyze repeated measures of outcome variables, whereas 2-sample t-test or nonparametric Wilcoxon rank-sum test will be used to perform univariate analysis. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
26
•
Nausea
Project Title: QUALITATIVE STUDY OF PROSTATE CANCER SYMPTOM MANAGEMENT Principal Investigator & Institution: Latini, David M.; Urology; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 941222747 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-AUG-2005 Summary: (provided by applicant.) Prostate cancer is the second-most common cancer among American men Various options for treatment exist, with approximately equal effectiveness However, the choice of treatment can result in different side effects that severely impact quality of life These side-effects include medical problems, such as erectile dysfunction and urinary and bowel incontinence The experience of those sideeffects can cause a number of emotional and psychological concerns, including changes in self-concept, difficulties in a man's primary relationship, and social isolation to avoid the embarrassment of incontinence in a social setting Numerous interventions have been developed for patients with other types of cancers, but few interventions have been developed for men with localized prostate cancer None of the existing prostate cancer interventions focus on symptom management, an important part of the prostate cancer survivor's quality of life Moreover, interventions that target more general cancer symptoms (e g, pain or nausea) have less relevance for the unique needs of men with localized prostate cancer Our study proposes to use the Critical Incident Technique to collect data on how patients with treatment-related side-effects are able to successfully manage the physical and psychosocial impact of their symptoms The critical incident reports will be organized into a taxonomy of effective and ineffective symptom management practices. As part of the proposed study, the investigator will accomplish the following aims: 1. Collect qualitative data describing effective and ineffective symptom management knowledge, skills, and behaviors in men treated for localized prostate cancer from prostate cancer patients, their partners, and health care providers. 2. Analyze the critical incidents to develop a hierarchical classification or taxonomy of critical symptom management competencies. 3. Using the taxonomy of symptom management competencies from Specific Aim 2, develop the instructional objectives for a tailored intervention that will help men treated for prostate cancer manage their treatment-related side-effects and related psychosocial concerns more effectively. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: QUANTITATIVE MRI AND 1H-MRS IN TRAUMATIC BRAIN INJURY Principal Investigator & Institution: Grossman, Robert I.; Chairman; Radiology; New York University School of Medicine 550 1St Ave New York, Ny 10016 Timing: Fiscal Year 2002; Project Start 15-SEP-2000; Project End 31-JUL-2005 Summary: (Adapted from Applicant's Abstract): Traumatic brain injury 9TBI) has an incidence of nearly 2,000,000 cases per year, and is the leading cause of disability and death in children and young adults (peak incidence in 15 to 24 year olds) in the United States. Following mild head injury patients may suffer from a multitude of cognitive deficits including decreased speed in information processing, poor attention, concentration, and memory, and impaired logical reasoning skill, as well as more focal deficits including impairment of language or constructional abilities. A variety of other symptoms including headache, dizziness, nausea, neurasthenia, hyperesthesia, and emotional liability are commonly perceived. Head injury has been associated with shortterm increased b-amyloid protein deposition and long-term neurotic plaques characteristic of Alzheimer's Disease. Epidemiological studies have observed a
Studies
27
statistically-significant relationship between TBI and the subsequent onset of AD. Indeed, there is growing evidence that head injury, even mild in nature, may have greater consequences than previously assumed. The investigators hypothesize that mild/moderate TBI can cause neuronal cell death (reflected primarily by gray matter volume lose) and that this is the primary factor in induction and progression of neurocognitive disability in head injured patients. The central hypothesis is to test this hypothesis that the investigators have developed and validated computerized quantitative methods based upon magnetic resonance (MR) imaging (MRI) to measure the effect of TBI on brain substance. The investigators have also devised and implemented a proton (+H) magnetic resonance spectroscopy (MRS) technique to quantitative the neuronal concentration of the entire brain based upon the measurement of N-acetylaspartate (WBNAA) which is considered to be a marker of neuronal integrity. This proposal will correlate these quantitative MR measures with clinical measures of disability and neurocognitive tests. The overarching goal is to utilize MRI and 'H MRS to detect and quantify the effects TBI in a well-characterized cohort of mild/moderate head injured patients over a duration of 5 years. The results from this research will provide new and important information regarding the full extent of TBI, aid in categorizing these patients, and serve as an arbiter to assess proposed treatment strategies. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SEX ANTINOCICEPTION
DIFFERENCES
IN
CANNABINOID-INDUCED
Principal Investigator & Institution: Tseng, Alan H.; Pharmacology-Toxicology; Washington State University 423 Neill Hall Pullman, Wa 99164 Timing: Fiscal Year 2002; Project Start 01-APR-2002 Summary: Cannabinoids have been shown to produce analgesia in rodents, monkeys and humans. However, males and females may be differentially sensitive to cannabinoids. For example, perinatal exposure to the cannabinoid delta-9-THC alters midbrain opioid receptor binding and opioid analgesia differentially in female vs. male rats. Sex differences have been found in midbrain cannabinoid receptor density and liver metabolism of cannabinoids, which may contribute to sex differences in the behavioral effects of cannabinoids. Because cannabinoids may provide a significant alternative analgesic pharmacotherapy to opioids -- and in fact are already being used for their anti-nausea and appetite stimulation effects -- it is important to determine whether these substances are equi-effective in men and women. The goal of the proposed research is to compare cannabinoid-induced antinociception in male vs. female rats. The first aim is to determine the potency and time course of cannabinoidinduced antinociception and sedation. Three agonists will be examined: the major psychoactive compound in marijuana, delta-9-THC; the major active metabolite of delta9-THC,11- hydroxy-delta-9-THC; and the synthetic cannabinoid, CP55,940. Complete dose- and time-effect curves will be obtained for each agonist administered i.p. on the warm water tail withdrawal, paw pressure and spontaneous locomotor activity tests. The second aim is to compare supraspinal vs. spinal CB1 receptor mediation of cannabinoid effects in males and females. Complete dose- and time-effect curves will be obtained for antagonism of i.p. CP55,940 by the CB1 receptor-selective antagonist SR141716A administered i.c.v. and i.t. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
28
•
Nausea
Project Title: SLOWING OF TRANSIT - THE THIRD ENTERIC FUNCTION OF 5HT Principal Investigator & Institution: Lin, Henry C.; Director Gastrointestinal Motility Progr; Cedars-Sinai Medical Center Box 48750, 8700 Beverly Blvd Los Angeles, Ca 900481804 Timing: Fiscal Year 2003; Project Start 01-SEP-2003; Project End 31-AUG-2006 Summary: (provided by applicant): In order to optimize nutrition, the movement of a meal through the small intestine must be precisely controlled to ensure that there is adequate time to complete the time-demanding steps of digestion and absorption. Abdominal pain, nausea, bloating, diarrhea and malnutrition are the consequences of impaired control of intestinal transit. After a fat-containing meal, inhibitory feedback mechanisms are activated by the proximal and distal small intestine as the jejunal and ileal brake, respectively. In contrast to this focus of the postprandial gut to slow transit, much of the research efforts over the past 100 years have been directed at the peristaltic reflex, which is responsible for the acceleration of intestinal transit and are known to be mediated by 5-HT. Currently, two roles of enteric 5-HT have been established: the triggering of the peristaltic and mucosal secretory reflexes via intrinsic primary afferent neurons and gut-to-CNS and gut-to-pancreas communications via extrinsic sensory nerves. We have recently found a third role of enteric 5-HT. Specifically, 5-HT is also involved in the slowing of transit by fat via a 5-HT3 pathway that is dependent on 5-HT transmission via myenteric neurons. In this proposal, we will test our overall hypothesis that slowing of intestinal transit by fat depends on primary afferent nerves, betaadrenergic pathway and 5-HT transmission via myenteric neurons, which in turn activates opioid neurons, that slow transit. We will test the hypotheses using pharmacologic and physiologic approaches. The results of these studies will help us to refine our hypotheses so that we can test the neuroanatomic components of this pathway using immunohistochemistry. We have developed a collaboration with 2 leading neuroscientists who will provide this project with additional expertise in immunohistochemistry. In addition, to test the role of a novel beta-adrenergic system in the slowing of intestinal transit by fat, we have developed a multi-disciplinary team approach by including a cardiologist experienced in the 13- adrenergic system. The PI has a track record of success in bench-to-bedside translational research in the area of nutrient control of intestinal transit. His experience includes the discovery of a novel, nutrient-based strategy to slow intestinal transit. This application will bring this new treatment back to basic research so that we can understand the neural pathways that underpin the slowing response to fat. The hypotheses to be tested in this project will expand our understanding of a new role for enteric 5-HT which may explain conditions such as irritable bowel syndrome and provide better understanding of the effects of drugs that are directed at 5-HT pathways. In addition, by investigating the mediators of the control of intestinal transit, we will gain knowledge that can be used to control the movement of a meal through the small intestine and, in turn, reduce symptoms and improve nutrition. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: ST. JOHN'S WORT VS PLACEBO IN SOCIAL PHOBIA Principal Investigator & Institution: Kobak, Kenneth A.; Senior Research Scientist; Dean Fdn for Health, Research & Educatn Research and Education Middleton, Wi 53562 Timing: Fiscal Year 2002; Project Start 17-SEP-2001; Project End 31-AUG-2004
Studies
29
Summary: (provided by applicant): Social Phobia is a prevalent and debilitating condition, with a lifetime prevalence rate to be 13.3 percent. Socially phobic patients have been found to be functionally impaired in the areas of education, employment and social relationships, to have poorer quality of life, and increased suicidal ideation and psychiatric comorbidity. Double-blind studies have found benzodiazepines, selective and non-selective MAOI inhibitors, several SSRIs, and the anticonvulsants pregabalin and gabapentin to be effective. However, side effects with these compounds suggests the need for better tolerated compounds, e.g., in the paroxetine multi-center trial (the only drug with an FDA approved indication), 27 percent reported somnolence, 26 percent nausea, and 37 percent of males reported delayed ejaculation; 34 percent of patients discontinued the trial early. There has been considerable worldwide interest in St. John's Wort (SJW) (Hypericum perforatum) as a treatment of mild to moderate depression. There have been 23 randomized trials suggesting SJW is more effective than placebo for the treatment of outpatients with mild to moderate depression. SJW is very well tolerated with mild side effects observed in only 2.5 percent of cases in a large (3250 patients) drug monitoring study. Pharmacokinetic studies have found Hypericum to have affinity for serotonin, dopamine and GABA alpha and GABA beta receptors, each of which have been implicated in social phobia, thus there is a suggestion that SJW may be effective for this disorder. This will be a 12-week, double blind, placebo-controlled trial, designed to generate effect size data that will be used to determine sample size needed to power a definitive study. Forty patients will be randomized to either SJW (LI 160) or matching placebo. This will be a flexible-dose design, starting at 300 mg tid to a maximum of 1800 mg total per day. An intent-to-treat analysis will be employed. Subjects will be evaluated weekly for two weeks, then bi-weekly thereafter. The primary outcome measure will be the change from baseline to endpoint on the Liebowitz Social Anxiety Scale. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: STUDY OF A CANNABINOID RECEPTOR INTERACTING PROTEIN Principal Investigator & Institution: Niehaus, Jason L.; Pharmacology and Toxicology; Medical College of Georgia 1120 15Th St Augusta, Ga 30912 Timing: Fiscal Year 2003; Project Start 24-SEP-2003; Project End 23-SEP-2005 Summary: (provided by applicant): Marijuana is the most widely abused illegal drug in the United States. Central nervous system responses to the active compound in marijuana include beneficial therapeutic effects, such as analgesia, appetite stimulation, and reduction of nausea and vomiting, while undesired effects include short-term memory and motor impairment, dysphoria, and sedation. The endogenous function of the cannabinoid receptor and the mechanism by which these effects are produced remains ill-defined. The goal of this project is to investigate the role of an uncharacterized cannabinoid receptor interacting protein on the signaling and function of the receptor. The proposed studies will use patch clamp recording of primary neurons to identify the effects of the interacting protein on ion channel modulation and receptor function. A yeast two-hybrid assay will identify the protein-protein interaction domains and confocal microscopy will be used to determine the effect of the novel protein on receptor expression and localization. The results of these studies will increase the knowledge of cannabinoid receptor signaling pathways and function, which is important to facilitate the design of new therapeutic strategies utilizing cannabinoid compounds to select for desired effects, while excluding side-effects. In addition, further insight into the cannabinoid system may lead to a better understanding of marijuana abuse, tolerance and dependence.
30
Nausea
Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: SYMPTOM CLUSTERS IN CANCER PATIENTS UNDERGOING TREATMENT Principal Investigator & Institution: Barsevick, Andrea M.; Associate Members; Fox Chase Cancer Center Philadelphia, Pa 19111 Timing: Fiscal Year 2003; Project Start 01-AUG-2003; Project End 31-JUL-2005 Summary: (provided by applicant): The specific aims of the proposed pilot research are to: 1) systematically examine the relationships between and among a group of physical symptoms (fatigue, insomnia, pain, and nausea/vomiting) typically experienced during cancer chemotherapy to determine whether or not they form one or more clusters; and, 2) test alternative models of the impact of these symptoms (and/or symptom clusters) on psychological and functional well-being. The overall goal of this research is to generate hypotheses for future research about the characteristics and effects of symptom clusters during cancer treatment. Indicators of a symptom cluster include two or more symptoms with a common predictor (or cause), pattern, or effect on another symptom(s). A longitudinal descriptive design will be used to examine symptoms and quality of life during one cycle of chemotherapy. Measures will be taken at three data points: 1) day 1 of cycle prior to receiving chemotherapy; 2) day 4 of cycle; 3) last day of cycle. Administering measures at these data points will allow us to track the pattern of symptoms from baseline before treatment to a known symptom high point (day 4) for fatigue, insomnia, and delayed nausea/vomiting to a known symptom low point (last day). The use of repeated measures will enable us to examine symptom patterns as well as temporal patterns by which symptoms could influence other symptoms over time. This design also will allow us to examine relationships between symptoms and other quality of life dimensions at each data point as well as changes over time. For aim #1, five research questions will be examined independently using correlation, multiple regressions, and/or repeated measures ANOVA. The result of each analysis will provide one indication of the presence or absence of a symptom cluster. The number of indicators and the nature of the relationships described will be used to decide whether or not the symptoms under investigation form a cluster. For aim #2, two hypotheses will be examined using multiple regression techniques to test whether functional well-being is a mediator between individual symptoms (or symptom clusters) and psychological well-being. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: THC AND MARIJUANA--EFFECTS IN INDIVIDUALS WITH HIV/AIDS Principal Investigator & Institution: Haney, Margaret; Assistant Professor; New York State Psychiatric Institute 1051 Riverside Dr New York, Ny 10032 Timing: Fiscal Year 2002; Project Start 01-AUG-2000; Project End 30-JUN-2004 Summary: (adapted from the applicant's abstract): The purpose of the proposed laboratory studies is to assess the effects of smoked marijuana (MJ) and oral delta-9 THC (the primary psychoactive component of smoked MJ) in individuals who have the human immunodeficiency virus infection (HIV+) with unintended weight loss (<90 percent body cell mass/height). In addition to a detailed analysis of food intake and body composition, we will measure mood, physical symptoms (e.g., nausea, stomach pain), psychomotor task performance, and sleep in order to determine the specificity of drug effects on food intake in relation to other behaviors. Experiment 1 will directly
Studies
31
compare the short-term effects of smoked MJ and oral THC in the same HIV+ individuals. Little is known about the efficacy and tolerability of oral THC versus smoked MJ in a clinically relevant population. Hypotheses include: 1) both smoked MJ and oral THC will increase food intake; 2) both smoked MJ and oral THC will be well tolerated because all participants will be current MJ smokers; and 3) oral THC will produce greater increases in food intake with repeated administration. Experiment 2 will determine whether maintenance on oral THC administration is well tolerated and increases body weight compared to maintenance on placebo in 2 groups of HIV+ individuals: those who currently smoke MJ and those who have smoked MJ but currently do not. It is not clear how THC's effects vary as a function of (1) the duration of treatment, or (2) the individual's current patterns of smoked MJ use. Hypotheses include: 1) THC will be well tolerated in both groups because the dose regimen will be adjusted to current MJ use; 2) THC administration will produce dose-dependent increases in body weight compared to placebo; and 3) tolerance will develop to THC's subjective effects, but not to THC's positive effects on food intake and body weight. The proposed studies will provide a much-needed experimental database on the behavioral, subjective and appetite-enhancing effects of oral THC and smoked MJ in HIV+ individuals with weight loss, and will contribute empirical data to the current policy debates occurring throughout the United States regarding the efficacy and safety of cannabinoids for medical use. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: THE EFFECTS OF MUSIC THERAPY-BASED STRESS REDUCTION ON * Principal Investigator & Institution: Sahler, Olle J.; Pediatrics; University of Rochester Orpa - Rc Box 270140 Rochester, Ny 14627 Timing: Fiscal Year 2002; Project Start 15-JUL-2001; Project End 30-JUN-2003 Summary: (provided by applicant): The regimen-related toxicities associated with bone marrow transplantation (BMT) can be severe and even life threatening. The overall goal of this randomized controlled pilot study in BMT patients is to determine the effect of relaxation/.stress reduction strategies on: (1) the frequency/severity of toxic side effects of marrow ablative chemotherapy, and (2) the timing of immune reconstitution. A substantial literature indicates that music therapy-based interventions are effective in inducing relaxation and also affect immune function by modulating circulating and salivary levels of such agents as cortisol, immunoglobulin A, interleukin-1, natural killer cells, and a variety of other immune system-related substances. Over the past two years, we have provided music therapy-based stress reduction/relaxation interventions to a convenience sample of patients undergoing BMT. Preliminary findings from this pilot feasibility study demonstrate that patients report significantly decreased pain (p<.004) and sense of nausea (p <.001) following an intervention. Average time-to-engraftment was 13.5 (+/- 2.85) days as compared to 15.5 (+/- 4.40) days (p <.O1) for a group of historical controls matched on diagnosis, type of transplant, conditioning regimen, date of transplant, age, and gender. Although highly promising, our data are limited by lack of randomization, an appropriate control condition, measurement of psychologic factors known to influence outcome in BMT, and systematic monitoring of early phase markers of immune reconstitution that could help explain the phenomena we have observed. This proposal corrects these shortcomings and especially highlights the potential mediational effect of cytokine release on regimen-related toxicities and the timing of immune reconstitution. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
32
•
Nausea
Project Title: TNF BLOCKADE IN PANCREATIC CANCER PATIENTS Principal Investigator & Institution: Villalona, Miguel A.; Associate Professor; Internal Medicine; Ohio State University 1960 Kenny Road Columbus, Oh 43210 Timing: Fiscal Year 2003; Project Start 30-SEP-2003; Project End 31-AUG-2005 Summary: (provided by applicant): The poor prognosis of patients with advanced pancreatic adenocarcinoma, with a median survival of less than 12 months, indicates an obvious need for more effective treatments. In addition, patients with pancreatic carcinoma are frequently debilitated by cachexia, anorexia, nausea/vomiting and abdominal pain. Pro-inflammatory cytokines like tumor necrosis factor (TNF) alpha, interleukin 6 (IL-6) and interleukin 1 (IL-1) have all been found to be elevated in pancreatic cancer patients and have been implicated in causing many of these symptoms, in addition to the possibility of directly promoting tumor progression. One potential target for anticancer therapy is blocking the effects of TNF. We hypothesize that TNF blockade should make chemotherapy more tolerable, should improve quality of life and should retard the time to tumor progression. In the current proposal, we seek to combine standard chemotherapy (gemcitabine) and TNF blockade with soluble TNF receptor molecules (etanercept) in a pilot trial in patients with metastatic or recurrent pancreatic cancer. We will evaluate if TNF blockade can improve the clinical benefit response, quality of life and the rate of cancer progression-free survival at six months obtained with chemotherapy. In addition, serial levels of TNF and other inflammatory cytokines, as well as the transcription factor NF-kappaB, a candidate pathway through which TNF stimulates tumor growth, will be obtained from peripheral blood mononuclear cells lysates. Quality of life and levels of the cytokines and NF-kappaB will also be measured in a control group of 10 patients receiving gemcitabine as a single agent. The observation of benefits in either quality of life or progression-free survival in patients undergoing TNF blockade would encourage evaluation of this novel strategy in properly powered randomized clinical trials. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
•
Project Title: TNF, VAGAL TONE AND GASTRIC MOTILITY Principal Investigator & Institution: Rogers, Richard C.; Professor; None; Lsu Pennington Biomedical Research Ctr 6400 Perkins Rd Baton Rouge, La 70808 Timing: Fiscal Year 2002; Project Start 15-JAN-1997; Project End 31-AUG-2007 Summary: (provided by applicant): Cytokine production by immune effector cells forms part of the host response to antigenic challenge, trauma or irradiation. Protection of the host relies on cytokine release to stimulate: immune attack on pathogens, wound healing, tissue remodeling and energy mobilization. However, elevation of the proinflammatory cytokine, tumor necrosis factor-alpha (TNF], following these insults is also associated with the onset of gastric stasis, nausea, vomiting and anorexia. Degradation of the control of gastrointestinal, fluid and nutritional homeostasis causes significant morbidity and mortality apart from that caused by the primary disease process.Our work has shown that: a) initiation of gastric inhibition by peripheral immune challenge is dependent on TNF synthesis, b) peripherally generated cytokines suppress CNS-commanded, vagally mediated increases in gastric motility and c) TNF can operate directly on neurons of the dorsal vagal complex [DVC] of the brainstem to produce profound gastroinhibition. These results satisfied the initial goals of the project, i.e., the unambiguous demonstration of a role for the dorsal medulla and vagal control circuitry in TNF-mediated gastric stasis.Now we wish to investigate the physiological mechanisms by which TNF dramatically alters vagal control of the stomach. The present
Studies
33
proposal focuses on three Specific Aims: 1) which vagal efferent pathway(s) are invoked by central TNF action, 2) the specific phenotype of brainstem neuron(s) activated by TNF and 3) the cellular mechanisms activated within the DVC by TNF. We expect that TNF suppresses gastric motility by acting at several sites within vago-vagal reflex circuits in the medulla. We predict that: 1) TNF enhances glutamate neurotransmission between vagal afferents and the solitary nucleus, 2) TNF directly affects the excitability of specific phenotypes of solitary neurons which control the activity of vagal efferent [DMN] neurons, and 3) these DMN neurons (which ultimately control gastric motility) are also likely to be under the direct influence of TNF. Perhaps TNF produces its profound and prolonged inhibition of gastric motility, (and, perhaps, the generation of nausea, emesis and suppression of feeding) by acting at several points in the DVC simultaneously. These hypotheses will be tested using a combination of in vivo and in vitro neurophysiological methods. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: TREATING ACUPRESSURE
CHEMOTHERAPY
INDUCED
NAUSEA
WITH
Principal Investigator & Institution: Dibble, Suzanne L.; Professor; Institute for Health and Aging; University of California San Francisco 500 Parnassus Ave San Francisco, Ca 941222747 Timing: Fiscal Year 2002; Project Start 02-AUG-2001; Project End 31-MAR-2004 Summary: Although the newer antiemetic agents have controlled a notable portion of the vomiting associated with chemotherapy administration, nausea continues to be a significant problem. Therefore, the specific aims of this [randomized clinical trial] are to compare differences in the nausea experience and intensity among three groups (Total N=237) undergoing doxorubicin hydrochloride (Addamycin ) and cyclophosphamide with or without fluorouracil chemotherapy for breast cancer. The groups are those receiving a) usual nausea care plus "Active Acupressure" via finger pressure on the nei guan point (P6), b) usual nausea care plus placebo acupressure and c) usual nausea care. Secondarily, the differences in quality of life, anxiety, and functional status among these group participants will be explored. Using eight oncology settings, participants will be recruited who had experienced nausea with their previous chemotherapy treatment. They will be randomly assigned to treatment groups. Stratification criteria will include regimen and site. The interventions will be conducted by carefully trained research assistants. All participants will be followed on a daily basis for two cycles of chemotherapy (a cycle is usually 21- 28 days). Analyses will be done using repeated measures analysis of variance and analysis of covariance, when baseline data is an appropriate covariate. A strength of this study is that it does not pit modem Western and Chinese medicine against each other to determine which is more effective. All participants will continue to receive their Western medical care, but the added value of acupressure will be explored. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen •
Project Title: VERTIGO
TREATMENTS
FOR
BENIGN
PAROXYSMAL
POSITIONAL
Principal Investigator & Institution: Cohen, Helen S.; Associate Professor; Otorhinolaryn & Communica Scis; Baylor College of Medicine 1 Baylor Plaza Houston, Tx 77030 Timing: Fiscal Year 2002; Project Start 01-AUG-1998; Project End 31-JUL-2003
34
Nausea
Summary: (Adapted from the Applicant's Abstract) Benign paroxysmal positional vertigo (BPPV), characterized by episodes of intense vertigo cause nausea, blurred vision, and falls. The most effective treatments have not yet been determined. No studies have systematically compared the accepted treatments to sham treatments while comparing systematic in treatment parameters or the influence of co- morbidity from other medical conditions. The clinical studies detailed in this application examine these accepted treatments and a control treatment to determine the immediate short-and longterm effectiveness of treatments for BPPV. The following specific aims will be addressed: 1) Determine the relative effectiveness of the Eply maneuver, the Semont maneuver, and Brandt-Daroff exercises compared to each other and to sham treatment in reducing the intensity and frequency of vertigo episodes and oculomotor responses to Dix-Hallpike maneuvers, and in increasing independence in activities of daily living; 2) Determine the relative effectiveness of habituation exercises designed to facilitate central habituation of vertigo, exercises designed to remove otoconial matter from the semicircular canals and the sham treatment; 3) Determine the relative contributions of variations on the most effective treatment from Specific Aim 2; 4) Determine the effect of co-morbid conditions on short-and long- term response to treatment. Website: http://crisp.cit.nih.gov/crisp/Crisp_Query.Generate_Screen
E-Journals: PubMed Central3 PubMed Central (PMC) is a digital archive of life sciences journal literature developed and managed by the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).4 Access to this growing archive of e-journals is free and unrestricted.5 To search, go to http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Pmc, and type “nausea” (or synonyms) into the search box. This search gives you access to fulltext articles. The following is a sample of items found for nausea in the PubMed Central database: •
Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. by Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ.; 2001 Jul 7; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=34325
•
Discordance between physical symptoms versus perception of severity by women with nausea and vomiting in pregnancy (NVP). by Chandra K MSc, Magee L MD, Koren G MD.; 2002; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=117801
•
Impact of Nausea and Vomiting on Quality of Life in Cancer Patients During Chemotherapy. by Ballatori E, Roila F.; 2003; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=212194
3 4
Adapted from the National Library of Medicine: http://www.pubmedcentral.nih.gov/about/intro.html.
With PubMed Central, NCBI is taking the lead in preservation and maintenance of open access to electronic literature, just as NLM has done for decades with printed biomedical literature. PubMed Central aims to become a world-class library of the digital age. 5 The value of PubMed Central, in addition to its role as an archive, lies in the availability of data from diverse sources stored in a common format in a single repository. Many journals already have online publishing operations, and there is a growing tendency to publish material online only, to the exclusion of print.
Studies
35
•
The use of CAM by women suffering from nausea and vomiting during pregnancy. by Hollyer T, Boon H, Georgousis A, Smith M, Einarson A.; 2002; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=113747
•
Treatment of established postoperative nausea and vomiting: a quantitative systematic review. by Kazemi-Kjellberg F, Henzi I, Tramer MR.; 2001; http://www.pubmedcentral.gov/articlerender.fcgi?tool=pmcentrez&artid=60651
The National Library of Medicine: PubMed One of the quickest and most comprehensive ways to find academic studies in both English and other languages is to use PubMed, maintained by the National Library of Medicine.6 The advantage of PubMed over previously mentioned sources is that it covers a greater number of domestic and foreign references. It is also free to use. If the publisher has a Web site that offers full text of its journals, PubMed will provide links to that site, as well as to sites offering other related data. User registration, a subscription fee, or some other type of fee may be required to access the full text of articles in some journals. To generate your own bibliography of studies dealing with nausea, simply go to the PubMed Web site at http://www.ncbi.nlm.nih.gov/pubmed. Type “nausea” (or synonyms) into the search box, and click “Go.” The following is the type of output you can expect from PubMed for nausea (hyperlinks lead to article summaries): •
A 15-year-old with blurred vision, nausea, back pain, and abdominal pain. Author(s): Kuensting LL. Source: Journal of Emergency Nursing: Jen : Official Publication of the Emergency Department Nurses Association. 2003 April; 29(2): 171-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12660705
•
A comparison of cyclizine, ondansetron and placebo as prophylaxis against postoperative nausea and vomiting in children. Author(s): O'Brien CM, Titley G, Whitehurst P. Source: Anaesthesia. 2003 July; 58(7): 707-11. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12886917
•
A comparison of granisetron, droperidol, and metoclopramide in the treatment of established nausea and vomiting after breast surgery: a double-blind, randomized, controlled trial. Author(s): Fujii Y, Tanaka H, Kawasaki T. Source: Clinical Therapeutics. 2003 April; 25(4): 1142-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12809962
6
PubMed was developed by the National Center for Biotechnology Information (NCBI) at the National Library of Medicine (NLM) at the National Institutes of Health (NIH). The PubMed database was developed in conjunction with publishers of biomedical literature as a search tool for accessing literature citations and linking to full-text journal articles at Web sites of participating publishers. Publishers that participate in PubMed supply NLM with their citations electronically prior to or at the time of publication.
36
Nausea
•
A comparison of intravenous ketoprofen versus pethidine on peri-operative analgesia and post-operative nausea and vomiting in paediatric vitreoretinal surgery. Author(s): Subramaniam R, Ghai B, Khetarpal M, Subramanyam MS. Source: Journal of Postgraduate Medicine. 2003 April-June; 49(2): 123-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12867686
•
A comparison of the effects of droperidol and the combination of droperidol and ondansetron on postoperative nausea and vomiting for patients undergoing laparoscopic cholecystectomy. Author(s): Awad IT, Murphy D, Stack D, Swanton BJ, Meeke RI, Shorten GD. Source: Journal of Clinical Anesthesia. 2002 November; 14(7): 481-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12477581
•
A comparison of three antiemetic combinations for the prevention of postoperative nausea and vomiting. Author(s): Sanchez-Ledesma MJ, Lopez-Olaondo L, Pueyo FJ, Carrascosa F, Ortega A. Source: Anesthesia and Analgesia. 2002 December; 95(6): 1590-5, Table of Contents. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12456422
•
A comparison of total intravenous with balanced anaesthesia for middle ear surgery: effects on postoperative nausea and vomiting, pain, and conditions of surgery. Author(s): Mukherjee K, Seavell C, Rawlings E, Weiss A. Source: Anaesthesia. 2003 February; 58(2): 176-80. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12622108
•
A prospective study of incidence of postoperative nausea and vomiting in a tertiary care hospital in Oman. Author(s): Maddali MM, Mathew J, Fahr J, Zarroug AW. Source: Middle East J Anesthesiol. 2003 February; 17(1): 131-41. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12754778
•
A randomized comparison of ginger and vitamin B6 in the treatment of nausea and vomiting of pregnancy. Author(s): Sripramote M, Lekhyananda N. Source: J Med Assoc Thai. 2003 September; 86(9): 846-53. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14649969
•
A randomized controlled trial of nerve stimulation for relief of nausea and vomiting in pregnancy. Author(s): Rosen T, de Veciana M, Miller HS, Stewart L, Rebarber A, Slotnick RN. Source: Obstetrics and Gynecology. 2003 July; 102(1): 129-35. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12850618
Studies
37
•
A response to 'A comparison of cyclizine, ondansetron and placebo as prophylaxis against postoperative nausea and vomiting in children' O'Brien CM, Titley G, Whitehurst P, Anaesthesia 2003; 58: 707-11. Author(s): Oldman M, Youngs P, Johnson A. Source: Anaesthesia. 2003 November; 58(11): 1151. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14616647
•
A systematic approach to the management of postoperative nausea and vomiting. Author(s): Golembiewski JA, O'Brien D. Source: Journal of Perianesthesia Nursing : Official Journal of the American Society of Perianesthesia Nurses / American Society of Perianesthesia Nurses. 2002 December; 17(6): 364-76. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12476402
•
Acupuncture compared to placebo-acupuncture for postoperative nausea and vomiting prophylaxis: a randomised placebo-controlled patient and observer blind trial. Author(s): Streitberger K, Diefenbacher M, Bauer A, Conradi R, Bardenheuer H, Martin E, Schneider A, Unnebrink K. Source: Anaesthesia. 2004 February; 59(2): 142-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14725517
•
Acupuncture to reduce nausea during chemotherapy treatment of rheumatic diseases. Author(s): Josefson A, Kreuter M. Source: Rheumatology (Oxford, England). 2003 October; 42(10): 1149-54. Epub 2003 May 30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12777644
•
Adding droperidol to morphine patient-controlled analgesia: effect on nausea and vomiting. Author(s): Sanansilp V, Soontarinka S, Kantigal P, Visalyaputra S, Deesawat J, Phadermwongsa P, Parakkamodom S, Vudhikamraksa S. Source: J Med Assoc Thai. 2002 September; 85 Suppl 3: S923-33. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12452231
•
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Author(s): Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F; Aprepitant Protocol 054 Study Group. Source: Cancer. 2003 June 15; 97(12): 3090-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12784346
38
Nausea
•
Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. Author(s): de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 November 15; 21(22): 4105-11. Epub 2003 October 14. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14559891
•
Advice on postop nausea and vomiting. Author(s): Ninger L. Source: Or Manager. 2003 November; 19(11): 25-6, 28. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14639792
•
An audit of post-operative nausea and vomiting, following cardiac surgery: scope of the problem. Author(s): Mace L. Source: Nursing in Critical Care. 2003 September-October; 8(5): 187-96. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14653525
•
Are health states 'timeless'? A case study of an acute condition: post-chemotherapy nausea and vomiting. Author(s): Franic DM, Pathak DS, Gafni A. Source: Journal of Evaluation in Clinical Practice. 2003 February; 9(1): 69-82. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12558704
•
Aromatherapy with peppermint, isopropyl alcohol, or placebo is equally effective in relieving postoperative nausea. Author(s): Anderson LA, Gross JB. Source: Journal of Perianesthesia Nursing : Official Journal of the American Society of Perianesthesia Nurses / American Society of Perianesthesia Nurses. 2004 February; 19(1): 29-35. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14770380
•
Arterial hypotension during induction of anesthesia may not be a risk factor for postoperative nausea and vomiting. Author(s): Kranke P, Roewer N, Rusch D, Piper SN. Source: Anesthesia and Analgesia. 2003 January; 96(1): 302-3; Author Reply 303. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12505973
Studies
39
•
Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5day recall. Author(s): Martin AR, Pearson JD, Cai B, Elmer M, Horgan K, Lindley C. Source: Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 2003 August; 11(8): 522-7. Epub 2003 June 25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12827483
•
Atrial fibrillation after ondansetron for the prevention and treatment of postoperative nausea and vomiting: a case report. Author(s): Kasinath NS, Malak O, Tetzlaff J. Source: Canadian Journal of Anaesthesia = Journal Canadien D'anesthesie. 2003 March; 50(3): 229-31. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12620943
•
Benefits and risks of newer treatments for chemotherapy-induced and postoperative nausea and vomiting. Author(s): Kovac AL. Source: Drug Safety : an International Journal of Medical Toxicology and Drug Experience. 2003; 26(4): 227-59. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12608887
•
Changes in family relationships affect the development of chemotherapy-related nausea symptoms. Author(s): Kim Y, Morrow GR. Source: Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 2003 March; 11(3): 171-7. Epub 2003 January 25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12618927
•
Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Author(s): Schnell FM. Source: The Oncologist. 2003; 8(2): 187-98. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12697943
•
Clinical comparison of the selective serotonin3 antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea and anorexia. Author(s): Feng F, Zhang P, He Y, Li Y, Zhou M, Chen G, Li L. Source: Chinese Medical Sciences Journal = Chung-Kuo I Hsueh K'o Hsueh Tsa Chih / Chinese Academy of Medical Sciences. 2002 September; 17(3): 168-72. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12901541
40
Nausea
•
Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma. Author(s): Numbenjapon T, Sriswasdi C, Mongkonsritragoon W, Leelasiri A, Prayoonwiwat W. Source: J Med Assoc Thai. 2002 November; 85(11): 1156-63. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12546311
•
Comparison of acupressure bands and droperidol for reducing post-operative nausea and vomiting in gynecologic surgery patients. Author(s): Schultz AA, Andrews AL, Goran SF, Mathew T, Sturdevant N. Source: Applied Nursing Research : Anr. 2003 November; 16(4): 256-65. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14608559
•
Comparison of acustimulation and ondansetron for the treatment of established postoperative nausea and vomiting. Author(s): Coloma M, White PF, Ogunnaike BO, Markowitz SD, Brown PM, Lee AQ, Berrisford SB, Wakefield CA, Issioui T, Jones SB, Jones DB. Source: Anesthesiology. 2002 December; 97(6): 1387-92. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12459663
•
Comparison of granisetron and granisetron plus dexamethasone for the prevention of postoperative nausea and vomiting after laparoscopic cholecystectomy. Author(s): Biswas BN, Rudra A. Source: Acta Anaesthesiologica Scandinavica. 2003 January; 47(1): 79-83. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12492802
•
Comparison of granisetron with granisetron plus droperidol combination prophylaxis in post-operative nausea and vomiting after laparoscopic cholecystectomy. Author(s): Ozmen S, Yavuz L, Ceylan BG, Tarhan O, Aydin C. Source: J Int Med Res. 2002 September-October; 30(5): 520-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12449522
•
Comparison of inhaled isopropyl alcohol and intravenous ondansetron for treatment of postoperative nausea. Author(s): Winston AW, Rinehart RS, Riley GP, Vacchiano CA, Pellegrini JE. Source: Aana Journal. 2003 April; 71(2): 127-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12776641
Studies
41
•
Comparison of three outpatient regimens in the management of nausea and vomiting in pregnancy. Author(s): Bsat FA, Hoffman DE, Seubert DE. Source: Journal of Perinatology : Official Journal of the California Perinatal Association. 2003 October; 23(7): 531-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14566347
•
Consensus guidelines for managing postoperative nausea and vomiting. Author(s): Gan TJ, Meyer T, Apfel CC, Chung F, Davis PJ, Eubanks S, Kovac A, Philip BK, Sessler DI, Temo J, Tramer MR, Watcha M; Department of Anesthesiology, Duke University Medical Center. Source: Anesthesia and Analgesia. 2003 July; 97(1): 62-71, Table of Contents. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12818945
•
Consensus guidelines for managing postoperative nausea and vomiting: is there a conflict of interest? Author(s): White PF. Source: Anesthesia and Analgesia. 2004 February; 98(2): 550; Author Reply 550-1. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14742406
•
Continuous PC6 wristband acupressure for relief of nausea and vomiting associated with acute myocardial infarction: a partially randomised, placebo-controlled trial. Author(s): Dent HE, Dewhurst NG, Mills SY, Willoughby M. Source: Complementary Therapies in Medicine. 2003 June; 11(2): 72-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12801491
•
Corticosteroids underemployment in delayed chemotherapy-induced nausea and emesis with poor adherence to American Society of Clinical Oncology guidelines: is this a reasonable clinical choice for the elderly? Author(s): Gridelli C, Maione P, Rossi A. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 November 1; 21(21): 4066-7; Author Reply 4067-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14581432
•
Cost-effectiveness of three combinations of antiemetics in the prevention of postoperative nausea and vomiting. Author(s): Pueyo FJ, Lopez-Olaondo L, Sanchez-Ledesma MJ, Ortega A, Carrascosa F. Source: British Journal of Anaesthesia. 2003 October; 91(4): 589-92. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14504165
42
Nausea
•
Delayed chemotherapy-induced nausea in women treated for breast cancer. Author(s): Dibble SL, Isreal J, Nussey B, Casey K, Luce J. Source: Oncology Nursing Forum. 2003 March-April; 30(2): E40-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12692669
•
Development of an instrument to measure nausea and vomiting in pregnancy. Author(s): Swallow BL, Lindow SW, Masson EA, Hay DM. Source: Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology. 2002 September; 22(5): 481-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12521412
•
Dexamethasone 8 mg in combination with ondansetron 4 mg appears to be the optimal dose for the prevention of nausea and vomiting after laparoscopic cholecystectomy. Author(s): Elhakim M, Nafie M, Mahmoud K, Atef A. Source: Canadian Journal of Anaesthesia = Journal Canadien D'anesthesie. 2002 November; 49(9): 922-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12419717
•
Dexamethasone is as effective as ondansetron for the prevention of postoperative nausea and vomiting following breast surgery. Author(s): Wattwil M, Thorn SE, Lovqvist A, Wattwil L, Gupta A, Liljegren G. Source: Acta Anaesthesiologica Scandinavica. 2003 August; 47(7): 823-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12859302
•
Dexamethasone prevents postoperative nausea and vomiting more effectively in women with motion sickness. Author(s): Lee Y, Lai HY, Lin PC, Huang SJ, Lin YS. Source: Canadian Journal of Anaesthesia = Journal Canadien D'anesthesie. 2003 March; 50(3): 232-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12620944
•
Diclectin therapy for nausea and vomiting of pregnancy: effects of optimal dosing. Author(s): Boskovic R, Einarson A, Maltepe C, Wolpin J, Koren G. Source: J Obstet Gynaecol Can. 2003 October; 25(10): 830-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14532951
•
Difference in risk factors for postoperative nausea and vomiting. Author(s): Stadler M, Bardiau F, Seidel L, Albert A, Boogaerts JG. Source: Anesthesiology. 2003 January; 98(1): 46-52. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12502978
Studies
43
•
Does meta-analysis increase our knowledge in the management of postoperative nausea and vomiting? Author(s): Tramer MR. Source: International Anesthesiology Clinics. 2003 Fall; 41(4): 33-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14574213
•
Does the routine prophylactic use of antiemetics affect the incidence of postdischarge nausea and vomiting following ambulatory surgery?: A systematic review of randomized controlled trials. Author(s): Gupta A, Wu CL, Elkassabany N, Krug CE, Parker SD, Fleisher LA. Source: Anesthesiology. 2003 August; 99(2): 488-95. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12883424
•
Dolasetron prophylaxis reduces nausea and postanaesthesia recovery time after remifentanil infusion during monitored anaesthesia care for extracorporeal shock wave lithotripsy. Author(s): Burmeister MA, Standl TG, Wintruff M, Brauer P, Blanc I, Schulte am Esch J. Source: British Journal of Anaesthesia. 2003 February; 90(2): 194-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12538377
•
Dolasetron, but not metoclopramide prevents nausea and vomiting in patients undergoing laparoscopic cholecystectomy. Author(s): Piper SN, Suttner SW, Rohm KD, Maleck WH, Larbig E, Boldt J. Source: Canadian Journal of Anaesthesia = Journal Canadien D'anesthesie. 2002 December; 49(10): 1021-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12477671
•
Effect of a ginger extract on pregnancy-induced nausea: a randomised controlled trial. Author(s): Willetts KE, Ekangaki A, Eden JA. Source: The Australian & New Zealand Journal of Obstetrics & Gynaecology. 2003 April; 43(2): 139-44. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14712970
•
Effect of acupressure on postoperative nausea and vomiting in laparoscopic cholecystectomy. Author(s): Samad K, Afshan G, Kamal R. Source: J Pak Med Assoc. 2003 February; 53(2): 68-72. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12705488
44
Nausea
•
Effect of drainage on postoperative nausea, vomiting, and pain after laparoscopic cholecystectomy. Author(s): Nursal TZ, Yildirim S, Tarim A, Noyan T, Poyraz P, Tuna N, Haberal M. Source: Langenbeck's Archives of Surgery / Deutsche Gesellschaft Fur Chirurgie. 2003 April; 388(2): 95-100. Epub 2003 April 02. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12684804
•
Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Author(s): Guttuso T Jr, Roscoe J, Griggs J. Source: Lancet. 2003 May 17; 361(9370): 1703-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12767738
•
Effect of supplemental pre-operative fluid on postoperative nausea and vomiting. Author(s): Ali SZ, Taguchi A, Holtmann B, Kurz A. Source: Anaesthesia. 2003 August; 58(8): 780-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12859471
•
Effectiveness of Gorei-san (TJ-17) for treatment of SSRI-induced nausea and dyspepsia: preliminary observations. Author(s): Yamada K, Yagi G, Kanba S. Source: Clinical Neuropharmacology. 2003 May-June; 26(3): 112-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12782911
•
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Author(s): Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ. Source: Cancer. 2003 May 1; 97(9): 2290-300. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12712486
•
Expectations of chemotherapy-related nausea: emotional and experiential predictors. Author(s): Montgomery GH, Bovbjerg DH. Source: Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine. 2003 Winter; 25(1): 48-54. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12581936
•
Ginger does not prevent postoperative nausea and vomiting after laparoscopic surgery. Author(s): Eberhart LH, Mayer R, Betz O, Tsolakidis S, Hilpert W, Morin AM, Geldner G, Wulf H, Seeling W. Source: Anesthesia and Analgesia. 2003 April; 96(4): 995-8, Table of Contents. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12651648
Studies
45
•
Granisetron in the control of nausea and vomiting associated with bone marrow transplantation: a review of its efficacy and tolerability. Author(s): Prentice HG. Source: Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 2003 August; 11(8): 501-8. Epub 2003 July 05. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12845514
•
Granisetron versus granisetron/dexamethasone combination for the treatment of nausea, retching, and vomiting after major gynecologic surgery: a randomized, double-blind study. Author(s): Fujii Y, Tanaka H. Source: Clinical Therapeutics. 2003 February; 25(2): 507-14. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12749510
•
Granisetron: is there a dose-response effect on nausea and vomiting? Author(s): Minami M. Source: Cancer Chemotherapy and Pharmacology. 2003 August; 52(2): 89-98. Epub 2003 May 29. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12783208
•
Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting. Author(s): Tan M. Source: Expert Opinion on Pharmacotherapy. 2003 September; 4(9): 1563-71. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12943486
•
Guidelines outline strategies to reduce post-operative nausea and vomiting. Author(s): Rollins G. Source: Rep Med Guidel Outcomes Res. 2002 April 19; 13(8): 9-10, 12. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12467270
•
Higher plasma 5-hydroxyindoleacetic acid levels are associated with SSRI-induced nausea. Author(s): Ueda N, Yoshimura R, Shinkai K, Sakata Y, Nakamura J. Source: Neuropsychobiology. 2003; 48(1): 31-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12886038
•
History of postoperative nausea and vomiting. Author(s): Raeder J. Source: International Anesthesiology Clinics. 2003 Fall; 41(4): 1-12. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14574211
46
Nausea
•
Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. Author(s): DeVane CL. Source: The Journal of Clinical Psychiatry. 2003; 64 Suppl 18: 14-9. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14700450
•
Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Author(s): Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S; 99-04 Palonosetron Study Group. Source: Cancer. 2003 December 1; 98(11): 2473-82. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14635083
•
Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. Author(s): Mertens WC, Higby DJ, Brown D, Parisi R, Fitzgerald J, Benjamin EM, Lindenauer PK. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 April 1; 21(7): 1373-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12663729
•
Incidence of postoperative nausea and vomiting in paediatric ambulatory surgery. Author(s): Villeret I, Laffon M, Duchalais A, Blond MH, Lecuyer AI, Mercier C. Source: Paediatric Anaesthesia. 2002 October; 12(8): 712-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12472709
•
Increased incidence of postoperative nausea and vomiting without additional analgesic effects when a low dose of intravenous fentanyl is combined with a caudal block. Author(s): Kokinsky E, Nilsson K, Larsson LE. Source: Paediatric Anaesthesia. 2003 May; 13(4): 334-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12753447
•
Intraoperative colloid administration reduces postoperative nausea and vomiting and improves postoperative outcomes compared with crystalloid administration. Author(s): Moretti EW, Robertson KM, El-Moalem H, Gan TJ. Source: Anesthesia and Analgesia. 2003 February; 96(2): 611-7, Table of Contents. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12538221
Studies
47
•
Intravenous fluid loading with or without supplementary dextrose does not prevent nausea, vomiting and pain after laparoscopy. Author(s): McCaul C, Moran C, O'Cronin D, Naughton F, Geary M, Carton E, Gardiner J. Source: Canadian Journal of Anaesthesia = Journal Canadien D'anesthesie. 2003 May; 50(5): 440-4. English, French. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12734150
•
Is there rationale to use an antiemetic in the same class for the treatment of patients who experience postoperative nausea and vomiting despite prophylaxis? Author(s): Kovac AL. Source: Anesthesia and Analgesia. 2003 December; 97(6): 1857. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14633582
•
Local active warming: an effective treatment for pain, anxiety and nausea caused by renal colic. Author(s): Kober A, Dobrovits M, Djavan B, Marberger M, Barker R, Bertalanffy P, Scheck T, Gustorff B, Hoerauf K. Source: The Journal of Urology. 2003 September; 170(3): 741-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12913687
•
Low incidence of nausea and vomiting with intravenous opiate analgesia in the ED. Author(s): Paoloni R, Talbot-Stern J. Source: The American Journal of Emergency Medicine. 2002 November; 20(7): 604-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12442238
•
Management of postoperative nausea and vomiting in ambulatory surgery. Author(s): Cameron D, Gan TJ. Source: Anesthesiology Clinics of North America. 2003 June; 21(2): 347-65. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12812400
•
Managing nausea and vomiting. Current strategies. Author(s): Garrett K, Tsuruta K, Walker S, Jackson S, Sweat M. Source: Critical Care Nurse. 2003 February; 23(1): 31-50; Quiz 51-2. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12640958
•
Measuring chemotherapy-induced nausea and emesis. Author(s): Martin CG, Rubenstein EB, Elting LS, Kim YJ, Osoba D. Source: Cancer. 2003 August 1; 98(3): 645-55. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12879484
48
Nausea
•
Metoclopramide pretreatment attenuates emergency contraceptive-associated nausea. Author(s): Ragan RE, Rock RW, Buck HW. Source: American Journal of Obstetrics and Gynecology. 2003 February; 188(2): 330-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12592235
•
Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine. Author(s): Yoshida K, Naito S, Takahashi H, Sato K, Ito K, Kamata M, Higuchi H, Shimizu T, Itoh K, Inoue K, Suzuki T, Ohkubo T. Source: Neuropsychobiology. 2003; 48(1): 10-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12886034
•
Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Author(s): Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR. Source: Cancer. 2003 June 1; 97(11): 2880-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12767103
•
Nausea and vomiting after fast-track cardiac anaesthesia. Author(s): Kogan A, Eidelman LA, Raanani E, Orlov B, Shenkin O, Vidne BA. Source: British Journal of Anaesthesia. 2003 August; 91(2): 214-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12878620
•
Nausea and vomiting after phacoemulsification using topical or retrobulbar anesthesia. Author(s): Chan JC, Lai JS, Lam DS. Source: Journal of Cataract and Refractive Surgery. 2002 November; 28(11): 1973-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12457672
•
Nausea and vomiting associate with increasing maternal androgen levels in otherwise uncomplicated pregnancies. Author(s): Carlsen SM, Vanky E, Jacobsen G. Source: Acta Obstetricia Et Gynecologica Scandinavica. 2003 March; 82(3): 225-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12694117
•
Nausea and vomiting during pregnancy. Author(s): Koch KL, Frissora CL. Source: Gastroenterology Clinics of North America. 2003 March; 32(1): 201-34, Vi. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12635417
Studies
49
•
Nausea and vomiting in early pregnancy. Author(s): Jewell D. Source: American Family Physician. 2003 July 1; 68(1): 143-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12887120
•
Nausea and vomiting in pregnancy in relation to prolactin, estrogens, and progesterone: a prospective study. Author(s): Lagiou P, Tamimi R, Mucci LA, Trichopoulos D, Adami HO, Hsieh CC. Source: Obstetrics and Gynecology. 2003 April; 101(4): 639-44. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12681864
•
Nausea and vomiting in pregnancy: results of a survey that identified interventions used by women to alleviate their symptoms. Author(s): Chandra K, Magee L, Einarson A, Koren G. Source: Journal of Psychosomatic Obstetrics and Gynaecology. 2003 June; 24(2): 71-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12854391
•
Nausea and vomiting in pregnancy: safety and efficacy of self-administered complementary therapies. Author(s): Tiran D. Source: Complementary Therapies in Nursing & Midwifery. 2002 November; 8(4): 191-6. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12463608
•
Nausea and vomiting of pregnancy. Author(s): Quinla JD, Hill DA. Source: American Family Physician. 2003 July 1; 68(1): 121-8. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12887118
•
Nausea and vomiting. Author(s): Hasler WL, Chey WD. Source: Gastroenterology. 2003 December; 125(6): 1860-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14724837
•
Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. Author(s): Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R. Source: Journal of Pain and Symptom Management. 2003 June; 25(6): 578-82. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12782438
50
Nausea
•
Olanzapine for intractable nausea in palliative care patients. Author(s): Jackson WC, Tavernier L. Source: Journal of Palliative Medicine. 2003 April; 6(2): 251-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12854942
•
Olfactory modulation of nausea during early pregnancy? Author(s): Hummel T, von Mering R, Huch R, Kolble N. Source: Bjog : an International Journal of Obstetrics and Gynaecology. 2002 December; 109(12): 1394-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12504977
•
Oncology Patient Evidence-Based Notes (OPEN): antiemetics for chemotherapyinduced nausea and vomiting. Author(s): Cope D. Source: Clinical Journal of Oncology Nursing. 2003 July-August; 7(4): 461-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12929282
•
Ondansetron disintegrating tablets of 8 mg twice a day for 3 days did not reduce the incidence of nausea or vomiting after laparoscopic surgery. Author(s): Thagaard KS, Steine S, Raeder J. Source: European Journal of Anaesthesiology. 2003 February; 20(2): 153-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12622501
•
Ondansetron for prevention of intrathecal opioids-induced pruritus, nausea and vomiting after cesarean delivery. Author(s): Yazigi A, Chalhoub V, Madi-Jebara S, Haddad F. Source: Anesthesia and Analgesia. 2004 January; 98(1): 264; Author Reply 264. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14693635
•
Ondansetron for the prevention and treatment of nausea and vomiting following pediatric strabismus surgery. Author(s): Caron E, Bussieres JF, Lebel D, Mathews S, Milot J, Jacob JL, Moride Y, Lortie L. Source: Can J Ophthalmol. 2003 April; 38(3): 214-22. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12733689
•
Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children. Author(s): Dupuis LL, Nathan PC. Source: Paediatric Drugs. 2003; 5(9): 597-613. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12956617
Studies
51
•
P6 acupressure may relieve nausea and vomiting after gynecological surgery: an effectiveness study in 410 women. Author(s): Alkaissi A, Evertsson K, Johnsson VA, Ofenbartl L, Kalman S. Source: Canadian Journal of Anaesthesia = Journal Canadien D'anesthesie. 2002 December; 49(10): 1034-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12477673
•
Pain, nausea, vomiting and ocular complications delay discharge following ambulatory microdiscectomy. Author(s): Shaikh S, Chung F, Imarengiaye C, Yung D, Bernstein M. Source: Canadian Journal of Anaesthesia = Journal Canadien D'anesthesie. 2003 May; 50(5): 514-8. English, French. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12734164
•
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Author(s): Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M. Source: Annals of Oncology : Official Journal of the European Society for Medical Oncology / Esmo. 2003 October; 14(10): 1570-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14504060
•
Pediatric orbital floor fractures: nausea/vomiting as signs of entrapment. Author(s): Cohen SM, Garrett CG. Source: Otolaryngology and Head and Neck Surgery. 2003 July; 129(1): 43-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12869915
•
Peroral tramadol premedication increases postoperative nausea and delays homereadiness in day-case knee arthroscopy patients. Author(s): Liukkonen K, Santanen U, Pere P, Erkola O, Rautoma P. Source: Scand J Surg. 2002; 91(4): 365-8. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12558088
•
Pharmacotherapy of postoperative nausea and vomiting. Author(s): Habib AS, Gan TJ. Source: Expert Opinion on Pharmacotherapy. 2003 April; 4(4): 457-73. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12667109
•
Postoperative nausea and vomiting and outcome. Author(s): Scuderi PE, Conlay LA. Source: International Anesthesiology Clinics. 2003 Fall; 41(4): 165-74. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14574220
52
Nausea
•
Postoperative nausea and vomiting in children and adolescents undergoing radiofrequency catheter ablation: a randomized comparison of propofol- and isoflurane-based anesthetics. Author(s): Erb TO, Hall JM, Ing RJ, Kanter RJ, Kern FH, Schulman SR, Gan TJ. Source: Anesthesia and Analgesia. 2002 December; 95(6): 1577-81, Table of Contents. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12456419
•
Postoperative nausea and vomiting in diagnostic gynaecological laparoscopic procedures: comparison of the efficacy of the combination of dexamethasone and metoclopramide with that of dexamethasone and ondansetron. Author(s): Maddali MM, Mathew J, Fahr J, Zarroug AW. Source: Journal of Postgraduate Medicine. 2003 October-December; 49(4): 302-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14699226
•
Postoperative nausea and vomiting in regional anesthesia: a review. Author(s): Borgeat A, Ekatodramis G, Schenker CA. Source: Anesthesiology. 2003 February; 98(2): 530-47. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12552215
•
Postoperative nausea and vomiting: a review of current literature. Author(s): Ku CM, Ong BC. Source: Singapore Med J. 2003 July; 44(7): 366-74. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14620731
•
Pregnancy outcome following women's participation in a randomised controlled trial of acupuncture to treat nausea and vomiting in early pregnancy. Author(s): Smith C, Crowther C, Beilby J. Source: Complementary Therapies in Medicine. 2002 June; 10(2): 78-83. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12481955
•
Prevention of postoperative nausea and vomiting after spinal morphine for Caesarean section: comparison of cyclizine, dexamethasone and placebo. Author(s): Nortcliffe SA, Shah J, Buggy DJ. Source: British Journal of Anaesthesia. 2003 May; 90(5): 665-70. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12697596
•
Prevention of postoperative nausea and vomiting. Author(s): Norred CL. Source: Aana Journal. 2002 October; 70(5): 343-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12425121
Studies
53
•
Prophylaxis of nausea and vomiting after laparoscopic cholecystectomy with ramosetron: randomised controlled trial. Author(s): Fujii Y, Uemura A, Tanaka H. Source: The European Journal of Surgery = Acta Chirurgica. 2002; 168(11): 583-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12699092
•
Prospective comparative study of the safety and effectiveness of ginger for the treatment of nausea and vomiting in pregnancy. Author(s): Portnoi G, Chng LA, Karimi-Tabesh L, Koren G, Tan MP, Einarson A. Source: American Journal of Obstetrics and Gynecology. 2003 November; 189(5): 1374-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14634571
•
Psychological health in early pregnancy: relationship with nausea and vomiting. Author(s): Swallow BL, Lindow SW, Masson EA, Hay DM. Source: Journal of Obstetrics and Gynaecology : the Journal of the Institute of Obstetrics and Gynaecology. 2004 January; 24(1): 28-32. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14675977
•
Psychosocial factors related to nausea, vomiting, and fatigue in early pregnancy. Author(s): Chou FH, Lin LL, Cooney AT, Walker LO, Riggs MW. Source: Journal of Nursing Scholarship : an Official Publication of Sigma Theta Tau International Honor Society of Nursing / Sigma Theta Tau. 2003; 35(2): 119-25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12854291
•
Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting. Author(s): Rabasseda X. Source: Drugs Today (Barc). 2002 February; 38(2): 75-89. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12532186
•
Randomized, double-blind trial of dolasetron versus droperidol for prophylaxis of postoperative nausea and vomiting in patients undergoing TRAM flap breast reconstruction surgery. Author(s): Loewen P, Lamb S, Clugston P. Source: Annals of Plastic Surgery. 2003 November; 51(5): 472-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14595183
•
Randomized, double-blinded comparison of tropisetron and placebo for prevention of postoperative nausea and vomiting after supratentorial craniotomy. Author(s): Madenoglu H, Yildiz K, Dogru K, Kurtsoy A, Guler G, Boyaci A. Source: Journal of Neurosurgical Anesthesiology. 2003 April; 15(2): 82-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12657991
54
Nausea
•
Relationship between anxiety/depression and nausea: causal or associative? Author(s): Jagadisha D. Source: General Hospital Psychiatry. 2003 January-February; 25(1): 52; Author Reply 53. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12583930
•
Relationship between vitamin use, smoking, and nausea and vomiting of pregnancy. Author(s): Kallen B, Lundberg G, Aberg A. Source: Acta Obstetricia Et Gynecologica Scandinavica. 2003 October; 82(10): 916-20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12956841
•
Reporting of clinical details in randomized controlled trials of acupuncture for the treatment of migraine/headaches and nausea/vomiting. Author(s): Elorriaga Claraco A, Hanna SE, Fargas-Babjak A. Source: Journal of Alternative and Complementary Medicine (New York, N.Y.). 2003 February; 9(1): 151-9. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12676043
•
Risk assessment of postoperative nausea and vomiting. Author(s): Apfel CC, Roewer N. Source: International Anesthesiology Clinics. 2003 Fall; 41(4): 13-32. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14574212
•
Small dose of propofol for preventing nausea and vomiting after third molar extraction. Author(s): Fujii Y, Uemura A, Nakano M. Source: Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons. 2002 November; 60(11): 1246-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12420256
•
Strategies to reduce postoperative nausea and vomiting: does metoclopramide have a role? Author(s): Beattie WS. Source: Canadian Journal of Anaesthesia = Journal Canadien D'anesthesie. 2002 December; 49(10): 1009-15. English, French. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12477669
•
Study of postoperative nausea and vomiting: recommending risk models for group comparisons. Author(s): Apfel CC, Koivuranta M, Sweeney B. Source: Anaesthesia. 2003 May; 58(5): 492-3; Author Reply 493. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12694019
Studies
55
•
Supplemental oxygen does not reduce postoperative nausea and vomiting after thyroidectomy. Author(s): Joris JL, Poth NJ, Djamadar AM, Sessler DI, Hamoir EE, Defechereux TR, Meurisse MR, Lamy ML. Source: British Journal of Anaesthesia. 2003 December; 91(6): 857-61. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14633758
•
Supplemental oxygen does not reduce the incidence of postoperative nausea and vomiting after ambulatory gynecologic laparoscopy. Author(s): Purhonen S, Turunen M, Ruohoaho UM, Niskanen M, Hynynen M. Source: Anesthesia and Analgesia. 2003 January; 96(1): 91-6, Table of Contents. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12505931
•
Supplemental oxygen for prevention of nausea and vomiting after breast surgery. Author(s): Purhonen S, Niskanen M, Wustefeld M, Mustonen P, Hynynen M. Source: British Journal of Anaesthesia. 2003 August; 91(2): 284-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12878631
•
The effect of caffeine consumption and nausea on the risk of miscarriage. Author(s): Giannelli M, Doyle P, Roman E, Pelerin M, Hermon C. Source: Paediatric and Perinatal Epidemiology. 2003 October; 17(4): 316-23. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14629312
•
The effect of craniotomy location on postoperative pain and nausea. Author(s): Irefin SA, Schubert A, Bloomfield EL, DeBoer GE, Mascha EJ, Ebrahim ZY. Source: Journal of Anesthesia. 2003; 17(4): 227-31. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14625709
•
The effect of mandibular nerve block on opioid consumption, nausea and vomiting in bilateral mandibular osteotomies. Author(s): Van Lancker P, Abeloos JV, De Clercq CA, Mommaerts MY. Source: Acta Anaesthesiol Belg. 2003; 54(3): 223-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14598619
•
The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting. A University of Rochester Cancer Center Community Clinical Oncology Program multicenter study. Author(s): Roscoe JA, Morrow GR, Hickok JT, Bushunow P, Pierce HI, Flynn PJ, Kirshner JJ, Moore DF, Atkins JN. Source: Journal of Pain and Symptom Management. 2003 August; 26(2): 731-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12906958
56
Nausea
•
The efficacy of ginger in prevention of post-operative nausea and vomiting after outpatient gynecological laparoscopy. Author(s): Pongrojpaw D, Chiamchanya C. Source: J Med Assoc Thai. 2003 March; 86(3): 244-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12757064
•
The management of nausea and vomiting of pregnancy. Author(s): Craig WS. Source: J Obstet Gynaecol Can. 2003 March; 25(3): 184; Discussion 184. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12610668
•
The management of nausea and vomiting of pregnancy. Author(s): Boyd JJ. Source: J Obstet Gynaecol Can. 2003 January; 25(1): 13; Author Reply 13. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12548318
•
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapyinduced nausea and vomiting: a multinational, randomized, double-blind, placebocontrolled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. Author(s): Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ; Aprepitant Protocol 052 Study Group. Source: Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2003 November 15; 21(22): 4112-9. Epub 2003 October 14. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14559886
•
The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Author(s): de Wit R, Herrstedt J, Rapoport B, Carides AD, Guoguang-Ma J, Elmer M, Schmidt C, Evans JK, Horgan KJ. Source: European Journal of Cancer (Oxford, England : 1990). 2004 February; 40(3): 40310. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14746859
•
The placebo response and effect of time in a trial of acupuncture to treat nausea and vomiting in early pregnancy. Author(s): Smith C, Crowther C. Source: Complementary Therapies in Medicine. 2002 December; 10(4): 210-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12594971
Studies
57
•
The psychophysiology of nausea. Author(s): Stern RM. Source: Acta Biol Hung. 2002; 53(4): 589-99. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12501940
•
The value of risks scores for predicting postoperative nausea and vomiting when used to compare patient group in a randomised controlled trial. Author(s): Thomas R, Jones NA, Strike P. Source: Anaesthesia. 2002 November; 57(11): 1119-28. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12428640
•
Transderm scopolamine: a painless, noninvasive option for control of postoperative nausea and vomiting. Author(s): Sandlin D. Source: Journal of Perianesthesia Nursing : Official Journal of the American Society of Perianesthesia Nurses / American Society of Perianesthesia Nurses. 2002 December; 17(6): 427-9. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12476411
•
Treating nausea and vomiting during pregnancy: case outcome. Author(s): Harker N, Montgomery A, Fahey T. Source: Bmj (Clinical Research Ed.). 2004 February 28; 328(7438): 503; Discussion 504. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14988187
•
Treatment of nausea and emesis during cancer chemotherapy. Discrepancies between antiemetic effect and well-being. Author(s): Borjeson S, Hursti TJ, Tishelman C, Peterson C, Steineck G. Source: Journal of Pain and Symptom Management. 2002 September; 24(3): 345-58. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12458116
•
Treatment of postoperative nausea and vomiting. Author(s): Tramer MR. Source: Bmj (Clinical Research Ed.). 2003 October 4; 327(7418): 762-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14525850
•
Unbalanced middle ear anaesthesia. A response to 'A comparison of total intravenous with balanced anaesthesia for middle ear surgery: effects on postoperative nausea and vomiting, pain and conditions of surgery', Mukherjee K et al., Anaesthesia 2003; 58: 176-9. Author(s): Walsh E. Source: Anaesthesia. 2003 June; 58(6): 620. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12846668
58
•
Nausea
Using diazepam and atropine before strabismus surgery to prevent postoperative nausea and vomiting: a randomized, controlled study. Author(s): Ozcan AA, Gunes Y, Haciyakupoglu G. Source: J Aapos. 2003 June; 7(3): 210-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12825062
59
CHAPTER 2. NUTRITION AND NAUSEA Overview In this chapter, we will show you how to find studies dedicated specifically to nutrition and nausea.
Finding Nutrition Studies on Nausea The National Institutes of Health’s Office of Dietary Supplements (ODS) offers a searchable bibliographic database called the IBIDS (International Bibliographic Information on Dietary Supplements; National Institutes of Health, Building 31, Room 1B29, 31 Center Drive, MSC 2086, Bethesda, Maryland 20892-2086, Tel: 301-435-2920, Fax: 301-480-1845, E-mail:
[email protected]). The IBIDS contains over 460,000 scientific citations and summaries about dietary supplements and nutrition as well as references to published international, scientific literature on dietary supplements such as vitamins, minerals, and botanicals.7 The IBIDS includes references and citations to both human and animal research studies. As a service of the ODS, access to the IBIDS database is available free of charge at the following Web address: http://ods.od.nih.gov/databases/ibids.html. After entering the search area, you have three choices: (1) IBIDS Consumer Database, (2) Full IBIDS Database, or (3) Peer Reviewed Citations Only. Now that you have selected a database, click on the “Advanced” tab. An advanced search allows you to retrieve up to 100 fully explained references in a comprehensive format. Type “nausea” (or synonyms) into the search box, and click “Go.” To narrow the search, you can also select the “Title” field.
7
Adapted from http://ods.od.nih.gov. IBIDS is produced by the Office of Dietary Supplements (ODS) at the National Institutes of Health to assist the public, healthcare providers, educators, and researchers in locating credible, scientific information on dietary supplements. IBIDS was developed and will be maintained through an interagency partnership with the Food and Nutrition Information Center of the National Agricultural Library, U.S. Department of Agriculture.
60
Nausea
The following is a typical result when searching for recently indexed consumer information on nausea: •
Nausea and vomiting in early pregnancy. Source: Sharman, Ivan. Nutr-Food-Sci. London, Jan/February 1983. (80) page 20-22. charts. 0034-6659
Eng.
:
Forbes
Publications.
The following information is typical of that found when using the “Full IBIDS Database” to search for “nausea” (or a synonym): •
Are we failing women? Advice for nausea and vomiting in pregnancy. Author(s): Bournemouth University. Source: Allen, R Pract-Midwife. 2001 April; 4(4): 20-2 1461-3123
•
Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Author(s): Department of Psychology, Wilfrid Laurier University, Waterloo, Ontario N2L 3C5, Canada. Source: Parker, Linda A Mechoulam, Raphael Schlievert, Coralynne Neuroreport. 2002 April 16; 13(5): 567-70 0959-4965
•
Chemotherapy-induced nausea and vomiting. Author(s): University of Pittsburgh School of Nursing, 3500 Victoria Street, Room 415, Victoria Building, Pittsburgh, PA 15261, USA.
[email protected] Source: Bender, Catherine M McDaniel, Roxanne W Murphy Ende, Kathleen Pickett, Mary Rittenberg, Cynthia N Rogers, Miriam P Schneider, Susan M Schwartz, Rowena N Clin-J-Oncol-Nurs. 2002 Mar-April; 6(2): 94-102 1092-1095
•
Ginger for nausea. Source: Anonymous Harv-Womens-Health-Watch. 1999 September; 7(1): 7 1070-910X
•
Nausea and vomiting of pregnancy: endocrine basis and contribution to pregnancy outcome. Author(s): Department of Biomedical Sciences, University of Nottinhgham, Queens Medical Centre, United Kingdom. Source: Furneaux, E C Langley Evans, A J Langley Evans, S C Obstet-GynecolSurvolume 2001 December; 56(12): 775-82 0029-7828
•
Powerful peppermint calms indigestion, sore throat, and nausea. Source: Ciesinski, T. Org-gard. [Emmaus, PA : Rodale Press, c1988-. May/June 2001. volume 48 (4) page 18. 0897-3792
•
Pre-emptive metoclopramide and ondansetron for nausea and vomiting associated with iloprost infusions. Author(s): Royal Devon & Exeter Hospital (Wonford), Barrack Road, Exeter, England EX2 5DW, UK. Source: Roome, C Thompson, J Pharm-World-Sci. 2001 June; 23(3): 122 0928-1231
•
The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Author(s): Hebrew University, Jerusalem, Israel.
[email protected] Source: Mechoulam, R Hanu, L Pain-Res-Manag. 2001 Summer; 6(2): 67-73 1203-6765
•
The management of post-operative nausea and vomiting. Author(s): In-patient Neuroscience Center, The Medical College of Virginia Hospitals, Virginia Commonwealth University, USA.
Nutrition
61
Source: Thompson, H J J-Adv-Nurs. 1999 May; 29(5): 1130-6 0309-2402 •
The use of nalmefene for intrathecal opioid-associated nausea in postpartum patients. Source: Ward, Robyn C Lawrence, Robert L Hawkins, Robert J DiChiara, Steven E Biegner, Andrew R Vacchiano, Charles A AANA-J. 2002 February; 70(1): 57-60 00946354
•
Use of reversal agents in day care procedures (with special reference to postoperative nausea and vomiting). Author(s): Department of Anaesthesia and Critical Care, University of the Saarland, D66421 Homburg/Saar, Germany.
[email protected] Source: Fuchs Buder, T Mencke, T Eur-J-Anaesthesiol-Suppl. 2001; 23: 53-9 0952-1941
Federal Resources on Nutrition In addition to the IBIDS, the United States Department of Health and Human Services (HHS) and the United States Department of Agriculture (USDA) provide many sources of information on general nutrition and health. Recommended resources include: •
healthfinder®, HHS’s gateway to health information, including diet and nutrition: http://www.healthfinder.gov/scripts/SearchContext.asp?topic=238&page=0
•
The United States Department of Agriculture’s Web site dedicated to nutrition information: www.nutrition.gov
•
The Food and Drug Administration’s Web site for federal food safety information: www.foodsafety.gov
•
The National Action Plan on Overweight and Obesity sponsored by the United States Surgeon General: http://www.surgeongeneral.gov/topics/obesity/
•
The Center for Food Safety and Applied Nutrition has an Internet site sponsored by the Food and Drug Administration and the Department of Health and Human Services: http://vm.cfsan.fda.gov/
•
Center for Nutrition Policy and Promotion sponsored by the United States Department of Agriculture: http://www.usda.gov/cnpp/
•
Food and Nutrition Information Center, National Agricultural Library sponsored by the United States Department of Agriculture: http://www.nal.usda.gov/fnic/
•
Food and Nutrition Service sponsored by the United States Department of Agriculture: http://www.fns.usda.gov/fns/
Additional Web Resources A number of additional Web sites offer encyclopedic information covering food and nutrition. The following is a representative sample: •
AOL: http://search.aol.com/cat.adp?id=174&layer=&from=subcats
•
Family Village: http://www.familyvillage.wisc.edu/med_nutrition.html
•
Google: http://directory.google.com/Top/Health/Nutrition/
•
Healthnotes: http://www.healthnotes.com/
62
Nausea
•
Open Directory Project: http://dmoz.org/Health/Nutrition/
•
Yahoo.com: http://dir.yahoo.com/Health/Nutrition/
•
WebMDHealth: http://my.webmd.com/nutrition
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
The following is a specific Web list relating to nausea; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
Vitamins Niacin Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,892,00.html Pyridoxine Source: Integrative Medicine Communications; www.drkoop.com Vitamin A Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10066,00.html Vitamin B Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10067,00.html Vitamin B3 Source: Healthnotes, Inc.; www.healthnotes.com Vitamin B6 Source: Prima Communications, Inc.www.personalhealthzone.com Vitamin B6 (Pyridoxine) Source: Integrative Medicine Communications; www.drkoop.com Vitamin C Source: Prima Communications, Inc.www.personalhealthzone.com Vitamin D Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,905,00.html
Nutrition
Vitamin E Alternative names: Alpha-Tocopherol, Beta-Tocopherol, D-Alpha-Tocopherol, Delta-Tocopherol, Gamma-Tocopherol Source: Integrative Medicine Communications; www.drkoop.com Vitamin K Source: Prima Communications, Inc.www.personalhealthzone.com •
Minerals Acetyl-l-carnitine Source: Healthnotes, Inc.; www.healthnotes.com Alpha-tocopherol Source: Integrative Medicine Communications; www.drkoop.com Beta-tocopherol Source: Integrative Medicine Communications; www.drkoop.com Biotin Source: Healthnotes, Inc.; www.healthnotes.com Boron Source: Healthnotes, Inc.; www.healthnotes.com Boron Source: Prima Communications, Inc.www.personalhealthzone.com Cisplatin Source: Healthnotes, Inc.; www.healthnotes.com Copper Source: Integrative Medicine Communications; www.drkoop.com Copper Source: Prima Communications, Inc.www.personalhealthzone.com Copper Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,886,00.html D-alpha-tocopherol Source: Integrative Medicine Communications; www.drkoop.com Delta-tocopherol Source: Integrative Medicine Communications; www.drkoop.com Fluoxetine Source: Healthnotes, Inc.; www.healthnotes.com
63
64
Nausea
Gamma-tocopherol Source: Integrative Medicine Communications; www.drkoop.com Lecithin and Choline Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10040,00.html Lecithin/Phosphatidylcholine/Choline Source: Healthnotes, Inc.; www.healthnotes.com Magnesium Source: Integrative Medicine Communications; www.drkoop.com Magnesium Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,890,00.html Paroxetine Source: Healthnotes, Inc.; www.healthnotes.com Potassium Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10086,00.html Retinol Source: Integrative Medicine Communications; www.drkoop.com Selenium Source: Prima Communications, Inc.www.personalhealthzone.com Selenium Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10055,00.html Vitamin A (Retinol) Source: Integrative Medicine Communications; www.drkoop.com Zinc Source: Healthnotes, Inc.; www.healthnotes.com Zinc Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10071,00.html
Nutrition
•
Food and Diet Artichoke Alternative names: Cynara scolymus Source: Healthnotes, Inc.; www.healthnotes.com Chondroitin Sulfate Source: Healthnotes, Inc.; www.healthnotes.com Fasting Diet Source: Healthnotes, Inc.; www.healthnotes.com Garlic Source: Prima Communications, Inc.www.personalhealthzone.com Garlic Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,786,00.html Nutritional Yeast Alternative names: Brewer's Yeast Source: Integrative Medicine Communications; www.drkoop.com Tyramine-Free Diet Source: Healthnotes, Inc.; www.healthnotes.com
65
67
CHAPTER 3. ALTERNATIVE MEDICINE AND NAUSEA Overview In this chapter, we will begin by introducing you to official information sources on complementary and alternative medicine (CAM) relating to nausea. At the conclusion of this chapter, we will provide additional sources.
The Combined Health Information Database The Combined Health Information Database (CHID) is a bibliographic database produced by health-related agencies of the U.S. federal government (mostly from the National Institutes of Health) that can offer concise information for a targeted search. The CHID database is updated four times a year at the end of January, April, July, and October. Check the titles, summaries, and availability of CAM-related information by using the “Simple Search” option at the following Web site: http://chid.nih.gov/simple/simple.html. In the drop box at the top, select “Complementary and Alternative Medicine.” Then type “nausea” (or synonyms) in the second search box. We recommend that you select 100 “documents per page” and to check the “whole records” options. The following was extracted using this technique: •
Effect of Therapeutic Touch on the Well-Being of Persons With Terminal Cancer Source: Journal of Holistic Nursing. 16(3): 383-398. September 1998. Summary: This journal article describes a study of the effects of therapeutic touch on the well-being of patients with terminal cancer. The participants were 20 inpatients with terminal cancer, ages 38 to 68 years, on the palliative care unit of a university-affiliated Canadian hospital. They were randomly assigned to three treatments with noncontact therapeutic touch (experimental group) or three rest periods (control group) on consecutive days. Both interventions lasted 15 to 20 minutes and took place at approximately the same time of day, 1 hour following a regularly prescribed analgesic. Well-being was assessed before and immediately after the intervention using the WellBeing Scale, a visual analogue scale measuring pain, nausea, depression, anxiety, shortness of breath, activity, appetite, relaxation, and inner peace. The mean well-being score increased significantly in the experimental group compared with the control group over the three intervention sessions. The mean score for the experimental group
68
Nausea
increased progressively that successive treatments, whereas that of the control group decreased slightly over time. The authors discuss factors which might explain the results, and offer suggestions for further research. The article has 1 figure, 6 tables, and 32 references. •
NIH Consensus Conference: Acupuncture Source: JAMA. Journal of the American Medical Association. 280(17): 1518-1524. November 4, 1998. Summary: This journal article presents the findings of the consensus conference on acupuncture, sponsored by the Office of Alternative Medicine and the Office of Medical Applications of Research, National Institutes of Health. The purpose of the conference was to provide clinicians, patients, and the general public with a reliable assessment of the use and effectiveness of acupuncture for a variety of conditions. A multidisciplinary panel evaluated evidence presented by experts and in the scientific literature, and developed a consensus statement addressing five issues: the efficacy of acupuncture compared with placebo or sham acupuncture, the place of acupuncture in clinical practice, the biological effects of acupuncture, the integration of acupuncture into the health care system, and directions for future research. The panel concluded that many of the efficacy studies of acupuncture provide equivocal results because of design, sample size, and other factors. The issue is further complicated by inherent difficulties in the use of appropriate controls. However, promising results have emerged showing the efficacy of acupuncture for adult postoperative and chemotherapy nausea and vomiting, and in postoperative dental pain. In other conditions such as addiction, stroke rehabilitation, headache, menstrual cramps, fibromyalgia, myofascial pain, osteoarthritis, tennis elbow, low back pain, carpal tunnel syndrome, and asthma, acupuncture may be useful as an adjunct treatment, an acceptable alternative, or part of a comprehensive management plan. This article has 66 references.
•
Complementary Therapies: Overview and State of the Art Source: Cancer Nursing. 22(1): 85-90. February 1999. Summary: This journal article provides an overview of the benefits and potential problems of complementary therapies for cancer. The author distinguishes between alternative and complementary therapies, noting that alternative therapies are used instead of conventional cancer treatment, whereas complementary therapies are used as adjuncts to mainstream care. In the author's opinion, alternative therapies can be dangerous clinically and also because their use may delay patient's receipt of mainstream care. The first part of this article reviews the evidence regarding the seven categories of alternative therapies established by the Office of Alternative Medicine. The second part describes the potential benefits of selected complementary therapies for some of the difficulties associated with cancer diagnosis, treatment, and survival including therapies for stress and anxiety, constipation, depression, diarrhea, and nausea. The third part outlines the risks associated with certain herbal products, including products with potentially harmful effects, products that are ineffective, products that are fake or highly contaminated, products with inaccurate labeling, and products based on unverified evidence. The article has 5 references.
•
Acupuncture: A Review of Its History, Theories, and Indications Source: Southern Medical Journal. 91(12): 1121-1125. December 1998.
Alternative Medicine 69
Summary: This journal article reviews the literature on the history, techniques, physiology, indications, adverse effects, and limitations of acupuncture. It describes six approaches to acupuncture that commonly are used in the United States: traditional Chinese medicine acupuncture, French energetics, Korean hand acupuncture, five element theory, auricular acupuncture, and myofascially-based acupuncture. It reviews neurophysiologic theories of the action of acupuncture; methodological difficulties in acupuncture research; and studies supporting the efficacy of acupuncture as a treatment for various pain syndromes, nausea, asthma, addiction, and stroke. It also identifies some of the adverse effects related to acupuncture which have been reported, and highlights studies suggesting that acupuncture may have only limited use. Finally, one of the authors describes his own personal and clinical experience with acupuncture. The article has 43 references. •
Acceptance of Some Acupuncture Applications Source: JAMA. Journal of the American Medical Association. 278(21): 1725-1727. December 3, 1997. Summary: This journal article summarizes the findings of the National Institutes of Health consensus panel on acupuncture. After evaluating current evidence for the efficacy of acupuncture, the 12-member panel concluded that there is clear evidence of efficacy in the control of postoperative nausea and vomiting, nausea and vomiting associated with chemotherapy and postoperative dental pain, and probably for nausea in early pregnancy. The panelists also found that the use of acupuncture, by itself or as an adjunct therapy, results in satisfactory treatment for a number of other conditions, although firm evidence of efficacy has not yet been established. The panelists concluded that more research is needed linking the use of acupuncture to physiological changes known to be associated with pain relief, and that more attention should be given to the issues involved in expanding the use of acupuncture into the health care system. In addition, the panelists noted that acupuncture has fewer side effects than many of the drugs or accepted medical procedures used for the same conditions. Finally, the panelists commended the progress the acupuncture educational community has made in establishing training and credentialing programs.
National Center for Complementary and Alternative Medicine The National Center for Complementary and Alternative Medicine (NCCAM) of the National Institutes of Health (http://nccam.nih.gov/) has created a link to the National Library of Medicine’s databases to facilitate research for articles that specifically relate to nausea and complementary medicine. To search the database, go to the following Web site: http://www.nlm.nih.gov/nccam/camonpubmed.html. Select “CAM on PubMed.” Enter “nausea” (or synonyms) into the search box. Click “Go.” The following references provide information on particular aspects of complementary and alternative medicine that are related to nausea: •
A pilot study of the use of progressive muscle relaxation training in the management of post-chemotherapy nausea and vomiting. Author(s): Molassiotis A. Source: European Journal of Cancer Care. 2000 December; 9(4): 230-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11829370
70
Nausea
•
A randomized comparison of ginger and vitamin B6 in the treatment of nausea and vomiting of pregnancy. Author(s): Sripramote M, Lekhyananda N. Source: J Med Assoc Thai. 2003 September; 86(9): 846-53. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14649969
•
A randomized controlled trial of ginger to treat nausea and vomiting in pregnancy. Author(s): Smith C, Crowther C, Willson K, Hotham N, McMillian V. Source: Obstetrics and Gynecology. 2004 April; 103(4): 639-45. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15051552
•
A randomized controlled trial of nerve stimulation for relief of nausea and vomiting in pregnancy. Author(s): Rosen T, de Veciana M, Miller HS, Stewart L, Rebarber A, Slotnick RN. Source: Obstetrics and Gynecology. 2003 July; 102(1): 129-35. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12850618
•
A systematic approach to the management of postoperative nausea and vomiting. Author(s): Golembiewski JA, O'Brien D. Source: Journal of Perianesthesia Nursing : Official Journal of the American Society of Perianesthesia Nurses / American Society of Perianesthesia Nurses. 2002 December; 17(6): 364-76. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12476402
•
Acupressure and acustimulation bands for control of nausea: a brief review. Author(s): Roscoe JA, Matteson SE. Source: American Journal of Obstetrics and Gynecology. 2002 May; 186(5 Suppl Understanding): S244-7. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12011894
•
Acupressure and ondansetron for postoperative nausea and vomiting after laparoscopic cholecystectomy. Author(s): Agarwal A, Bose N, Gaur A, Singh U, Gupta MK, Singh D. Source: Canadian Journal of Anaesthesia = Journal Canadien D'anesthesie. 2002 JuneJuly; 49(6): 554-60. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12067865
•
Acupressure wristbands for the prevention of postoperative nausea and vomiting in adults undergoing cardiac surgery. Author(s): Klein AA, Djaiani G, Karski J, Carroll J, Karkouti K, McCluskey S, Poonawala H, Shayan C, Fedorko L, Cheng D.
Alternative Medicine 71
Source: Journal of Cardiothoracic and Vascular Anesthesia. 2004 February; 18(1): 68-71. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14973803 •
Acupuncture and acupressure for the management of chemotherapy-induced nausea and vomiting. Author(s): Collins KB, Thomas DJ. Source: Journal of the American Academy of Nurse Practitioners. 2004 February; 16(2): 76-80. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=15055425
•
Acupuncture compared to placebo-acupuncture for postoperative nausea and vomiting prophylaxis: a randomised placebo-controlled patient and observer blind trial. Author(s): Streitberger K, Diefenbacher M, Bauer A, Conradi R, Bardenheuer H, Martin E, Schneider A, Unnebrink K. Source: Anaesthesia. 2004 February; 59(2): 142-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14725517
•
Acupuncture for postoperative nausea and vomiting prophylaxis: where's the point? Author(s): Cohn AI. Source: Anesthesiology. 2002 October; 97(4): 1038-9; Author Reply 1039. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12357192
•
Acupuncture to reduce nausea during chemotherapy treatment of rheumatic diseases. Author(s): Josefson A, Kreuter M. Source: Rheumatology (Oxford, England). 2003 October; 42(10): 1149-54. Epub 2003 May 30. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12777644
•
Acupuncture to treat nausea and vomiting in early pregnancy: a randomized controlled trial. Author(s): Smith C, Crowther C, Beilby J. Source: Birth (Berkeley, Calif.). 2002 March; 29(1): 1-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11843784
•
Acustimulation wristbands for the relief of chemotherapy-induced nausea. Author(s): Roscoe JA, Morrow GR, Bushunow P, Tian L, Matteson S. Source: Alternative Therapies in Health and Medicine. 2002 July-August; 8(4): 56-7, 5963. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12126174
•
Are we failing women? Advice for nausea and vomiting in pregnancy. Author(s): Allen R.
72
Nausea
Source: Pract Midwife. 2001 April; 4(4): 20-2. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12026609 •
Aromatherapy with peppermint, isopropyl alcohol, or placebo is equally effective in relieving postoperative nausea. Author(s): Anderson LA, Gross JB. Source: Journal of Perianesthesia Nursing : Official Journal of the American Society of Perianesthesia Nurses / American Society of Perianesthesia Nurses. 2004 February; 19(1): 29-35. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14770380
•
Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Author(s): Parker LA, Mechoulam R, Schlievert C. Source: Neuroreport. 2002 April 16; 13(5): 567-70. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11973447
•
Capsicum plaster at the korean hand acupuncture point reduces postoperative nausea and vomiting after abdominal hysterectomy. Author(s): Kim KS, Koo MS, Jeon JW, Park HS, Seung IS. Source: Anesthesia and Analgesia. 2002 October; 95(4): 1103-7, Table of Contents. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12351304
•
Chemotherapy-induced nausea and vomiting. Author(s): Bender CM, McDaniel RW, Murphy-Ende K, Pickett M, Rittenberg CN, Rogers MP, Schneider SM, Schwartz RN. Source: Clinical Journal of Oncology Nursing. 2002 March-April; 6(2): 94-102. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11889684
•
Chemotherapy-related nausea and vomiting - past reflections, present practice and future management. Author(s): Miller M, Kearney N. Source: European Journal of Cancer Care. 2004 March; 13(1): 71-81. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14961778
•
Comparative efficacy of acustimulation (ReliefBand) versus ondansetron (Zofran) in combination with droperidol for preventing nausea and vomiting. Author(s): White PF, Issioui T, Hu J, Jones SB, Coleman JE, Waddle JP, Markowitz SD, Coloma M, Macaluso AR, Ing CH. Source: Anesthesiology. 2002 November; 97(5): 1075-81. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12411789
Alternative Medicine 73
•
Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma. Author(s): Numbenjapon T, Sriswasdi C, Mongkonsritragoon W, Leelasiri A, Prayoonwiwat W. Source: J Med Assoc Thai. 2002 November; 85(11): 1156-63. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12546311
•
Comparison of acupressure bands and droperidol for reducing post-operative nausea and vomiting in gynecologic surgery patients. Author(s): Schultz AA, Andrews AL, Goran SF, Mathew T, Sturdevant N. Source: Applied Nursing Research : Anr. 2003 November; 16(4): 256-65. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14608559
•
Comparison of acustimulation and ondansetron for the treatment of established postoperative nausea and vomiting. Author(s): Coloma M, White PF, Ogunnaike BO, Markowitz SD, Brown PM, Lee AQ, Berrisford SB, Wakefield CA, Issioui T, Jones SB, Jones DB. Source: Anesthesiology. 2002 December; 97(6): 1387-92. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12459663
•
Continuous PC6 wristband acupressure for relief of nausea and vomiting associated with acute myocardial infarction: a partially randomised, placebo-controlled trial. Author(s): Dent HE, Dewhurst NG, Mills SY, Willoughby M. Source: Complementary Therapies in Medicine. 2003 June; 11(2): 72-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12801491
•
Effect of a ginger extract on pregnancy-induced nausea: a randomised controlled trial. Author(s): Willetts KE, Ekangaki A, Eden JA. Source: The Australian & New Zealand Journal of Obstetrics & Gynaecology. 2003 April; 43(2): 139-44. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14712970
•
Effect of acupressure on nausea and vomiting during pregnancy. A randomized, placebo-controlled, pilot study. Author(s): Werntoft E, Dykes AK. Source: J Reprod Med. 2001 September; 46(9): 835-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11584487
•
Effect of acupressure on postoperative nausea and vomiting in laparoscopic cholecystectomy. Author(s): Samad K, Afshan G, Kamal R.
74
Nausea
Source: J Pak Med Assoc. 2003 February; 53(2): 68-72. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12705488 •
Effectiveness of Gorei-san (TJ-17) for treatment of SSRI-induced nausea and dyspepsia: preliminary observations. Author(s): Yamada K, Yagi G, Kanba S. Source: Clinical Neuropharmacology. 2003 May-June; 26(3): 112-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12782911
•
Electroacupuncture prophylaxis of postoperative nausea and vomiting following pediatric tonsillectomy with or without adenoidectomy. Author(s): Rusy LM, Hoffman GM, Weisman SJ. Source: Anesthesiology. 2002 February; 96(2): 300-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11818760
•
Ginger does not prevent postoperative nausea and vomiting after laparoscopic surgery. Author(s): Eberhart LH, Mayer R, Betz O, Tsolakidis S, Hilpert W, Morin AM, Geldner G, Wulf H, Seeling W. Source: Anesthesia and Analgesia. 2003 April; 96(4): 995-8, Table of Contents. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12651648
•
Guidelines outline strategies to reduce post-operative nausea and vomiting. Author(s): Rollins G. Source: Rep Med Guidel Outcomes Res. 2002 April 19; 13(8): 9-10, 12. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12467270
•
Interventions for nausea and vomiting in early pregnancy. Author(s): Jewell D, Young G. Source: Cochrane Database Syst Rev. 2003; (4): Cd000145. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14583914
•
Interventions for nausea and vomiting in early pregnancy. Author(s): Jewell D, Young G. Source: Cochrane Database Syst Rev. 2002; (1): Cd000145. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11869567
•
Korean hand acupressure reduces postoperative nausea and vomiting after gynecological laparoscopic surgery. Author(s): Boehler M, Mitterschiffthaler G, Schlager A.
Alternative Medicine 75
Source: Anesthesia and Analgesia. 2002 April; 94(4): 872-5, Table of Contents. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11916788 •
Management of postoperative nausea and vomiting in children. Author(s): De Negri P, Ivani G. Source: Paediatric Drugs. 2002; 4(11): 717-28. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12390043
•
Managing nausea and vomiting. Current strategies. Author(s): Garrett K, Tsuruta K, Walker S, Jackson S, Sweat M. Source: Critical Care Nurse. 2003 February; 23(1): 31-50; Quiz 51-2. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12640958
•
Managing nausea, vomiting, and diarrhea. Author(s): Highleyman L. Source: Beta. 2002 Spring; 15(2): 29-39. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12064304
•
Medical, social, and legal implications of treating nausea and vomiting of pregnancy. Author(s): Brent R. Source: American Journal of Obstetrics and Gynecology. 2002 May; 186(5 Suppl Understanding): S262-6. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12011898
•
Nausea and vomiting in early pregnancy. Author(s): Jewell D. Source: American Family Physician. 2003 July 1; 68(1): 143-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12887120
•
Nausea and vomiting in early pregnancy. Author(s): Jewell D. Source: Clin Evid. 2002 June; (7): 1277-83. Review. No Abstract Available. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12230746
•
Nausea and vomiting in pregnancy: safety and efficacy of self-administered complementary therapies. Author(s): Tiran D. Source: Complementary Therapies in Nursing & Midwifery. 2002 November; 8(4): 191-6. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12463608
76
Nausea
•
Nausea and vomiting of pregnancy. Author(s): Quinla JD, Hill DA. Source: American Family Physician. 2003 July 1; 68(1): 121-8. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12887118
•
Nausea as a complication of low-frequency repetitive transcranial magnetic stimulation of the posterior fossa. Author(s): Satow T, Mima T, Hara H, Oga T, Ikeda A, Hashimoto N, Shibasaki H. Source: Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology. 2002 September; 113(9): 1441-3. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12169326
•
Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children. Author(s): Dupuis LL, Nathan PC. Source: Paediatric Drugs. 2003; 5(9): 597-613. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12956617
•
Overview of nausea and vomiting of pregnancy with an emphasis on vitamins and ginger. Author(s): Niebyl JR, Goodwin TM. Source: American Journal of Obstetrics and Gynecology. 2002 May; 186(5 Suppl Understanding): S253-5. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12011896
•
P6 acupoint injections are as effective as droperidol in controlling early postoperative nausea and vomiting in children. Author(s): Wang SM, Kain ZN. Source: Anesthesiology. 2002 August; 97(2): 359-66. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12151925
•
P6 acupressure may relieve nausea and vomiting after gynecological surgery: an effectiveness study in 410 women. Author(s): Alkaissi A, Evertsson K, Johnsson VA, Ofenbartl L, Kalman S. Source: Canadian Journal of Anaesthesia = Journal Canadien D'anesthesie. 2002 December; 49(10): 1034-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12477673
•
Postoperative nausea and vomiting--can it be eliminated? Author(s): Gan TJ.
Alternative Medicine 77
Source: Jama : the Journal of the American Medical Association. 2002 March 13; 287(10): 1233-6. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11886298 •
Pregnancy outcome following women's participation in a randomised controlled trial of acupuncture to treat nausea and vomiting in early pregnancy. Author(s): Smith C, Crowther C, Beilby J. Source: Complementary Therapies in Medicine. 2002 June; 10(2): 78-83. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12481955
•
Prospective comparative study of the safety and effectiveness of ginger for the treatment of nausea and vomiting in pregnancy. Author(s): Portnoi G, Chng LA, Karimi-Tabesh L, Koren G, Tan MP, Einarson A. Source: American Journal of Obstetrics and Gynecology. 2003 November; 189(5): 1374-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14634571
•
Psychological factors in the etiology and treatment of severe nausea and vomiting in pregnancy. Author(s): Buckwalter JG, Simpson SW. Source: American Journal of Obstetrics and Gynecology. 2002 May; 186(5 Suppl Understanding): S210-4. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12011888
•
Relationship between vitamin use, smoking, and nausea and vomiting of pregnancy. Author(s): Kallen B, Lundberg G, Aberg A. Source: Acta Obstetricia Et Gynecologica Scandinavica. 2003 October; 82(10): 916-20. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12956841
•
Reporting of clinical details in randomized controlled trials of acupuncture for the treatment of migraine/headaches and nausea/vomiting. Author(s): Elorriaga Claraco A, Hanna SE, Fargas-Babjak A. Source: Journal of Alternative and Complementary Medicine (New York, N.Y.). 2003 February; 9(1): 151-9. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12676043
•
Safe, successful nausea suppression in early pregnancy with P-6 acustimulation. Author(s): Slotnick RN. Source: J Reprod Med. 2001 September; 46(9): 811-4. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11584482
•
Taking ginger for nausea and vomiting during pregnancy. Author(s): Chandra K, Einarson A, Koren G.
78
Nausea
Source: Can Fam Physician. 2002 September; 48: 1441-2. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12371300 •
The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: a randomised controlled trial. Author(s): Molassiotis A, Yung HP, Yam BM, Chan FY, Mok TS. Source: Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 2002 April; 10(3): 237-46. Epub 2001 December 18. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11904789
•
The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting. A University of Rochester Cancer Center Community Clinical Oncology Program multicenter study. Author(s): Roscoe JA, Morrow GR, Hickok JT, Bushunow P, Pierce HI, Flynn PJ, Kirshner JJ, Moore DF, Atkins JN. Source: Journal of Pain and Symptom Management. 2003 August; 26(2): 731-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12906958
•
The efficacy of acupressure to prevent nausea and vomiting in post-operative patients. Author(s): Ming JL, Kuo BI, Lin JG, Lin LC. Source: Journal of Advanced Nursing. 2002 August; 39(4): 343-51. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12139646
•
The efficacy of ginger in prevention of post-operative nausea and vomiting after outpatient gynecological laparoscopy. Author(s): Pongrojpaw D, Chiamchanya C. Source: J Med Assoc Thai. 2003 March; 86(3): 244-50. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12757064
•
The management of nausea and vomiting of pregnancy. Author(s): Arsenault MY, Lane CA, MacKinnon CJ, Bartellas E, Cargill YM, Klein MC, Martel MJ, Sprague AE, Wilson AK. Source: J Obstet Gynaecol Can. 2002 October; 24(10): 817-31; Quiz 832-3. English, French. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12405123
•
The placebo response and effect of time in a trial of acupuncture to treat nausea and vomiting in early pregnancy. Author(s): Smith C, Crowther C. Source: Complementary Therapies in Medicine. 2002 December; 10(4): 210-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12594971
Alternative Medicine 79
•
The use of CAM by women suffering from nausea and vomiting during pregnancy. Author(s): Hollyer T, Boon H, Georgousis A, Smith M, Einarson A. Source: Bmc Complementary and Alternative Medicine [electronic Resource]. 2002 May 17; 2(1): 5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12033990
•
Transcutaneous acupoint electrical stimulation in preventing and treating nausea and vomiting in patients receiving electroconvulsive therapy. Author(s): Kramer BA, Kadar AG, Clark K. Source: The Journal of Ect. 2003 December; 19(4): 194-6. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=14657771
•
Understanding anticipatory nausea. Author(s): Eckert RM. Source: Oncology Nursing Forum. 2001 November-December; 28(10): 1553-8; Quiz 155960. Review. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=11759303
•
Use of transcutaneous nerve stimulation wristband to treat methotrexate-induced nausea. Author(s): Wilson JK, Phelps KC, Feldman SR. Source: Journal of Cutaneous Medicine and Surgery. 2002 November-December; 6(6): 551-3. Epub 2002 October 31. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=A bstract&list_uids=12404040
Additional Web Resources A number of additional Web sites offer encyclopedic information covering CAM and related topics. The following is a representative sample: •
Alternative Medicine Foundation, Inc.: http://www.herbmed.org/
•
AOL: http://search.aol.com/cat.adp?id=169&layer=&from=subcats
•
Chinese Medicine: http://www.newcenturynutrition.com/
•
drkoop.com: http://www.drkoop.com/InteractiveMedicine/IndexC.html
•
Family Village: http://www.familyvillage.wisc.edu/med_altn.htm
•
Google: http://directory.google.com/Top/Health/Alternative/
•
Healthnotes: http://www.healthnotes.com/
•
MedWebPlus: http://medwebplus.com/subject/Alternative_and_Complementary_Medicine
•
Open Directory Project: http://dmoz.org/Health/Alternative/
•
HealthGate: http://www.tnp.com/
80
Nausea
•
WebMDHealth: http://my.webmd.com/drugs_and_herbs
•
WholeHealthMD.com: http://www.wholehealthmd.com/reflib/0,1529,00.html
•
Yahoo.com: http://dir.yahoo.com/Health/Alternative_Medicine/
The following is a specific Web list relating to nausea; please note that any particular subject below may indicate either a therapeutic use, or a contraindication (potential danger), and does not reflect an official recommendation: •
General Overview Abdominal Wall Inflammation Source: Integrative Medicine Communications; www.drkoop.com AIDS and HIV Source: Integrative Medicine Communications; www.drkoop.com Alcoholism Source: Integrative Medicine Communications; www.drkoop.com Alzheimer's Disease Source: Integrative Medicine Communications; www.drkoop.com Amenorrhea Source: Integrative Medicine Communications; www.drkoop.com Anaphylaxis Source: Integrative Medicine Communications; www.drkoop.com Anxiety Source: Integrative Medicine Communications; www.drkoop.com Appendicitis Source: Integrative Medicine Communications; www.drkoop.com Ascariasis Source: Integrative Medicine Communications; www.drkoop.com Asthma Source: Prima Communications, Inc.www.personalhealthzone.com Athletic Performance Source: Healthnotes, Inc.; www.healthnotes.com Bladder Infection Alternative names: Urinary Tract Infection [UTI] Source: Prima Communications, Inc.www.personalhealthzone.com Bone Loss Source: Integrative Medicine Communications; www.drkoop.com
Alternative Medicine 81
Brain Cancer Source: Integrative Medicine Communications; www.drkoop.com Breast Cancer Source: Integrative Medicine Communications; www.drkoop.com Bronchitis Source: Healthnotes, Inc.; www.healthnotes.com Bulimia Nervosa Source: Integrative Medicine Communications; www.drkoop.com Bursitis Source: Integrative Medicine Communications; www.drkoop.com Cancer Prevention (Reducing the Risk) Source: Prima Communications, Inc.www.personalhealthzone.com Chronic Fatigue Syndrome Source: Integrative Medicine Communications; www.drkoop.com Colorectal Cancer Source: Integrative Medicine Communications; www.drkoop.com Congestive Heart Failure Source: Integrative Medicine Communications; www.drkoop.com Depression Source: Integrative Medicine Communications; www.drkoop.com Depression (Mild to Moderate) Source: Prima Communications, Inc.www.personalhealthzone.com Diabetes Mellitus Source: Integrative Medicine Communications; www.drkoop.com Diarrhea Source: Healthnotes, Inc.; www.healthnotes.com Diverticular Disease Source: Healthnotes, Inc.; www.healthnotes.com Diverticular Disease Source: Integrative Medicine Communications; www.drkoop.com Dysmenorrhea Source: Healthnotes, Inc.; www.healthnotes.com Dysmenorrhea Source: Integrative Medicine Communications; www.drkoop.com
82
Nausea
Epilepsy Source: Integrative Medicine Communications; www.drkoop.com Fainting Source: Integrative Medicine Communications; www.drkoop.com Flu Source: Integrative Medicine Communications; www.drkoop.com Food Allergy Source: Integrative Medicine Communications; www.drkoop.com Food Poisoning Source: Integrative Medicine Communications; www.drkoop.com Gallbladder Disease Source: Integrative Medicine Communications; www.drkoop.com Gallstones Source: Healthnotes, Inc.; www.healthnotes.com Gallstones Source: Prima Communications, Inc.www.personalhealthzone.com Gastritis Source: Integrative Medicine Communications; www.drkoop.com Gout Source: Integrative Medicine Communications; www.drkoop.com Guinea Worm Disease Source: Integrative Medicine Communications; www.drkoop.com Heart Attack Source: Healthnotes, Inc.; www.healthnotes.com Heart Attack Source: Integrative Medicine Communications; www.drkoop.com Heat Exhaustion Source: Integrative Medicine Communications; www.drkoop.com Hemorrhoids Source: Integrative Medicine Communications; www.drkoop.com Hepatitis Source: Healthnotes, Inc.; www.healthnotes.com High Blood Pressure Source: Integrative Medicine Communications; www.drkoop.com
Alternative Medicine 83
High Cholesterol Source: Integrative Medicine Communications; www.drkoop.com High Cholesterol Source: Prima Communications, Inc.www.personalhealthzone.com HIV and AIDS Source: Integrative Medicine Communications; www.drkoop.com Hookworm Source: Integrative Medicine Communications; www.drkoop.com Hypercholesterolemia Source: Integrative Medicine Communications; www.drkoop.com Hyperparathyroidism Source: Integrative Medicine Communications; www.drkoop.com Hypertension Source: Integrative Medicine Communications; www.drkoop.com Hypochondriasis Source: Integrative Medicine Communications; www.drkoop.com Infection Source: Healthnotes, Inc.; www.healthnotes.com Inflammatory Bowel Disease Source: Integrative Medicine Communications; www.drkoop.com Influenza Source: Healthnotes, Inc.; www.healthnotes.com Influenza Source: Integrative Medicine Communications; www.drkoop.com Insect Bites and Stings Source: Integrative Medicine Communications; www.drkoop.com Intestinal Parasites Source: Integrative Medicine Communications; www.drkoop.com Iron-Deficiency Anemia Source: Healthnotes, Inc.; www.healthnotes.com Irritable Bowel Syndrome Alternative names: Spastic Colon Source: Prima Communications, Inc.www.personalhealthzone.com Kidney Stones Source: Integrative Medicine Communications; www.drkoop.com
84
Nausea
Loiasis Source: Integrative Medicine Communications; www.drkoop.com Lupus Source: Integrative Medicine Communications; www.drkoop.com Lymphatic Filariasis Source: Integrative Medicine Communications; www.drkoop.com Ménière's Disease Source: Healthnotes, Inc.; www.healthnotes.com Macular Degeneration Source: Integrative Medicine Communications; www.drkoop.com Menopause Source: Integrative Medicine Communications; www.drkoop.com Menstrual Pain Source: Integrative Medicine Communications; www.drkoop.com Migraine Headache Source: Integrative Medicine Communications; www.drkoop.com Migraine Headaches Source: Healthnotes, Inc.; www.healthnotes.com Migraine Headaches Source: Prima Communications, Inc.www.personalhealthzone.com Morning Sickness Source: Healthnotes, Inc.; www.healthnotes.com Motion Sickness Source: Healthnotes, Inc.; www.healthnotes.com Motion Sickness Source: Integrative Medicine Communications; www.drkoop.com MSG Sensitivity Source: Healthnotes, Inc.; www.healthnotes.com Mumps Source: Integrative Medicine Communications; www.drkoop.com Myocardial Infarction Source: Integrative Medicine Communications; www.drkoop.com Nausea Source: Prima Communications, Inc.www.personalhealthzone.com
Alternative Medicine 85
Obesity Source: Integrative Medicine Communications; www.drkoop.com Osteoarthritis Source: Integrative Medicine Communications; www.drkoop.com Osteoporosis Source: Integrative Medicine Communications; www.drkoop.com Pancreatitis Source: Integrative Medicine Communications; www.drkoop.com Parasites Source: Healthnotes, Inc.; www.healthnotes.com Parkinson's Disease Source: Integrative Medicine Communications; www.drkoop.com Peptic Ulcer Source: Healthnotes, Inc.; www.healthnotes.com Peptic Ulcer Source: Integrative Medicine Communications; www.drkoop.com Peritonitis Source: Integrative Medicine Communications; www.drkoop.com Pertussis Source: Integrative Medicine Communications; www.drkoop.com Photodermatitis Source: Integrative Medicine Communications; www.drkoop.com Pinworm Source: Integrative Medicine Communications; www.drkoop.com PMS Source: Integrative Medicine Communications; www.drkoop.com PMS Alternative names: Premenstrual Stress Syndrome Source: Prima Communications, Inc.www.personalhealthzone.com Pregnancy and Postpartum Support Source: Healthnotes, Inc.; www.healthnotes.com Premenstrual Syndrome Source: Integrative Medicine Communications; www.drkoop.com Prostate Cancer Source: Integrative Medicine Communications; www.drkoop.com
86
Nausea
Radiation Damage Source: Integrative Medicine Communications; www.drkoop.com River Blindness Source: Integrative Medicine Communications; www.drkoop.com Roundworms Source: Integrative Medicine Communications; www.drkoop.com Seizure Disorders Source: Integrative Medicine Communications; www.drkoop.com Serum Sickness Source: Integrative Medicine Communications; www.drkoop.com Sickle Cell Anemia Source: Healthnotes, Inc.; www.healthnotes.com Stomach Inflammation Source: Integrative Medicine Communications; www.drkoop.com Sunburn Source: Integrative Medicine Communications; www.drkoop.com Syncope Source: Integrative Medicine Communications; www.drkoop.com Systemic Lupus Erythematosus Source: Healthnotes, Inc.; www.healthnotes.com Systemic Lupus Erythematosus Source: Integrative Medicine Communications; www.drkoop.com Tension Headache Source: Integrative Medicine Communications; www.drkoop.com Threadworm Source: Integrative Medicine Communications; www.drkoop.com Trichinosis Source: Integrative Medicine Communications; www.drkoop.com Ulcerative Colitis Source: Healthnotes, Inc.; www.healthnotes.com Ulcerative Colitis Source: Integrative Medicine Communications; www.drkoop.com Urinary Tract Infection Source: Healthnotes, Inc.; www.healthnotes.com
Alternative Medicine 87
Varicose Veins Source: Prima Communications, Inc.www.personalhealthzone.com Vertigo Source: Healthnotes, Inc.; www.healthnotes.com Visceral Larva Migrans Source: Integrative Medicine Communications; www.drkoop.com Whipworm Source: Integrative Medicine Communications; www.drkoop.com Whooping Cough Source: Integrative Medicine Communications; www.drkoop.com •
Alternative Therapy Acupressure Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,662,00.html Acupuncture Source: Integrative Medicine Communications; www.drkoop.com Acupuncture Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,663,00.html Aromatherapy Source: Integrative Medicine Communications; www.drkoop.com Aromatherapy Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,664,00.html Colon Therapy Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,682,00.html Fasting Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,694,00.html Guided Imagery Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,699,00.html
88
Nausea
Shiatsu Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,733,00.html Testing for Stomach Acidity Source: Healthnotes, Inc.; www.healthnotes.com Therapeutic Touch Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,739,00.html Traditional Chinese Medicine Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10085,00.html •
Chinese Medicine Baifuzi Alternative names: Giant Typhonium Rhizome; Rhizoma Typhonii Source: Chinese Materia Medica Banxia Alternative names: Pinellia Tuber; Rhizoma Pinelliae Source: Chinese Materia Medica Bichengqie Alternative names: Mountain Spicy Fruit; Fructus Litseae Source: Chinese Materia Medica Biwen San Alternative names: Biwen Powder Source: Pharmacopoeia Commission of the Ministry of Health, People's Republic of China Caodoukou Alternative names: Katsumada Galangal Seed; Semen Alpiniae Katsumadai Source: Chinese Materia Medica Doukou Alternative names: Round Cardamon Fruit; Fructus Amomi Rotundus Source: Chinese Materia Medica Erchen Wan Alternative names: rchen; Erchen Wan (Er Chen Wan Source: Pharmacopoeia Commission of the Ministry of Health, People's Republic of China
Alternative Medicine 89
Fuzi Alternative names: Beivedere Fruit; Difuzi; Fructus Kochiae Source: Chinese Materia Medica Hongling San Alternative names: Hongling Powder Source: Pharmacopoeia Commission of the Ministry of Health, People's Republic of China Huajuhong Alternative names: Pummelo Peel; Exocarpium Citri Grandis Source: Chinese Materia Medica Huanglian Alternative names: Golden Thread; Rhizoma Coptidis Source: Chinese Materia Medica Huangqi Alternative names: Milkvetch; Radix Astragali Source: Chinese Materia Medica Huangqin Alternative names: Baical Skullcap Root; Radix Scutellariae Source: Chinese Materia Medica Jianpi Wan Alternative names: Jianpi Pills Source: Pharmacopoeia Commission of the Ministry of Health, People's Republic of China Juhong Alternative names: Pummelo Peel; Huajuhong; Exocarpium Citri Grandis Source: Chinese Materia Medica Liuhe Dingzhong Wan Alternative names: Liuhe Dingzhong Pills Source: Pharmacopoeia Commission of the Ministry of Health, People's Republic of China Meiguihua Alternative names: Rose Flower; Flos Rosae Rugosae Source: Chinese Materia Medica Muxiang Fenqi Wan Alternative names: Muxiang Fenqi Pills Source: Pharmacopoeia Commission of the Ministry of Health, People's Republic of China Peilan Alternative names: Fortune Eupatorium Herb; Herba Eupatorii Source: Chinese Materia Medica
90
Nausea
Renshen Jianpi Wan Alternative names: enshen Jianpi Pills; Renshen Jianpi Wan(Ren Shen Jian Pi Wan Source: Pharmacopoeia Commission of the Ministry of Health, People's Republic of China Shedan Chenpi San Alternative names: hedan Chenpi Powder; Shedan Chenpi San (She Dan Chen Pi San Source: Pharmacopoeia Commission of the Ministry of Health, People's Republic of China Shihu Alternative names: Dendrobium; Herba Dendrobii Source: Chinese Materia Medica Sizheng Wan Alternative names: izheng Pills; Sizheng Wan (Si Zheng Wan Source: Pharmacopoeia Commission of the Ministry of Health, People's Republic of China Xuanfuhua Alternative names: Inula Flower; Flos Inulae Source: Chinese Materia Medica Zisuye Alternative names: Perilla Leaf; Folium Perillae Source: Chinese Materia Medica •
Herbs and Supplements 5-HTP Source: Integrative Medicine Communications; www.drkoop.com 5-Hydroxytryptophan Source: Healthnotes, Inc.; www.healthnotes.com 5-Hydroxytryptophan (5-HTP) Source: Integrative Medicine Communications; www.drkoop.com Activated Charcoal Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,832,00.html Adrenal Extract Source: Healthnotes, Inc.; www.healthnotes.com Aloe Alternative names: Aloe vera L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org
Alternative Medicine 91
Amino Acids Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10003,00.html Aminoglycosides Source: Integrative Medicine Communications; www.drkoop.com Ananas Comosus Source: Integrative Medicine Communications; www.drkoop.com Antioxidants Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10004,00.html Arctostaphylos Alternative names: Bearberry; Arctostaphylos uva-ursi (L.) Spreng. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Ava Source: Integrative Medicine Communications; www.drkoop.com Bismuth Subsalicylate Source: Healthnotes, Inc.; www.healthnotes.com Black Cohosh Alternative names: Cimicifuga racemosa Source: Healthnotes, Inc.; www.healthnotes.com Black Cohosh Alternative names: Cimicifuga racemosa (actea), Black Snakeroot Source: Integrative Medicine Communications; www.drkoop.com Black Snakeroot Source: Integrative Medicine Communications; www.drkoop.com Blackberry Alternative names: Rubus fructicosus Source: Healthnotes, Inc.; www.healthnotes.com Bloodroot Alternative names: Sanguinaria canadensis Source: Healthnotes, Inc.; www.healthnotes.com Bloodroot Source: Prima Communications, Inc.www.personalhealthzone.com Blue Cohosh Alternative names: Caulophyllum thalictroides Source: Healthnotes, Inc.; www.healthnotes.com
92
Nausea
Blue Flag Alternative names: Iris versicolor Source: Healthnotes, Inc.; www.healthnotes.com Boneset Alternative names: Eupatorium perfoliatum Source: Healthnotes, Inc.; www.healthnotes.com Borago Alternative names: Borage; Borago officinalis Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Boric Acid Source: Healthnotes, Inc.; www.healthnotes.com Boswellia Alternative names: Boswellia serrata Source: Healthnotes, Inc.; www.healthnotes.com Boswellia Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,759,00.html Brahmi Alternative names: Centella asiatica , Centella, March Pennywort, Indian Pennywort, Hydrocotyle, Brahmi (Sanskrit), Luei Gong Gen (Chinese)(Note: Gotu kola should not be confused with kola nut.) Source: Integrative Medicine Communications; www.drkoop.com Brewer's Yeast Alternative names: Nutritional Yeast Source: Integrative Medicine Communications; www.drkoop.com Bromelain Alternative names: Ananas comosus, Bromelainum Source: Integrative Medicine Communications; www.drkoop.com Bromelain Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,760,00.html Bromelainum Source: Integrative Medicine Communications; www.drkoop.com Butcher’s Broom Alternative names: Ruscus aculeatus Source: Healthnotes, Inc.; www.healthnotes.com Centella Source: Integrative Medicine Communications; www.drkoop.com
Alternative Medicine 93
Centella asiatica Alternative names: Centella asiatica , Centella, March Pennywort, Indian Pennywort, Hydrocotyle, Brahmi (Sanskrit), Luei Gong Gen (Chinese)(Note: Gotu kola should not be confused with kola nut.) Source: Integrative Medicine Communications; www.drkoop.com Chamomile Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,766,00.html Chaparral Alternative names: Larrea tridentata Source: Healthnotes, Inc.; www.healthnotes.com Chemotherapy Source: Healthnotes, Inc.; www.healthnotes.com Chrysanthemum parthenium Source: Integrative Medicine Communications; www.drkoop.com Cimicifuga racemosa (Actea) Source: Integrative Medicine Communications; www.drkoop.com Cinnamomum Alternative names: Cinnamon; Cinnamomum zeylanicum Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Citalopram Source: Healthnotes, Inc.; www.healthnotes.com Coenzyme Q Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,768,00.html Conjugated Linoleic Acid Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10102,00.html Corydalis Alternative names: Corydalis turtschaninovii, Corydalis yanhusuo Source: Healthnotes, Inc.; www.healthnotes.com Cyclophosphamide Source: Healthnotes, Inc.; www.healthnotes.com Cysteine Source: Integrative Medicine Communications; www.drkoop.com
94
Nausea
Dimenhydrinate Source: Healthnotes, Inc.; www.healthnotes.com Dioscorea Villosa Source: Integrative Medicine Communications; www.drkoop.com Docetaxel Source: Healthnotes, Inc.; www.healthnotes.com Elderberry Alternative names: Sambucus nigra Source: Healthnotes, Inc.; www.healthnotes.com Elderberry Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10024,00.html Ephedra Alternative names: Ephedra sinensis, Ma huang Source: Integrative Medicine Communications; www.drkoop.com Ephedra Source: Prima Communications, Inc.www.personalhealthzone.com Ephedra (Ma huang) Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,777,00.html Ephedra sinensis Source: Integrative Medicine Communications; www.drkoop.com Eucalyptus Alternative names: Eucalyptus globulus Source: Healthnotes, Inc.; www.healthnotes.com Eucalyptus Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,778,00.html Evening Primrose Alternative names: Oenothera biennis, Sun Drop Source: Integrative Medicine Communications; www.drkoop.com False Unicorn Alternative names: Chamaelirium luteum Source: Healthnotes, Inc.; www.healthnotes.com False Unicorn Root Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com
Alternative Medicine 95
Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10075,00.html Fennel Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,849,00.html Fenugreek Alternative names: Trigonella foenum-graecum Source: Healthnotes, Inc.; www.healthnotes.com Feverfew Alternative names: Tanacetum parthenium, Chrysanthemum parthenium Source: Integrative Medicine Communications; www.drkoop.com Feverfew Source: Prima Communications, Inc.www.personalhealthzone.com Feverfew Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,780,00.html Fluorouracil Source: Healthnotes, Inc.; www.healthnotes.com Fluvoxamine Source: Healthnotes, Inc.; www.healthnotes.com GABA Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10027,00.html Gamma-oryzanol Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10028,00.html General Anesthetics Source: Healthnotes, Inc.; www.healthnotes.com Ginger Alternative names: Zingiber officinale Source: Healthnotes, Inc.; www.healthnotes.com Ginger Alternative names: Zingiber officinale Source: Integrative Medicine Communications; www.drkoop.com
96
Nausea
Ginger Source: Prima Communications, Inc.www.personalhealthzone.com Ginger Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,787,00.html Ginkgo Biloba Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,788,00.html Ginseng Source: Prima Communications, Inc.www.personalhealthzone.com Glucosamine Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,790,00.html Goldenseal Alternative names: Hydrastis canadensis Source: Integrative Medicine Communications; www.drkoop.com Goldenseal Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,791,00.html Gotu Kola Alternative names: Centella asiatica , Centella, March Pennywort, Indian Pennywort, Hydrocotyle, Brahmi (Sanskrit), Luei Gong Gen (Chinese)(Note: Gotu kola should not be confused with kola nut.) Source: Integrative Medicine Communications; www.drkoop.com Gotu Kola Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10031,00.html Greater Celandine Alternative names: Chelidonium majus Source: Healthnotes, Inc.; www.healthnotes.com Green-lipped Mussel Source: Healthnotes, Inc.; www.healthnotes.com Gugulipid Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10033,00.html
Alternative Medicine 97
Hawthorn Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10035,00.html Horse Chestnut Alternative names: Aesculus hippocastanum Source: Healthnotes, Inc.; www.healthnotes.com Horse Chestnut Source: Prima Communications, Inc.www.personalhealthzone.com Huperzia Source: Healthnotes, Inc.; www.healthnotes.com Huperzine A Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10038,00.html Hydrastis Canadensis Source: Integrative Medicine Communications; www.drkoop.com Hydrocotyle Source: Integrative Medicine Communications; www.drkoop.com Hypericum Perforatum Source: Integrative Medicine Communications; www.drkoop.com Indapamide Source: Healthnotes, Inc.; www.healthnotes.com Indian Pennywort Source: Integrative Medicine Communications; www.drkoop.com Indian Tobacco Source: Integrative Medicine Communications; www.drkoop.com Ipecac Alternative names: Cephaelis ipecacuanha Source: Healthnotes, Inc.; www.healthnotes.com Ivy Leaf Alternative names: Hedera helix Source: Healthnotes, Inc.; www.healthnotes.com Jamaica Dogwood Alternative names: Piscidia erythrina, Piscidia piscipula Source: Integrative Medicine Communications; www.drkoop.com
98
Nausea
Kava Kava Alternative names: Piper methysticum, Ava Source: Integrative Medicine Communications; www.drkoop.com Ketoprofen Source: Healthnotes, Inc.; www.healthnotes.com Klamathweed Source: Integrative Medicine Communications; www.drkoop.com Lapacho Source: Integrative Medicine Communications; www.drkoop.com Lavender Alternative names: Lavandula officinalis Source: Healthnotes, Inc.; www.healthnotes.com Lecithin Source: Prima Communications, Inc.www.personalhealthzone.com Lobelia Alternative names: Lobelia inflata Source: Healthnotes, Inc.; www.healthnotes.com Lobelia Alternative names: Lobelia inflata, Indian Tobacco Source: Integrative Medicine Communications; www.drkoop.com Lobelia Source: The Canadian Internet Directory for Holistic Help, WellNet, Health and Wellness Network; www.wellnet.ca Lobelia Inflata Source: Integrative Medicine Communications; www.drkoop.com Lomatium Alternative names: Lomatium dissectum Source: Healthnotes, Inc.; www.healthnotes.com Loop Diuretics Source: Integrative Medicine Communications; www.drkoop.com Ma huang Source: Integrative Medicine Communications; www.drkoop.com Marsh Pennywort Alternative names: Centella asiatica , Centella, March Pennywort, Indian Pennywort, Hydrocotyle, Brahmi (Sanskrit), Luei Gong Gen (Chinese)(Note: Gotu kola should not be confused with kola nut.) Source: Integrative Medicine Communications; www.drkoop.com
Alternative Medicine 99
Meadowsweet Source: The Canadian Internet Directory for Holistic Help, WellNet, Health and Wellness Network; www.wellnet.ca Meclizine Source: Healthnotes, Inc.; www.healthnotes.com Methotrexate Source: Healthnotes, Inc.; www.healthnotes.com Metoclopramide Source: Healthnotes, Inc.; www.healthnotes.com Milk Thistle Alternative names: Silybum marianum, Carduus marianus Source: Healthnotes, Inc.; www.healthnotes.com Milk Thistle Source: Prima Communications, Inc.www.personalhealthzone.com Miscellaneous Preparations Source: Integrative Medicine Communications; www.drkoop.com Mistletoe Alternative names: Viscum album Source: Healthnotes, Inc.; www.healthnotes.com NAC (N-Acetyl Cysteine) Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,809,00.html N-Acetyl Cysteine Source: Healthnotes, Inc.; www.healthnotes.com Nitrous Oxide Source: Healthnotes, Inc.; www.healthnotes.com Oenothera Biennis Source: Integrative Medicine Communications; www.drkoop.com Organ Mountain Crape Source: The Canadian Internet Directory for Holistic Help, WellNet, Health and Wellness Network; www.wellnet.ca PABA Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10049,00.html Paclitaxel Source: Healthnotes, Inc.; www.healthnotes.com
100 Nausea
Passion Flower Alternative names: Passiflora incarnata Source: Healthnotes, Inc.; www.healthnotes.com Pau D’arco Alternative names: Tabebuia avellanedae, Tabebuia impestiginosa Source: Healthnotes, Inc.; www.healthnotes.com Pau D'arco Alternative names: Tabebuia avellanedae, Lapacho Source: Integrative Medicine Communications; www.drkoop.com Pau D'arco Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,811,00.html Peppermint Source: Prima Communications, Inc.www.personalhealthzone.com Peppermint Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,812,00.html Perphenazine Source: Healthnotes, Inc.; www.healthnotes.com Phenylalanine Source: Healthnotes, Inc.; www.healthnotes.com Phosphatidylserine (PS) Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,813,00.html Piper Methysticum Source: Integrative Medicine Communications; www.drkoop.com Piroxicam Source: Healthnotes, Inc.; www.healthnotes.com Piscidia Erythrina Source: Integrative Medicine Communications; www.drkoop.com Piscidia Piscipula Source: Integrative Medicine Communications; www.drkoop.com Prochlorperazine Source: Healthnotes, Inc.; www.healthnotes.com
Alternative Medicine 101
Promethazine Source: Healthnotes, Inc.; www.healthnotes.com Pygeum Africanum Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10052,00.html Red Raspberry Alternative names: Rubus idaeus Source: Healthnotes, Inc.; www.healthnotes.com S-Adenosylmethionine (SAMe) Source: Integrative Medicine Communications; www.drkoop.com Salicylates Source: Integrative Medicine Communications; www.drkoop.com SAMe Source: Integrative Medicine Communications; www.drkoop.com SAMe (S-Adenosylmethionine) Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,818,00.html Sanguinaria Alternative names: Bloodroot; Sanguinaria canadensis L. Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Saw Palmetto Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,819,00.html Sertraline Source: Healthnotes, Inc.; www.healthnotes.com Spirulina and Kelp Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10058,00.html St. John's Wort Alternative names: Hypericum perforatum, Klamathweed Source: Integrative Medicine Communications; www.drkoop.com Stimulant Laxatives Source: Integrative Medicine Communications; www.drkoop.com Suma Source: Healthnotes, Inc.; www.healthnotes.com
102 Nausea
Sun Drop Source: Integrative Medicine Communications; www.drkoop.com Tabebuia Avellanedae Source: Integrative Medicine Communications; www.drkoop.com Tanacetum Parthenium Source: Integrative Medicine Communications; www.drkoop.com Thiazide Diuretics Source: Integrative Medicine Communications; www.drkoop.com Trace Minerals Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10061,00.html Tylophora Alternative names: Tylophora indica, Tylophora asthmatica Source: Healthnotes, Inc.; www.healthnotes.com Tyrosine Source: Prima Communications, Inc.www.personalhealthzone.com Uricosuric Agents Source: Integrative Medicine Communications; www.drkoop.com Uva Ursi Alternative names: Arctostaphylos uva-ursi Source: Healthnotes, Inc.; www.healthnotes.com Uva Ursi Source: Prima Communications, Inc.www.personalhealthzone.com Uva Ursi Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10063,00.html Valerian Alternative names: Valeriana officinalis Source: Healthnotes, Inc.; www.healthnotes.com Valerian Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10064,00.html White Willow Bark Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10069,00.html
Alternative Medicine 103
Wild Indigo Alternative names: Baptisia tinctoria Source: Healthnotes, Inc.; www.healthnotes.com Wild Yam Alternative names: Dioscorea villosa Source: Healthnotes, Inc.; www.healthnotes.com Wild Yam Alternative names: Dioscorea villosa Source: Integrative Medicine Communications; www.drkoop.com Wild Yam Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,10070,00.html Willow Bark Alternative names: There are several species of willow includingSalix alba, Salix nigra, Salix fragilis, Salix purpurea, Salix babylonica, White Willow, European Willow, Black Willow, Pussy Willow, Crack Willow, Purple Willow, Weeping Willow, Liu-zhi Source: Integrative Medicine Communications; www.drkoop.com Wormwood Alternative names: Artemisia absinthium Source: Healthnotes, Inc.; www.healthnotes.com Yohimbe Alternative names: Pausinystalia yohimbe Source: Healthnotes, Inc.; www.healthnotes.com Yohimbe Source: Prima Communications, Inc.www.personalhealthzone.com Yohimbe Source: WholeHealthMD.com, LLC.; www.wholehealthmd.com Hyperlink: http://www.wholehealthmd.com/refshelf/substances_view/0,1525,830,00.html Zingiber Alternative names: Ginger; Zingiber officinale Roscoe Source: Alternative Medicine Foundation, Inc.; www.amfoundation.org Zingiber Officinale Source: Integrative Medicine Communications; www.drkoop.com
General References A good place to find general background information on CAM is the National Library of Medicine. It has prepared within the MEDLINEplus system an information topic page
104 Nausea
dedicated to complementary and alternative medicine. To access this page, go to the MEDLINEplus site at http://www.nlm.nih.gov/medlineplus/alternativemedicine.html. This Web site provides a general overview of various topics and can lead to a number of general sources.
105
CHAPTER 4. DISSERTATIONS ON NAUSEA Overview In this chapter, we will give you a bibliography on recent dissertations relating to nausea. We will also provide you with information on how to use the Internet to stay current on dissertations. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical dissertations that use the generic term “nausea” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on nausea, we have not necessarily excluded non-medical dissertations in this bibliography.
Dissertations on Nausea ProQuest Digital Dissertations, the largest archive of academic dissertations available, is located at the following Web address: http://wwwlib.umi.com/dissertations. From this archive, we have compiled the following list covering dissertations devoted to nausea. You will see that the information provided includes the dissertation’s title, its author, and the institution with which the author is associated. The following covers recent dissertations found when using this search procedure: •
Demons, Nausea and Resistance in the Autobiography of Isabel De Jesus (1611-1682) (Spain) by Velasco, Sherry M., PhD from University of California, Los Angeles, 1992, 293 pages http://wwwlib.umi.com/dissertations/fullcit/9301562
•
Early Pregnancy Associated Nausea and Vomiting: Maternal Risk Factors, Fetal Outcome, and Reproductive Success (Morning Sickness, Biological Fitness, Estrogen Sensitivity, Emetic Center, Multiple Regression) by Weigel, Mary-Margaret, PhD from University of California, Los Angeles, 1985, 200 pages http://wwwlib.umi.com/dissertations/fullcit/8603999
•
The Assessment and Treatment of Nausea and Vomiting Associated with Cancer Chemotherapy by Rosberger, Zeev; PhD from Concordia University (Canada), 1988 http://wwwlib.umi.com/dissertations/fullcit/NL44883
106 Nausea
Keeping Current Ask the medical librarian at your library if it has full and unlimited access to the ProQuest Digital Dissertations database. From the library, you should be able to do more complete searches via http://wwwlib.umi.com/dissertations.
107
CHAPTER 5. CLINICAL TRIALS AND NAUSEA Overview In this chapter, we will show you how to keep informed of the latest clinical trials concerning nausea.
Recent Trials on Nausea The following is a list of recent trials dedicated to nausea.8 Further information on a trial is available at the Web site indicated. •
A Randomized Study of Electroacupuncture Treatment for Delayed Chemotherapyinduced Nausea and Vomiting in Patients with Pediatric Sarcomas Condition(s): Sarcoma; Nausea; Vomiting Study Status: This study is currently recruiting patients. Sponsor(s): National Center for Complementary and Alternative Medicine (NCCAM); National Cancer Institute (NCI); National Institute of Dental and Craniofacial Research (NIDCR) Purpose - Excerpt: This study will investigate the efficacy of electroacupuncture to reduce delayed chemotherapy-induced nausea in pediatric and young adult patients with pediatric sarcoma. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00034996
•
Acupressure in Treating Nausea in Women Receiving Combination Chemotherapy for Breast Cancer Condition(s): Breast Cancer; nausea and vomiting Study Status: This study is currently recruiting patients.
8
These are listed at www.ClinicalTrials.gov.
108 Nausea
Sponsor(s): M.D. Anderson Cancer Center; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Acupressure may help to reduce or prevent nausea in patients who are undergoing chemotherapy. It is not yet known if acupressure plus standard care for nausea is more effective than standard care for nausea alone in women who are receiving chemotherapy for breast cancer. PURPOSE: Randomizedphase III trial to determine the effectiveness of acupressure in treating nausea in women who are receiving combination chemotherapy for breast cancer. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00046865 •
Acupressure to Treat Nausea and Vomiting in HIV/AIDS Patients Condition(s): HIV Infections Study Status: This study is currently recruiting patients. Sponsor(s): National Institute of Nursing Research (NINR) Purpose - Excerpt: The purpose of this study is to see whether acupressure (acupuncture using pressure applied by the hands instead of needles) can help nausea and vomiting in persons with HIV/AIDS. Phase(s): Phase I Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00017823
•
Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer Condition(s): unspecified adult solid tumor, protocol specific; nausea and vomiting; Quality of Life Study Status: This study is currently recruiting patients. Sponsor(s): James P. Wilmot Cancer Center; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients being treated with chemotherapy. PURPOSE: Randomizedphase III trial to compare the effectiveness of different antiemetic drugs in preventing delayed nausea after chemotherapy in patients who have cancer. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00020657
•
Ginger Control of Chemotherapy Induced Nausea and Vomiting Condition(s): Nausea; Vomiting; Chemotherapy Study Status: This study is currently recruiting patients.
Clinical Trials 109
Sponsor(s): National Center for Complementary and Alternative Medicine (NCCAM) Purpose - Excerpt: This is a trial to determine the safety and efficacy of ginger in reducing the prevalence and severity of chemotherapy induced nausea and vomiting. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00065221 •
Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer Condition(s): nausea and vomiting; unspecified adult solid tumor, protocol specific Study Status: This study is currently recruiting patients. Sponsor(s): University of Michigan Comprehensive Cancer Center; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: The herb ginger may help to reduce or prevent nausea and vomiting in patients receiving chemotherapy for cancer. PURPOSE: Randomizedphase II trial to study the effectiveness of ginger in reducing or preventing nausea and vomiting in patients who are receiving chemotherapy for cancer. Phase(s): Phase II Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00064272
•
Ginger in Treating Nausea in Patients Receiving Chemotherapy for Cancer Condition(s): nausea and vomiting; unspecified adult solid tumor, protocol specific Study Status: This study is currently recruiting patients. Sponsor(s): University of Rochester; National Cancer Institute (NCI) Purpose - Excerpt: RATIONALE: Ginger may help reduce or prevent nausea. It is not yet known if antiemetic drugs are more effective with or without ginger in treating nausea caused by chemotherapy. PURPOSE: Randomizedphase II/III trial to determine the effectiveness of antiemetic drugs with or without ginger in treating nausea in patients who are receiving chemotherapy for cancer. Phase(s): Phase II; Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00040742
•
Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Condition(s): Endocrine Cancer; female reproductive cancer; Gastrointestinal Cancer; nausea and vomiting; Quality of Life Study Status: This study is currently recruiting patients.
110 Nausea
Sponsor(s): National Cancer Institute of Canada Purpose - Excerpt: RATIONALE: Antiemetic drugs may help to reduce or prevent vomiting in patients treated with radiation therapy. It is not yet known if ondansetron is more effective with or without dexamethasone in preventing vomiting caused by radiation therapy. PURPOSE: Randomizedphase III trial to compare the effectiveness of ondansetron with or without dexamethasone in preventing vomiting in patients with cancer who are receiving radiation therapy to the upper abdomen. Phase(s): Phase III Study Type: Interventional Contact(s): see Web site below Web Site: http://clinicaltrials.gov/ct/show/NCT00016380
Keeping Current on Clinical Trials The U.S. National Institutes of Health, through the National Library of Medicine, has developed ClinicalTrials.gov to provide current information about clinical research across the broadest number of diseases and conditions. The site was launched in February 2000 and currently contains approximately 5,700 clinical studies in over 59,000 locations worldwide, with most studies being conducted in the United States. ClinicalTrials.gov receives about 2 million hits per month and hosts approximately 5,400 visitors daily. To access this database, simply go to the Web site at http://www.clinicaltrials.gov/ and search by “nausea” (or synonyms). While ClinicalTrials.gov is the most comprehensive listing of NIH-supported clinical trials available, not all trials are in the database. The database is updated regularly, so clinical trials are continually being added. The following is a list of specialty databases affiliated with the National Institutes of Health that offer additional information on trials: •
For clinical studies at the Warren Grant Magnuson Clinical Center located in Bethesda, Maryland, visit their Web site: http://clinicalstudies.info.nih.gov/
•
For clinical studies conducted at the Bayview Campus in Baltimore, Maryland, visit their Web site: http://www.jhbmc.jhu.edu/studies/index.html
•
For cancer trials, visit the National Cancer Institute: http://cancertrials.nci.nih.gov/
•
For eye-related trials, visit and search the Web page of the National Eye Institute: http://www.nei.nih.gov/neitrials/index.htm
•
For heart, lung and blood trials, visit the Web page of the National Heart, Lung and Blood Institute: http://www.nhlbi.nih.gov/studies/index.htm
•
For trials on aging, visit and search the Web site of the National Institute on Aging: http://www.grc.nia.nih.gov/studies/index.htm
•
For rare diseases, visit and search the Web site sponsored by the Office of Rare Diseases: http://ord.aspensys.com/asp/resources/rsch_trials.asp
•
For alcoholism, visit the National Institute on Alcohol Abuse and Alcoholism: http://www.niaaa.nih.gov/intramural/Web_dicbr_hp/particip.htm
Clinical Trials 111
•
For trials on infectious, immune, and allergic diseases, visit the site of the National Institute of Allergy and Infectious Diseases: http://www.niaid.nih.gov/clintrials/
•
For trials on arthritis, musculoskeletal and skin diseases, visit newly revised site of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health: http://www.niams.nih.gov/hi/studies/index.htm
•
For hearing-related trials, visit the National Institute on Deafness and Other Communication Disorders: http://www.nidcd.nih.gov/health/clinical/index.htm
•
For trials on diseases of the digestive system and kidneys, and diabetes, visit the National Institute of Diabetes and Digestive and Kidney Diseases: http://www.niddk.nih.gov/patient/patient.htm
•
For drug abuse trials, visit and search the Web site sponsored by the National Institute on Drug Abuse: http://www.nida.nih.gov/CTN/Index.htm
•
For trials on mental disorders, visit and search the Web site of the National Institute of Mental Health: http://www.nimh.nih.gov/studies/index.cfm
•
For trials on neurological disorders and stroke, visit and search the Web site sponsored by the National Institute of Neurological Disorders and Stroke of the NIH: http://www.ninds.nih.gov/funding/funding_opportunities.htm#Clinical_Trials
113
CHAPTER 6. PATENTS ON NAUSEA Overview Patents can be physical innovations (e.g. chemicals, pharmaceuticals, medical equipment) or processes (e.g. treatments or diagnostic procedures). The United States Patent and Trademark Office defines a patent as a grant of a property right to the inventor, issued by the Patent and Trademark Office.9 Patents, therefore, are intellectual property. For the United States, the term of a new patent is 20 years from the date when the patent application was filed. If the inventor wishes to receive economic benefits, it is likely that the invention will become commercially available within 20 years of the initial filing. It is important to understand, therefore, that an inventor’s patent does not indicate that a product or service is or will be commercially available. The patent implies only that the inventor has “the right to exclude others from making, using, offering for sale, or selling” the invention in the United States. While this relates to U.S. patents, similar rules govern foreign patents. In this chapter, we show you how to locate information on patents and their inventors. If you find a patent that is particularly interesting to you, contact the inventor or the assignee for further information. IMPORTANT NOTE: When following the search strategy described below, you may discover non-medical patents that use the generic term “nausea” (or a synonym) in their titles. To accurately reflect the results that you might find while conducting research on nausea, we have not necessarily excluded non-medical patents in this bibliography.
Patents on Nausea By performing a patent search focusing on nausea, you can obtain information such as the title of the invention, the names of the inventor(s), the assignee(s) or the company that owns or controls the patent, a short abstract that summarizes the patent, and a few excerpts from the description of the patent. The abstract of a patent tends to be more technical in nature, while the description is often written for the public. Full patent descriptions contain much more information than is presented here (e.g. claims, references, figures, diagrams, etc.). We
9Adapted
from the United States Patent and Trademark Office: http://www.uspto.gov/web/offices/pac/doc/general/whatis.htm.
114 Nausea
will tell you how to obtain this information later in the chapter. The following is an example of the type of information that you can expect to obtain from a patent search on nausea: •
.DELTA.9 Tetrahydrocannabinol (.DELTA.9 THC) solution metered dose inhaler Inventor(s): Byron; Peter R. (Richmond, VA), Lichtman; Aron H. (Richmond, VA), Martin; Billy R. (Richmond, VA), Peart; Joanne (Richmond, VA) Assignee(s): Virginia Commonwealth University (richmond, Va) Patent Number: 6,509,005 Date filed: March 22, 1999 Abstract: The present invention provides therapeutic formulations for solutions of.DELTA.sup.9 -tetrahydrocannabinol (.DELTA.sup.9 THC) to be delivered by metered dose inhalers. The formulations, which utilize non-CFC propellants, provide a stable aerosol-deliverable source of.DELTA.sup.9 THC for the treatment of various medical conditions, such as: nausea and vomiting associated with chemotherapy; muscle spasticity; pain; anorexia associated with AIDS wasting syndrome; epilepsy; glaucoma; bronchial asthma; and mood disorders. Excerpt(s): The invention is generally related to the therapeutic use of.DELTA.sup.9 Tetrahydrocannabinol (.DELTA.sup.9 THC). In particular, the invention provides a metered dose inhaler (MDI) for the aerosol administration of.DELTA.sup.9 THC to patients suffering from nausea and vomiting associated with cancer chemotherapy, muscle spasticity, pain, anorexia associated with AIDS wasting syndrome, epilepsy, glaucoma, bronchial asthma, mood disorders, and the like. When marijuana is used illegally as a recreational psychoactive drug, the active ingredient.DELTA.sup.9 THC is usually delivered to the lungs as an impure non-pharmaceutical aerosol in the form of marijuana smoke. Aerosolized.DELTA.sup.9 THC in the inhaled smoke is absorbed within seconds and delivered to the brain efficiently. Table 2 and references 19-20 describe the pharmacokinetics of the administration of.DELTA.sup.9 THC. As can be seen, inhalation is the preferred route of delivery for.DELTA.sup.9 THC. When compared to oral delivery, inhalation provides a more rapid onset of pharmacological action and peak plasma levels. The effects achieved via inhalation are comparable to those achieved when the drug is administered intravenously, but inhalation is a much less invasive technique. Currently, the sources of.DELTA.sup.9 THC for patients who could benefit from the drug are very limited. An oral form of.DELTA.sup.9 THC (MARINOL) is marketed as a treatment for nausea and vomiting related to cancer chemotherapy, and as an appetite stimulant in patients suffering from AIDS wasting syndrome. In MARINOL, pharmaceutical grade.DELTA.sup.9 THC is dissolved in sesame oil, encapsulated in gelatin capsules and delivered orally. However, when the drug is taken orally, the absorption is slower and more variable than when inhaled, with an onset of action between 30 minutes and 2 hours (Table 2). Alternatively, some cancer patients do manage to obtain and smoke marijuana in order to alleviate such conditions as nausea and vomiting due to chemotherapy. This is, however, technically illegal and is thus obviously a less than ideal treatment protocol. There is no currently available pharmaceutically acceptable aerosol form of.DELTA.sup.9 THC. Web site: http://www.delphion.com/details?pn=US06509005__
Patents 115
•
2-{4-[4-(4,5-dichloro-2-methylimidazol-1-yl)butyl]-1-piperazinyl}-5-fluorop yrimidine, its preparation and its therapeutic use Inventor(s): Frigola-Constansa; Jordi (Barcelone, ES), Merce-Vidal; Ramon (Barcelone, ES) Assignee(s): Laboratorios Del Dr. Esteve, S.a. (barcelone, Es) Patent Number: 6,303,608 Date filed: February 29, 2000 Abstract: 2-{4-[4-(4,5-dichloro-2-methylimidazol-1-yl)butyl]-1-piperazinyl}-5-fluorop yrimidine, and its physiologically acceptable salts; pharmaceutical compositions containing these compounds, and a method of treating vertigo, travel sickness, nausea, depression, anxiety, gastric acid secretion, obsessive/compulsive disorders, panic attacks or sleep apnea using these compounds are disclosed. Excerpt(s): Patents EP 382,637 and EP 497,659 of the Applicant Company disclosed various pyrimidinylpiperazinylalkylazole derivatives having anxiolytic and/or tranquilizing properties. Although Patent EP 382,637 claims pyrimidinylpiperazinylalkylazole derivatives substituted at the 5-position of the pyrimidine by a halogen atom, only two examples of compounds of this type are disclosed and, in both cases, it is a bromine atom. The Applicant Company has now discovered that the introduction of a fluorine atom as substituent at the 5-position of the pyrimidine, in the special case where the azole is an imidazole trisubstituted by a methyl group at the 2-position and by two chlorine atoms at the 4- and 5-positions, gives rise to the compound which is the subject-matter of the present patent, which compound exhibits some advantageous biological properties which make it of particular use in its application in human and/or veterinary therapeutics. In particular, the compound which is the subject-matter of the present patent is of use as an antiemetic against seasickness (nausea caused by motion), as an antidepressant or anxiolytic, as an inhibitor of gastric acid secretion or obsessive-compulsive disorders, in panic attacks and in sleep apnea in mammals, including man. It is possible to prepare the compound 2-{4-[4-(4,5-dichloro-2-methylimidazol-1-yl)butyl]-1-piperazinyl}-5-fluoro pyrimidine and its physiologically acceptable salts according to the invention by one of the processes shown hereinbelow. Web site: http://www.delphion.com/details?pn=US06303608__
•
Acceleration of the rate of digestion of a protein Inventor(s): Ballevre; Olivier (Lausanne, CH), Beaufrere; Bernard (Chamalieres, FR), Dangin; Martial (Clermont-Ferrand, FR), Garcia-Rodenas; Clara Lucia (Mollie-Margot, CH) Assignee(s): Nestec S.a. (vevey, Ch) Patent Number: 6,544,515 Date filed: June 7, 2000 Abstract: The invention thus relates to a method for accelerating the rate of digestion of a protein matter, in which a protein matter is treated with transglutaminase, and it is mixed with anionic polysaccharides. The invention also relates to the use of the rapidly digested protein matter for preparing a food or pharmaceutical composition intended for oral administration to a mammal, to induce a postprandial peak of plasmatic
116 Nausea
increase in amino acids. This composition is intended for modulating the postprandial protein gain, limiting the problems linked to gastrointestinal motility disorders, limiting the postprandial sensations of nausea in pregnant women, and/or limiting the postprandial risks of regurgitation and/or gastro-esophageal reflux. Finally, a subject of the invention is also a food or pharmaceutical composition comprising anionic polysaccharides and a protein matter treated with transglutaminase. Excerpt(s): The subject of the invention.is a method for accelerating the rate of digestion of a protein, and the use of a protein thus modified for preparing a food or pharmaceutical composition for modulating the postprandial plasmatic level of amino acids. In humans, during a nycthemeron, food intake is discontinuous. Postprandial periods, i.e. the phases of nutrient assimilation from the digestive tract, alternate with periods of physiological fast. These diurnal variations in the nutritional status affect the components of protein metabolism, and consequently the protein balance. Thus, the consumption of proteins results in an increase in the plasmatic level of amino acids (Aoki et al., Am. J. Olin. Nutr., 41, 1-18, 1987). Similarly, the elevation of the plasmatic level of amino acids is associated with a decline in proteolysis and a stimulation of the oxidation of amino acids and of protein synthesis (Castellino et al., Am. J. Physiol., 262, 162-176, 1992; Giordano et al., Diabetes, 45, 393-399, 1996; Clugston et al., Olin. Nutr., 36, 57-70, 1982; Motil et al., Am. J. Physiol., 240, E712-721, 1981; Melville et al., Metabolism., 30, 248-255, 1989; Pacy et al., Olin. Sci., 86, 103-118, 1994). Web site: http://www.delphion.com/details?pn=US06544515__ •
Acupressure device Inventor(s): Berger; Allen (Wainscott, NY), Johnson; Chris (Irvine, CA), O'Connell; Drew (Cold Spring Harbor, NY) Assignee(s): Cirrus Air Technologies Llc (locust Valley, Ny) Patent Number: 6,007,503 Date filed: May 14, 1998 Abstract: An acupressure device is especially adapted for use as an anti-nausea prophylactic. The device comprises a substantially flat base having first and second opposing surfaces and a central aperture. A rounded button is disposed within the central aperture, the rounded pressure-applying surface of the button facing in the same direction as the first surface of the base. A pluraliy of spokes extend from the button to the perimeter of the central aperture, thereby supporting the button within the aperture. The first surface of the base has an adhesive coating so that the device may be adhered to the skin with the button contacting a desired acupressure point. Excerpt(s): The present invention relates generally to a device for applying pressure to an acupuncture or acupressure point on the human body. More specifically, the present invention relates to an acupressure device for relieving nausea. The effectiveness of acupuncture and acupressure for relieving pain and for treating certain physical disorders has been known for several thousand years. In acupuncture, fine needles are inserted into the skin at specific locations on the anatomy in order to treat specific disorders. Since it is an invasive procedure, acupuncture should be administered only by a skilled practitioner. Even with normal clinical precautions, there is a danger of infection at acupuncture sites. Due, at least in part, to the disadvantages of acupuncture, acupressure has enjoyed increasing popularity. The same anatomical locations used for acupuncture are also used for acupressure; however, only pressure is applied to the
Patents 117
location. Pressure alone has proven to be effective for the treatment of certain disorders and for certain symptomatic relief. In particular, it has been found that pressure applied to the interior of the wrist can be effective in relieving nausea due, for example, to motion sickness. Web site: http://www.delphion.com/details?pn=US06007503__ •
Amelioration of apomorphine adverse effects Inventor(s): El-Rashidy; Ragab (Deerfield, IL), Ronsen; Bruce (River Forest, IL) Assignee(s): Pentech Pharmaceuticals, Inc. (buffalo Grove, Il) Patent Number: 5,994,363 Date filed: August 24, 1998 Abstract: Symptoms of Parkinson's disease and psychogenic male erectile dysfunction (MED) can be ameliorated through the use of apomorphine. The adverse side effects of apomorphine administration, such as nausea, vomiting, yawning, and cardiovascular effects, can be significantly reduced by a dose escalating method of acclimatization. An initial dose of apomorphine is administered to the patient, and subsequently increased over a period of time until a final apomorphine dose in excess of a desired therapeutic dose has been received by the patient. Thereafter a therapeutic dose of apomorphine, less than the final apomorphine dose, is administered to the patient with attendant reduced side effects. Excerpt(s): This invention relates to amelioration of the adverse effects, such as nausea, yawning, vomiting, and cardiovascular effects, caused to human patients when taking apomorphine for Parkinson's disease, psychogenic male erectile dysfunction (MED), and female sexual dysfunction, or the like afflictions. Apomorphine has been used to treat Parkinsonian patients. See, for example, Deffond et al., J. Neurology, Neurosurgery, and Psychiatry 56:101-103 (1993) and Durif et al., Clinical Neuropharmacology 16(2):157-166 (1993). Additionally, apomorphine has been considered for the treatment of alcoholism, schizophrenia, dystonia musculorum deformans, hallucinations, migraine headaches, hiccups, Huntington's chorea, tardative dyskinesia, and more recently male erectile dysfunction. Administration of large doses of apomorphine to mammals such as humans, dogs and the like usually results in nausea and vomiting, and is believed to be due to the action of apomorphine on the chemoreceptor trigger zone (CTZ) of the medulla oblongata, a structure of the mammalian central nervous system. It is also believed that additional chemoreceptors triggering emesis are present in the gastrointestinal tract as well. Web site: http://www.delphion.com/details?pn=US05994363__
•
Analgesic composition for treatment of migraine headaches Inventor(s): Mauskop; Alexander (17A Lafayette Rd., Larchment, NY 10538) Assignee(s): None Reported Patent Number: 5,914,129 Date filed: July 23, 1996 Abstract: Magnesium-containing analgesic compositions used for the alleviation of pain, in particular, migraine headache pain, and methods for using the same are described
118 Nausea
herein. The compositions consist essentially of an analgesic agent, a magnesium salt, a stimulant, optionally an effervescing agent, and a pharmacetically acceptable carrier or vehicle. The symptoms of migraine headache intended to be alleviated include nausea, unilateral pain, dizziness, pulsatile pain, worsening of pain by light physical activity, photophobia and phonophobia. Excerpt(s): This invention relates to magnesium-based analgesic compositions for treating migraine headaches, and methods for using the same. Analgesic compositions comprising magnesium salts have been used to treat a variety of ailments as well as reduce the gastric irritancy often accompanying the oral administration of such analgesic compositions. U.S. Pat. 2,801,951 to Cooper, Jr. discloses the use of an analgesic composition comprising acetylsalicylic acid, citric acid, p-ethoxyacetanilide, caffeine and MgCO.sub.3 or Mg(OH).sub.2 /Al(OH).sub.3. U.S. Pat. No. 3,865,933 to Mudge teaches the use of a mixture comprising magnesium gluconate, stramonium extract and 3-(2methylphenoxy)-1,2-propanediol to relieve headache pain. U.S. Pat. No. 3,759,980 to Rosen et al. teaches the use of a mixture of magnesium salicylate and choline salicylate as an analgesic, anti-pyretic, anti-inflammatory and anti-rheumatic agent. U.S. Pat. No. 3,385,886 to Nicholson et al. teaches the use of phenylpropionic acid magnesium salts for the relief of pain, fever and inflammation. U.S. Pat. No. 3,359,166 to McClure teaches the use of magnesium 4-thiazolidinecarboxylate as an analgesic agent. U.S. Pat. No. 4,083,951 to Goudie et al. teaches the use of magnesium acetylsalicylate in conjunction with sodium bicarbonate as an analgesic having reduced gastric irritancy properties. U.S. Pat. No. 4,217,340 to Tobert discloses the use of a phenylbenzoic acid compound and magnesium hydroxide for treating pain and inflammation. Such compositions have employed magnesium salts for their solubility, absorption properties and buffering effects. A deficiency of magnesium, i.e., hypomagnesemia, has been suggested to play a role in migraine headaches (B.A. Web site: http://www.delphion.com/details?pn=US05914129__ •
Anandamide inhibitors as analgesic agents Inventor(s): Hill; William Adam (Ashford, CT), Lin; Sonyan (Storrs, CT), Makriyannis; Alexandros (Ashford, CT) Assignee(s): University of Connecticut (farmington, Ct) Patent Number: 6,391,909 Date filed: April 20, 2000 Abstract: Disclosed is a method of inhibiting anandamide amidase in an individual or animal and novel inhibitors of anandamide amidase. The disclosed method can be used to reduce pain in an individual or animal suffering from pain, reducing nausea in an individual undergoing chemotherapy, suppressing appetite in an individual, reducing intraocular pressure in the eye of an individual or animal suffering from glaucoma and suppressing the immune system in an individual with an organ transplant. Excerpt(s): Arachidonyl ethanolamide (anandamide) is a naturally-occurring brain constituent that acts as a CB1 and CB2 agonist and exhibits pharmacological activity in mice comparable to cannabinoids (Fride and Mechoulam (1993), Crawley et al. (1993) and Smith et al. (1994)). Anandamide is cleaved in vivo by anandamide amidase. Thus, inhibitors of anandamide amidase have the effect of indirectly stimulating the CB1 and CB2 receptors by increasing in vivo levels of anandamide. In addition to acting at the CB1 and CB2 receptors, cannabinoids also affect cellular membranes, thereby producing
Patents 119
undesirable side effects such as drowsiness, impairment of monoamide oxidase function and impairment of non-receptor mediated brain function. The addictive and psychotropic properties of cannabinoids also limit their therapeutic value. Inhibitors of anandamide amidase are not expected to have the undesired membrane-related sideeffects produced by cannabinoids. By providing an alternate mechanism for stimulating the CB1 and CB2 receptor, anandamide inhibitors might not have the addictive and psychotropic properties of cannabinoids. However, present inhibitors of anandamide amidase have disadvantages. For example, phenylmethylsulfonyl fluoride (PMSF) is toxic to cells. Thus, there is a need for new and more potent inhibitors of anandamide amidase which have reduced toxicity towards cells and which do not significantly interact with the CB1 or CB2 receptor at inhibitory concentrations. It has now been found that long chain fatty acids and aromatic acid analogs of long chain fatty acids with head groups capable of irreversibly binding to a nucleophilic group at an enzyme active site are potent inhibitors of anandamide amidase. For example, palmitylsulfonyl fluoride was found to increase the level of undegraded anandamide 55-fold at 10 nM in intact neuroblastoma cells (Example 1) and is therefore more than 100 fold more potent than phenylmethylsulfonyl fluoride at inhibiting anandamide amidase. At the same time, the inhibitors disclosed herein have a low affinity for the CB1 receptor (Example 3). For example, the binding affinity of palmitylsulfonyl fluoride for the CB1 receptor is about 10 times lower than anandamide. In addition, it has been found that palmitylsulfonyl fluoride causes some of the same pharmacological effects in rats as do compounds which stimulate the CB1 receptor directly, such as.DELTA.sup.9 tetrahydrocannabinol. For example, palmitylsulfonyl fluoride is shown herein to induce analgesia in rats (Example 4). Based on these results, methods of inhibiting anandamide amidase, thereby stimulating the CB1 and CB2 receptors, in an individual or animal are disclosed. Also disclosed are novel compounds which inhibit anandamide amidase. Web site: http://www.delphion.com/details?pn=US06391909__ •
Anti-nausea compositions and methods Inventor(s): Hermelin; Marc S. (Glendale, MO), Kirschner; Mitchell I. (St. Louis, MO), Levinson; R. Saul (Chesterfield, MO) Assignee(s): Drugtech Corporation (wilmington, De) Patent Number: 6,197,329 Date filed: May 3, 1999 Abstract: The present disclosure is directed to novel nutritional anti-nausea compositions, anti-emetic compositions, and methods of using same. The compositions provide improved relief from nausea and/or vomiting. The compositions are particularly useful for pregnant women. Excerpt(s): The present invention is directed to novel nutritional anti-nausea compositions, anti-emetic compositions and methods of using the same to provide relief from nausea and/or vomiting. The present compositions are also nonteratogenic and are therefore highly useful to pregnant women. Nausea and vomiting are two of the most common symptoms of illness and are also commonly experienced as side effects of numerous medical treatments. Both nausea and vomiting are also commonly experienced as a result of various external factors (e.g., travel) and during various conditions (e.g., pregnancy). Nausea and vomiting can occur individually or in conjunction with one another. A common cause of nausea and vomiting is motion sickness. Motion sickness typically occurs when humans are subjected to long-lasting
120 Nausea
external movement or transportation accompanied by unusual movements such as shaking, waving, atmospheric changes (e.g., flying in an airplane), great acceleration, and uneven road conditions, etc. Motion sickness is not viewed as a disease but as a physiological symptom complex wherein the symptoms experienced, of which nausea and vomiting are common, depend on the individual in question. When the individual experiences motion sickness in a work environment, i.e., truck drivers, air pilots, air craft staff members and the like, the potential for a disadvantageous and dangerous condition result. Such individuals are often required to exhibit high level concentration and intellect, and the presence of motion sickness symptoms can severely detract from their ability to do so. Web site: http://www.delphion.com/details?pn=US06197329__ •
Arginine/ascorbic acid mixed powder as an oral supplement Inventor(s): Kimoto; Eiji (Jonan-ku, JP), Morishige; Fukumi (2-10-13, Miyakono, Oamishirasato-machi, Sanbu-gun, Chiba-ken, JP) Assignee(s): Kimoto; Sachiko (jonan-ku, Jp), Morishige; Fukumi (sanbu-gun, Jp) Patent Number: 6,552,074 Date filed: November 13, 2001 Abstract: A mixture obtained by mixing ascorbic acid powder with arginine powder in a weight ratio (ascorbic acid/arginine) of 1/5 to 20, especially 1/5 to 1/4; and a supplement such as a nutrient preparation and a health-care food containing the mixture. Mixing of arginine powder and ascorbic acid powder in the weight ratios eliminates stringent taste specific to arginine and alleviates stringent feeling in the stomach (heartburn, nausea or vomiting) after oral intake thereof. The mixture prevents also peroxidative injuries of cells caused by an administration of a great amount of arginine alone. Further, mixing of arginine powder with ascorbic acid powder prevents browning of the mixture after long-term storage. Excerpt(s): The present invention relates to a method for eliminating the stringent taste and alleviating stringent feeling in the stomach of L-arginine (hereinafter referred to as arginine) by mixing L-ascorbic acid (hereinafter referred to as ascorbic acid) and for alleviating the toxicity of arginine-derived NO radical by arginine-ascorbic acidcombined treatment. From late 1970's to 1980's, a research group of Illinois University reevaluated that dietary arginine is indispensable for optimal health of adult and especially aged humans. (see E. Kimoto, "Nutritional Chemistry of L-Arginine", Kaisei Publishing Co. Ltd., Tokyo, 1999 (Literature 2), page 93). In 1987, it was reported that NO radical participating in a wide variety of physiological functions such as blood pressure control and prevention of infections is derived from arginine as a source. This led to increased attention paid to arginine in the field of amino acid nutrition science (see Literature 2, page 57). Web site: http://www.delphion.com/details?pn=US06552074__
Patents 121
•
Compositions containing the nonprescription combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine Inventor(s): Armellino; Joseph (Chester, NJ), Koslo; Randy (West Windsor Township, NJ) Assignee(s): Bristol-myers Squibb Company (new York, Ny) Patent Number: 5,972,916 Date filed: February 10, 1998 Abstract: The invention provides a safe and economical nonprescription combination of acetaminophen, aspirin and caffeine (APAP/ASA/CAF) for use in treating migraine pain and the cluster of symptoms characteristic of migraine attack, such as nausea, photophobia, phonophobia and functional disabilities. The use of the APAP/ASA/CAF combination is also effective in aborting the prodrome phase of a migraine attack. Excerpt(s): The present invention relates generally to compositions and methods used to alleviate the symptoms and pain associated with acute migraine attack. More particularly, the present invention relates to the use of a nonprescription combination of acetaminophen, aspirin and caffeine for treating individuals afflicted with pre-migraine conditions, migraine-associated symptoms and/or migraine pain of mild to severe intensity. An estimated 23 to 25 million Americans--about 18% of women and 6% of men--suffer from migraine pain and migraine-related symptoms.sup.1. Attacks are common, with more than 50% of sufferers experiencing one or more episodes per month.sup.2. Migraine, a heterogeneous disorder, produces a wide spectrum of pain and associated disabilities, both within and among individual sufferers. The spectrum includes mild pain and no disability in approximately 5-15% of migraine attacks, moderate to severe pain and disability in approximately 60-70% of attacks, and incapacitating pain and total disability in the remaining approximately 25-35% of attacks.sup.3,4. Web site: http://www.delphion.com/details?pn=US05972916__
•
Derivatives of amide analogs of certain methano bridged quinolizines Inventor(s): Gittos; Maurice W. (Plobsheim, FR) Assignee(s): Merrell Pharmaceuticals, Inc. (cincinnati, Oh) Patent Number: 5,955,470 Date filed: October 29, 1998 Abstract: This invention relates to novel amide derivatives of certain 2,6-methano-2Hquinolizine-type compounds, to the intermediates and processes for their preparation, to their ability to antagonize the effects of serotonin at the 5HT.sub.3 receptors, and to their end-use application in the treatment of chemotherapeutically-induced nausea and vomiting, as anti-anxiety agents, in the symptomatic treatment of pain associated with migraine, as anti-arrhythmic agents, in the treatment of cognitive disorders, in treating hallucinatory endogenous psychoses of the type manifested in patients suffering from schizophrenia, and mania, in the treatment of glaucoma, for stimulating gastric motility, to combat drug abuse, to treat sleep apnea and to treat irritable bowel syndrome. Excerpt(s): This invention relates to novel amide derivatives of certain 2,6-methano-2Hquinolizines-type compounds, to the intermediates and processes for their preparation, to their ability to antagonize the effects of serotonin at the 5HT.sub.3 receptors, and to
122 Nausea
their end-use application in the treatment of chemotherapeutically-induced nausea and vomiting, as anti-anxiety agents, in the symptomatic treatment of pain associated with migraine, as anti-arrhythmic agents, in the treatment of cognitive disorders, in treating hallucinatory endogenous psychoses of the type manifested in patients suffering from schizophrenia, and mania, in the treatment of glaucoma, for stimulating gastric motility, to combat drug abuse, to treat sleep apnea and to treat irritable bowel syndrome. (g) R.sub.2 substituted-1H-benzotriazoles. The pharmaceutically acceptable acid addition salts referred to above can be non-toxic salts with suitable acids such as those with inorganic acids, for example, hydrochloric, hydrobromic, nitric, sulfuric or phosphoric acids; or with organic acids such as organic carboxylic acids, for example, acetic, propionic, glycolic, maleic, hydroxymaleic, malic, tartaric, citric, salicylic, 2acetyloxybenzoic, nicotinic or isonicotinic; or organic sulfonic acids, for example, methanesulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, 4-toluenesulfonic or 2naphthalenesulfonic. Quaternary ammonium salts are formed with alkyl halides such as methyl chloride, methyl bromide, methyl iodide or ethyl bromide; or with sulfate esters such as methyl 4-toluenesulfonate or methyl 2-naphthalenesulfonate. Web site: http://www.delphion.com/details?pn=US05955470__ •
Device and method for decreasing nausea and vomiting Inventor(s): Langevin; Paul B. (Gainesville, FL) Assignee(s): University of Florida (gainesville, Fl) Patent Number: 6,030,631 Date filed: February 18, 1998 Abstract: The subject invention relates to devices that are specifically designed to safely and efficiently administer alcohol vapor for innocuous insufflation or inhalation, and to related methods of administering alcohol in this manner. The subject invention is preferably used to treat a patient suffering from post-operative nausea or vomiting that are side effects that often accompany the use of anesthetics for surgical applications. Excerpt(s): Nausea and emesis are often induced by stimulation of either the chemoreceptor trigger zone or the emesis (or vomiting) center in the central nervous system. Such stimulation can be caused by afferent stimulation (e.g., tactile pharyngeal impulses, labrynthine disturbances, motion, increased intracranial pressure, pain, distention of viscera or psychologic factors) or blood born emetic substances (e.g., as seen during pregnancy, cancer chemotherapy, uremia, radiation therapy, electrolyte and endocrine disturbances, or the presence of chemical emetic substances). Nausea and vomiting are also common post-operative side effects that result from the use of anesthetics. These symptoms are known as post-operative nausea and vomiting (PONV). A series of medication alternatives are currently used to combat PONV. The drugs used most frequently are benzamides (e.g. Metoclopramide),phenothiazines(e.g. Phenergan) and Serotonin inhibitors (e.g. Ondancetron). In order to minimize the side effects, these drugs are most often administered in this sequence. If Metroclopramide fails to produce adequate relief, Phenergan is administered. If sufficient relief is still not experienced, Ondancetron is given to the patient. In efforts to control cost and potential side effects, these medications are usually given in sequence at 30 minute intervals. This methodology can significantly prolong the time the patient remains in the recovery room, an area of the hospital where every additional minute represents enormous expense. The most common side effects of metroclopramide, which are experienced by about 10% of treated patients involve the central nervous system (CNS) and include
Patents 123
restlessness, fatigue, drowsiness and lassitude. Insomnia, headache and dizziness occur less frequently. Delirium, severe dysphoria, obsessive rumination, mania, depression, and suicidal indication have also been reported. Extrapyramidal effects also result from dopaminergic blockage. This usually presents in the form of akathisia and occurs most often in children and young adults. Dystonic reactions resembling acute dyskinesia occur in less than 1% of young patients receiving low doses of Metroclopramide, but occur as often as in 25% of patients receiving higher doses. Web site: http://www.delphion.com/details?pn=US06030631__ •
Drug-withdrawal-syndrome auricle-therapeutic device Inventor(s): Qingmin; Wu (Room 102, Flat 4, 17# Huaxin Xiang, Nanjing, Jiangsu Province, CN) Assignee(s): None Reported Patent Number: 6,296,652 Date filed: May 26, 1999 Abstract: A device for treating the undesirable symptoms resulting from cessation of habitual drug use, which can include insomnia, anxiety, tremors, loss of appetite, drowsiness, nausea, and sweating, and for reducing the rate of recurrence of drug use following treatment through the use of a programmed series of acupuncture, massage, and/or moxibustion treatments of acupuncture points in a subject's ear(s). The device includes a housing that conforms to the contour of a human ear containing a plurality of acupuncture needles held in an elastomeric structure and connected to a movable elongate member such that the plurality of needles may be brought into intermittent contact with the inner surface of the ear with an approximately equal force. The device further includes a control circuit adapted to automatically control the application of acupuncture stimulating current, moxibustion, and/or massage in a programmable manner. The device allows a user to program a treatment regimen into the device, removably affix the device adjacent at least one of a subject's ears, and provide the programmed acupuncture, moxibustion, and/or massage treatments to a plurality of known acupuncture points on the inner surface of the subject's ear(s). In one embodiment, the acupuncture needles are made of a permanently magnetic material to include an auxiliary magnetic treatment. In an alternative embodiment, the device also includes a vocal and/or musical sound generating component as additional therapy. Excerpt(s): The invention concerns a therapeutic device, particularly, a therapeutic device for treating drug withdrawal syndrome. What is called drug withdrawal syndrome means such serious syndrome as being anger for drug, anxiety, frequently giving yawn, sweating, running with tears, running nose, drowsing, dilated pupil, being goose flesh, tremor, shivering, muscle aching, headache, losing appetite, insomnia, even blood pressure rising, frequency and depth of breath increasing, pulse quickening, restless, nausea, curling, vomiting, diarrhea, spermatorrhea, etc. occurred after stopping drug-taking. Chemotherapy of entire course integrated the three phases addictionremoving, consolidation and rehabilitation is adopted in drug-giving-up treatment now. Body acupuncture and ear acupuncture therapies by hand-needling or electroimpulse output only are used for an auxiliary means. Modern drug-giving-up therapy is a pure chemotherapy. Addiction-removing therapy taking opium acceptor analeptic such as methadone, opium, dihydroetorphine and others or opium acceptor partial analeptic-buprenorphine as alternatives, or addiction-removing taking non-opium clonidine, existing preserving treatment taking naltrexone or methadone in consolidation therapy.
124 Nausea
The above-mentioned therapies, generally speaking, have many advantages such as reliable efficiency, fast addiction-removing action and relative safety. While there exist problems with them. These include more undesirable reaction, heavier toxic side effects, undetermined effect in giving up abuse of many drugs due to addiction to narcotic drug, trend of some medicines producing dependence, consequently treating medicines having been turned new narcotic drugs and leading new addiction to them. After addiction-removed by modern drug-giving-up treatment, some procrastinated withdrawal syndromes still exists at different extents with sufferers, even though taking naltrexone to consolidate effect, 90.about.95% drug-retaking rate still occurs during six months after addiction-removing treatment using different giving-up medicines in modern drug-giving-up therapy, in result, the vicious circle of habituation--addictionremoving--Addiction-recovering--addiction-re-removi ng almost can not be broken. The existing acupuncture or ear acupuncture therapy and electronics designed based the principle of science of acupuncture and moxibustion is a pure physical therapy, and is only used as an auxiliary means. Hand-needling treatment is not easy to master exactly and may cause pain and infection due to improper operation. Drug-giving-up effect may be unsatisfactory and unsteady when design of the devices is unreasonable, or the devices are not convenient to use due to their low automatic degree. Consequently, popularization of the treatment method in the drug-giving-up field is blocked. Web site: http://www.delphion.com/details?pn=US06296652__ •
Electro-acupuncture device with stimulation electrode assembly Inventor(s): Duffy; Robert J. (Carlsbad, CA), Grey; Thomas L. (Carlsbad, CA), Gruzdowich; Gregory J. (Carlsbad, CA), Mann; Thomas L. (Carlsbad, CA), Tait; Hogar (Carlsbad, CA) Assignee(s): Woodside Biomedical, Inc. (carlsbad, Ca) Patent Number: 6,567,695 Date filed: November 24, 2000 Abstract: An electro-acupuncture device for controlling nausea. The device includes a base unit which is includes a wrist-watch like housing, circuitry for generating electroacupuncture stimulus disposed within the housing, and a strap for securing the housing to the wrist. The base unit has a standardized construction. The device also includes a releasably attachable electrode assembly. The electrode assembly attaches to the base unit of the device. The electrode assembly includes a pair of electrodes and connectors for connecting the electrodes to the circuitry of the base unit. The output of the device is dependent upon the circuitry of the electrode assembly. Thus various electrode assemblies can be made. The circuitry of the base unit modifies the output of the device depending upon which electrode assembly is attached to the base unit. Excerpt(s): The methods and devices described below relate to the field of electroacupuncture and non-invasive stimulation of nerves. We have developed an electroacupuncture device which has proven effective for the control of nausea and vomiting. The device, marketed under the trademark Relief-Band.RTM., is worn on the wrist like a wristwatch, with a watch-like housing which is positioned on the underside of the wrist. The housing has two electrodes on the inside face (the face in contact with the wrist when secured to the wrist), a battery and circuitry inside the housing, and control buttons on the outer face. A patient suffering from nausea or vomiting (from seasickness, morning sickness, chemotherapy, or anesthesia) can strap the device onto their wrist and turn it on. When turned on, the device emits an electrical stimulation
Patents 125
pulse over the P6 acupuncture point (corresponding to the superficial course of the meridian nerve through the wrist). Within several minutes, most patients experience a substantial relief of nausea. The device uses non-invasive nerve stimulation whereby electricity is passed through two electrodes to stimulate nerves located on the ventral side of the wrist (this anatomical position is sometimes referred to as the palmar side of the wrist). The treatment provided by the device is sometimes referred to as electroacupuncture, which is a form of acupuncture, and the ventral site of application is referred to in the acupuncture art as the P6 point, pericardium 6 point, or master point of the pericardium meridian (sometimes referred to as the vascular meridian). A primary object of the invention is to provide a non-chemical, non-invasive, painless and inexpensive method of alleviating nausea. It is also portable, self-contained and convenient to the patient. Electrical pulse repetition rate of approximately 70 pulses per second and a pulse width of 80 microseconds has been found to provide effective relief of nausea in a patient. Our currently preferred electrical pulse pattern comprises about 350 microsecond pulse width at about 31 pulses per second at power levels of about 1035 milli-amps peak pulse height. Thus a wide range of pulse patterns may be used in non-invasive nerve stimulation devices. The device is described in Bertolucci, Nausea Control Device, U.S. Pat. No. 4,981,146 (Jan. 1, 1991). Previously, we have provided devices in several models, each providing a different strength of stimulation deemed appropriate for particular patients and indications. We have also marketed a version of the device which included circuitry and operator controls which allowed the patient to select from a wide range of power setting and stimulation patterns. Currently, we are marketing over-the-counter devices and prescription devices. Both the over-the-counter device and the prescription are provided in embodiments in which the device is disposable (the batteries cannot be replaced after depletion) and in which the device is reusable, (the batteries may be replaced indefinitely). In each of these versions, we have provided complete circuitry, power supply, and electrodes in each device manufactured. Thus, for each version of the device, different circuitry had to be provided. The devices and methods described below provide for easier manufacturing of a line of devices with different characteristics. Web site: http://www.delphion.com/details?pn=US06567695__ •
Extended release formulation of venlafaxine hydrochloride Inventor(s): Clark; John C. (Peru, NY), Lamer; John U. (St. Albans, VT), Sherman; Deborah M. (Plattsburgh, NY), White; Steven A. (Champlain, NY) Assignee(s): American Home Products Corporation (madison, Nj) Patent Number: 6,274,171 Date filed: January 20, 2000 Abstract: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose.
126 Nausea
Excerpt(s): Extended release drug formulations are conventionally produced as compressed tablets by hydrogel tablet technology. To produce these sustained release tablet drug dosage forms, the active ingredient is conventionally compounded with cellulose ethers such as methyl cellulose, ethyl cellulose or hydroxypropylmethylcellulose with or without other excipients and the resulting mixture is pressed into tablets. When the tablets are orally administered, the cellulose ethers in the tablets swell upon hydration from moisture in the digestive system, thereby limiting exposure of the active ingredient to moisture. As the cellulose ethers are gradually leached away by moisture, water more deeply penetrates the gel matrix and the active ingredient slowly dissolves and diffuses through the gel, making it available for absorption by the body. An example of such a sustained release dosage form of the analgesic/anti-inflammatory drug etodolac (Lodine.RTM.) appears in U.S. Pat. No. 4,966,768. U.S. Pat. No. 4,389,393 discloses sustained release therapeutic compressed solid unit dose forms of an active ingredient plus a carrier base comprised of a high molecular weight hydroxypropylmethylcellulose, methyl cellulose, sodium carboxymethylcellulose and or other cellulose ether. Where the production of tablets is not feasible, it is conventional in the drug industry to prepare encapsulated drug formulations which provide extended or sustained release properties. In this situation, the extended release capsule dosage forms may be formulated by mixing the drug with one or more binding agents to form a uniform mixture which is then moistened with water or a solvent such as ethanol to form an extrudable plastic mass from which small diameter, typically 1 mm, cylinders of drug/matrix are extruded, broken into appropriate lengths and transformed into spheroids using standard spheronization equipment. The spheroids, after drying, may then be film-coated to retard dissolution. The film-coated spheroids may then be placed in pharmaceutically acceptable capsules, such as starch or gelatin capsules, in the quantity needed to obtain the desired therapeutic effect. Spheroids releasing the drug at different rates may be combined in a capsule to obtain desired release rates and blood levels. U.S. Pat. No. 4,138,475 discloses a sustained release pharmaceutical composition consisting of a hard gelatin capsule filled with film-coated spheroids comprised of propanolol in admixture with microcrystalline cellulose wherein the film coating is composed of ethyl cellulose, optionally, with hydroxypropylmethylcellulose and/or a plasticizer. Venlafaxine, 1-[2dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol, is an important drug in the neuropharmacological arsenal used for treatment of depression. Venlafaxine and the acid addition salts thereof are disclosed in U.S. Pat. No. 4,535,186. Venlafaxine hydrochloride is presently administered to adults in compressed tablet form in doses ranging from 75 to 350 mg/day, in divided doses two or three times a day. In therapeutic dosing with venlafaxine hydrochloride tablets, rapid dissolution results in a rapid increase in blood plasma levels of the active compound shortly after administration followed by a decrease in blood plasma levels over several hours as the active compound is eliminated or metabolized, until subtherapeutic plasma levels are approached after about twelve hours following administration, thus requiring additional dosing with the drug. With the plural daily dosing regimen, the most common side effect is nausea, experienced by about forty five percent of patients under treatment with venlafaxine hydrochloride. Vomiting also occurs in about seventeen percent of the patients. Web site: http://www.delphion.com/details?pn=US06274171__
Patents 127
•
Intravaginal rings with insertable drug-containing core Inventor(s): Bardin; C. Wayne (New York, NY), Harmon; Troy (Lansdale, PA), Nash; Harold A. (Harrington Park, NJ), Saleh; Saleh Ismail (Assuit, EG) Assignee(s): The Population Council, Inc. (new York, Ny) Patent Number: 5,972,372 Date filed: May 2, 1997 Abstract: Disclosed is a vaginal ring intended for the release of at least one drug over a prolonged time period. The vaginal ring contains a ring body made of a first polymeric material having at least one hollow internal channel defining an opening to the exterior of the ring body and which channel is adapted to receive a, drug-containing core through the opening, and an intravaginally administerable drug-containing core disposed in the channel. The core is positioned in the vaginal ring body suitably prior to use in order to substantially avoid initial bursts of drug into the tissues of the subject and resultant side effects such as nausea and vomiting. The core contains a pharmaceutically effective amount of at least one intravaginally administerable drug dispersed in a second polymeric material. The first and second polymeric materials may be the same or different. Representative drugs include contraceptive agents and other steroidal substances for use in hormone replacement therapy. Also disclosed are methods for preparing the vaginal rings, kits for assembling the vaginal rings, and methods of using the vaginal rings to achieve intravaginal delivery of drugs to a female. Excerpt(s): The present invention is directed to intravaginal drug delivery devices and methods for the intravaginal administration of drugs, and more particularly, the intravaginal administration of contraceptive agents and agents for hormone replacement therapy. Vaginal rings are torous shaped devices designed to deliver a relatively constant dose of drug to the vagina usually over a period of weeks to months. Typically, they are made of a silicone elastomer and contain a drug released by diffusion though the elastomer. The most common commercial applications have been to deliver low doses of steroids for post-menopausal vaginal conditions. They have also been under development for use in contraception and hormone replacement therapy. Vaginal rings have also been used to administer spermicides, as well as a variety of locally or systematically active medicaments. Vaginal rings have provided several advantages in that their use is controlled by the female; they allow for a better regulated dose of drug without attention by the user; and they avoid the destruction (by the intestine and by first pass through the liver) of an appreciable portion of the daily dosage of some steroids compared to their orally delivered counterparts. The use of a vaginal ring to deliver drugs requires a ring design that regulates the release rate so as to provide the user with the appropriate daily dose. Among the important factors governing release are the solubility of the drug in the ring elastomer, the surface area of the drug reservoir, the distance the drug must diffuse through the ring body to reach its surface and the molecular weight of the drug. If very high release rates are desired, they can be attained by a drug load at the ring surface as is characteristic of the homogeneous matrix ring design. This design, however, suffers from rapidly declining release rates as the distance the drug must travel to reach the ring surface increases as the drug load near the surface is depleted. If moderately high release rates are needed to provide the appropriate dose, a design which modulates release rate by imposing a layer of drug-free elastomer between the drug reservoir and the ring exterior is appropriate. This may be attained by coating a homogeneous ring, or to conserve drug, by incorporating a drug-free core, a shell design may be used. If an even lower release rate is desired, the drug may be confined to a small diameter at the center of the ring ("core ring"). Finally, the drug-
128 Nausea
loaded core may not encircle the ring but instead be of short length. Numerous types of vaginal rings have been described in the patent and non-patent literature alike. See, e.g., U.S. Pat. Nos. 4,012,496 and 4,155,991 (both to Schopflin et al.), 4,292,965 (Nash), 3,545,439 (Duncan), 3,920,805 (Roseman), 3,991,760 and 3,995,634 (both to Drobish et al.), 3,995,633 (Gougen), 4,250,611 and 4,286,587 (both to Wong), 4,596,576 (de Nijs); W095/00199 (Lehtinen et al.), NL 8500-470-A; and Apter et al., Contraception 42:285-295 (1990), Burton et al., Contraception 17:221-230 (1978), Burton et al., contraception 19:507516 (1979), Jackanicz, Contraception 24:323-339 (1981), Sivin et al., Contraception 24:341358 (1981), Timmer et al., Contraception 43:629-642 (1990), and Toivonen, Contraception 20:511-518 (1979). Web site: http://www.delphion.com/details?pn=US05972372__ •
Medicaments for gastrointestinal disorders Inventor(s): Challoner; Teresa Elizabeth (Regents Park, GB), Tyers; Michael Brian (Welwyn, GB) Assignee(s): Glaxo Group Limited (brentford, Gb) Patent Number: 6,544,550 Date filed: November 24, 1993 Abstract: The invention relates to the co-administration in human or veterinary medicine of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4Hcarba zol-4-one or a physiologically acceptable salt or solvate thereof and dexamethasone or a physiologically acceptable salt or ester thereof. The two active ingredients, which may be administered separately either simultaneously or sequentially, or may be combined in a single pharmaceutical preparation, are useful in the relief and/or prevention of nausea and vomiting. Excerpt(s): This invention relates to improvements in the treatment of gastrointestinal disorders. More particularly it relates to the use of a compound having antagonist activity at 5HT.sub.3 receptors and dexamethasone in the treatment of emesis, and to pharmaceutical compositions containing the two compounds. and physiologically acceptable salts, solvates and physiologically acceptable equivalents thereof. In the aforementioned specification the compounds are described as potent and selective antagonists of 5- hydroxytryptamine (5HT) at `neuronal` 5HT receptors of the type located on terminals of primary afferent nerves, and which are also present in the central nervous system. Receptors of this type are now designated 5HT.sub.3 receptors. The compounds are described as being of use in the treatment of a human or animal subject suffering from a condition caused by a disturbance of neuronal 5HT function, for example in the treatment of migraine pain or a psychotic disorder such as schizophrenia. The compounds may also be useful in the treatment of conditions such as anxiety, obesity and mania. Web site: http://www.delphion.com/details?pn=US06544550__
Patents 129
•
Method and composition for treatment of headache using magnesium Inventor(s): Altura; Bella T. (Beechhurst, NY), Altura; Burton M. (Beechhurst, NY), Mauskop; Alexander (Larchmont, NY) Assignee(s): Research Foundation of the State University of New York (albany, Ny) Patent Number: 6,218,192 Date filed: February 17, 1995 Abstract: A method of treating headache is provided using a water soluble magnesium salt. Specifically, a method of treating a headache is provided for an individual having a serum ionized magnesium concentration of 0.44 mmoles/L to 0.53 mmoles/L and having at least one headache symptom by administering an amount of a water soluble magnesium salt sufficaent to inhibit at least one headache symptom in the individual within 24 hours and to raise the serum ionized magnesium concentration in the individual to within a normal ionized magnesium concentration range of 0.54 mmoles/L to 0.67 mmoles/L. Headache symptoms which may be inhibited include: pain, aura, photophobia, nausea, unilateral pain and phonophobia. Excerpt(s): Magnesium (Mg) is the second most abundant cation in the body [Altura, B. M. et al., Drugs 28 (Suppl.I):120-142, 1984]. It is cofactor for more than 325 cellular enzymes involved in cellular energy production and storage, protein synthesis, DNA and RNA synthesis, cell growth and reproduction, adenylate cyclase synthesis, maintenance of cellular electrolyte composition, and stabilization of mitochondrial membranes [Altura, B. M. et al, Drugs 28 (Suppl.I):120-142, 1984; Wacker, W. E. C. Magnesium and Man, Harvard Univ. Press, Cambridge, 1980]. As a consequence of these biochemical activities, Mg plays a pivotal role in control of neuronal activity, cardiac excitability, neuromuscular transmission, muscular contraction, and vasomotor tone [Altura, B. M. et al., Drugs 28 (Suppl.I):120-142, 1984; Wacker, W. E. C. Magnesium and Man, Harvard Univ. Press, Cambridge, 1980; Altura, B. M. et al., in: Metal Ions in Biological Systems, ed. by H. Sigel and A. Sigel, Vol 26: Compendium on Magnesium and Its Role in Biology, Nutrition, and Physiology, pp 359-416, Marcel Dekker, Inc. New York, 1990]. Most clinical data of Mg determinations are derived from blood levels of total Mg (Wacker, W. E. C. Magnesium and Man, 1980; Elin, R. J. Clin. Chem. 33:19651970, 1987). Total serum Mg concentrations reflect protein-bound (30-40%), chelated (712%), and free or ionized Mg (Mg.sup.2+) (60-70%) fractions. The exact proportion of these fractions has been extremely difficult to determine precisely, and, moreover, there is no way to rapidly make such determinations. Precise information about Mg activity is pivotal to our understanding of Mg metabolism. The free or ionized form (Mg.sup.2+) is the active form of the mineral (Wacker, W. E. C. Magnesium and Man, 1980; Elin, R. J. Clin. Chem. 33:1965-1970, 1987; Ryan, M. F. Ann. Clin. Biochem. 28:19-26, 1991). Alterations in circulating protein levels (primarily albumin), which are seen in numerous pathophysiologic states, will alter the interpretation of Mg status (very similar to calcium) (Elin, R. J. Clin. Chem. 33:1965-1970, 1987). Although numerous methods are available clinically, to determine total Mg in serum, plasma, urine, cerebral spinal fluid and other body fluids (e.g., atomic absorption spectrophotometry, atomic emission spectrophotometry, colorimetry, fluorometry, compleximetry and chromatograph for quantifying total Mg), none of these can determine ionized or free Mg.sup.2+ (Elin, R. J. Cin. Chem. 33:1965-1970, 1987; Wills, M. R. et al. Magnesium 5:317-327, 1986). Web site: http://www.delphion.com/details?pn=US06218192__
130 Nausea
•
Method of treating symptoms of hormonal variation, including hot flashes Inventor(s): Guttuso, Jr.; Thomas J. (Rochester, NY) Assignee(s): University of Rochester (rochester, Ny) Patent Number: 6,310,098 Date filed: July 21, 2000 Abstract: One aspect of the present invention relates to a method of treating hot flashes in a patient which is carried out by providing a compound which binds a.alpha.sub.2.delta. subunit of a voltage-gated calcium channel and administering the compound to a patient experiencing hot flashes under conditions effective to treat the hot flashes. Another aspect of the present invention relates to a method for treating a symptom of hormonal variation in a patient which is carried out by providing a compound which binds a.alpha.sub.2.delta. subunit of a voltage-gated calcium channel and administering the compound to a patient experiencing a symptom of hormonal variation under conditions effective to treat the symptom of hormonal variation. Further aspects of the present invention relate to the administration of a compound which binds a.alpha.sub.2.delta. subunit of a voltage-gated calcium channel as an anti-pyretic agent (for treating fever) or as an anti-emetic agent (for treating nausea and emesis). Excerpt(s): The present invention relates generally to methods of treating symptoms of hormonal variation, including hot flashes, treating fever, and treating nausea and emesis. Hot flashes or flushing occur commonly in menopausal women. This is characterized by a sudden onset of warmth in the face and neck and often progressing to the chest. Such an episode generally lasts several minutes and is evidenced by a visible flushing of the skin. Often such episodes are accompanied by sweating, dizziness, nausea, palpitations and diaphoresis. Such symptoms can disrupt sleep and interfere with the quality of life. Although the cause of hot flashes are not completely understood, they are thought to be a disorder of thermoregulation resulting from a transient lowering of the hypothalamic temperature regulatory set point (Kronenberg et al., "Thermoregulatory Physiology of Menopausal Hot Flashes: A Review," Can. J. Physiol. Pharmacol., 65:1312-1324 (1987)). In post-menopausal woman, the cause of such hot flashes is believed to be a consequence of declining estrogen levels. Thus, it is not surprising that hot flashes also occur in a high percentage of women taking the antiestrogen drug tamoxifen. Men may also have hot flashes following androgendeprivation therapy (from bilateral orchiectomy or treatment with a gonadotrophinreleasing-hormone agonist) for metastatic prostate cancer. Web site: http://www.delphion.com/details?pn=US06310098__
•
Method of treatment of nausea, vomiting, and other disorders using estrogens Inventor(s): Steele; Joy Ann (14334 Park Drive, Edmonton Alberta, CA) Assignee(s): None Reported Patent Number: 6,239,122 Date filed: January 5, 2000 Abstract: The use of estrone or derivatives of estrone, equilin, or equilenin, including pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising these compounds as a therapeutic agent in humans or in animals is claimed. The
Patents 131
asserted use is as an antiemetic agent or for the treatment of other disorders that can be ameliorated by noncompetitive antagonism of the 5-hydroxytryptamine type 3 receptor. Excerpt(s): Not applicable. Web site: http://www.delphion.com/details?pn=US06239122__ •
Methods and compositions involving opioids and antagonists thereof Inventor(s): Farrar; John J. (Chester Springs, PA) Assignee(s): Adolor Corporation (exton, Pa) Patent Number: 6,451,806 Date filed: November 29, 2000 Abstract: Novel methods and compositions comprising opioids In preferred embodiments, the methods and compositions peripheral mu opioid antagonist compounds. The methods particularly suitable for treating and/or preventing side effects including, for example, constipation, vomiting and/or nausea.
and opioid antagonists. comprise opioids and and compositions are associated with opioids
Excerpt(s): The present invention relates to novel methods and compositions comprising opioids and opioid antagonists. More particularly, the present invention relates to novel methods and compositions comprising opioids and peripheral mu opioid antagonist compounds. It is well known that opioid drugs target three types of endogenous opioid receptors (i.e., mu, delta and kappa receptors) in biological systems. Most opioids, such as morphine, are mu opioid agonists that are often used as analgesics for the treatment of severe pain due to their activation of mu opioid receptors in the brain and central nervous system (CNS). Opioid receptors are, however, not limited to the CNS, and may be found in other tissues throughout the body. A number of side effects of opioid drugs may be caused by activation of these peripheral receptors. Administration of mu opioid agonists often results in intestinal dysfunction due to the large number of receptors in the wall of the gut (Wittert, G., Hope, P. and Pyle, D., Biochemical and Biophysical Research Communications 1996, 218, 877-881; Bagnol, D., Mansour, A., Akil, A. and Watson, S. J., Neuroscience 1997, 81, 579-591). Specifically, opioids are generally known to cause nausea and vomiting as well as inhibition of normal propulsive gastrointestinal function in animals and man (Reisine, T., and Pasternak, G., Goodman & Gilman's The Pharmacological Basis of Therapeutics Ninth Edition 1996, 521-555) resulting in side effects such as, for example, constipation. It has been reported that acute nausea or vomiting may occur in up to about 33% of patients who receive oral narcotic analgesics and in up to about 80% of patients who receive injectable narcotics following surgery or trauma. This is due, at least in part, to direct effects of narcotics on the gastrointestinal (GI) tract. Opioid-induced side effects, such as nausea, vomiting, and inhibited gastrointestinal propulsive activity remain serious problems for patients being administered opioid analgesics for both short term and long term pain management. Opioid antagonist compounds that do not readily cross the blood-brain barrier (peripherally acting drugs) have been tested for use in curbing opioid-induced side effects. For instance, the peripheral mu opioid antagonist compound methylnaltrexone and related compounds have been suggested for use in curbing opioid-induced side effects in patients. U.S. Pat. Nos. 5,972,954, 5,102,887, 4,861,781, and 4,719,215 disclose the use of methylnaltrexone and related compounds in controlling opioid-induced pruritus, nausea, and/or vomiting. Additionally, methylnaltrexone has been shown to effectively reduce the incidence of opioid-induced nausea and pruritus as disclosed by
132 Nausea
Yuan, C. -S. et al. Drug and Alcohol Dependence 1998, 52, 161. Similarly, U.S. Pat. Nos. 5,250,542, 5,434,171, 5,159,081, and 5,270,328, disclose peripherally selective piperidineN-alkylcarboxylate opioid antagonists as being useful for the treatment of the opioid side effects constipation, nausea or vomiting, as well as irritable bowel syndrome and idiopathic constipation. Web site: http://www.delphion.com/details?pn=US06451806__ •
Methods for treating behavioral and other disorders using optically pure R(+) ondansetron Inventor(s): Young; James W. (Still River, MA) Assignee(s): Sepracor Inc. (marlborough, Ma) Patent Number: 5,962,494 Date filed: January 23, 1998 Abstract: Methods and compositions are disclosed utilizing the optically pure R(+) isomer of ondansetron. This compound is a potent drug for the treatment of nausea and vomiting associated with chemotherapy and radiation therapy, while avoiding the concomitant liability of adverse effects associated with the racemic mixture of ondansetron. The R(+) isomer of ondansetron is also useful for the treatment of behavioral disorders such as mood anxiety and schizophrenia, and such other conditions as may be related to R(+) ondansetron's activity as a competitive antagonist of serotonin receptor subtype 5-HT.sub.3 such as disorders of gastrointestinal motility, depression, migraine, and as an aid for alcohol withdrawal, nicotine withdrawal, and drug (benzodiazepine et al.) withdrawal, without the concomitant liability of adverse effects associated with the racemic mixture of ondansetron. Furthermore, the R(+) isomer of ondansetron is also useful for the treatment of cognitive disorders such as dementia or age-associated memory impairment, while avoiding the concomitant liability of adverse effects associated with the racemic mixture of ondansetron. Excerpt(s): This invention relates to novel compositions of matter containing optically pure R(+) ondansetron. These novel compositions have potent antiemetic activity and are useful in ameliorating the nausea and vomiting otherwise induced by cancer chemotherapeutic agents and higher dose radiotherapeutic treatment procedures while avoiding adverse effects including but not limited to headache, constipation and increases in transaminase levels, which are associated with the administration of the racemic mixture of ondansetron. Additionally, these novel compositions of matter containing optically pure R(+) ondansetron are useful in treating behavioral disorders such as mood anxiety and schizophrenia, and such other conditions as may relate to R(+) ondansetron's activity as a competitive antagonist of serotonin receptor subtype 5HT.sub.3, including but not limited to disorders of gastrointestinal motility,-depression, migraine, alcohol, nicotine or drug (benzodiazepine et al.) withdrawal, while avoiding adverse effects associated with the administration of the racemic mixture of ondansetron. Furthermore, these novel compositions of matter containing optically pure R(+) ondansetron are useful in treating cognitive disorders such as dementia and ageassociated memory impairment, while avoiding the adverse effects associated with the administration of the racemic mixture of ondansetron. Also disclosed are methods for treating the above described conditions in a human while avoiding the adverse effects that are associated with the racemic mixture of ondansetron, by administering the R(+) isomer of ondansetron to said human. The active compound of this composition, and method is an optical isomer of the compound, ondansetron which is described in U.S.
Patents 133
Pat. No. 4,695,578. Chemically, the active compound is the R(+) isomer of 1,2,3,9tetrahydro-9-methyl-3-›(2-methyl-1H-imidazol-1-yl)methyl!-4H-carba zol-4-one. This isomer will hereinafter be referred to as R(+) ondansetron. Many organic compounds exist in optically active forms, i.e., they have-the ability to rotate the plane of planepolarized light. In describing an optically active compound, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes (+) and (-) or d and 1 are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or 1 meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these compounds, called stereoisomers, are identical except that they are mirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric or racemic mixture. Web site: http://www.delphion.com/details?pn=US05962494__ •
Migraine medicine and method for treating same Inventor(s): Imanzahrai; Ashkan (1642 Nord La., San Jose, CA 95125) Assignee(s): None Reported Patent Number: 6,642,243 Date filed: June 14, 2000 Abstract: This invention is a safe and effective composition and method for treating acute migraine attacks using pseudoephedrine, acetaminophen, and other agents in an orally administrated form to alleviate the pain and cluster of symptoms characteristic of migraine attacks such as nausea, photophobia, phonophobia, and functional disabilities as well as the prodrome phase of a migraine attack. Excerpt(s): The present invention relates generally to compositions and methods used to alleviate the symptoms and pain associated with an acute migraine attack. Many migraine sufferers use single-agent nonprescription analgesics such as acetaminophen, or aspirin, or non-steroidal anti-inflammatory agents to treat their attacks. (Lipton R B, Newman L C, Solomon S. Over-the-counter medication and the treatment of migraine. Headache 1994; 34:547-548.) In other countries, a number of nonprescription drugs are specifically approved for migraine pain. (Lipton R B, Newman L C, Solomon S. Overthe-counter medication and the treatment of migraine. Headache 1994; 34:547-548.) The effectiveness of self-treatment of a migraine and the effectiveness of most such nonprescription drugs in relieving or aborting migraine pain and/or the characteristic symptoms of a migraine has not been adequately studied in well-controlled clinical trials. (Lipton R B, Newman L C, Solomon S. Over-the-counter medication and the treatment of migraine. Headache 1994; 34:547-548.) Acetaminophen, aspirin, and caffeine are approved for relief of nonspecific headaches and tension headaches (Migliardi J R, Armellino J J, Friedman M, Gillings D B, Beaver W T. Caffeine as an analgesic adjuvant in tension headache. Clin Pharmacol Ther 1994; 56:576-586), which are clinical and physiologically distinct from a migraine. Caffeine is widely consumed and has also been indicated for use to treat asthma, drowsiness, fatigue, lumbar puncture headache, and neonatal apnea. [(Reents S. Clinical Pharmacology. Gold Standard Multimedia, Inc. (www.gsm.com) 1999. Available from URL:https://home.po.com.)] Caffeine is also an analgesic adjuvant for a variety of pain conditions and has been included in combination with other analgesics, ergot alkaloids, and barbiturates in prescription formulations for a migraine. (Laska E M, Sunshine A,
134 Nausea
Mueller F, Elvers W B, Siegel C, Rubin A. Caffeine as an analgesic adjuvant. JAMA 1984; 251:1711-1718; Olesen J. A review of current drugs for migraine. J Neurology 1991; 238 Suppl 1:S23-S27; Solomon G D. Therapeutic advances in migraine. J Clin Pharmacol 1993; 33:200-209; and Sawynok J. Pharmacological rationale for the clinical use of Caffeine. Drugs 1995; 49:37-50.) Caffeine itself may act to relieve a migraine. Caffeine has shown to reduce cerebral blood flow in humans and to be a nonselective adenosine receptor antagonist. Reduction of cerebral blood flow may be due to caffeine inhibition of the adenosine A2 receptor. (Sawynok J. Pharmacological rationale for the clinical use of Caffeine. Drugs 1995; 49:37-50.) A2 receptors are on cerebral vascular muscles, and act to cause vasodilation. Hence, their inhibition would have the effect of vasoconstriction similar to other medications used to abort the migraine headache. Web site: http://www.delphion.com/details?pn=US06642243__ •
Motion sickness/vertigo prevention device and method Inventor(s): Butnaru; Hanan (1 Somerville Ct., San Antonio, TX 78257) Assignee(s): None Reported Patent Number: 5,966,680 Date filed: February 13, 1997 Abstract: A device and method which operates as an artificial labyrinth to eliminate sensory mismatch between the natural labyrinth/vestibular system and the vision system of an individual. The present invention provides an alternative means for the user to determine the true orientation of his body with respect to the surrounding environment. The method can be effected by means of a device which senses true body orientation and displays corresponding visual orientation cues that the brain can use to confirm other visual position information. The display can be projected into space in front of the user, directly onto the user's retina, or effected by pictorial scene averaging. The device is particularly useful in the rehabilitation treatment of persons suffering from vestibular nervous system defect or damage, and in providing relief to those suffering from the symptoms of nausea and/or vertigo which are often experienced as a result of the aforementioned sensory mismatch. Excerpt(s): The present invention relates generally to a device for the relief of nausea, disorientation, and other disabling symptoms resulting from sensory mismatch and, more particularly, to an artificial labyrinth which provides the user an alternate means of determining his actual, physical orientation with respect to the surrounding environment. Motion sickness does not discriminate. It can attack anyone, at any time. It is always disabling, to a greater or lesser degree, depending on the person. It is known from research that certain types of sensory mismatch are the leading cause of motion sickness. This mismatch occurs when the brain perceives that the body is in motion (through signals originating in the labyrinth and transmitted to the brain by the vestibular nerve system), but the motion sensed does not match what the eye can see and verify. The reverse is also true (i.e. sensory mismatch may also occur when the eye perceives motion, but the labyrinth does not provide confirming signals to the brain). There are many causes of this mismatch, including: time delay between the arrival of labyrinth motion signals and visual confirmation signals within the brain, or conflict between these signals when they do manage to arrive at the same time. In addition, the labyrinth's signals may be corrupted by various physical defects, conflict with each other within the labyrinth, or be missing entirely, as is the case when a person has the vestibular system disconnected (via operation, accident, or birth defect). All causes of
Patents 135
this type of sensory mismatch are not precisely known, but it is well-established that such conditions can drastically affect an individual's quality of life and performance of everyday tasks. One example of sensory mismatch is vertigo, which is the sensation the brain encounters when it perceives that the body is in motion (when in fact there is no motion), and it attempts to correct bodily posture to counteract the perceived physical sensation. Another example of sensory mismatch occurs when the eye perceives motion, but no motion actually occurs. This can be described as a type of "virtual reality" sickness, which is normally experienced users of video games or flight simulators. The reverse situation, when the body feels motion but there are no visual cues, is a much more common occurrence. Examples include: passengers in an airplane with no access to a window, sailors in a submarine, and ship passengers that cannot see the horizon. Such persons sense actual changes in body position, but have nothing in the environment which allows their eye to confirm the motion they perceive. Web site: http://www.delphion.com/details?pn=US05966680__ •
Pharmaceutical compositions containing granisetron and dexamethasone Inventor(s): Dott; Christopher Stuart (Redhill, GB), Sanger; Gareth John (Sawbridgeworth, GB) Assignee(s): Smithkline Beecham P.l.c. (brentford, Gb) Patent Number: 5,929,059 Date filed: July 28, 1997 Abstract: A method of treatment of nausea and vomiting is disclosed which comprises administering to a human or animal subject granisetron and an antiemetic corticosteroid. Excerpt(s): This invention relates to a method of treatment and/or prophylaxis of nausea and vomiting, comprising the administration of a compound having 5-HT.sub.3 receptor antagonist activity. The anti-emetic properties of granisetron are potentially enhanced by administering the compound in conjunction with systemic corticosteroids, such as dexamethasone. Dexamethasone is a systemic anti-inflammatory corticosteroid, which is known to have anti-emetic properties and to be useful in the treatment of emesis resulting from chemotherapy, especially cancer chemotherapy involving the use of, for example, cisplatin. Accordingly, the present invention provides a pharmaceutical product comprising granisetron and steroid such as dexamethasone as a combined preparation for simultaneous, separate or sequential use in the treatment and/or prevention of nausea and vomiting. Web site: http://www.delphion.com/details?pn=US05929059__
•
Phosphatidic acid-comprising compositions Inventor(s): Shenfeld; Avner (Rehovot, IL), Shinitzky; Meir (Shmariyahu, IL) Assignee(s): Modus Biological Membranes Ltd. (rehovot, Il) Patent Number: 6,051,564 Date filed: February 24, 1999
136 Nausea
Abstract: The invention is to a method for the treatment of withdrawal symptoms selected from the group consisting of nausea, sweating, shaking, substance craving and hot flushes. Excerpt(s): The present invention concerns lipid-based compositions and use of such compositions in the treatment of withdrawal syndromes or cancer. Withdrawal syndromes can occur during rehabilitation from addiction to drugs, alcohol, cigarettes and from an abrupt decline in the level of various hormones such as that occurring in menopause women. It is expressed in symptoms of seizures, sweat, tremor, nausea, depression, increase in rate of heart beat and in blood pressure, and others. Typically such addiction is treated by a "wash out" period in which the dependency is gradually removed with or without drug intervention. This process is painful and tedious and candidates are thus very often discouraged from entering it. There is thus a strong need for a solution that can ease the difficult period of withdrawal and that would allow people to return to normal life without much complications. A basic biochemical phenomenon shared by most of the withdrawal syndromes is a change in the composition and in the structure of neuronal cell membranes which is expressed in membrane "fluidity" (Hannan, Am. Rev. Respir. Dis., 140 (1989), 1668-73; Crews, Psycho-pharmacology, 81 (1983), 208-13; Harris, Life Sci., 35 (1984), 2601-8; Heron et al., Eur. J. Pharmacol., 83 (1982), 253-261). These changes can at times be counteracted by administration of special natural preparations, resulting in the reduction of the symptoms related to the withdrawal processes (Heron et al., Eur. J. Pharmacol, 83 (1982) 253-261; Shinitzky, Physiology of membrane fluidity, (1984), Vol I, Chapt. 1). Web site: http://www.delphion.com/details?pn=US06051564__ •
Pillow for an individual and the method for producing a pillow for an individual Inventor(s): Takashima; Hisato (5-18, Kasuga-cho, Takatsuki-shi, Osaka-fu, 569-0053, JP) Assignee(s): None Reported Patent Number: 6,151,733 Date filed: January 25, 1999 Abstract: The object of the present invention is to provide a pillow which has the pillow user's most comfortable height and shape and which he can have a comfortable sleep with a relaxed posture and in which he is not prevented from turning in bed and in which is free from headache or nausea from receiving pressure on his neck. The method for producing a pillow which can have the most comfortable height and shape which differs in accord with body shape and sleeping posture is shown and described. Furthermore, a pillow is disclosed for an individual having a flat pad and a cushion having a convex portion as its basic components, and in which necessary numbers of pads used for adjusting height as well as pads for adjusting pressure on cervical vertebra can be added into a flat pad and said cushion having a convex portion and insertable into a cover. The flat pad, the cushion having a convex portion, the pad for adjusting a height and the pad for adjusting pressure on cervical vertebra are then prepared and a bottom of the cushion having a convex portion is flat and the upper surface of it is curved for fitting a shape of a portion along from a pillow user's head to neck. Excerpt(s): A pillow has a great influence in a comfortable sleep and is believed to determine whether people can sleep comfortably. The most important factor is the use of the most comfortable pillow for each person for a comfortable sleep. Although at first
Patents 137
thought, the factors as a condition of comfortable sleep might seem to be pillow height, hardness, material, size, fragrance, color and sound fitting the individual taste of a pillow user, other conditions include, non-stuffiness conditions relating to the head's ventilation, absorption of humidity and moisture vaporization, especially since it is advantageous to superior to naturally absorb and release sweat during sleep. Further, heat insulation and the ability to naturally turn in bed are also considered as elements of the most comfortable pillow. Recently, it has been found that having a structure to support the cervical vertebra properly in order to avoid prevention of blood running to the nervous system and tissue near the a cervical vertebra, and thus this is also considered as one of elements of a most comfortable pillow. Currently there are many kinds of pillow shapes produced for supporting cervical vertebra. For example, there are a pillows having a concave portion for supporting the head between two apex shapes which act as a support for a portion of the cervical vertebra, and is referred to as a concave shaped pillow or a doughnut-shaped pillow. This pillow has a portion touching the neck which is high, and a portion touching the head is low. A center portion has a hollow shape. The present invention was produced to solve the aforementioned problems. The present in invention relating to the claims is a pillow, for an individual, having a flat pad and a cushion having a convex portion as a basic component, and wherein necessary numbers of pads for adjusting height and pads for adjusting pressure on cervical vertebra are added into the flat pad and cushion having a convex portion to be inserted into a cover, and further comprising that the flat pad, the cushion having a convex portion, the pad for adjusting a height and the pad for adjusting pressure on cervical vertebra are pre-prepared. In addition a bottom of the cushion having a convex portion is flat and an upper surface of the cushion having a convex portion is curved for fitting a shape of a portion of a user's anatomy to conform to a pillow user's head and cervical vertebra. Web site: http://www.delphion.com/details?pn=US06151733__ •
Therapeutic use and formulation Inventor(s): Huckle; Richard Michael (Cambridge, GB) Assignee(s): Darwin Discovery, Ltd. (gb) Patent Number: 6,297,286 Date filed: November 8, 2000 Abstract: Substantially single-enantiomer(-)-tramadol, and its metabolites and structural and/or functional analogues, are useful for the prevention and/or treatment of one or more symptoms selected from nausea, vomiting, dizziness, blurred vision, drowsiness, somnolence, hallucinations, respiratory depression, constipation and euphoria. In particular, substantially single enantiomer (-)-tramadol, and its o-desmethyl metabolite, have been found to be potent anti-emetics. Excerpt(s): This invention relates to new therapeutic uses of tramadol and its structural and/or functional analogues, and to new formulations thereof. Tramadol has the chemical name (+/-)-trans (RR,SS)-2-[(di-methylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol, and which is generally, and erroneously, referred to in literature as the cis(RS,SR) diastereomer, is a centrally acting, binary analgesic that is neither opiatederived, nor is a non-steroidal, anti-inflammatory drug (NSAID). It is used to control moderate pain in chronic pain settings, such as osteoarthritis and postoperative cases, and acute pain, such as dental pain. Used in therapy as a racemic mixture, the (+)enantiomer binds to the.mu.-opioid receptor, and both enantiomers inhibit 5-
138 Nausea
hydroxytryptamine (serotonin) and noradrenaline (norepinephrine) reuptake. Tramadol's major active metabolite, O-desmethyltramadol (M1), shows higher affinity for the.mu.-opioid receptor and has at least twice the analgesic potency of the parent drug. Web site: http://www.delphion.com/details?pn=US06297286__ •
Use of granisetron for the treatment of postoperative nausea and vomiting Inventor(s): Davey; Philip Timothy (Bishop's Stortford, GB), Dott; Christopher Stuart (Reigate, GB), Sanger; Gareth John (Sawbridgeworth, GB) Assignee(s): Smithkline Beecham P.l.c. (brentford, Gb) Patent Number: 5,952,340 Date filed: May 23, 1996 Abstract: The present invention is directed to a method for the treatment of postoperative nausea and vomiting wherein granisetron is administered to a patient in need thereof. Excerpt(s): This invention relates to prevention and treatment of post-operative nausea and vomiting (PONV), and pharmaceutical compositions therefor. Thus from the point of view of patients and clinicians, the control of PONV is essential. Financially, the control of PONV is also important. In regions such as the U.S.A., a lot of surgery is done in the day-care setting and the importance of being able to send patients home without an overnight stay is financially attractive. In other countries the popularity of day-care surgery is increasing and it may reach to over 50% in 5-10 years time. Web site: http://www.delphion.com/details?pn=US05952340__
•
Use of orexin receptor antagonists Inventor(s): Irving; Elaine Alison (Bengeo, GB), Sanger; Gareth John (Sawbridgeworth, GB) Assignee(s): Smithkline Beecham P.l.c. (brentford, Gb) Patent Number: 6,506,774 Date filed: November 30, 2001 Abstract: The use of orexin receptor antagonists as neuroprotectants, and in the treatment of nausea and vomiting, irritable bowel syndrome and other conditions associated with visceral pain. Excerpt(s): The present invention relates to the use of orexin receptor antagonists as neuroprotectants, and in the treatment of nausea and vomiting, irritable bowel syndrome and other conditions associated with visceral pain. Many medically significant biological processes are mediated by proteins participating in signal transduction pathways that involve G-proteins and/or second messengers. Polypeptides and polynucleotides encoding the human 7-transmembrane G-protein coupled neuropeptide receptor, orexin-1 (HFGAN72), have been identified and are disclosed in U.S. Pat. Nos. 5,935,814, 6,020,157 and 6,410,701. Polypeptides and polynucleotides encoding a second human orexin receptor, orexin-2 (HFGANP), have been identified and are disclosed in U.S. Pat. No. 6,166,193.
Patents 139
Web site: http://www.delphion.com/details?pn=US06506774__
Patent Applications on Nausea As of December 2000, U.S. patent applications are open to public viewing.10 Applications are patent requests which have yet to be granted. (The process to achieve a patent can take several years.) The following patent applications have been filed since December 2000 relating to nausea: •
3-azabicyclo[3.1.0]hexane derivatives useful in therapy Inventor(s): Banks, Bernard Joseph; (Kent, GB), Critcher, Douglas James; (Kent, GB), Fenwick, Ashley Edward; (Kent, GB), Gethin, David Morris; (Kent, GB), Gibson, Stephen Paul; (Kent, GB) Correspondence: Paul H. Ginsburg; Pfizer Inc; 20th Floor; 235 East 42nd Street; New York; NY; 10017-5755; US Patent Application Number: 20020025948 Date filed: June 18, 2001 Abstract: Compounds of formula I, 1where the substituents are as defined herein, and the pharmaceutically or veterinarily acceptable derivatives or prodrugs thereof, are pharmaceutically and veterinarily useful, in particular they bind to opiate receptors (e.g. mu, kappa and delta opioid receptors). They are likely to be useful in the treatment of diseases or conditions modulated by opiate receptors, for example irritable bowel syndrome; constipation; nausea; vomiting; pruritic dermatoses, such as allergic dermatitis and atopy; eating disorders; opiate overdoses; depression; smoking and alcohol addiction; sexual dysfunction; shock; stroke; spinal damage; and head trauma. Excerpt(s): This invention relates to pharmaceutically useful compounds, in particular compounds that bind to opiate receptors (e.g. mu, kappa and delta opioid receptors). Compounds that bind to such receptors are likely to be useful in the treatment of diseases modulated by opiate receptors, for example irritable bowel syndrome; constipation; nausea; vomiting; and pruritic dermatoses, such as allergic dermatitis and atopy in animals and humans. Compounds that bind to opiate receptors have also been indicated in the treatment of eating disorders, opiate overdoses, depression, smoking and alcohol addiction, sexual dysfunction, shock, stroke, spinal damage and head trauma. There is a particular need for an improved treatment of itching. Itching, or pruritus, is a common dermatological symptom that can give rise to considerable distress in both humans and animals. Pruritus is often associated with inflammatory skin diseases which may be caused by hypersensitivity reactions, including reactions to insect bites, such as flea bites, and to environmental allergens, such as house dust mite or pollen; by bacterial and fungal infections of the skin; or by ectoparasite infections. Existing treatments that have been employed in the treatment of pruritus include the use of corticosteroids and antihistamines. However, both of these treatments are known to have undesirable side effects. Other therapies that have been employed include the use of essential fatty acid dietary supplements, though these have the disadvantages of being slow to act, and of offering only limited efficacy against allergic dermatitis. A variety of emollients such as soft paraffin, glycerine and lanolin are also employed, but with limited success.
10
This has been a common practice outside the United States prior to December 2000.
140 Nausea
Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Amines that inhibit a mammalian anandamide transporter, and methods of use thereof Inventor(s): Aquila, Brian M.; (Marlborough, MA), Hopkins, Seth C.; (Clinton, MA), Lockshin, Curtis A.; (Lexington, MA), Wang, Fengjiang; (Northborough, MA) Correspondence: Foley Hoag, Llp; Patent Group, World Trade Center West; 155 Seaport Blvd; Boston; MA; 02110; US Patent Application Number: 20040048907 Date filed: May 15, 2003 Abstract: One aspect of the present invention relates to amines. A second aspect of the present invention relates to the use of the amines as inhibitors of a mammalian anandamide transporter. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to asthma, neuropathic pain, persistent pain, inflammatory pain, hyperactivity, hypertension, brain ischemia, Parkinson's disease, spasticity, Tourette's syndrome, schizophrenia, hemorrhagic shock, septic shock, cardiac shock, migrane, Horton's headache, multiple sclerosis, anorexia, AIDS wasting syndrome, organ rejection, autoimmune diseases, allergy, arthritis, Crohn's disease, malignant gliomas, neurodegenerative diseases, Huntington's chorea, glaucoma, nausea, anxiety, psychosis, attention deficit hyperactivity disorder, premature ejaculation, and stroke. Another aspect of the present invention relates to combinatorial libraries of amines, and methods for preparing the libraries. Excerpt(s): This application claims the benefit of priority to U.S. Provisional Patent Application serial No. 60/381,041, filed May 16, 2002. The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types of G-protein-coupled membrane receptors: the central CB.sub.1 receptors (Matsuda, L. A.; Lolait, S. J.; Brownstein, M. J.; Young, A. C.; Bonner, T. I. Structure of a Cannabinoid Receptor and Functional Expression of the Cloned cDNA. Nature 1990, 346, 561-564); and the peripheral CB.sub.2 receptors (Munro, S.; Thomas, K. L.; Abu-Shaar, M. Molecular Characterization of a Peripheral Receptor for Cannabinoids. Nature 1993, 365, 61-65). Also included among the elements of the ECS are the endogenous ligands anandamide (Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor. Science 1992, 258, 19461949), 2-arachidonoylglycerol (Sugiura, T.; Kondo, S.; Sukagawa, A.; Nakane, S.; Shinoda, A.; Itoh, K; Yamashita, A.; Waku, K. 2-Arachidonoylglycerol: a Possible Endogenous Cannabinoid Receptor Ligand in Brain. Biochem. Biophys. Res. Commun. 1995, 215, 89-97), and the recently reported 2-arachidonyl glyceryl ether (Hanus, L.; Abu-Lafi, S.; Fride, E.; Breuer, A.; Vogel, Z.; Shalev, D. E.; Kustanovich, I.; Mechoulam, R. 2-Arachidonyl Glyceryl Ether, an Endogenous Agonist of the Cannabinoid CBI Receptor. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3662-3665). A mechanism for the termination of the biological activity of the endogenous ligands has been elucidated, composed of a carrier-mediated transport system (anandamide transporter (AT)) and a hydrolyzing enzyme, named fatty acid amide hydrolase (FAAH). Hillard, C. J.; Edgemond, W. S.; Jarrahian, A; Campbell, W. B. Accumulation of N-
Patents 141
Arachidonoylehanolamine (Anandamide) into Cerebellar Granule Cells Occurs via Facilitated Diffusion. J. Neurochem. 1997, 69, 631-638; Beltramo, M.; Stella, N.; Calignano, A.; Lin, S. Y.; Makriyannis, A.; Piomelli, D. Functional Role of High-Affinity Anandamide Transport, as Revealed by Selective Inhibition. Science 1997, 277, 10941097; Hillard, C. J.; Jarrahian, A. The Movement of N-arachidonoylethanolamine (Anandamide) across Cellular Membranes. Chem. Phys. Lipids 2000, 108, 123-134; and Ueda, N.; Puffenbarger, R. A.; Yamamoto, S.; Deutsch, D. G. The Fatty Acid Amide Hydrolase (FAAH). Chem. Phys. Lipids 2000, 108, 107-121. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Analgesic and anti-inflammatory compositions comprising domperidone and methods of using same Inventor(s): On, Ninh; (London, GB) Correspondence: Arent Fox Kintner Plotkin & Kahn; 1050 Connecticut Avenue, N.W.; Suite 600; Washington; DC; 20036; US Patent Application Number: 20020025971 Date filed: September 21, 2001 Abstract: The present invention provides a method for eliciting an onset hastened analgesic and anti-inflammatory response and combating nausea in acute migraine attacks. This method comprises administering a pharmaceutical composition comprising more than one active ingredient, wherein said more than one active ingredient consist essentially of:(i) domperidone or an analogue thereof in an amount sufficient to hasten the onset of the analgesic and anti-inflammatory response and to combat nausea in an acute migraine attack, and(ii) a NSAID, a pharmaceutically acceptable salt thereof or a pure (-) or pure (+) optical isomeric form thereof in an analgesically and antiinflammatory effective amount, wherein said NSAID is selected from the group consisting of proprionic acid derivatives, acetic acid derivatives, fenamic acid derivatives, biphenylcarboxylic acid derivatives and oxicams. Excerpt(s): The current means of combating migraine attacks include simple analgesics such as aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDS) and paracetamol, taken at the earliest signs of an attack [1,2,3]. Aspirin, paracetamol and phenacetin have long been among the most commonly used members of the NSAIDS class. Amongst the newer NSAIDS are ibuprofen, ketoprofen, mefenamic acid, diflunisal, naproxen and piroxicam. The most widely used NSAIDS available over the counter that have fewer gastro intestinal side effects than aspirin are paracetamol and ibuprofen. Combined preparations of paracetamol or aspirin with an anti-emetic agent such as buclizine or metoclopramide, have been used to alleviate the nausea symptoms that often accompanied a migraine attack. Commercially, they are available as Migraleve Duo.RTM., Paramax.RTM., Migravess.RTM. Narcotic analgesics such as codeine have also been employed together with NSAIDS to obtain synergistic analgesia, for example Migraleve Yellow.RTM., co-codamol. Gastric stasis, commonly present in migraine[4], causes the poor absorption of the analgesics. Dispersible and effervescent formulations have been used in an attempt to overcome this [4]. Metoclopramide, an anti-emetic, also relieves gastric stasis which has been found useful counteracting the reduced analgesic effects of paracetamol in migraine attacks [1,4,5]. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
142 Nausea
•
Antiemetic, anti-motion sustained release drug delivery system Inventor(s): Drizen, Alan; (Downsview, CA), Nath, Gary M.; (Bethesda, MD) Correspondence: Nath & Associates Pllc; 6th Floor; 1030th 15th Street, N.W.; Washington; DC; 20005; US Patent Application Number: 20020172712 Date filed: March 19, 2001 Abstract: This invention relates to a stable, sterilized, purified composition having a polymer matrix and a therapeutically effective amount of a drug, wherein the drug can be used to prevent or treat drug-induced, alcohol-induced, biologically-induced, trauma-induced or pain-induced nausea, vomiting, dizziness and other adverse effects arising from but not limited to motion sickness, cancer therapy, and pregnancy. In particular, the polymer matrix may be conformable to topical application on animal skin. Excerpt(s): This invention relates to a dermal dressing for conformable topical application and sustained release of a polymer matrix containing a drug or combinations of drugs to animal skin. The drug can be any pharmaceutically effective amount useful for preventing and treating nausea, vomiting, dizziness and other adverse effects arising from but not limited to motion sickness, cancer therapy, and pregnancy in an animal. Over the years, methods have been developed to achieve the efficient delivery of a therapeutic drug to a mammalian body part requiring pharmaceutical treatment. Intravenous delivery and oral ingestion are two examples of current delivery techniques. While these techniques are generally effective, they suffer from several pharmacokinetic limitations and often result in substantial non-compliance by patients. For example, the therapeutic benefit from conventional methods often wear off within several hours after the initial dosing while the pain and discomfort associated with injections and intravenous lines often lead to difficulties in administration and maintenance of intravenous lines. Even oral administration can be ineffective where a patient cannot ingest due to nausea and/or vomiting. Topical administration of a pharmaceutically effective agent may avoid the problems associated with known drug delivery methods. One known method of topical administration uses an aqueous liquid that is applied at room temperature but forms a semi-solid gel when warmed to body temperature. This technique has the reported benefit of being easier to use and improving drug retention at the treatment site. For example, U.S. Pat. No. 4,188,373 uses PLURONIC.RTM. polyols in aqueous compositions to thermally gel aqueous systems. A sol-gel transition temperature is adjusted by varying the concentration of the polyols. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Anti-nausea and anti-vomiting activity of cannabidiol compounds Inventor(s): Breuer, Aviva; (Jerusalem, IL), Mechoulam, Raphael; (Jerusalem, IL), Parker, Linda; (Waterloo, CA) Correspondence: John R. Van Amsterdam, PH.D., ESQ.; 600 Atlantic Avenue; Boston; MA; 02210; US Patent Application Number: 20030225156 Date filed: February 19, 2003
Patents 143
Abstract: The present invention relates the use of certain cannabidiol derivatives and of their dimethyl heptyl homologs (CBD-DMH) in the treatment of nausea, in particular chemotherapy-induced nausea, and of anti vomiting activity. The present invention relates also to the use of said cannabidiol derivatives being part of a pharmaceutical composition. Excerpt(s): The present invention relates the use of certain cannabidiol derivatives and of their dimethyl heptyl homologs (CBD-DMH) in the treatment of nausea and of anti vomiting activity. c. a group --(CH.sub.2).sub.n--O-alkyl, where n is an integer from 1 to 7 and the alkyl group contains 1 to 5 carbon atoms, are antiiflammatory agents and have analgesic, antianxiety, anticonvulsive, neuroprotective, antipsychotic and anticancer activity. There are known many compounds being present in marihuana which have anti-nausea and anti-vomiting activity. However, many of them are psychoactive which is undesired for this purpose. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Apomorphine-containing dosage form for ameliorating male erectile dysfunction Inventor(s): El-Rashidy, Ragab; (Deerfield, IL), Ronsen, Bruce; (River Forest, IL) Correspondence: Olson & Hierl, LTD.; 36th Floor; 20 North Wacker Drive; Chicago; IL; 60606; US Patent Application Number: 20030073715 Date filed: October 23, 2001 Abstract: Impotence can be ameliorated without substantial undesirable side effects by nasal administration of apomorphine, optionally with an antiemetic agent present in an amount sufficient to substantially reduce nausea symptoms that may be associated with the use of apomorphine. Excerpt(s): This application is a continuation-in-part of our application U.S. Ser. No. 09/606,919, filed on Jun. 29, 2000 and now U.S. Pat. No. 6,306,437, which is a continuation of U.S. Ser. No. 09/102,406, filed on Jun. 22, 1998 and now U.S. Pat. No. 6,121,276, which is a continuation-in-part of U.S. Ser. No. 08/546,498 filed on Oct. 20, 1995 and now U.S. Pat. No. 5,770,606, which in turn is a continuation-in-part of U.S. Ser. No. 08/231,250, filed on Apr. 22, 1994, abandoned. This invention, in one aspect, relates to dosage forms and methods for ameliorating erectile dysfunction in psychogenic male patients. In another aspect this invention relates to diagnosis of erectile dysfunction. More particularly, this invention relates to the use of apomorphine-containing compositions for amelioration of erectile dysfunction in male patients and for diagnostic purposes. A normal erection occurs as a result of a coordinated vascular event in the penis. This is usually triggered neurally and consists of vasodilation and smooth muscle relaxation in the penis and its supplying arterial vessels. Arterial inflow causes enlargement of the substance of the corpora cavernosa. Venous outflow is trapped by this enlargement, permitting sustained high blood pressures in the penis sufficient to cause rigidity. Muscles in the perineum also assist in creating and maintaining penile rigidity. Erection may be induced centrally in the nervous system by sexual thoughts or fantasy, and is usually reinforced locally by reflex mechanisms. Erectile mechanics are substantially similar in the female for the clitoris. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
144 Nausea
•
Bisarylimidazolyl fatty acid amide hydrolase inhibitors Inventor(s): Sit, Sing-Yuen; (Meriden, CT), Xie, Kai; (Wallingford, CT) Correspondence: Stephen B. Davis; Bristol-myers Squibb Company; Patent Department; P.O. Box 4000; Princeton; NJ; 08543-4000; US Patent Application Number: 20020188009 Date filed: April 23, 2002 Abstract: The present invention relates to bisarylimidazolyl derivatives and pharmaceutical compositions comprising said compounds inhibiting fatty acid amide hydrolase and useful for the treatment of pain, particularly neuropathic pain, psychomotor disorder, hypertension, cardiovascular disease, eating disorder, nausea, AIDS-related complex, glaucoma, inflammation, psoriasis or multiple sclerosis, and other conditions the treatment of which can be effected by inhibiting fatty acid amide hydrolase. Excerpt(s): This non-provisional application claims priority from provisional application U.S. Serial No. 60/286,827 filed Apr. 27, 2001. The present invention relates to bisarylimidazolyl derivatives and pharmaceutical compositions comprising said derivatives which inhibit fatty acid amide hydrolase and are useful for the treatment of conditions affected by inhibiting fatty acid amide hydrolase. Neuropathic pain is caused by injury to nerves as the result of many factors including physical damage (e.g., trauma, surgery), drugs such as Zidovudine (AZT), Carmustine (BCNU) and disease (e.g., diabetes, herpes zoster). The prevalence in the United States of neuropathies associated with diabetes, herpes and amputation is estimated at 1.5 million. The worldwide prevalence of diabetic neuropathy alone is expected to reach 12 million by 2007. Nerve injury can result in both allodynia and hyperalgesia. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Composition and method for treating the effects of diseases and maladies Inventor(s): Gelber, Daniel; (Woodland Hills, CA), Kleinberger, Richard; (Sherman Oaks, CA) Correspondence: Terry W. Kramer; Kramer & Associates; 2001 JEFF. Davis HWY., Suite 1101; Arlington; VA; 22202; US Patent Application Number: 20020034555 Date filed: January 5, 2001 Abstract: A medicinal composition for treating pain resulting from a migraine headache comprises at least one pain relieving and anti-inflammatory pharmaceutical and at least one nutraceutical in a pharmaceutically acceptable base. The pharmaceutical is preferably acetaminophen or a non-steroidal anti-inflammatory drug (NSAID). The nutraceutical is preferably an antivasospastic agent or a vascular dilator; an anti-nausea agent; or a liver protectant. Methods of using these compositions to treat migraine pain are also disclosed. Excerpt(s): This application claims the benefit of U.S. Provisional Application No. 60/184,351 entitled "Composition and Method For Treating The Effects of A Cold or Flu," filed on Feb. 23, 2000. The present invention relates to the field of medicinal compositions and methods of using said compositions for treating diseases and maladies. In particular, the present invention relates to formulations comprising
Patents 145
combinations of a pharmaceutical in combination with a nutraceutical, which when administered to a person in need thereof have the effect of increasing the beneficial effects of the pharmaceutical utilized. Beginning in prehistoric times, humans have attempted to treat every known type of illness and malady with naturally occurring products. Such products were initially in their natural state, such as leaves, berries, roots, tree cuttings and extracts. With the advance of science, and greater understanding of chemistry, humans have been able to synthetically produce and extract a great variety of pharmaceuticals which were previously unknown or unidentified. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
COMPOSITION FOR INDUCING SMOKING ALKALOIDS FROM RADIX IPECAUANHAE
CESSATION
COMPRISING
Inventor(s): Ahn, Byung-Zun; (Taejeon, KR), Park, Hwa-Mok; (Seoul, KR) Correspondence: Birch Stewart Kolasch & Birch; PO Box 747; Falls Church; VA; 220400747; US Patent Application Number: 20030054051 Date filed: September 13, 2001 Abstract: This invention relates to a composition for inducing smoking cessation comprising as active ingredient alkaloids from Radix ipecauanhae. In smoking cessation program using the composition, the considerable number of volunteers participated in the program became nausea and thus ultimately to have no craving for smoking. Excerpt(s): This invention relates to a composition for inducing smoking cessation comprising as active ingredient alkaloids from Radix ipecauanhae. More specifically, it relates to a composition comprising as active ingredient basic alkaloid fraction from Radix ipecauanhae or basic emetine, optionally in combination with one or more auxiliary agents selected from Nicotiana tabacum, Fructus Phyllanthus emblica, Herba adenophorae, Herba leonuri, Herba foeniculi, Folia valerianae, Herba centellae or Circii herba. The invention also provides a method for using the same. Nicotiana tabacum contains harmful ingredients to human body such as nicotine, tar, dioxin and the like in large quantities. It is a one's favorite known to increase incidence of diseases related lung and cancers through long-term smoking. Various kinds of smoking cessation medicines or aids have been hitherto developed for smoking cessation. However, they have frequently adverse effects on human body or fail to successfully induce smoking cessation. Accordingly, it is absolutely needed to develop more efficient smoking cessation method or smoking cessation aid. Radix ipecauanhae, as emetic, has been used for detoxification and the treatment of dysentery, and used as expectorant, depending upon its dosage (Deutsches Arzneibuch, British Herbal Pharmacopoeia, Gerhardt Madaus's Lehrbuch der Biologischen Heilmittel, Georg Olms 1976). However, it has never been used for inducing smoking cessation. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
146 Nausea
•
Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects Inventor(s): Barbier, Remi; (San Francisco, CA), Crain, Stanley M.; (State College, PA), Friedmann, Nadav; (Lafayette, CA), Remien, Mary; (San Francisco, CA), Shen, Ke-Fei; (Flushing, NY), Sherman, Barry; (Hillsborough, CA) Correspondence: Mcandrews Held & Malloy, Ltd; 500 West Madison Street; Suite 3400; Chicago; IL; 60661 Patent Application Number: 20030148941 Date filed: March 12, 2002 Abstract: The invention generally relates to compositions and methods with tramadol and an opioid antagonist to enhance analgesic potency and/or attenuate one or more adverse effects of tramadol, including adverse side effect(s) in humans such as nausea, vomiting, dizziness, headache, sedation (somnolence) or pruritis. This invention relates to compositions and methods for selectively enhancing the analgesic potency of tramadol and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of tramadol. The methods of the present invention comprise administering to a subject an analgesic or subanalgesic amount of tramadol and an amount of excitatory opioid receptor antagonist such as naltrexone or nalmefene effective to enhance the analgesic potency of tramadol and attenuate the anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects of tramadol. Excerpt(s): This is a continuation-in-part of co-pending application Ser. No. 09/306,164 filed May 6, 1999, the content of which is hereby incorporated by reference in its entirety. Morphine or other bimodally-acting opioid agonists are administered to relieve severe pain due to the fact that they have analgesic effects mediated by their activation of inhibitory opioid receptors on nociceptive neurons (see North, Trends Neurosci., Vol. 9, pp. 114-117 (1986) and Crain and Shen, Trends Pharmacol. Sci., Vol. 11, pp. 77-81 (1990)). However, morphine and other bimodally-acting opioid agonists also activate opioid excitatory receptors on nociceptive neurons, which attenuate the analgesic potency of the opioids and result in the development of physical dependence and increased tolerance (see Shen and Crain, Brain Res., Vol. 597, pp. 74-83 (1992)), as well as hyperexcitability, hyperalgesia and other undesirable (excitatory) side effects. As a result, a long-standing need has existed to develop a method of both enhancing the analgesic (inhibitory) effects of bimodally-acting opioid agonists and blocking or preventing undesirable (excitatory) side effects caused by such opioid agonists. Tramadol is an orally active, clinically effective, centrally acting analgene compound with opioid and non-opioid activity. This synthetic analgesic has a novel mechanism of action involving a complementary and synergistic interaction between inhibition of neuronal monamine uptake and weak affinity for opioid receptors (Raffa et al., Rev. Contemp. Pharmacother. 6:485-497 (1995)). Tramadol is generally well tolerated, with dizziness, nausea, constipation, headache, somnolence (sedation), vomiting, pruritis, CNS stimulation, sezures, asthenia, dyspepsia, diarrhea, dry mouth and/or sweating as adverse side effects. Respiratory depression is uncommon (Lee et al., Drugs 46: 313-340 (1993); Vickers et al., Anaesthesia 47: 291-296 (1992)). Tramadol is marketed in the United States as ULTRAM.RTM. Data from a double-blind, crossover study suggest that oral tramadol 120 mg is equipotent to oral morphine 30 mg (Wilder et al., Ann. Oncol. 5: 141-146 (1994)). A need thus exists for compositions and methods that could enhance the analgesic potency of tramadol and/or block or prevent its adverse side effects, particularly its principal adverse effects in humans.
Patents 147
Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Compositions and Methods for Reducing Respiratory Depression and Attendant SIde Effects of Mu Opioid Compounds Inventor(s): Bishop , Michael J.; ( Durham, NC), Chang , Kwen-Jen; ( Chapel Hill, NC), McNutt , Robert W. Jr.; ( Durham, NC), Pettit , Hugh O.; ( Cary, NC) Correspondence: Steven J. Hultquist; Marianne Fuierer; 6320 Quadrangle, Suite 110; Chapel Hill; NC; 27517; US Patent Application Number: 20020111359 Date filed: October 9, 2001 Abstract: A method of reducing, treating or preventing drug-mediated respiratory depression, muscle rigidity, or nausea/vomiting in an animal, incident to the administration to said animal of a mixed delta/mu opioid agonist or a respiratory depression-mediating drug, comprising administering to the animal receiving said drug an effective amount of a delta receptor agonist compound. Preferred examples of such delta receptor agonist compound include diarylmethyl piperazine compounds and diarylmethyl piperidine compounds, and pharmaceutical compositions thereof, having utility in medical therapy for reducing respiratory depression associated with certain analgesics, such as mu opiates. Excerpt(s): This is a divisional application of United States patent application no. 09/352,308 filed July 12, 1999 and issued October 9, 2001 as U.S. Patent 6,300,332, which claims priority to United States patent application 08/887,312 filed July 3, 1997, which is a continuation-in-part of United States patent application no. 08/658,726, filed June 5, 1996. The disclosures of the following applications are hereby incorporated herein by reference in their entirety: United States patent application no. 08/658,726 filed June 5, 1996; United States patent application no. 08/169,879 filed December 17, 1993; United States patent application no. 08/098,333 filed July 30, 1993; United States patent application no. 08/430,677 filed April 28, 1995; International Patent Application no. PCT/GB93/00216 filed February 2, 1993; Great Britain patent application 9202238.3 filed 3 February 1992; and all applications from which they claim priority, or from which priority is claimed. This invention relates generally to methods for reducing, treating, reversing or preventing drug-mediated respiratory depression, such as may be directly or indirectly caused by use of various bioactive compositions, including anaesthetics, barbiturates, analgesics, etc. The invention further relates to diarylmethyl piperazine compounds and diarylmethyl piperidine compounds, and pharmaceutical compositions thereof, having utility in medical therapy especially for reducing respiratory depression associated with certain analgesics, such as mu opiates. This invention additionally relates to diarylmethyl piperazine compounds and diarylmethyl piperidine compounds having utility in assays for determining the respiratory reducing characteristics of other bioactive compounds, including other diarylmethyl piperazine compounds and other diarylmethyl piperidine compounds. In the study of opioid biochemistry, a variety of endogenous opioid compounds and non-endogenous opioid compounds has been identified. In this effort, significant research has been focused on understanding the mechanism of opioid drug action, particularly as it relates to cellular and differentiated tissue opiate receptors. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
148 Nausea
•
Co-therapy for the treatment of migraine comprising anticonvulsant derivatives and anti-migraine agents Inventor(s): Livingstone, Ian R.; (Princeton, NJ) Correspondence: Audley A. Ciamporcero JR.; Johnson & Johnson; One Johnson & Johnson Plaza; New Brunswick; NJ; 08933-7003; US Patent Application Number: 20030225002 Date filed: February 25, 2003 Abstract: The present invention describes a method for the treatment and/or prevention of migraine and associated symptoms (nausea, vomiting, photophobia, phonophobia, etc.) comprising co-therapy with a therapeutically effective amount of one or more antimigraine agents and one or more anticonvulsant derivatives. Excerpt(s): This application claims the benefit of U.S. Provisional Application 60/359,894, filed on Feb. 26, 2002, which is incorporated by reference herein in its entirety. Migraine is a chronic, episodic and debilitating clinical condition that is diagnosed by the presence of moderate to severe pulsating unilateral headaches lasting between 4 and 72 h. Additionally, the headache is sometimes associated with temporary sensory (photophobia and phonophobia) and/or gastrointestinal (nausea, vomiting) disturbances. Migraine headaches can present without or with aura. Migraine without aura is defined by at least five attacks fulfilling the following criteria: (a) the headache attacks lasting 4-72 hours with the headache having at least two of the following features: unilateral location, pulsating quality, moderate or severe intensity with a direct influence on activities of daily living, and aggravation by walking up stairs or similar routines; (b) during the headache at least one of the following occurs: nausea and/or vomiting, photophobia or phonophobia (Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. Cephalalgia 1988;8 Suppl 7:1-96). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Delta9 tetrahydrocannabinol (Delta9 THC) solution metered dose inhalers and methods of use Inventor(s): Byron, Peter R.; (Richmond, VA), Lichtman, Aron H.; (Richmond, VA), Martin, Billy R.; (Richmond, VA), Peart, Joanne; (Richmond, VA) Correspondence: Mcguire Woods; Tysons Corner; Suite 1800; 1750 Tysons Boulevard; Mclean; VA; 22102-4215; US Patent Application Number: 20020031480 Date filed: September 4, 2001 Abstract: The present invention provides therapeutic formulations for solutions of.DELTA.sup.9-tetrahydrocannabinol (.DELTA.sup.9 THC) to be delivered by metered dose inhalers. The formulations, which use non-CFC propellants, provide a stable aerosol-deliverable source of.DELTA.sup.9 THC for the treatment of various medical conditions, such as: nausea and vomiting associated with chemotherapy--muscle spasticity; pain; anorexia associated with AIDS wasting syndrome, epilepsy; glaucoma; bronchial asthma; and mood disorders. Excerpt(s): This application is a continuation-in-part of pending U.S. Ser. No. 09/273,766 which claims priority of U.S. provisional application serial No. 60/105,850 filed Oct. 27,
Patents 149
1998, and the complete contents of those applications are incorporated herein by reference. The invention is generally related to the therapeutic use of.DELTA.sup.9 Tetrahydrocarnabinol (.DELTA.sup.9 THC). In particular, the invention provides a metered dose inhaler (MDI) for the aerosol administration of.DELTA.sup.9 THC to patients suffering from nausea and vomiting associated with cancer chemotherapy, muscle spasticity, pain, anorexia associated with AIDS wasting syndrome, epilepsy, glaucoma, bronchial asthma, mood disorders, and the like. In 1997, the National Institutes of Health (NIH) released a review of the scientific data concerning potential therapeutic uses for marijuana. In that review, the NIH found that marijuana may indeed have beneficial medicinal effects and recommended that researchers develop alternative dosage forms for the drug, such as a "smoke free" inhaled delivery system. Workshop on the medical utility of marijuana, National Institutes of Health, August 1997. Studies have documented therapeutically beneficial medicinal uses of the major active component of marijuana,.DELTA.sup.9 tetrahydrocannabinol (.DELTA.sup.9 THC). Beal, J. A., Olson, R., Lefkowitz, L., Laubenstein, L., Bellman, P., Yangco, B., Morales, J. O., Murphy, R., Powderly, W., Plasse, T. F., Mosdell, K. W. and Shepard, K. W., Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia, J Pain. Symptom Manage. 14:7-14 (1997); Beal, J. A., Olson, R., Laubenstein, L., Morales, J. O., Beliman, B., Yangco, B., Lefkowitz, L., Plasse, T. F. and Shepard, K. V. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS, J Pain. Symptom Manage,. 10: 89-97 (1995); McCabe, M., Smith, F. P., MacDonald, J. S., Wooley, P. V., Goldberg, D. and Schein, P. S., Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy, Invest. New Drugs 6:243-246 (1988); Lucas, V. S. and Laszlo, J.DELTA.sup.9-THC for refractory vomiting induced by cancer chemotherapy, JAMA 243:1241-1243 (1980); Sallan, S. E., Cronin, C., Zelen, M. and Zinberg, N. E., Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of.DELTA.sup.9 THC and prochlorperazine, N. Engl. J Med., 302:135-138 (1980); Frytak, S., Moertel, C. G., O'Fallon, J R., Rubin, J., Creagan, E. T., O'Connell, M. J., Schutt, A. J. and Schwartau, N. W., Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy: a comparison with prochlorperazine and a placebo, Ann. Inter. Med 91:825-830 (1979); Chang, A. E., Shiling, D. J., Stillman, R. C., Goldgerg, N. H., Seipp, C. A., Barofdky, I., Simon, R. M. and Rosenberg S A,.DELTA.sup.9 THC as an antiemitic in cancer patients receiving high-dose methotrexate. Ann. Internal Med. 91:819-824 (1979); Sallan, S. E., Zinberg, N. E. and Frei, I. E., Antiemetic effect of.DELTA.sup.9 THC in patients receiving cancer chemotherapy, New Engl. J Med. 293:795-797 (1975); Noyes, J R., Brunk, S. F., Baram, D. A. and Canter, A., The analgesic properties of.DELTA.sup.9 THC and codeine. J Clin. Pharmacol 15:139-143 (1975); Noyes, R., Jr., Brunk, S. F., Baram, D. A. and Canter, A., Analgesic effect of.DELTA.sup.9 tetrahydrocannabinol, Clin. Pharmacol & Ther 18:84-89 (1975); Brenneisen, R., Egli, A., Elosohlly, M. A., Henn, V. and Spiess, Y., The effect of orally and rectally administered.DELTA.sup.9 THC on spasticity: a pilot study with 2 patients, Int. J Clin. J Pharmocol Ther. 34:446-452 (1996); Ungerleider, J. T., Andyrsiak, T. F. L., Ellison, G. W. and Myers, L. W.,.DELTA.sup.9 THC in the treatment of spasticity associated with multiple sclerosis, Adv. Alcohol Subst. Abuse 7:39-50 (1987); Clifford, D. B., Tetra-hydrocannabinol for tremor in multiple sclerosis, Ann. Neurol 13:669-171 (1983); Petro, D. J. and Ellenberger, C., Treatment of human spasticity with delta 9-tetrahydrocannabinol, J Clin. Pharmacol 21:413S-416S (1981); Maurer, M., Henn, V., Dittrich, A. and Hofman, A., Delta 9tetrahydrocannabinol shows antispastic and analgesic effects in a single case doubleblind trial, Eur. Arch. Psychiatry Neurol Sci. 240:1-4 (1990); Merrift, J., Crawford, W., Alexander, P., Anduze, A. and Gelbart, S., Effects of marihuana on intra ocular and blood pressure in glaucoma, Opht. 87:222-228 (1980); Cooler, P. and Gregg, J. M., Effect
150 Nausea
of delta 9-.DELTA.sup.9 THC on intra ocular pressure in humans. South. Med J 70:951954 (1977). Table 1 summarizes the findings of these studies. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Efficacious dosage regimen of galantamine that reduces side effects Inventor(s): Parys, Wim Louis Julien; (Gaithersburg, MD), Pontecorvo, Michael; (Lawrenceville, NJ) Correspondence: Audley A. Ciamporcero JR.; Johnson & Johnson; One Johnson & Johnson Plaza; New Brunswick; NJ; 08933-7003; US Patent Application Number: 20030139391 Date filed: October 3, 2002 Abstract: Galantamine has be used in the treatment of a number of chronic diseases. The use of this drug is associated with side effects such as, nausea or vomiting, and headaches. It has been demonstrated that by slowly introducing the patient to the drug these side effects can be reduced. It has also been shown that this slower titration results in the ability to use a lower effective dose of the drug. Excerpt(s): The present invention relates to a slower titration regimen that results in a safe and effective use of galantamine at from about 16 mg/day to about 24 mg/day for the treatment of galantamine responsive conditions, with improved tolerability of the drug. Galantamine is a reversible cholinesterase inhibitor that can be isolated from a number of different plant sources, including daffodil bulbs. Galantamine interacts competitively with the enzyme, acetylcholinesterase, and demonstrates a 10 to 50 fold selectivity for acetyl vs. butyryl cholinesterase. Galantamine has been used for the treatment of a number of chronic diseases, where life-long treatment may be necessary. Galantamine has been shown to be effective in the treatment of arthritic disorders (Canadian Patent application 2,251,114); fatigue syndromes (Canadian Patent application 2,108,880); mania (Canadian Patent application 2,062,094);schizophrenia (Canadian Patent application 2,108,880); memory dysfunction, including Alzheimer's Disease (U.S. Pat. No. 4,663,318); alcoholism (Canadian Patent 2,039,197); nicotine dependence (Canadian Patent application 2,153,570); disorders of attention (PCT published application WO 99/21561) and jet lag (Canadian Patent application 2,193,473). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Electro-acupuncture device with D-shaped stimulation electrodes Inventor(s): Giuntoli, David M.; (Carlsbad, CA), Grey, Thomas L.; (Carlsbad, CA), Gruzdowich, Gregory J.; (Carlsbad, CA) Correspondence: Crockett &: Crockett; 24012 Calle DE LA Plata, Suite 400; Laguna Hills; CA; 92653; US Patent Application Number: 20030004555 Date filed: June 29, 2001 Abstract: An electro-acupuncture device for controlling nausea. The device includes a wristwatch like housing, circuitry for generating electro-acupuncture stimulus disposed within the housing, and a strap for securing the housing to the wrist. The device also includes a pair of D-shaped electrodes disposed on the bottom outer surface of the
Patents 151
housing. A gasket made of an electrically non-conductive material is applied to the bottom outer surface of the housing. The gasket has apertures which are sized and shaped to receive the D-shaped electrodes. When the device is strapped to a patient's wrist, the electrodes contact the wrist and provide electric stimulation to the wrist. Excerpt(s): The devices described below relate to the field of electro-acupuncture and non-invasive stimulation of nerves. We have developed an electro-acupuncture or nerve stimulation device which has proven effective for the control of nausea and vomiting. The basic device is described in Bertolucci, Nausea Control Device, U.S. Pat. No. 4,981,146 (Jan. 1, 1991). The device, marketed under the trademark Relief-Band.RTM., is worn on the wrist like a wristwatch, with a watch-like housing which is positioned on the underside of the wrist. The housing has two electrodes on the inside face (the face in contact with the wrist when secured to the wrist), a battery and circuitry inside the housing, and control buttons on the outer face. A patient suffering from nausea or vomiting (from motion sickness, morning sickness, chemotherapy, or anesthesia) can strap the device onto their wrist and turn it on. When turned on, the device emits an electrical stimulation pulse over the P6 acupuncture point (corresponding to the superficial course of the meridian nerve through the wrist). Within several minutes, most patients experience a substantial relief of nausea. The device uses non-invasive nerve stimulation whereby electricity is passed through the electrodes to stimulate nerves located on the ventral side of the wrist (this anatomical position is sometimes referred to as the palmar side of the wrist). The treatment provided by the device is sometimes referred to as electro-acupuncture, which is a form of acupuncture, and the ventral site of application is referred to in the acupuncture art as the P6 point, pericardium 6 point, or master point of the pericardium meridian (sometimes referred to as the vascular meridian). It is also portable, self-contained and convenient to the patient. Electrical pulse repetition rate of approximately 70 pulses per second and a pulse width of 80 microseconds have been found to provide effective relief of nausea in a patient. Our currently preferred electrical pulse pattern comprises about 350 microsecond pulse width at about 31 pulses per second at power levels of about 10-35 milliamps peak pulse height. Thus a wide range of pulse patterns may be used in noninvasive nerve stimulation devices. In each of our electro-acupuncture products, the stimulation and effect are greatly enhanced if the patient applies a gel to the skin before strapping the device onto the wrist. This gel serves as an electronic to ionic current conversion layer between the electrodes and the dry outer skin layer. This electrical conduction layer, sometimes referred to as an impedance matching layer, greatly enhances the effect of the device and lowers the power requirements for the device. The patient applies the gel to the skin before strapping the device onto the wrist. The gel may be referred to as a conductivity gel or an electro-medical coupling agent. The users may use too much gel, too little gel, or apply it too infrequently. Some users may omit application of the gel, either through forgetfulness or ignorance of need to use it. Additionally, gel may be removed by water in the environment of use, such as where the device is used for seasickness on a small sail boat while the user is operating the sail boat. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
152 Nausea
•
Extended release formulation Inventor(s): Clark, John C.; (Peru, NY), Lamer, John U.; (Albans, VT), Sherman, Deborah M.; (Plattsburg, NY), White, Steven A.; (Champlain, NY) Correspondence: American Home Products Corporation; Five Giralda Farms; Patent Law; Madison; NJ; 07940; US Patent Application Number: 20010055612 Date filed: June 19, 2001 Abstract: This invention relates to a 24 hour extended release dosage formulation and unit dosage form thereof of venlafaxine hydrochloride, an antidepressant, which provides better control of blood plasma levels than conventional tablet formulations which must be administered two or more times a day and further provides a lower incidence of nausea and vomiting than the conventional tablets. More particularly, the invention comprises an extended release formulation of venlafaxine hydrochloride comprising a therapeutically effective amount of venlafaxine hydrochloride in spheroids comprised of venlafaxine hydrochloride, microcrystalline cellulose and, optionally, hydroxypropylmethylcellulose coated with a mixture of ethyl cellulose and hydroxypropylmethylcellulose. Excerpt(s): This application continuation-in-part of application Ser. No. 08/964,328, filed Nov. 5, 1997, which is a continuation-in-part of copending application Ser. No. 08/821,137, filed Mar. 20, 1997, which, in turn, claims priority from Provisional Application No. 60/014,006 filed Mar. 25, 1996. Extended release drug formulations are conventionally produced as compressed tablets by hydrogel tablet technology. To produce these sustained release tablet drug dosage forms, the active ingredient is conventionally compounded with cellulose ethers such as methyl cellulose, ethyl cellulose or hydroxypropylmethylcellulose with or without other excipients and the resulting mixture is pressed into tablets. When the tablets are orally administered, the cellulose ethers in the tablets swell upon hydration from moisture in the digestive system, thereby limiting exposure of the active ingredient to moisture. As the cellulose ethers are gradually leached away by moisture, water more deeply penetrates the gel matrix and the active ingredient slowly dissolves and diffuses through the gel, making it available for absorption by the body. An example of such a sustained release dosage form of the analgesic/anti-inflammatory drug etodolac (Lodine.RTM.) appears in U.S. Pat. No. 4,966,768. U.S. Pat. No. 4,389,393 discloses sustained release therapeutic compressed solid unit dose forms of an active ingredient plus a carrier base comprised of a high molecular weight hydroxypropylmethylcellulose, methyl cellulose, sodium carboxymethylcellulose and or other cellulose ether. Where the production of tablets is not feasible, it is conventional in the drug industry to prepare encapsulated drug formulations which provide extended or sustained release properties. In this situation, the extended release capsule dosage forms may be formulated by mixing the drug with one or more binding agents to form a uniform mixture which is then moistened with water or a solvent such as ethanol to form an extrudable plastic mass from which small diameter, typically 1 mm, cylinders of drug/matrix are extruded, broken into appropriate lengths and transformed into spheroids using standard spheronization equipment. The spheroids, after drying, may then be film-coated to retard dissolution. The film-coated spheroids may then be placed in pharmaceutically acceptable capsules, such as starch or gelatin capsules, in the quantity needed to obtain the desired therapeutic effect. Spheroids releasing the drug at different rates may be combined in a capsule to obtain desired release rates and blood levels. U.S. Pat. No. 4,138,475 discloses a sustained release pharmaceutical composition consisting of a hard gelatin capsule
Patents 153
filled with film-coated spheroids comprised of propanolol in admixture with microcrystalline cellulose wherein the film coating is composed of ethyl cellulose, optionally, with hydroxypropylmethylcellulose and/or a plasticizer. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Fentanyl composition for nasal administration Inventor(s): Grarup, Jesper; (Roskilde, DK), Nielsen, Hanne Wulf; (Svenborg, DK) Correspondence: Wenderoth, Lind & Ponack, L.L.P.; 2033 K Street N. W.; Suite 800; Washington; DC; 20006-1021; US Patent Application Number: 20040034059 Date filed: July 14, 2003 Abstract: The treatment of acute pain with a sufficient dosage by intranasal administration of fentanyl results in a time to onset of action comparable to intravenous administration and a significantly faster onset of action than nasal titration of fentanyl. The nasal administration of a sufficient amount of fentanyl to obtain pain relief has lower maximum plasma concentrations comparable to intravenous administration and results in lower rates of adverse events like respiratory depression, nausea and vomiting. Compositions fur use in the method are also disclosed. Excerpt(s): The present invention relates to a pharmaceutical composition for use in the treatment of acute pain such as breakthrough pain by means of a non-invasive administration of fentanyl or a pharmaceutically acceptable salt thereof, said composition being such that at least 70.mu.g of fentanyl is delivered in a dosage unit. The method comprises administration of a treatment dosage sufficient to treat the acute pain with time to onset of action comparable to intravenous administration. The treatment typically comprises intranasal administration of a relatively concentrated composition of fentanyl citrate. In addition, the invention relates to a pharmaceutical kit comprising a treatment dosage of fentanyl for nasal administration for treatment of acute pain together with a delivery system of an analgesic for a continuous treatment of chronic pain. Fentanyl is a potent narcotic analgesic with pharmacological effects similar to morphine. Fentanyl is 50 to 100 times more potent than morphine on a weight basis. Fentanyl is a mu-receptor agonist acting on receptors distributed in the brain, spinal cord and other tissues. Opioids produce both analgesia and sedation. Opiate agonists appear to prevent the release of beta-endorphin, possibly by altering the patients perceived level of pain and anxiety, although the presence of pain may still be recognised (1). Parenteral fentanyl is indicated for anaesthesia, treating postoperative pain, and as a premedicant. Transdermal fentanyl is used for managing chronic pain in patients requiring opioids. Fentanyl lozenge/sucker (Oralet.RTM.) is indicated to induce anxiolysis and analgesia prior to surgery in pediatric and adult patients. Oral transmucosal fentanyl (Actiq.RTM.) is indicated for the management of breakthrough cancer pain in adults with malignancies who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Fentanyl Oralet.RTM. is only indicated for use in a hospital setting as an anaesthetic pre-medication in the operating room setting or to induce conscious sedation prior to a diagnostic or therapeutic procedure in other monitored anaesthesia care settings in the hospital. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
154 Nausea
•
Galenical preparations of dapsone and related sulphones, and method of therapeutic and preventative treatment of disease Inventor(s): Aberg, A K Gunnar; (Sarasota, FL), Bain, Allen I; (Vancouver, CA), Zolotoy, Alexander; (Richmond, CA) Correspondence: Kevin S Lemack; Neilds & Lemack; 176 E Main Street; Westboro; MA; 01581; US Patent Application Number: 20030092635 Date filed: August 26, 2002 Abstract: Dapsone and related sulfones are known to have therapeutic activity against leprosy, dermatitis herpetiformis, actinomycotic mycetoma, asthma, malaria, rheumatoid arthritis, Kaposis sarcoma, pneumocystis carini (pneumonia), subcorneal pustular dermatosis and cystic acne, in patients in need of such therapy. These sulfones are also known to have therapeutic activity against memory loss in patients in need of such therapy, including patients suffering from Alzheimer's disease and related neurodegenerative disorders. It has now been found that new, modified-release formulations of dapsone and related sulfones may also be used that decrease side effects and increase effectiveness of the drugs. New methods are disclosed utilizing certain formulations of dapsone and related sulfones that improve the therapeutic index of said drugs. Side effects of these drugs are known to those skilled in the art and include, but are not restricted to anorexia, psychosis, agranulocytosis, peripheral neuritis, hemolysis, methemoglobinemia, nausea, vomiting, headache, dizziness, tachycardia, nervousness, insomnia and skin disorders. Modified-release (as defined herein) formulations of dapsone have now been found to avoid some or all of these side effects, and to have more efficacy on potency. Excerpt(s): The object of the present invention pertains to a method of treating or preventing certain diseases in a human being while increasing compliance, reducing side effects and improving efficacy of the active therapeutic ingredient(s) within a large therapeutic range. The method comprises the use of modified-release dosage formulations of sulfone compounds including 4,4'-diaminodiphenylsulfone, its didextrose sulfonate derivative(s), their analogs, metabolites, any enantiomers, any diasteriomers, or mixtures thereof and/or therapeutically acceptable salts thereof. Dapsone is an active substance that is known in the treatment of various infectious diseases and inflammatory conditions. There is a wealth of data and experimental studies regarding the activity of dapsone and related sulfones. In particular, there is a large amount of data regarding the bioavailability and pharmacokinetics of the drug. It is also known in the prior art that dapsone has therapeutic activity against leprosy, dermatitis herpetiformis, actinomycotic mycetoma, asthma, malaria, rheumatoid arthritis, Kaposis sarcoma, pneumocystis carinii (pneumonia), subcorneal pustular dermatosis and cystic acne, in patients in need of such therapy. However, since the acute or chronic toxicity of dapsone is unacceptable at the doses necessary to treat most diseases, it is not possible to use this compound for these indications in the presently available formulation(s). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 155
•
Intravaginal mucosal or transmucosal delivery of antimigraine and antinausea drugs Inventor(s): Pauletti, Giovanni M.; (Loveland, OH), Ritschel, Wolfgang A.; (Cincinnati, OH), Soderstrom, Richard; (Seattle, WA) Correspondence: Hana Verny; Peters, Verny, Jones & Schmitt, Llp; Suite 6; 385 Sherman Avenue; Palo Alto; CA; 94306; US Patent Application Number: 20040043071 Date filed: June 20, 2003 Abstract: A method, composition and device for intravaginal mucosal or transmucosal delivery of antimigraine and/or antinausea drugs to a female subject for treatment of migraine and other diseases accompanied by or associated with nausea and vomiting. A mucoadhesive composition comprising antimigraine or antinausea drugs, mucoadhesive agent, penetration enhancer or sorption promoter and a hydrophilic or lipophilic carries. An intravaginal device for delivery of antimigraine or antinausea drugs. Excerpt(s): This application is based on and claims priority of the Provisional Application Ser. No. 60/390,748 filed on Jun. 21, 2002. The present invention concerns a method, composition and device for intravaginal mucosal or transmucosal delivery of antimigraine and/or antinausea drugs to a female subject for treatment of migraine and other diseases accompanied by or associated with nausea and vomiting. In particular, the invention concerns a method, composition, and device for mucosal delivery of antimigraine and/or antinausea drugs to the vagina for topical vaginal treatment or for transmucosal delivery of these drugs into the systemic blood circulation for systemic therapy using a mucoadhesive composition comprising these drugs. The composition is administered directly or incorporated into an intravaginal device. The mucoadhesive composition of the invention or intravaginal device incorporated with said composition delivers the antimigraine and/or antinausea drug into the vagina, provides a continuous contact with the vaginal mucosa, releases the therapeutic agent from the formulation in timely fashion and at controllable quantities, and delivers the drugs transmucosally across the vaginal epithelial barrier into the systemic circulation. The mucoadhesive composition adheres to the vaginal mucosa and promotes topical adhesion of the drug released from said composition to the vaginal mucosa and further promotes delivery of the drug transmucosally through the vaginal mucosa and wall to the systemic circulation. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Measurement of pain Inventor(s): Laserow, Kay; (Malmo, SE) Correspondence: Oblon Spivak Mcclelland Maier & Neustadt PC; Fourth Floor; 1755 Jefferson Davis Highway; Arlington; VA; 22202; US Patent Application Number: 20010049472 Date filed: August 13, 2001 Abstract: The invention relates to a measuring instrument for the measurement of an existing pain or a feeling of nausea of a patient. The measuring instrument induces pain in an arbitrary body part of said patient, by supplying an electrical current. The measuring instrument provides a current increase into said body part, until said
156 Nausea
induced pain is experienced by the patient as being as great as the existing pain/nausea. The current is supplied from a current source arranged in the measuring instrument via wires (H, I) and electrodes (C, D), said electrodes being applied onto that part of the body in which pain is to be induced. When the pain induced is experienced to be as great as the existing pain/nausea, the body part is removed from the electrodes, whereupon a pain value is registered and shown on a display (F). (FIG. 6). Excerpt(s): The present invention relates to a measuring instrument and a method of measuring, by means of said instrument, an existing pain experienced by a patient. When a person in need of medical treatment first comes into contact with a doctor, a physiotherapist, a nurse etc., this person generally tries to describe his pain verbally, so that the medical staff are at least able to make a primary diagnosis of the patient's condition and suggest a suitable treatment. However, this creates a significant problem for the medical staff, depending upon different persons experiencing, and therefore describing, their pain or symptoms in different ways. One person may e.g. be more resistant to pain than others. Another person may e.g. have become used to his pain after a certain period of time and may therefore describe his/her pain in milder terms than he/she would have done if the pain had arisen recently. The varying descriptions of pain which a diagnostician may be exposed to, complicate a quick and exact diagnosis of a person's ailment or injury. For the sake of simplicity, in the below text the patient is always referred to as being male. It should of course be understood, however, that the same applies to female patients. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system Inventor(s): Becher, Frank; (Koblenz, DE), Klink, Ann-Katrin; (Waldesch, DE) Correspondence: D. Peter Hochberg CO. L.P.A.; 1940 East 6th Street; Cleveland; OH; 44114; US Patent Application Number: 20020187183 Date filed: May 21, 2002 Abstract: A method for the protection of a human being against any health impairment as a result of the ingestion of the whole or parts of a transdermal therapeutic system containing at least one pharmacologically active ingredient, which is toxic or induces nausea or addiction at oral, but not at transdermal administration is disclosed. The method comprises adding to said transdermal therapeutic system a substance being able to keep off a human being from said ingestion. Excerpt(s): This is a continuation-in-part application of application Ser. No. 09/486,214 filed May 3, 2000. The present invention relates to a method for the protection of a human being against any health impairment as a result of the ingestion of the whole or parts of a transdermal therapeutic system (TTS). More specifically, the present invention relates to a method for the protection of a human being against any health impairments as a result of the ingestion of the whole or parts of a transdermal therapeutic system, comprising at least one pharmacologically active ingredient-containing, especially a pressure-sensitive adhesive layer and at least on active-ingredient-impermeable backing layer, and further comprising a substance, which does not interact with the pharmacologically active ingredient and is able to keep off a human being from said ingestion. A series of transdermal therapeutic systems present an acute danger of
Patents 157
undesired side effects if administered orally by a human being in order to extract a soluble active agent. This is true whether the system is a new one or a used one. For example, infants have a tendency to stick anything interesting into their mouths and to at least suck or chew on it. This cannot be avoided especially if children happen to attain access to such systems by chance, especially systems with a release liner. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Method for treating or preventing depression Inventor(s): Reines, Scott A.; (New Hope, PA), Robichaud, Annette; (Montreal, CA), Tattersall, Frederick D.; (Bishops Stortford, GB) Correspondence: Merck And CO Inc; P O Box 2000; Rahway; NJ; 070650907 Patent Application Number: 20010049368 Date filed: February 27, 2001 Abstract: A neurokinin-1 antagonist or an alpha-2 adrenoreceptor agonist provide an effective therapy in conjunction with a PDE4 inhibitor for the treatment or prevention of depression and/or anxiety. These combinations minimize the side effects of nausea and/or emesis associated with the PDE4 inhibitor and may also provide beneficial antidepressant and/or anti-anxiety effects. Excerpt(s): Depression is characterised by feelings of intense sadness and despair, mental slowing and loss of concentration, pessimistic worry, agitation, and selfdeprecation. Physical changes also occur, especially in severe or "melancholic" depression. These include insomnia or hypersomnia, anorexia and weight loss (or sometimes overeating), decreased energy and libido, and disruption of normal circadian rhythms of activity, body temperature, and many endocrine functions. Treatment regimens commonly include the use of tricyclic antidepressants, monoamine oxidase inhibitors, some psychotropic drugs, lithium carbonate, and electroconvulsive therapy (ECT) (see R. J. Baldessarini in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edition, Chapter 19, McGraw-Hill, 1996 for a review). More recently, new classes of antidepressant drugs are being developed including selective serotonin reuptake inhibitors (SSRIs), specific monoamine reuptake inhibitors and 5-HT1A receptor agonists, antagonists and partial agonists. Anxiety is an emotional condition characterised by feelings such as apprehension and fear accompanied by physical sympoms such as tachycardia, increased respiration, sweating and tremor. It is a normal emotion but when it is severe and disabling it becomes pathological. Anxiety disorders are generally treated using benzodiazepine sedative-antianxiety agents. Potent benzodiazepines are effective in panic disorder as well as in generalised anxiety disorder, however, the risks associated with drug dependency may limit their long-term use. 5-HT1A receptor partial agonists also have useful anxiolytic and other psychotropic activity, and less likelihood of sedation and dependance (see R. J. Baldessarini in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edition, Chapter 18, McGraw-Hill, 1996 for a review). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
158 Nausea
•
Migraine medicine and method of treating the same without caffeine Inventor(s): Imanzahrai, Ashkan; (San Jose, CA) Correspondence: Kevin D. Mccarthy, ESQ.; Hodgson Russ Llp; Suite 2000; One M&t Plaza; Buffalo; NY; 14203-2391; US Patent Application Number: 20020091162 Date filed: January 4, 2002 Abstract: This invention is a safe and effective composition and method for treating acute migraine attacks using pseudoephedrine, acetaminophen, and other agents in an orally administrated form to alleviate the pain and cluster of symptoms characteristic of migraine attacks such as nausea, photophobia, phonophobia, and functional disabilities as well as the prodrome phase of a migraine attack. Excerpt(s): This application claims priority as a divisional application of U.S. nonprovisional patent application serial no. 09/593,238 (filed on Jun. 14, 2000) which relies on the priority of provisional patent application Serial Number 60/144,973 which was filed on Jul. 22, 1999. The present invention relates generally to compositions and methods used to alleviate the symptoms and pain associated with an acute migraine attack. Many migraine sufferers use single-agent nonprescription analgesics such as acetaminophen, or aspirin, or non-steroidal anti-inflammatory agents to treat their attacks. (Lipton R B, Newman L C, Solomon S. Over-the-counter medication and the treatment of migraine. Headache 1994; 34:547-548.) In other countries, a number of nonprescription drugs are specifically approved for migraine pain. (Lipton R B, Newman L C, Solomon S. Over-the-counter medication and the treatment of migraine. Headache 1994; 34:547-548.) The effectiveness of self-treatment of a migraine and the effectiveness of most such nonprescription drugs in relieving or aborting migraine pain and/or the characteristic symptoms of a migraine has not been adequately studied in well-controlled clinical trials. (Lipton R B, Newman L C, Solomon S. Over-the-counter medication and the treatment of migraine. Headache 1994; 34:547-548.) Acetaminophen, aspirin, and caffeine are approved for relief of nonspecific headaches and tension headaches (Migliardi J R, Armellino J J, Friedman M, Gillings D B, Beaver W T. Caffeine as an analgesic adjuvant in tension headache. Clin Pharmacol Ther 1994; 56:576-586), which are clinical and physiologically distinct from a migraine. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Novel anandamide amidase inhibitors as analgesic agents Inventor(s): Hill, William Adam; (Ashford, CT), Lin, Sonyan; (Storrs, CT), Makriyannis, Alexandros; (Ashford, CT) Correspondence: Alix Yale & Ristas Llp; 750 Main Street; Suite 600; Hartford; CT; 06103 Patent Application Number: 20020091153 Date filed: February 6, 2002 Abstract: Disclosed is a method of inhibiting anandamide amidase in an individual or animal and novel inhibitors of anandamide amidase. The disclosed method and novel compounds can be used to reduce pain in an individual or animal suffering from pain, reducing nausea in an individual undergoing chemotherapy, for example cancer chemotherapy, suppressing appetite in an individual, reducing intraocular pressure in
Patents 159
the eye of an individual or animal suffering from glaucoma and suppressing the immune system in an individual with an organ transplant. Excerpt(s):.DELTA.sup.9-Tetrahydrocannabinol, the pyschoactive marijuana derived cannabinoid, binds to the CB1 receptor in the brain and to the CB2 receptor in the spleen. Compounds which stimulate the CB1 receptor have been shown to induce analgesia and sedation, to cause mood elevation, to control nausea and appetite and to lower intraocular pressure (Mechoulam, Cannabinoids as Therapeutic Agents, CRC Press, Boca Raton, Fla. (1986), Fride and Mechoulam, Eur. J. Pharmacol. 231:313 (1993), Crawley et al., Pharmacol. Biochem. Behav. 40:907 (1993) and Smith et al., J. Pharm. Exp. Therap. 270:219 (1994)). Cannabinoids have also been shown to suppress the immune system (Mechoulam, Cannabinoids as Therapeutic Agents, CRC Press, Boca Raton, Fla. (1986). Thus, compounds which stimulate the CB1 or CB2 receptor, directly or indirectly, are potentially useful in treating glaucoma, preventing tissue rejection in organ transplant patients, controlling nausea in patients undergoing chemotherapy, controlling pain and enhancing the appetite and controlling pain in individuals with AIDS Wasting Syndrome. Arachidonyl ethanolamide (anandamide) is a naturallyoccurring brain constituent that acts as a CB1 and CB2 agonist and exhibits pharmacological activity in mice comparable to cannabinoids (Fride and Mechoulam (1993), Crawley et al. (1993) and Smith at al. (1994)). Anandamide is cleaved in vivo by anandamide amidase. Thus, inhibitors of anandamide amidase have the effect of indirectly stimulating the CB1 and CB2 receptors by increasing in vivo levels of anandamide. In addition to acting at the CB1 and CB2 receptors, cannabinoids also affect cellular membranes, thereby producing undesirable side effects such as drowsiness, impairment of monoamine oxidase function and impairment of nonreceptor mediated brain function. The addictive and psychotropic properties of cannabinoids also limit their therapeutic value. Inhibitors of anandamide amidase are not expected to have the undesired membrane-related side-effects produced by cannabinoids. By providing an alternate mechanism for stimulating the CB1 and CB2 receptor, anandamide inhibitors might not have the addictive and psychotropic properties of cannabinoids. However, present inhibitors of anandamide amidase have disadvantages. For example, phenylmethylsulfonyl fluoride (PMSF) is toxic to cells. Thus, there is a need for new and more potent inhibitors of anandamide amidase which have reduced toxicity towards cells and which do not significantly interact with the CB1 or CB2 receptor at inhibitory concentrations. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Novel arginine/ascorbic acid mixed powder as an oral supplement Inventor(s): Kimoto, Eiji; (Jonan-ku, JP), Morishige, Fukumi; (Sanbu-gun, JP) Correspondence: Oliff & Berridge, Plc; P.O. Box 19928; Alexandria; VA; 22320; US Patent Application Number: 20020091156 Date filed: November 13, 2001 Abstract: A mixture obtained by mixing ascorbic acid powder with arginine powder in a weight ratio (ascorbic acid/arginine) of 1/5 to 20, especially 1/5 to 1/4; and a supplement such as a nutrient preparation and a health-care food containing the mixture. Mixing of arginine powder and ascorbic acid powder in the weight ratios eliminates stringent taste specific to arginine and alleviates stringent feeling in the stomach (heartburn, nausea or vomiting) after oral intake thereof. The mixture prevents also peroxidative injuries of cells caused by an administration of a great amount of
160 Nausea
arginine alone. Further, mixing of arginine powder with ascorbic acid powder prevents browning of the mixture after long-term storage. Excerpt(s): The present invention relates to a method for eliminating the stringent taste and alleviating stringent feeling in the stomach of L-arginine (hereinafter referred to as arginine) by mixing L-ascorbic acid (hereinafter referred to as ascorbic acid) and for alleviating the toxicity of arginine-derived NO radical by arginine-ascorbic acidcombined treatment. From late 1970's to 1980's, a research group of Illinois University reevaluated that dietary arginine is indispensable for optimal health of adult and especially aged humans. (see E. Kimoto, "Nutritional Chemistry of L-Arginine", Kaisei Publishing Co. Ltd., Tokyo, 1999 (Literature 2), page 93). In 1987, it was reported that NO radical participating in a wide variety of physiological functions such as blood pressure control and prevention of infections is derived from arginine as a source. This led to increased attention paid to arginine in the field of amino acid nutrition science (see Literature 2, page 57). Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them Inventor(s): Salyi, Szabolcs; (Debrecen, HU), Szabo, Csaba; (Debrecen, HU), Tamas, Tivadar; (Debrecen, HU), Aronhime, Judith; (Rehovot, IL), Meszaros Sos, Erzsebet; (Debrecen, HU), Molnar, Sandor; (Debrecen, HU) Correspondence: Kenyon & Kenyon; One Broadway; New York; NY; 10004; US Patent Application Number: 20040019093 Date filed: April 29, 2003 Abstract: Ondansetron crystalline Forms A and B are useful in the treatment of nausea and vomiting. Form B has a uniquely high melting point of about 244.degree. C. and both forms are stable against thermally induced polymorphic transition from 30.degree. C. up to their melting points. Excerpt(s): This application claims the benefit under 35 U.S.C.sctn.1.119(e) of Provisional Application Serial No. 60/376,395, filed Apr. 30, 2002, and is incorporated herein by reference. The present invention relates to (.+-.) 1,2,3,9-tetrahydro-9-methyl- -3-[2methyl-1h-imidazol-1-yl)methyl]-4h-carbazol-4-one (ondansetron). More particularly, it relates to a newly discovered high melting crystalline form of ondansetron, to a second newly discovered crystalline form, to processes for producing the new forms, to pharmaceutical compositions containing them and methods of treating nausea and vomiting using them. and formula C.sub.18H.sub.19N.sub.3O is a selective 5-HT.sub.3 receptor antagonist. It is a nitrogen-containing compound capable of existence in free base and salt forms. The free base is known by the generic name ondansetron. Ondansetron is useful for reducing nausea in patients undergoing chemotherapy. Grunberg, S. M.; Hesketh, P.J. "Control of Chemotherapy-Induced Emesis" N. Engl. J. Med. 1993, 329, 1790-96. It is approved by the United States Food and Drug Administration for prophylactic treatment of nausea and vomiting associated with some cancer chemotherapy, radiotherapy and postoperative nausea and/or vomiting. Ondansetron is commercially available in orally disintegrating tablets under the trade name Zofran.RTM. ODT. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 161
•
Novel methods and compositions involving opioids and antagonists thereof Inventor(s): Farrar, John J.; (Chester Springs, PA) Correspondence: David A. Cherry, Esquire; Woodcock Washburn Kurtz; Mackiewicz & Norris Llp; One Liberty Place-46th Floor; Philadelphia; PA; 19103; US Patent Application Number: 20010047005 Date filed: November 29, 2000 Abstract: Novel methods and compositions comprising opioids In preferred embodiments, the methods and compositions peripheral mu opioid antagonist compounds. The methods particularly suitable for treating and/or preventing side effects including, for example, constipation, vomiting and/or nausea.
and opioid antagonists. comprise opioids and and compositions are associated with opioids
Excerpt(s): The present invention relates to novel methods and compositions comprising opioids and opioid antagonists. More particularly, the present invention relates to novel methods and compositions comprising opioids and peripheral mu opioid antagonist compounds. It is well known that opioid drugs target three types of endogenous opioid receptors (i.e., mu, delta and kappa receptors) in biological systems. Most opioids, such as morphine, are mu opioid agonists that are often used as analgesics for the treatment of severe pain due to their activation of mu opioid receptors in the brain and central nervous system (CNS). Opioid receptors are, however, not limited to the CNS, and may be found in other tissues throughout the body. A number of side effects of opioid drugs may be caused by activation of these peripheral receptors. Administration of mu opioid agonists often results in intestinal dysfunction due to the large number of receptors in the wall of the gut (Wittert, G., Hope, P. and Pyle, D., Biochemical and Biophysical Research Communications 1996, 218, 877-881; Bagnol, D., Mansour, A., Akil, A. and Watson, S. J., Neuroscience 1997, 81, 579-591). Specifically, opioids are generally known to cause nausea and vomiting as well as inhibition of normal propulsive gastrointestinal function in animals and man (Reisine, T., and Pasternak, G., Goodman & Gilman's The Pharmacological Basis of Therapeutics Ninth Edition 1996, 521-555) resulting in side effects such as, for example, constipation. It has been reported that acute nausea or vomiting may occur in up to about 33% of patients who receive oral narcotic analgesics and in up to about 80% of patients who receive injectable narcotics following surgery or trauma. This is due, at least in part, to direct effects of narcotics on the gastrointestinal (GI) tract. Opioid-induced side effects, such as nausea, vomiting, and inhibited gastrointestinal propulsive activity remain serious problems for patients being administered opioid analgesics for both short term and long term pain management. Opioid antagonist compounds that do not readily cross the blood-brain barrier (peripherally acting drugs) have been tested for use in curbing opioid-induced side effects. For instance, the peripheral mu opioid antagonist compound methylnaltrexone and related compounds have been suggested for use in curbing opioid-induced side effects in patients. U.S. Pat. Nos. 5,972,954, 5,102,887, 4,861,781, and 4,719,215 disclose the use of methylnaltrexone and related compounds in controlling opioid-induced pruritus, nausea, and/or vomiting. Additionally, methylnaltrexone has been shown to effectively reduce the incidence of opioid-induced nausea and pruritus as disclosed by Yuan, C. -S. et al. Drug and Alcohol Dependence 1998, 52, 161. Similarly, U.S. Pat. Nos. 5,250,542, 5,434,171, 5,159,081, and 5,270,328, disclose peripherally selective piperidineN-alkylcarboxylate opioid antagonists as being useful for the treatment of the opioid side effects constipation, nausea or vomiting, as well as irritable bowel syndrome and idiopathic constipation.
162 Nausea
Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Nutritional drink Inventor(s): Bjorkstrom, Jane; (Stockholm, SE), Bodemar, Goran; (Stockholm, SE), Lindewald, Gusta; (Stockholm, SE), Sjoberg, Lars-Borje; (Stockholm, SE) Correspondence: Larson & Taylor, Plc; 1199 North Fairfax Street; Suite 900; Alexandria; VA; 22314; US Patent Application Number: 20030118713 Date filed: September 18, 2002 Abstract: Nutritional drink which can with good tolerance be taken by persons suffering from feeling of nausea, or which are expected to be sick when consuming food or drink, which nutritional drink have an energy value of not more than 85, or preferably 40-60 kcal/100 ml drink, and an osmolality of not more than 600, or preferably 350-400 mOsmol/kg water, and which mainly contains proteins in an amount of 0.5-5.0 g/100 ml drink, carbohydrates in an amount of 6-20 g/100 ml drink, salts and acidifying agents that give a pH-value in the final drink of between 3 and 6, aroma, flavouring agents and vitamins. Excerpt(s): This invention pertains to a nutritional drink which with good tolerance can be ingested by persons suffering from nausea, or which are expected to be sick when consuming food or drink, e.g. persons who are treated with composition which can cause nausea, such as cytostatics, or persons who have become sick after consuming a certain type of food or drink, or persons who have been submitted to some form of surgical operation including anaesthesia, analgesia or narcosis, or persons in general who by different reasons easily get nauseous. It is important that patients get enough nutrition. The drink is clear and contains mainly proteins, carbohydrates, salts, acidifying agents, aroma, flavouring agents and vitamins. At chronic diseases the appetite often decreases, and if you are also nauseous, the nutritional intake is even more difficult. At nausea the nutritional intake from regular food is to small and leads to loss of weight and muscular mass. Malnutrition and loss of muscular strength and thus decreased general well-being, leads to decreased tolerance to treatments, e.g. radiotherapy and treatment with cytotoxic drugs at tumoural diseases, but also the result of the treatment itself is reduced. This is especially obvious after surgical operations if you are malnourished before the operation. Earlier, administration of nutrition by injecting into the blood stream, so called intravenous nutrition, was used to ameliorate the nutritional condition and to increase the muscular strength at severe diseases. Nowadays, it is known that, if nutrition can instead be administered in regular ways or through enteral probe nutrition to the stomach and the intestines, the administration of nutrition is tolerated better and the ability of the body to assimilate the nutrition is facilitated. It is not fully understood which mechanisms lead to nausea and low tolerance towards ingested food. It is however known that at nausea food and drink remain in the stomach a prolonged time, or reversed, that nausea makes food and drink remain in the stomach a prolonged time. When food and drink remain in the stomach a prolonged time often a feeling of uneasiness occurs with nausea as a consequence. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
Patents 163
•
Nutritional formulations Inventor(s): Hermelin, Marc S.; (Glendale, MO), Kirschner, Mitchell I.; (St. Louis, MO), Levinson, R. Saul; (Chesterfield, MO) Correspondence: Gary M. Nath; Nath & Associates Pllc; 6th Floor; 1030 15th Street, N.W.; Washington; DC; 20005; US Patent Application Number: 20020044961 Date filed: October 9, 2001 Abstract: This invention relates to novel dosage formulations for nutritional compositions comprising fatty acids derived from both plant and animal sources and methods for minimizing unpleasant taste, regurgitation, gastroesophageal reflux, dyspepsia, nausea, or difficulty in swallowing or ingesting nutritional agents. The nutritional compositions are intended for use by pregnant or lactating women. Excerpt(s): This invention is directed to novel soft gelatin nutritional supplements, particularly soft gelatin nutritional supplements for pregnant women comprising fatty acids, methods of using said supplements to reduce the unpleasant taste, regurgitation, gastroesophageal reflux, dyspepsia, and nausea associated with the administration of traditional prenatal nutritional supplements, and processes for manufacturing said supplements. Gastrointestinal motility problems are common in women at all stages of pregnancy. Approximately 45% to 85% of women report experiencing digestive disturbances during pregnancy. Olans, et al., "Gastroesophageal reflux in pregnancy", Gastrointest Endosc Clin N Am 4(4):699-712 (1994). Typical symptoms experienced by pregnant women include belching, heartburn, gastroesophageal reflux, dyspepsia, regurgitation, increased sensitivity to unpleasant odors and/or tastes, nausea and vomiting. The Merck Manual, 1850-1866 (16.sup.th Ed. 1992). These symptoms are thought to be brought about, in part, by the physiological changes which occur in the female body during pregnancy. As pregnancy progresses, gastrointestinal motility decreases due to elevated progesterone levels which cause the smooth muscles associated with the digestive tract to relax. Id. The delay in gastric emptying time and relaxation of the sphincter located at the junction of the esophagus and stomach can cause a reflux of gastric fluids into the esophagus, e.g. gastroesophogeal reflux. Id. The relaxation of the diaphragmatic hiatus can exacerbate this condition. Id. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Oral pediatric trimethobenzamide formulations and methods Inventor(s): Bruns, Robert G.; (Johnson City, TN), Cirotta, Dean R.; (Webster, NY), Gregory, Jefferson J.; (Bristol, TN), Pamplin, Charles L. III; (Chapel Hill, NC), Rogers, Thomas K. III; (Bristol, TN) Correspondence: Edwards & Angell, Llp; P.O. Box 9169; Boston; MA; 02209; US Patent Application Number: 20040034102 Date filed: February 6, 2003 Abstract: Oral pediatric trimethobenzamide compositions and methods for treating and controlling nausea and/or vomiting are disclosed in warm blooded animals, especially humans including children. The oral pediatric trimethobenzamide compositions and methods of the present invention are believed to be at least as effective as a 200 mg intramuscular (I.M.) trimethobenzamide HCl injectable formulation when administered
164 Nausea
at a dose of about 100 mg. In addition, an oral pediatric composition containing about 120 mg of trimethobenzamide HCl is believed to be uniquely approximately bioequivalent to a 200 mg intramuscular (I.M.) trimethobenzamide HCl injectable formulation when administered at a dose of about 100 mg. Excerpt(s): This application for U.S. patent is filed as a provisional application under U.S.C., Title 35,.sctn.111(b). The present invention is concerned with oral pediatric trimethobenzamide compositions and methods useful for treating and controlling nausea and/or vomiting or emesis in warm-blooded animals, especially children. The process of nausea and vomiting is regulated by the chemoreceptor trigger zone ("CTZ") which is located in the vomiting center. The vomiting center is located in the medulla. The chemoreceptor trigger zone is the primary trigger for emesis. Because the chemoreceptor trigger zone must first stimulate the vomiting center to induce emesis, the chemoreceptor trigger zone, by itself, cannot induce vomiting. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Orally ingestible preparation of mistletoe lectins and method Inventor(s): Pryme, Ian; (Bergen, NO) Correspondence: Christian D. Abel; Onsagers AS; Postboks 6963 ST. Olavs Plass; Norway; N-0130; NO Patent Application Number: 20040052869 Date filed: September 22, 2003 Abstract: An orally ingestible preparation consisting essentially of Mistletoe lectin I (ML-I), Mistletoe lectin II (ML-II), and Mistletoe lectin III (ML-III), which specifically excludes the nausea-inducing compounds present in mistletoe extracts. The invention also provides for a method of producing said preparation, a method of using said preparation to produce pharmaceutical preparations, and a method for using said preparation in the treatment of patients suffering from cancer and auto immune diseases. Excerpt(s): The present invention relates to medicinally useful preparations derived from mistletoe, methods for making such preparations and treatment methods employing such preparations. More specifically, the invention relates to an orally ingestible preparation of mistletoe lectins useful in the treatment of cancer and other diseases. The cytotoxic cells of the immune system, cytolytic T cells (CTL), natural killer (NK) cells and macrophages, can seek out and ultimately lyse tumor cells either spontaneously or more often after appropriate activation. Spontaneous cytotoxic activity against tumor cells is mainly a result of NK cells. Various cytokines, alone or in combination, have been shown to augment anti-tumor activity : IL-2, IL-7, IL-12 and IFN-.gamma. induce cytotoxic activity in NK and T-cells while IFN-.gamma. and TNF.alpha. are potent activators of macrophages and monocytes. Most of the studies that have demonstrated these effects have been confined to in vitro systems although recently the anti-tumor effect of some of these cytokines has also been demonstrated in vivo in animals and also in humans. Lymphocytes cultured in the presence of high amounts of IL-2 are refered to as lymfokine-activated killer (LAK) cells. LAK cells are characterised by their ability to kill NK-resistant tumor cells without major histocompatibility complex (MHC) restriction. Although both NK and T cells are responsible for LAK activity, the former are responsible for mediating most of the activity. Macrophages and monocytes are known to accumulate around tumors.
Patents 165
Following the TNF.alpha. and IFN-.gamma. stimulated activation of these cells it is predicted that a local release of cytokines would occur from these activated cells directly into the tumor. This in turn would be expected to induce apoptosis and ultimately cause death of the tumor cells. Besides cytokines, a variety of natural or synthetically produced protein mixtures have been reported to exert immunomodulating properties. The commercially available mistletoe extracts belong to this category of agents. Biochemical analysis has shown that the immunomodulating capacity is due to the presence of mistletoe lectins (ML-I, ML-II and ML-III) in the extracts. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Pharmaceutical composition and method of modulating cholinergic function in a mammal Inventor(s): Coe, Jotham W.; (Niantic, CT), Sands, Steven B.; (Stonington, CT) Correspondence: Pfizer Inc; 150 East 42nd Street; 5th Floor - Stop 49; New York; NY; 10017-5612; US Patent Application Number: 20030008892 Date filed: March 25, 2002 Abstract: A pharmaceutical composition and method of modulating cholinergic function in a mammal comprising administration of a NRPA compound or a pharmaceutically acceptable salt thereof; and an anti-emetic/anti-nausea agent or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. The NRPA compound and the anti-emetic/anti-nausea agent are present in amounts that render the composition effective modulating cholinergic function or in the treatment of a diorder or condition selected from inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multiinfarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome. The method of using these compositions is also disclosed. Excerpt(s): The present invention relates to pharmaceutical compositions for modulating cholinergic function in a mammal comprising a nicotinic receptor partial agonist compound in combination with an anti-emetic/anti-nausea agent and a pharmaceutically acceptable carrier. The nicotinic receptor partial agonists (NRPAs) included herein are aryl fused azapolycyclic compounds. NRPAs are not limited to those described here. The term NRPA refers to all chemical compounds which bind at neuronal nicotinic acetylcholine specific receptor sites in mammalian tissue and elicit a partial agonist response. A partial agonist response is defined here to mean a partial, or incomplete functional effect in a given functional assay. Additionally, a partial agonist will also exhibit some degree of antagonist activity by its ability to block the action of a
166 Nausea
full agonist (Feldman, R. S., Meyer, J. S. & Quenzer, L. F. Principles of Neuropsychopharmacology, 1997; Sinauer Assoc. Inc.). The present invention may be used to treat mammals (e.g. humans) for inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multiinfarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome with a decrease in the incidence and severity of unwanted side effects such as nausea and/or stomach upset. The present invention also relates to the combination use of NRPAs and anti-emetic/anti-nausea agents resulting in modulation of cholinergic function without nausea. The combination will provide an improved treatment paradigm than NRPAs alone. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Pharmaceutical compositions for headache, migraine, nausea and emesis Inventor(s): Barkan, Raphael; (Zion, IL), Mirimsky, Alexander; (Rehovot, IL) Correspondence: Winston & Strawn; Patent Department; 1400 L Street, N.W.; Washington; DC; 20005-3502; US Patent Application Number: 20040006044 Date filed: March 5, 2003 Abstract: S-alkylsiothiouronium derivatives such as S-ethylisothiouronium diethylphosphate are used for the treatment of headaches, in particular, migraines, as well as for the prevention or treatment of nausea and vomiting. The compositions of the invention are also effective in preventing or alleviating emesis associated with migraines or other medical conditions such as chemotherapy or radiotherapy, as well as other symptoms of migraines including phonophobia and photophobia. Excerpt(s): The present invention relates to the use of S-alkylisothiouronium derivatives, including, but not limited to, S-ethylisothiouronium diethylphosphate, for the prevention or treatment of headache, including but not limited to migraine, and for the prevention or treatment of emesis, and more particularly, to the alleviation of migraine symptoms, including but not limited to headache, nausea and vomiting. Headache is a term used to describe a varied set of symptoms, ranging in intensity from mild discomfort to the very severe syndrome known by the name of migraine. While the most severe and debilitating form of headache is migraine headache there are several other types of headaches that warrant consideration in terms of prevalence, including but not limited to premenstrual syndrome (PMS) associated headaches and the condition associated with morning after alcohol consumption, commonly referred to as hangover. Symptoms such as headache, fever, chills, nausea, muscle and nerve pain, lethargy, and others are often manifested during the syndrome known as hangover.
Patents 167
Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-- hexadeca-2 (11),3,5,7,9-pentaene Inventor(s): Am Ende, Mary T.; (Waterford, CT), Moses, Sara Kristen; (Mystic, CT), Quan, Ernest S.; (East Lyme, CT), Roy, Michael C.; (Groton, CT), Smith, Scott W.; (San Diego, CA), Waterman, Kenneth C.; (East Lyme, CT) Correspondence: Pfizer Inc; 150 East 42nd Street; 5th Floor - Stop 49; New York; NY; 10017-5612; US Patent Application Number: 20030180360 Date filed: November 20, 2002 Abstract: The present invention is directed to controlled-release (CR) oral pharmaceutical dosage forms of 5,8,14-triazatetracyclo[10.3.1.0.sup.2,11.- 0.sup.4,9]hexadeca-2(11),3,5,7,9-pentaene, 1, and pharmaceutically acceptable salts thereof, and methods of using them to reduce nicotine addiction or aiding in the cessation or lessening of tobacco use while reducing nausea as an adverse effect. The present invention also relates to an immediate-release (IR) low dosage composition having a stable formulation with uniform drug distribution and potency. 1 Excerpt(s): Compound 1, also known as 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]-benzazepine, binds to neuronal nicotinic acetylcholine specific receptor sites and are useful in modulating cholinergic function. Accordingly, this compound is useful in the treatment of inflammatory bowel disease (including but not limited to ulcerative colitis, pyoderma gangrenosum and Crohn's disease), irritable bowel syndrome, spastic dystonia, chronic pain, acute pain, celiac sprue, pouchitis, vasoconstriction, anxiety, panic disorder, depression, bipolar disorder, autism, sleep disorders, jet lag, amyotrophic lateral sclerosis (ALS), cognitive dysfunction, hypertension, bulimia, anorexia, obesity, cardiac arrhythmias, gastric acid hypersecretion, ulcers, pheochromocytoma, progressive supranuclear palsy, chemical dependencies and addictions (e.g., dependencies on, or addictions to nicotine (and/or tobacco products), alcohol, benzodiazepines, barbiturates, opioids or cocaine), headache, migraine, stroke, traumatic brain injury (TBI), obsessive-compulsive disorder (OCD), psychosis, Huntington's chorea, tardive dyskinesia, hyperkinesia, dyslexia, schizophrenia, multi-infarct dementia, age-related cognitive decline, epilepsy, including petit mal absence epilepsy, senile dementia of the Alzheimer's type (AD), Parkinson's disease (PD), attention deficit hyperactivity disorder (ADHD) and Tourette's Syndrome. Compound 1 and pharmaceutically acceptable acid addition salts thereof are referred to in International Patent Publication WO 99/35131, published Jul. 15, 1999, which is incorporated herein by reference in its entirety. Whereas immediate release (IR) dosage forms of the aforementioned compound, that is, dosage forms designed to provide the drug in a dissolved form upon swallowing in less than about 30 minutes, provide therapeutically useful levels of drug in the blood and brain, it has been observed that there is a significant level of nausea in patients, especially at doses sufficiently high to be therapeutically useful for some patients. Since nausea can lead to poor patient compliance with a dosing regimen, there is a need to provide 1 in a form that reduces the incidence of nausea. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
168 Nausea
•
Polymer conjugates of opioid antagonists Inventor(s): Bentley, Michael David; (Huntsville, AL), Cheng, Lin; (Huntsville, AL), Roberts, Michael James; (Williamsburg, VA), Shen, Xiaoming; (Madison, AL) Correspondence: Alston & Bird Llp; Bank OF America Plaza; 101 South Tryon Street, Suite 4000; Charlotte; NC; 28280-4000; US Patent Application Number: 20030124086 Date filed: October 18, 2002 Abstract: The invention provides polymer conjugates of opioid antagonists comprising a polymer, such as poly(ethylene glycol), covalently attached to an opioid antagonist. The linkage between the polymer and the opioid antagonist is preferably hydrolytically stable. The invention also includes a method of treating one or more side effects associated with the use of opioid analgesics, such as constipation, nausea, or pruritus, by administering a polymer conjugate of the invention. Excerpt(s): This application claims the benefit of Provisional Application Serial No. 60/330,400, filed Oct. 18, 2001, which is incorporated herein by reference in its entirety. This invention relates to water-soluble polymer conjugates of biologically active molecules, and in particular, to water-soluble polymer conjugates of opioid antagonists, such as naloxone, and related pharmaceutical compositions and uses thereof. Natural and synthetic alkaloids of opium (i.e., opioids) are useful as analgesics for the treatment of severe pain. Opioids target three types of endogenous opioid receptors:.mu.-,.delta.-, and.kappa.-receptors. Many opioids, such as morphine, are Preceptor agonists that are highly efficacious analgesic compounds due to their activation of opioid receptors in the brain and central nervous system (CNS). Opioid receptors are, however, not only limited to the CNS, but may be found in other tissues throughout the body. These receptors located outside the CNS are referred to as peripheral receptors. A number of side effects associated with opioid use are caused by activation of these peripheral receptors. For example, administration of opioid agonists often results in intestinal dysfunction due to action of the opioid agonist upon the large number of receptors in the intestinal wall. Specifically, opioids are generally known to cause nausea and vomiting as well as inhibition of normal propulsive gastrointestinal function in animals, resulting in side effects such as constipation. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
PROKINETIC AGENTS FOR TREATING GASTRIC HYPOMOTILITY AND RELATED DISORDERS Inventor(s): ANDREWS, PAUL L. R.; (LONDON, GB), WATSON, JOHN W.; (LEDYARD, CT), WOODS, ANTHONY J.; (LONDON, GB) Correspondence: Pfizer Inc; 150 East 42nd Street; 5th Floor - Stop 49; New York; NY; 10017-5612; US Patent Application Number: 20030176421 Date filed: December 30, 1999 Abstract: Stasis is treated or prevented in all or any part or parts of the stomach of a patient, especially a human patient, in need of such treatment, where said stasis results from hypomotility in the stomach, particularly gastric hypomotility with delayed emptying of the liquid and/or solid contents of the stomach. Gastric or gastrointestinal
Patents 169
disorders are also treated which are characterized by one or more symptoms selected from pain, nausea, vomiting, heartburn, postprandial discomfort, indigestion and gastroesophageal reflux. Such treatment or prevention is achieved by administering to the patient a therapeutically effective amount of an inhibitor of phosphodiesterase-4 (PDE4), including isozyme subtypes thereof, sufficient to treat or prevent such hypomotility or gastric or gastrointestinal disorder in said patient. The PDE4 inhibitor comprises a compound of Formula (IA) or (IB): 1where in a preferred embodiment, R is cyclopentyl or cyclohexyl; R.sup.1 is (C.sub.1-C.sub.2) alkyl; one of R.sup.2.sub.a and R.sup.2.sub.b is hydrogen and the other is a substituent of partial Formula (1.0.0) above, where the dashed line represents a single bond, m is 0, R.sup.113 and R.sup.114 are in a cis relationship to each other, R.sup.113 is cyano, R.sup.115 is hydrogen, and R.sup.114 is carboxy, --CH.sub.2OH, or --CH.sub.2C(.dbd.O)NH.sub.2.Pharmaceutical compositions are also described which are useful for carrying out the above-mentioned methods of treatment and prevention, and which are also useful in the treatment of a gastric or gastrointestinal disorder in a patient which comprises with respect to said patient, (i) a sign or concomitant of diabetic neuropathy, anorexia nervosa, achlorhydria, gastrointestinal surgery, post-surgical recovery in the period of emergence from general anesthesia; or the administration of morphine and morphine-like opioids; (ii) a secondary aspect of a primary disease or disorder in said patient which is organic, wherein said disease or disorder involves particularly a gastroenteric or gastroesophageal organ or tissue, or an organ or tissue of the central nervous system of said patient; or (iii) an adverse side effect of a different therapeutic agent administered to said patient in the course of treating another unrelated disease or disorder in said patient. Excerpt(s): The method of treatment of the present invention involves a therapeutic agent having a prokinetic effect on, i.e., that promotes activity with regard to gastric motility. This type of drug is useful in treating gastric hypomotility with delayed gastric emptying of liquid and/or solid contents of the antrum (stomach), which is a component of a number of gastric or gastrointestinal disorders. The symptoms of such gastric or gastrointestinal disorders can be quite serious and include pain, nausea, vomiting, heartburn, postprandial discomfort, indigestion, and gastroesophageal reflux. In particular, the present invention relates to therapeutic agents which by various mechanisms are able to elevate cAMP in populations of neurons in the myenteric plexus, leading to release of excitatory transmitters, e.g., acetylcholine, and subsequent stimulation with resulting contraction of the smooth muscle of the antrum. The therapeutic compounds useful as active ingredients in the pharmaceutical compositions and methods of treatment of the present invention are closely related, in terms of their chemical structure and biological activity, to inhibitors of the phosphodiesterase-IV (PDE4) isoenzyme. However, to date the art has incorrectly taught that PDE4 inhibitors antagonize gastrointestinal contractile responses, suggesting their use as antikinetic agents for treating hypermotility disorders; rather than as prokinetic agents for treating gastric hypomotility, as surprisingly discovered in accordance with the present invention. The gastrointestinal system must preserve a proper balance between absorption and secretion of water and electrolytes in order to keep nutrients, wastes, electrolytes and water in a life-sustaining flux. Equally important to successful performance of this ongoing process is the maintenance along the gastrointestinal tract of the appropriate anterograde motility. Gastrointestinal motility is also known to be a key component of vomiting. This aspect of its role is important in light of the fact that some antiemetic agents have enhanced gastric emptying as a significant aspect of their actions. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
170 Nausea
•
System and method for sensing and evaluating physiological parameters and modeling an adaptable predictive analysis for symptoms management Inventor(s): Geatz, Michael W.; (Maple Groove, MN), Roiger, Richard J.; (Mankato, MN) Correspondence: Stuart R. Hemphill; Dorsey & Whitney Llp; Intellectual Property Department; 50 South Sixth Street, Suite 1500; Minneapolis; MN; 55402-1498; US Patent Application Number: 20030144829 Date filed: January 24, 2003 Abstract: A system senses various physiological parameters of a patient such as heart rate or temperature to evaluate the patient and predict when an episode of a chronic symptom may occur. The system further includes a modeling component which generates an individualized predictive model for a given patient wherein the patient's previous episodes of the symptom are utilized to shape the model. The system tests the model to assure accuracy and can revise the model as necessary. Once the model is established, the system monitors patient parameters and can alert the patient to the expected onset of the symptom and/or automatically administer an appropriate drug or other therapy to control the expected symptom. The system is applicable to allergic reactions, anxiety attacks, attention deficit hyperactivity disorders, backaches, depression, dizziness, drowsiness, epileptic seizures, fatigue, heart malfunction, hunger pangs, joint or other pain, loss of motor control, migraines, motion sickness, muscle spasm, nausea, nicotine fits, numbness, shaking, shortness of breath, sleep or sleep disorders, tremors, unconsciousness, vision impairment or other chronic symptoms. Excerpt(s): This patent application claims priority from provisional patent application No. 60/351,575, filed Jan. 25, 2002. This invention relates generally to medical devices, and more specifically to a method and apparatus for sensing and reacting to patient physiological data. Many people suffer from chronic or recurring symptoms or various other unpleasant or disturbing indications caused by a wide variety of medical ailments. Some possibilities include: allergic reactions, anxiety attacks, attention deficit hyperactivity disorders, backaches, depression, dizziness, drowsiness, epileptic seizures, fatigue, heart malfunction, hunger pangs, joint or other pain, loss of motor control, migraines, motion sickness, muscle spasm, nausea, nicotine "fit", numbness, shaking, shortness of breath, sleep or sleep disorders, tremors, unconsciousness, and vision impairment. In fact, approximately 1 in 5 people suffer from some sort of chronic acute symptoms during their lifetime. Understandably, these people desire and seek relief from the medical community. A typical patient suffering from such chronic symptoms might spend anywhere from $500 to $35,000 annually to treat or minimize their symptoms. Treatments for symptoms involve various drug and/or physical therapies, chiropractic care, acupuncture, meditation and yoga. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
•
Treatment method Inventor(s): Dedrick, Russell L.; (Kensington, CA), Garovoy, Marvin R.; (San Anselmo, CA), Kramer, Susan M.; (San Francisco, CA), Starko, Karen M.; (Hillsborough, CA) Correspondence: Genentech, INC.; 1 Dna Way; South San Francisco; CA; 94080; US Patent Application Number: 20030223988 Date filed: June 20, 2003
Patents 171
Abstract: A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need thereof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on a target mammalian cell; and administering a second therapeutic dose of the compound, wherein the second dose is higher than the first dose. Excerpt(s): This application is a continuation of Ser. No. 09/819,921, filed on Mar. 28, 2001, which is a divisional of Ser. No. 09/527,957, filed on Mar. 17, 2000 (now abandoned) which claims the benefit under USC.sctn.119(e)(1) to provisional patent applications Serial No. 60/125,228 and Serial No. 60/125,351, both filed on Mar. 19, 1999, the disclosures of which are incorporated by reference herein in their entirety. The invention relates to methods of treating mammals, for example humans, to reduce the occurrence of undesired administration reactions, to treat an LFA-1 mediated disease, to condition a mammal to tolerate high doses of a therapeutic compound and to down modulate a cell surface receptor. Administration of many therapeutic agents rapidly induces adverse side effects, or events, including but not limited to fever, headache, nausea, vomiting, breathing difficulties and changes in blood pressure. These adverse events limit the amount of a drug or therapeutic compound that can be given, which in turn limits the therapeutic effectiveness that could be achieved with higher doses of the drug. There is a continuing need to develop techniques which limit the toxicity of higher drug doses so that therapeutic efficacy can be improved. This need exists for both polypeptide and non-polypeptide compounds. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html •
Two-component anti-emetic composition Inventor(s): Jannetta, Anthony; (Haverford, PA) Correspondence: Patent Adminstrator; Katten Muchin Zavis; Suite 1600; 525 West Monroe Street; Chicago; IL; 60661; US Patent Application Number: 20020055495 Date filed: September 5, 2001 Abstract: The invention relates to an anti-emetic composition containing dexamethasone (DEX) and metoclopramide (MTC). In a particular embodiment, a composition containing DEX:MTC in a relative weight ratio of about 1 to less than 1.25 is found to be effective in providing relief from the discomfort caused by symptoms of both vomiting and nausea in all patients receiving the composition. Alternatively, an effective suppository composition may contain DEX:MTC in a relative weight ratio of about 1:112.5. Other effective compositions and methods of their use are also disclosed. Excerpt(s): This application claims the benefit of an earlier-filed provisional application No. 60/229,547 filed Sep. 5, 2000, the entire disclosure of which is incorporated herein by reference. The present invention relates to both a therapeutic composition comprising a synergistic combination of antiemetic drugs and to a method for treating emesis, including nausea. Nausea and vomiting can follow the administration of many drugs, particularly anticancer or chemotherapeutic agents. The symptoms also often accompany infectious and non-infectious gastrointestinal disorders. Web site: http://appft1.uspto.gov/netahtml/PTO/search-bool.html
172 Nausea
Keeping Current In order to stay informed about patents and patent applications dealing with nausea, you can access the U.S. Patent Office archive via the Internet at the following Web address: http://www.uspto.gov/patft/index.html. You will see two broad options: (1) Issued Patent, and (2) Published Applications. To see a list of issued patents, perform the following steps: Under “Issued Patents,” click “Quick Search.” Then, type “nausea” (or synonyms) into the “Term 1” box. After clicking on the search button, scroll down to see the various patents which have been granted to date on nausea. You can also use this procedure to view pending patent applications concerning nausea. Simply go back to http://www.uspto.gov/patft/index.html. Select “Quick Search” under “Published Applications.” Then proceed with the steps listed above.
173
CHAPTER 7. BOOKS ON NAUSEA Overview This chapter provides bibliographic book references relating to nausea. In addition to online booksellers such as www.amazon.com and www.bn.com, excellent sources for book titles on nausea include the Combined Health Information Database and the National Library of Medicine. Your local medical library also may have these titles available for loan.
Book Summaries: Federal Agencies The Combined Health Information Database collects various book abstracts from a variety of healthcare institutions and federal agencies. To access these summaries, go directly to the following hyperlink: http://chid.nih.gov/detail/detail.html. You will need to use the “Detailed Search” option. To find book summaries, use the drop boxes at the bottom of the search page where “You may refine your search by.” Select the dates and language you prefer. For the format option, select “Monograph/Book.” Now type “nausea” (or synonyms) into the “For these words:” box. You should check back periodically with this database which is updated every three months. The following is a typical result when searching for books on nausea: •
Uninvited Guests: The Inside Story on Intestinal Parasites and How to Protect Yourself from Them Source: New Canaan, CT: Keats Publishing, Inc. 1996. 48 p. Contact: Available from Keats Publishing, Inc. 27 Pine Street, Box 876, New Canaan, CT 06840-0876. (800) 540-9440. Fax (800) 998-3103. PRICE: $3.95 plus shipping and handling. ISBN: 0879837365. Summary: Human bodies are perfect homes for parasites, providing food and housing for any number of these uninvited guests. Relatively few patients and doctors realize that parasites cause some of the most common intestinal infections in the U.S. This booklet describes common parasites, from the water poisoning Cryptosporidium to the 15 foot fish tapeworm. The protozoan family of parasites, single celled organisms like Giardia intestinalis (formerly known as Giardia lamblia) and Cryptosporidium parvum are the ones most frequently found in Americans. Diarrhea, nausea, fevers, and
174 Nausea
abdominal pain may be some of the initial symptoms of infections. Bowel disorders, muscle and joint pain, fibromyalgia, fatigue, malnutrition, and allergic reactions may develop when parasites take up long term, undetected residence in a human body. The author discusses sources of contamination, definitions and symptoms, parasitic infections, the parasites themselves, treatment options, and prevention strategies. Sources of contamination include water, food, pets, day care centers, sexual practices, and widespread global travel. Parasites are discussed in four basic categories: Protozoa (microscopic, single celled organisms), Trematodes (flukes), Cestoda (tapeworms), and Nematoda (round, pin, and hook worms). The author reviews the incidence, symptoms, and transmission of each of these parasitic infections. A questionnaire that can be useful in diagnosis is included in the booklet. Treatment options discussed include chemotherapeutic agents, herbal alternatives, and diet and other supportive measures. The author stresses that the best prevention strategy is to build a strong, healthy immune system. 1 figure. 33 references. •
Heartburn and What to Do About It Source: Garden City Park, NY: Avery Publishing Group. 1998. 182 p. Contact: Available from Avery Publishing Group. 120 Old Broadway, Garden City Park, NY 11040. (800) 548-5757 or (516) 741-2155. Fax (516) 742-1892. E-mail:
[email protected]. PRICE: $10.95 plus shipping and handling. ISBN 0895297922. Summary: In this book, the authors tell readers how to banish heartburn and other digestive symptoms once and for all, using natural therapies that are gentle on one's system. The authors emphasize that a lack of balance in the digestive tract, caused by improper diet and the stresses of modern life, is at the root of most people's intestinal upsets, and they explain both the problem and the solution in clear, nontechnical language. In Part One, after surveying the scope of the nation's digestive difficulties, the authors review the most common digestion related disorders. They discuss ulcers and the infection (Helicobacter pylori) that causes ulcers. The authors then look at disorders that can cause both common digestive symptoms, such as diarrhea, constipation, nausea, and gas, and symptoms that most readers may not associate with the digestive system, such as fatigue and skin rashes. In Part Two, the authors explain how to relieve and prevent digestive troubles through the use of proper diet, yogurt, and intestinal cleansers. Finally, the authors offer a detailed discussion of probiotics, the friendly bacteria that not only help protect the digestive tract from bad bacteria and assist in digestion itself, but also improve overall health. The authors conclude that restoring intestinal health first requires a change in diet, with a reduction in or elimination of highly processed, sugary, and fatty foods, and a corresponding increase in whole grains, fresh fruits and vegetables, limited amounts of organically raised meat, and cultured foods such as yogurt. These changes in diet must be supported by adequate exercise, rest, and stress reduction. The book concludes with a resource list, a suggested reading list, a list noting sources of products and services, endnotes, and a subject index. 250 references.
•
PDR for Herbal Medicines. 1st ed Source: Montvale, NJ: Medical Economics Company. 1998. 1244 p. Contact: Available from Medical Economics Publishing Inc. P.O. Box 10689, Des Moines, IA 50336. (800) 922-0937. Fax (515) 284-6714. Website: www.medecbookstore.com. PRICE: $59.99. ISBN: 1563632926.
Books
175
Summary: Most of today's herbal remedies exhibit varying degrees of therapeutic value. Some, such as ginkgo, valerian, and saw palmetto, seem genuinely useful, while others, such as ephedra, tansy, and nightshade, can actually be dangerous. As the use of unfamiliar botanicals spreads, the need to steer patients toward the few truly useful preparations and warn them away from ineffective, dangerous alternatives is becoming an increasingly significant priority. This volume, from the publishers of Physicians Desk Reference, brings together the findings of the German Regulatory Authority's herbal watchdog agency (commonly caused Commission E). This agency conducted an intensive assessment of the peer-reviewed literature on some 300 common botanicals, weighing the quality of the clinical evidence and identifying the uses for which the herb can reasonably be considered effective. This reference book contains profiles of over 600 medicinal herbs. Each entry contains up to 9 standard sections: name(s), description, actions and pharmacology, indications and usage, contraindications, precautions and adverse reactions, overdosage, dosage, and literature. The entries have also been indexed by scientific and common name, indications, therapeutic category, and side effects. To assist in identification, the reference book includes a section of full-color plates of the plants included. The book concludes with a glossary of the specialized botanical nomenclature and other unfamiliar terminology, a list of poison control centers, and a list of drug information centers. Some of the herbs are listed for use for abdominal cramps or distress, acid indigestion, appetite stimulation, rectal bleeding, various bowel disorders, stomach cancer, cholelithiasis (gallstones), colic, colitis, constipation, dehydration, diarrhea, digestive disorders, dysentery, enteritis, anal fissure, flatulence (intestinal gas), gastritis, gastroenteritis, gastrointestinal disorders, gout, helminthiasis, hemorrhage, hemorrhoids, hepatitis, hypercholesterolemia, jaundice, liver and gall bladder complaints, liver disorders, malaria, nausea, abdominal pain, and vomiting. •
Orofacial Pain with a Neurological or Vascular Background Source: in Scully, C. Handbook of Oral Disease: Diagnosis and Management. New York, NY: Thieme New York. 2001. p.39-52. Contact: Available from Thieme New York. 333 Seventh Avenue, New York, NY 10001. (212) 760-0888, ext 110. PRICE: $35.00 plus shipping and handling. ISBN: 1841840874. Summary: Pain is the most common oral complaint. Usually it has a local cause, but neurological (nervous system), vascular (blood vessel), psychogenic (of psychological cause), and other causes should be excluded. This chapter on orofacial pain with a neurological or vascular background is from a handbook of oral disease that is intended to be used by all members of the dental team who need a ready office reference. The handbook covers the more common and important soft tissue orofacial disorders and gives clinically relevant aspects of the etiology, diagnosis, treatment, and prevention. This chapter covers causalgia (a persistent burning pain that follows surgery or trauma), cranial arteritis (also called temporal arteritis or giant-cell arteritis); Frey's syndrome, a burning pain, usually in the temporal area in front of the ear, associated with flushing and sweating on eating; glossopharyngeal neuralgia; herpetic and postherpetic neuralgia, which is pain that persists after herpes zoster (shingles); migraine, a severe headache associated with nausea and sometimes photophobia (light sensitivity); migrainous neuralgia or cluster headache; referred pain; and trigeminal neuralgia. For each condition, the authors note etiology (cause), diagnosis, symptoms, epidemiology, risk factors, treatment, and prevention (where possible). Much of the information is provided in table format for ease of reference. Full color photographs illustrate some conditions. 4 figures. 2 tables. 25 references.
176 Nausea
•
Dyspepsia Source: Philadelphia, PA: American College of Physicians. 191 p. Contact: Available from American College of Physicians (ACP). 190 N. Independence Mall West, Philadelphia, PA 19106-1572. (800) 523-1546 or (215) 351-2600. Website: www.acponline.org. PRICE: $35.00 plus shipping and handling. ISBN: 0943126975. Summary: The term dyspepsia represents a variety of symptoms pertaining to the upper gastrointestinal tract, including upper abdominal pain, discomfort, heartburn, nausea, bloating, and regurgitation. This book offers a guide to the clinical challenge of daily management of patients with dyspepsia. To accommodate the realities of managed health care and fiscal concerns, the authors emphasize cost effective strategies that achieve optimal clinical outcomes. The symptom pattern and response to empirical therapy are helpful in establishing the classification. The authors provide a bridge from the medical literature to informed decision making, covering epidemiology, etiology, natural history, motility problems, quality of life issues, and alternative therapies. The complexities of gastroesophageal reflux disease (GERD) and Helicobacter pylori infection are explored. Clinical vignettes demonstrate how experts approach frequently encountered dilemmas by using hypothetical case histories and posing treatment questions. The authors note that the diagnosis of dyspepsia in itself has significant cost implications; however, the ultimate goal of the physician is to balance the appropriate diagnostic strategy with the optimal use of health care resources. Similarly, the appropriate use of medical therapy should always focus on the medication that achieves the best symptomatic response. In addition, it is becoming increasingly well recognized that no or poor treatment of upper gastrointestinal visceral diseases has a significant effect on quality of life. Each chapter concludes with a list of key points and a reference list; a subject index concludes the book.
•
Diabetes Problem Solver Source: Alexandria, VA: American Diabetes Association. 1999. 511 p. Contact: Available from American Diabetes Association (ADA). Order Fulfillment Department, P.O. Box 930850, Atlanta, GA 31193-0850. (800) 232-6733. Fax (770) 4429742. Website: www.diabetes.org. PRICE: $19.95 for members; plus shipping and handling. ISBN: 1570400091. Summary: This book is a reference guide that helps people who have diabetes identify and prevent the most common diabetes-related problems they encounter on a daily basis. The book is divided into two major sections. The first section consists of a series of flowcharts to help readers decide what they need to do about a particular condition or symptom. Flowcharts focus on arm and hand pain, back pain, blurry vision, chest pain, confusion, convulsions or seizures, difficulty breathing, dizziness, dry skin, eating disorders, emotional problems, emotional changes in women, feeling tired, fever, foot problems, headache, hyperglycemia, hypoglycemia, injection site problems, and intestinal problems. Other flowcharts deal with leg and foot pain, loss of consciousness, muscular weakness, nausea, numbness and tingling, pain or discomfort in women, palpitations, problems with the mouth, problems with blood glucose in women, sexual problems in men and women, skin discoloration, skin lesions, skin rashes and itchy skin, sleeping problems, stomach pain, sweating, swelling, thickening of the skin, urinary problems, vision problems, and vomiting. The second section provides more detailed information about many of the problems people who have diabetes face. Solutions are provided for monitoring and testing problems; hypoglycemia and hyperglycemia problems; insulin delivery and oral medication problems; circulation, neuropathy,
Books
177
kidney, vision, gastrointestinal, infection, foot, and skin problems; men's, women's, and children's problems; eating, exercise, and weight problems; lifestyle problems; coping problems; discrimination and insurance problems; and other medical problems. Each section provides the reader with information on the symptoms of the condition, who is at risk and what risk the particular condition poses for the reader, what the reader's immediate course of action should be, treatment in a medical setting, and how to prevent the condition from developing. The reader may use the book in two ways. If the reader knows he or she has a particular condition or wants more information, he or she can go straight to the second section and look up the condition. The reader may use the book as a guide to possible conditions that may be causing symptoms by referring to the flowcharts in the first section. The book also includes a glossary, resources, and an index. 6 figures. 5 tables. •
Managing the Side Effects of Chemotherapy and Radiation Therapy: A Guide for Patients and Their Families. 3rd ed Source: San Francisco, CA: UCSF Nursing Press. 1996. 198 p. Contact: Available from UCSF Nursing Press. 521 Parnassus Avenue, Room N-535C, San Francisco, CA 94143-0608. (415) 476-4992 or (415) 476-2626. Fax (415) 476-6042. PRICE: $20.00 plus $6.00 shipping and handling. ISBN: 0943671120. Summary: This book is designed to help patients and their families learn to cope with the many side effects of cancer chemotherapy and radiation therapy. The chemotherapy section lists every frequently used cancer drug and common side effects of each. This information is first presented in chart format, then discussed in some detail. Suggestions for managing each side effect are included. The section on side effects includes a description of the problem, its likely duration, recommended self-care measures, and when to consult with a health care provider. The remainder of the book discusses the common side effects of radiation therapy, with the same type of information and in the same format. Side effects particularly relevant to the digestive system include abdominal pain, constipation, diarrhea, liver damage, sore mouth or difficulty swallowing, nausea and vomiting, and stomach irritation and ulcers. A subject index concludes the book.
•
Indigestion: Living Better with Upper Intestinal Problems from Heartburn to Ulcers and Gallstones Source: New York, NY: Oxford University Press. 1992. 227 p. Contact: Available from Oxford University Press. Order Department, 2001 Evans Road, Cary, NC 27513. (800) 451-7556. Fax (919) 677-1303. PRICE: $11.95 plus shipping and handling. ISBN: 019508554X. Summary: This book offers advice on how to take care of and avoid a whole complex of disturbances categorized as indigestion. The author begins with an overview of the anatomy and physiology of digestion, including a chapter on terminology and definitions. After an additional chapter on diagnostic testing, the author turns to specific problems, including acid related problems (heartburn, esophagitis, and hiatal hernia), peptic ulcers, nonulcer dyspepsia, chest pain, gallbladder problems and gallstones, pancreatic diseases, jaundice, malabsorption and maldigestion, food intolerance and food allergies, the impact of aging on the upper digestive tract (including the role of medications and drug interactions), and the brain gut connection. The appendices of the book offer coverage of related problems, including belching, nausea and vomiting, dry mouth and bitter taste, difficulty in tasting, lump in the throat, butterflies, difficulties in
178 Nausea
swallowing, delayed stomach emptying, the effects of diabetes on the upper digestive system, and the controversy over yeast. The author hopes to foster a cooperative dialogue between patients and their physicians as they work together to diagnose and manage upper digestive tract problems. A subject index concludes the book. 8 figures. 6 tables. •
Irritable Bowel Syndrome and the Mind-Body Brain-Gut Connection Source: Columbus, OH: Parkview Publishing. 1997. 302 p. Contact: Available from Parkview Publishing. P.O. Box 1103, Columbus, OH 43216. (888) 599-6464 or (614) 258-4848. Fax (614) 258-7272. PRICE: $19.95. ISBN: 0965703894. Summary: This book offers readers a guide to understanding and treating their functional gastrointestinal (GI) disorders, focusing on irritable bowel syndrome (IBS). The author emphasizes the role that individuals can play in managing their own symptoms and future. The book is framed around eight steps to positive change; eight chapters cover the GI tract and the mind-body connection; the common functional GI disorders; healing with diagnosis and education; understanding one's own symptoms and GI tract; identifying gut 'triggers'; emphasizing self-care and wellness; taking action if symptoms persist; and managing the functional GI disorder. Specific topics include the interplay between stress, psychology and symptoms; colitis and inflammatory bowel disease (IBD); the International Foundation for Functional Gastrointestinal Disorders (IFFGD); self-tests for personal and psychological problems; the role of a history of abuse; cognitive behavioral factors; food and symptom diaries; food allergy versus food intolerance and sensitivity; inflammation and infection; the menstrual cycle; seasonal changes; nutrition; weight; exercise; the impact of alcohol, nicotine, and tobacco; the use of an elimination diet; stress, emotional, and psychological issues; chronic pain management; and managing the symptoms of chest pain, heartburn, dysphagia, dyspepsia, nausea, vomiting, aerophagia (burping and belching), abdominal bloating, rectal gas and flatulence, abdominal pain, diarrhea, constipation, bowel incontinence, and anal and rectal pain. The book includes black and white photographs, charts, and figures; a subject index concludes the volume.
•
Eating Hints for Cancer Patients: Before, During and After Treatment Source: Bethesda, MD: National Cancer Institute (NCI), National Institutes of Health (NIH). 1999. 60 p. Contact: Available from National Cancer Institute (NCI). Publications Ordering Service, P.O. Box 24128, Baltimore, MD 21227. Voice (800) 422-6237. TTY (800) 332-8615. Fax (301) 330-7968. PRICE: Single copy free; bulk rates available. NIH Publication Number 99-2079. Summary: This booklet contains a variety of ideas about food needs and eating problems that patients undergoing cancer therapy may encounter. The authors emphasize the need for eating well during cancer treatment and outline the nutrition problems that may arise with different cancer treatments. Strategies for coping with side effects are provided for loss of appetite, sore mouth or throat, changed sense of taste or smell, dry mouth, nausea, vomiting, diarrhea, constipation, weight gain, tooth decay, and lactose intolerance. The next section provides suggestions for increasing protein and calorie intake, including the use of healthy snacks. Another section discusses diets for patients with special needs, including the clear liquid diet, full liquid diet, soft diet, fiber restricted diet, low lactose diet, and commercial products to improve nutrition. The booklet includes a glossary of related terms and the contact information for two resource
Books
179
organizations: the Cancer Information Service (800-422-6237) and the American Cancer Society (800-227-2345). The booklet then provides 40 pages of recipes designed to help patients achieve better nutrition during cancer treatment. A recipe index is provided. Colorful drawings illustrate the booklet. 8 tables. •
Keep Yourself Healthy at Home: A Guide for Adults with Diabetes Source: South Deerfield, MA: Channing L. Bete Co., Inc. 2000. 60 p. Contact: Available from Channing L. Bete, Co., Inc. 200 State Road, South Deerfield, MA 01373-0200. (800) 628-7733. Fax (800) 499-6464. PRICE: $3.50 each; plus shipping and handling; quantity discounts available. Order number 97915. Summary: This illustrated handbook provides adults who have diabetes with information on health care. Section one provides general information about health care, the prevention of health problems, and the use of diabetes and general medications. Section two discusses specific problems and their treatment, focusing on allergies, appendicitis, asthma; back pain; bites and stings; bronchitis; bruises, cuts, and scrapes; burns and sunburns; chest pain; colds, flu, and cough; constipation; diarrhea; dizziness and fainting; fever; foot and leg problems; headaches; heartburn; mouth problems; nausea and vomiting; sexual concerns; sexually transmitted diseases; skin problems; sprains and strains; urinary tract infections; and vaginitis. Section three focuses on conditions of special concern for people who have diabetes, including heart disease and stroke and eye, kidney, and nerve diseases. Section four explains how to deal with hypoglycemia and hyperglycemia and provides space for writing down emergency numbers and other emergency information.
•
Clinical Practice of Gastroenterology. Volume One Source: Philadelphia, PA: Current Medicine. 1999. 783 p. Contact: Available from W.B. Saunders Company. Order Fulfillment, 6277 Sea Harbor Drive, Orlando, FL 32887. (800) 545-2522. Fax (800) 874-6418 or (407) 352-3445. Website: www.wbsaunders.com. PRICE: $235.00 plus shipping and handling. ISBN: 0443065209 (two volume set); 0443065217 (volume 1); 0443065225 (volume 2). Summary: This lengthy textbook brings practitioners up to date on the complexities of gastroenterology practice, focusing on the essentials of patient care. This first volume includes 86 chapters in four sections: esophagus, stomach and duodenum, small bowel, and colon. Specific topics include normal esophageal physiology, gastroesophageal reflux disease (GERD), motor disorders of the esophagus, esophageal foreign bodies, esophagitis, esophageal trauma, esophageal surgery, gastric and duodenal histology and histopathology, gastroduodenal motility and motility disorders, abdominal pain, nausea and vomiting, dyspepsia (heartburn), Helicobacter pylori, gastric and duodenal ulcer, gastric cancer, gastric infection, gastric surgery, small intestine anatomy and physiology, symptoms and signs of small bowel disease, maldigestion and malabsorption, intestinal obstruction and pseudoobstruction, immunologic disorders, small intestinal malignancies (cancer), short bowel syndrome, Whipple's disease, infectious diarrhea, parasitic diseases of the small intestine, foodborne diseases of the small intestine, gastroenteritis, Crohn's disease, anatomy and physiology of the colon, irritable bowel syndrome (IBS), secretory diarrhea, constipation and fecal impaction, fecal incontinence, gas and flatulence, gastrointestinal bleeding, colitis (including ulcerative colitis), diverticulitis and diverticular hemorrhage, appendicitis, benign tumors of the colon and polyposis syndrome, malignant tumors of the colon, and anorectal disorders. The chapters include figures, algorithms, charts, graphs,
180 Nausea
radiographs, endoscopic pictures, intraoperative photographs, photomicrographs, tables, and extensive references. The volume concludes with a detailed subject index and a section of color plates. •
AIDS: Nutritional Care of the Patient With AIDS Contact: Bristol Meyers Squibb Company, Mead Johnson Nutritional Group, 2400 W Lloyd Expy, Evansville, IN, 47721, (812) 429-5000, http://www.meadjohnson.com. Summary: This manual provides information on Acquired immunodeficiency syndrome (AIDS) and nutrition, and guidelines on caring for patients with nutritional problems. The first section examines the pathophysiology of nutritional complications, including anorexia, diarrhea, nausea, and metabolic disorders. The second section explains the effects that nutrition may have on the functioning of the immune system. The manual then outlines components of nutritional care, including goals and assessment. Recommendations are given on nutrients, symptom-management, food safety, and nutritional support. The manual concludes with a look at future trends in care and treatment.
•
Nutrition: Your Ammunition for AIDS Contact: University of California San Diego, Medical Center, Department of Clinical Nutrition, 225 Dickinson St H-802, San Diego, CA, 92103-1990, (619) 543-3783. Summary: This monograph addresses nutritional needs, especially for persons with HIV/AIDS. It states that the best nutritional status is maintained with a well-balanced diet and an ample amount of calories to prevent weight loss. It explains that symptoms of AIDS, such as fevers, nausea, vomiting, diarrhea, candidiasis (thrush), infection, and herpetic and Kaposi's sarcoma lesions have a direct effect on specific nutritional needs and lists ways to reduce such symptoms. Eating a variety of food from the basic food groups in frequent but small amounts is also recommended. It encourages taking vitamins, minerals, protein, and calorie supplements. Difficulties with chewing, swallowing, nausea, vomiting, diarrhea, are also addressed. It offers suggestions for eliminating loss of appetite, feeling full too soon, and being too tired to cook food. It also includes intake guidelines for males, females, and vegetarians with HIV/AIDS, highcalorie recipes, and foods that can be stored for days when a person with HIV/AIDS may be too tired to cook.
•
Marijuana & AIDS: Pot, Politics, & PWAs in America Contact: Galen Press, PO Box 53318, Washington, DC, 20009, (202) 483-8595. Summary: This monograph examines the controversy surrounding the use of marijuana in medical treatment for Acquired immunodeficiency syndrome (AIDS). Proponents of the controlled substance say that it alleviates nausea and increases appetite, serious symptoms that often affect persons with Human immunodeficiency virus (HIV) infection. It presents four case studies of Persons with AIDS (PWA's) who obtained legal access to marijuana for treatment, then looks at the laws and legal issues surrounding the question.
•
Pass the Calories, Please! Contact: American Dietetic Association, 216 W Jackson Blvd Ste 800, Chicago, IL, 606066995, (800) 877-1600, http://www.eatright.org.
Books
181
Summary: This monograph is designed as a practical guide for people who need suggestions on ways to increase calories in their diets. Practical tips are given on how to handle conditions that prevent one from eating well, such as nausea, vomiting, diarrhea, sore or dry mouth, or a general loss of appetite. The recipes included are rich in the nutrients that may be needed at such times, including vitamins, protein, and fiber. The book also discusses eating out, commercial supplements, and food safety. •
20 Common Problems in Gastroenterology Source: New York, NY: McGraw-Hill, Inc. 2002. 317 p. Contact: Available from McGraw-Hill, Inc. 1221 Avenue of the Americas, New York, NY 10020. (612) 832-7869. Website: www.bookstore.mcgraw-hill.com. PRICE: $45.00;plus shipping and handling. ISBN: 0070220557. Summary: This text is one from a series that provides concise, practical information for health care professionals. This book focuses on the most common gastroenterological problems encountered in a primary practice setting and represents a selection of 20 clinical issues that every practitioner of primary care and general gastroenterology will encounter on a regular basis. The chapters are organized to support rapid access to the information necessary to evaluate and treat most patients with these problems. The text features three sections: general gastroenterology, gastrointestinal (GI) bleeding, and hepatic (liver) and biliary problems. Twenty chapters cover heartburn, nausea and vomiting, dysphagia (swallowing difficulties), weight loss, dyspepsia, chronic abdominal pain (functional GI disorders), acute abdominal pain, acute upper GI bleeding, acute lower GI bleeding, occult (hidden) bleeding and iron deficiency anemia, flatulence (gasiness), acute diarrhea in adults, constipation, colorectal cancer screening, anal pain, viral hepatitis, right upper quadrant pain (gallbladder disease and its complications), liver masses, abnormal liver function tests, and biliary obstruction. Each chapter includes a chapter outline for quick reference, the text itself, a diagnostic and treatment algorithm, and selected references. The text concludes with a subject index. Color photographs are provided in a special section; black and white photographs, figures, and charts illustrate the volume.
•
Functional Disorders of the Gut Source: London, England: Churchill Livingstone. 1998. 370 p. Contact: Available from Harcourt Brace and Company. Foots Cray High Street, Sidcup, Kent, DA14 5 HP, United Kingdom. 02083085700. Fax 02083085702. E-mail:
[email protected]. Website: www.harcourt-international.com. PRICE: $65.00 plus shipping and handling. ISBN: 0443054207. Summary: This textbook provides practical, clinical advice on the management of patients with symptoms of abnormal gastrointestinal (GI) function. Experts in the field offer information about the conflicting management options in order to support patient care. The first section of the book deals with topics, including neurobiology, that are relevant to several or perhaps all functional disorders of the gut. Topics in this section include functional anatomy and physiology, enteric neuropathobiology, clinical pharmacology (drug therapy), epidemiology (incidence and prevalence), psychopathology of functional disorders of the gut, chronic abdominal pain, and hypersensitivity and food intolerance. The remainder of the book offers two parallel tracks through the successive regions of the digestive tract. The first summarizes the present views on physiology and pathophysiology, while the second addresses the problems of clinical management. Topics in this section include the esophagus,
182 Nausea
including disorders of swallowing and chest pain; nausea, vomiting and other food related symptoms of stomach problems; the clinical physiology of the small bowel; the colon and anorectum, including constipation, urgency, and pain syndromes; the clinical management of irritable bowel syndrome (IBS); and the symptoms and management of biliary tract problems. The text concludes with a postscript chapter summarizing both the changes and the consistencies in the field of functional bowel disorders. Each chapter concludes with numerous references, and a subject index concludes the volume. Drawings, charts, and reproductions are in black and white.
Book Summaries: Online Booksellers Commercial Internet-based booksellers, such as Amazon.com and Barnes&Noble.com, offer summaries which have been supplied by each title’s publisher. Some summaries also include customer reviews. Your local bookseller may have access to in-house and commercial databases that index all published books (e.g. Books in Print). IMPORTANT NOTE: Online booksellers typically produce search results for medical and non-medical books. When searching for “nausea” at online booksellers’ Web sites, you may discover nonmedical books that use the generic term “nausea” (or a synonym) in their titles. The following is indicative of the results you might find when searching for “nausea” (sorted alphabetically by title; follow the hyperlink to view more details at Amazon.com): •
Cancer Treatment & Marijuana Therapy: Marijuana's Use in the Reduction of Nausea and Vomiting and for Appetite Stimulation in Cancer Patients. Testimony from Historic Federal Hearings on m (Marijuana, Medicine & the Law Series) by R. C. R